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ABSTRACT	  	  	  Clinical	  scores,	  serum	  and	  faecal	  markers,	  and	  endoscopy	  all	  have	  limitations	  in	  their	   use	   as	   instruments	   to	   monitor	   disease	   activity	   in	   Crohn’s	   disease	   (CD).	  Recently,	   18F-­‐FDG-­‐PET	   and	   novel	   MRI	   techniques	   have	   been	   proposed	   as	  sensitive	  and	  specific	  methods	  to	  quantify	  the	  inflammatory	  load.	  The	  aim	  of	  this	  work	  was	  to	  assess	  the	  reliability,	  responsiveness	  and,	  to	  an	  extent,	  the	  validity	  of	   outcome	  measures	   in	   these	  modalities,	   in	  monitoring	   inflammatory	   activity	  over	   a	   12-­‐week	   interval.	   	   In	   addition,	   two	   receptors,	   TSPO	   and	   IL-­‐2R	   were	  assessed	   on	   tissue	   specimens	   ex-­‐vivo	   for	   their	   potential	   to	   act	   as	   alternative	  targets	  for	  molecular	  imaging	  in	  CD.	  	  Three	  distinct	  groups	  of	  patients	  were	  recruited,	  2	  of	  which	  participated	   in	  the	  clinical	   imaging	   study,	   and	   one	   to	   donate	   tissue	   for	   the	   laboratory	  work.	   Dual	  timepoint	  FDG-­‐PET	  and	  MRI	  scanning	  was	  performed	  within	  1	  week	  (Group	  1)	  to	  assess	  the	  test-­‐retest	  reliability	  of	  the	  imaging	  outcome	  measures,	  and	  before,	  and	   twelve	   weeks	   into	   anti-­‐TNFα	   therapy	   (Group	   2)	   to	   assess	   their	  responsiveness	   indices.	   The	   third	   group	   contributed	   tissue	   during	   scheduled	  intestinal	   resection	   for	   assessment	   of	   TSPO	   and	   IL-­‐2R	   interactions	   with	   their	  corresponding	   radioligands.	   To	   support	   the	   latter	   study,	   stored	   tissue	   sections	  were	   also	   obtained	   for	   immunohistochemical	   assessment	   of	   target	   receptor	  expression.	  	  Results	   on	   22	   patients	   show	   that	   PET	   endpoints	   such	   as	   SUVMAX	  and	   SUVMEAN	  have	   high	   responsiveness	   and	   reliability	   indices	   and	   demonstrated	   significant	  differences	  in	  anti-­‐TNF	  responders	  compared	  to	  non-­‐responders.	  The	  finding	  of	  luminal	   FDG	   signal	   may	   affect	   the	   face	   validity	   of	   the	   scan.	   MRI	   modalities	  appeared	   less	   responsive	   at	   three	   months.	   Analysis	   on	   ex-­‐vivo	   specimens	  showed	   increased	   abundance	   of	   TSPO	   in	   normal	   bowel,	   but	   a	   relative	   over-­‐expression	   in	   inflamed	   specimens	  which	  was	  not	   statistically	   significant.	   IL-­‐2R	  appeared	   more	   abundant	   in	   transmural	   sections	   containing	   severe	   CD,	   but	  autoradiographic	  corroboration	  was	  not	  achieved	  for	  technical	  reasons.	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   1.1 EPIDEMIOLOGY,	  CLINICAL	  FEATURES	  AND	  PATHOPHYSIOLOGY	  OF	  CROHN’S	  DISEASE	  	  	   Crohn’s	  	  disease	  	  (CD)	  	  is	  	  a	  	  chronic	  	  idiopathic	  	  disorder	  	  affecting	  	  the	  	  gastro	  	  –intestinal	  	  (GI)	  tract	  	  and,	  	  less	  	  frequently,	  	  extra-­‐-­‐-­‐intestinal	  	  tissues.	  	  Its	  	  characteristic	  	  features	  	  are	  	  those	  	  of	  segmental	  	  	  inflammation	  	  	  affecting	  	  	  any	  	  	  part	  	  	  of	  	  	  the	  	  	  gastrointestinal	  	  	  tract,	  	  	  with	  	  	  lesions	  extending	  across	  the	  full	  thickness	  of	  the	  bowel.	  	  	   The	  highest	   incidences	  of	  CD	  have	  been	  observed	   in	   the	  USA,	   the	  UK	  and	  Northern	  Europe,	  as	  	  well	  	  as	  	  New	  	  Zealand	  	  with	  	  up	  	  to	  	  16.5	  	  new	  	  cases	  	  per	  	  100,000	  	  population	  	  each	  	  year.	  Moreover,	   there	   is	  an	   increasing	   incidence	   from	  regions	  with	  a	  very	   low	  prevalence	  such	  as	  the	  	  Far-­‐-­‐-­‐East,	  	  south-­‐-­‐-­‐east	  	  Asia	  	  and	  	  eastern	  	  and	  	  northern	  	  Mediterranean.	  	  The	  	  disease	  	  most	  commonly	  presents	  in	  the	  3rd	  	  decade,	  with	  up	  to	  20%	  of	  cases	  occurring	  in	  children	  1.	  	  	   The	  pathogenesis	  of	   the	  condition	  has	  not	  been	   fully	  elucidated.	  The	  current	  pathogenetic	  paradigm	   proposes	   the	   disturbance	   of	   the	   mucosal	   barrier	   and	   microbiotal	   balance	   in	  response	  to	  environmental	  triggers	  in	  genetically	  susceptible	  individuals.	  These	  events	  lead	  to	  the	  disruption	  of	  intestinal	  mucosal	  homeostasis	  2	  3	  .	  	  	   Study	  	   into	  	   the	  	   immunogenetics	  	  of	  	   IBD,	  	  predominantly	  	   through	  	  the	  	   latest	  	  genome-­‐-­‐-­‐wide	  association	  studies	  has	  identified	  at	  least	  163	  associated	  loci.	  Analysis	  of	  these	  findings	  offer	  insight	  	  	  into	  	  	  the	  	  	  biological	  	  	  mechanisms	  	  	  of	  	  	  the	  	  	  inflammatory	  	  	  bowel	  	  	  diseases,	  	  	  such	  	  	  as	  autophagy,	  barrier	  defence	  and	  T-­‐-­‐-­‐cell	  differentiation	  signalling,	  as	  well	  as	  provide	  a	  focus	  for	  the	  discovery	  of	  new	  therapeutic	  pathways	  4	  	  5.	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The	  	  	  natural	  	  	  history	  	  	  of	  	  	  the	  	  	  disease	  	  	  has	  	  	  been	  	  	  thoroughly	  	  	  characterised.	  	  	  Even	  	  	  though	  	  	  a	  hallmark	  	  of	  	  the	  	  disease	  	  is	  	  its	  	  potential	  	  to	  	  involve	  	  any	  	  region	  	  of	  	  the	  	  GI	  	  tract	  	  from	  	  mouth	  	  to	  anus,	  in	  a	  large	  majority	  its	  distribution	  follows	  one	  of	  three	  characteristic	  patterns.	  Patients	  typically	   present	  with	   either	   isolated	   small	   bowel	   disease,	   exclusive	   colonic	   disease	   or	   ileo-­‐-­‐-­‐	  colonic	  	  disease,	  	  which	  	  occur	  	   in	  	  approximately	  	  equal	  	  proportions	  	  (37%,	  	  22%	  	  and	  	  33%	  respectively)6,7,8.	  	  While	  	  the	  	  disease	  	  distribution	  	  at	  	  presentation	  	  tends	  	  to	  	  remain	  	  stable	  	  in	  approximately	   80%	  of	   patients	   over	   time	   9,10,	   the	   individual	   lesions	   themselves	   behave	   in	   a	  highly	  dynamic	  manner.	  	  	   Several	  	  macroscopic	  	  histo-­‐-­‐-­‐pathological	  	  abnormalities	  	  are	  	  encountered	  	  in	  	  CD.	  	  The	  	  disease	  typically	  affects	  the	  gut	  in	  a	  transmural	  fashion	  and	  the	  lesions	  are	  discontinuous,	  separated	  by	  uninvolved	  or	  ‘skip’	  areas.	  Mucosal	  ulcers	  start	  as	  punctiform	  superficial	  erosions	  termed	  ‘aphthoid’	  ulcers,	  which,	   in	   time	  evolve	   into	  much	   larger	  confluent	   ‘serpiginous’	  ulcerations,	  which	  	  	  run	  	  	  transversely	  	  	  and	  	  	  longitudinally	  	  	  along	  	  	  the	  	  	  involved	  	  	  mucosa	  	  	  giving	  	  	  it	  	  	  its	  characteristic	  	  ‘cobblestone’	  	  appearance.	  	  Transmural	  	  extension	  	  of	  	  these	  	  ulcers	  	  can	  	  occur,	  typically	  	  on	  	  the	  	  mesenteric	  	  aspect	  	  of	  	  the	  	  intestine,	  	  which	  	  penetrate	  	  through	  	  the	  	  serosa	  producing	  	  	  fistulae	  	  	  or	  	  	  abscesses.	  	  	  Moreover,	  	  	  tissue	  	  	  oedema	  	  	  causing	  	  	  widening	  	  	  of	  	  	  the	  submucosa	   is	   observed,	   a	   sign	  of	   active	  disease.	   	   	  Stricturing	   is	   another	   typical	  macroscopic	  complication	  	  	  of	  	  	  CD,	  	  	  characterised	  	  	  by	  	  	  bowel	  	  	  wall	  	  	  thickening	  	  	  and	  	  	  luminal	  	  	  narrowing,	  expansion	  of	  the	  muscularis	  secondary	  to	  smooth	  muscle	  cell	  hyperplasia,	  and	  deposition	  of	  collagen,	  	  	  	  laminin	  	  	  	  and	  	  	  	  tenascin.	  	  	  	  Expansion	  	  	  	  of	  	  	  	  the	  	  	  	  mesenteric	  	  	  	  fat	  	  	  	  which	  	  	  	  extends	  circumferentially	  	  	  around	  	  	  the	  	  	  affected	  	  	  bowel	  	  	  loops	  	  	  is	  	  	  also	  	  	  seen,	  	  	  commonly	  	  	  termed	  	  	  ‘fat	  wrapping’,	  	  which	  	  results	  	  in	  	  separation	  	  of	  	  diseased	  	  loops	  	  from	  	  uninvolved	  	  adjacent	  	  ones.	  Finally,	  	  prominent	  	  blood	  	  vessels	  	  are	  	  seen	  	  in	  	  the	  	  serosal	  	  surface,	  	  and	  	  swollen	  	  lymph	  	  nodes	  can	  be	  observed	  in	  association	  with	  diseased	  segments	  11.	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On	  	  	  a	  	  	  microscopic	  	  	  level	  	  	  the	  	  	  characteristic	  	  	  feature	  	  	  of	  	  	  CD	  	  	  is	  	  	  non-­‐-­‐-­‐caseating	  	  	  granulomata,	  collections	  	  	  of	  	  	  macrophages	  	  	  and	  	  	  monocytes,	  	  	  as	  	  	  well	  	  	  as	  	  	  giant	  	  	  cells,	  	  	  lymphocytes	  	  	  and	  occasionally	   fibroblasts	   12.	  Villous	  or	  crypt	  architectural	  distortion	   is	  observed	  as	  well	  as	  an	  increase	   in	  both	  acute	   inflammatory	   (neutrophils,	  macrophages)	  especially	   around	   the	  base	  of	  	  ulcerations	  	  and	  	  along	  	  fistular	  	  tracts,	  	  and	  	  chronic	  	  inflammatory	  	  cell	  	  types	  	  (lymphocytes	  and	  plasma	  cells)	  seen	  diffusely	  across	  all	  layers	  13.	  	  	   The	  	  macroscopic	  	  features	  	  of	  	  ulceration,	  	  fistulisation,	  	  abscesses,	  	  bowel	  	  wall	  	  oedema,	  	  and	  prominence	  of	   serosal	   vasculature	   are	  discussed	   again	   later	   in	   this	   thesis,	   as	   they	   form	  	  the	  basis	  	  of	  	   the	  	   identification	  	  of	  	  diseased	  	   segments	  	  by	  	   cross-­‐-­‐-­‐sectional	  	   imaging	  	   techniques.	  However,	  	  with	  	  the	  	  exception	  	  of	  	  ulcers,	  	  these	  	  are	  	  indicators	  	  of	  	  transmural	  	  pathology	  	  in	  	  CD.	  While	  	  	  the	  	  	  response	  	  	  of	  	  	  mucosal	  	  	  lesions	  	  	  is	  	  	  a	  	  	  well-­‐-­‐-­‐described	  	  	  endpoint	  	  	  of	  	  	  treatment,	  	  	  the	  potential	  	  reversibility	  	  of	  	  these	  	  features	  	  of	  	  transmural	  	  inflammation	  	  in	  	  CD	  	  remains	  	  to	  	  be	  determined.	  	  	  Moreover,	  	  	  acute	  	  	  and	  	  	  chronic	  	  	  inflammatory	  	  	  infiltrates	  	  	  underpin	  	  	  functional	  imaging	  modalities	   that	  can	  potentially	  quantify	  disease	   load,	  such	  as	  FDG-­‐-­‐-­‐PET,	  and	  are	  also	  examined	  in	  detail	  later	  in	  this	  work.	  	  	  
De	   novo	   lesion	   development	   from	   normal	   mucosa	   has	   been	   studied	   in	   patients	   following	  intestinal	  resection	  and	  anastomosis.	  The	  process	  is	   initiated	  shortly	  after	  the	  resection	  by	  the	  development	  of	  an	  inflammatory	  cellular	  infiltrate	  proximal	  to	  the	  anastomosis,	  followed	  by	  aphthous	  ulcers	  within	  a	  few	  months14.	  At	  presentation,	  a	  majority	  of	  patients	  with	   ileal	  disease	  and	  almost	  all	  with	  colonic	  distribution	  only	  exhibit	  inflammatory	  lesions.	  Over	  time,	  an	  increasing	  proportion	  of	  lesions	  develop	  a	  stricturing	  and/or	  penetrating	  character,	  and	  after	  five	  to	  seven	  years	  more	  than	  half	  the	  patients	  have	  one	  of	  these	  phenotypes,	  at	  least	  those	   with	   small	   bowel	   distribution.	   This	   pattern	   of	   development	   has	   not	   changed	  significantly	  over	   the	   last	  decade	   15,1.	   Strictures	   and	   fistulae	   are	   the	  major	   contributors	   in	  the	  	   overall	  	  morbidity	  	   of	  	   CD,	  	   have	  	   significant	  	   impact	  	   in	  	   quality	  	   of	  	   life,	  	   and	  	   result	  	   in	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hospitalisation,	  surgery	  and	  a	  significant	  cost	  burden	  16,17.	  This	  pattern	  of	  progression	  is	  not	  necessarily	  reflected	  in	  patients’	  symptoms,	  with	  many	  patients	  progressing	  to	   structuring	  or	   fistulising	   disease	   despite	   minor	   or	   relapsing	   and	   remitting	   symptoms.	   The	   currently	  accepted	   paradigm	   on	   the	   predominant	   natural	   history	   of	   CD	   is	   that	   of	   progressive	   and	  accumulating	   bowel	   damage	   irrespective	   of	   symptomatology.	   This	   has	   now	   been	  demonstrated	  in	  large	  studies	  from	  both	  referral	  centres8	  and	  population	  based	  cohorts18.	  	  	   Despite	  this	  progress	  in	  understanding	  the	  pathogenesis	  the	  prognosis	  of	  CD	  is	  very	  variable	  and	  monitoring	  the	  disease	  can	  be	  challenging.	  A	  number	  of	  different	  modalities	  have	  been	  considered,	  outlined	  below,	  but	  there	  still	  remains	  significant	  unmet	  need.	  	  	   1.2 DISEASE	  MONITORING	  IN	  CROHN’S	  DISEASE	  	  	  	   Appropriate	   instruments	   that	  monitor	  disease	  activity	   in	  CD	  are	  essential	   for	  a	  number	  of	  reasons:	   Firstly,	   symptom	   perception	   and	   reporting	   are	   often	   not	   in	   keeping	   with	   the	  evolving	  course	  of	  underlying	  pathology,	  and,	  as	  such,	  they	  are	  poor	  predictors	  of	  worsening	  morbidity	  and	  complications.	  	  	   Secondly,	  novel	  biologic	  therapies	  are	  becoming	  a	  mainstay	  in	  the	  management	  of	  CD	  due	  to	  their	  	  disease-­‐-­‐-­‐modifying	  	  potential19,20,	  	  but	  	  a	  	  significant	  	  proportion	  	  of	  	  patients	  	  either	  	  fail	  	  to	  respond	  at	  induction,	  or	  lose	  their	  response	  after	  a	  variable	  period	  of	  successful	  therapy21,22.	  In	  	  addition	  	  to	  	  being	  	  associated	  	  with	  	  considerable	  	  toxicity	  	  and	  	  side	  	  effects23,	  	  these	  	  agents	  pose	  	  a	  	  significant	  	  cost	  	  burden	  	  to	  	  health	  	  services	  	  with	  	  annual	  	  rates	  	  of	  	  therapy	  	  estimated	  	  in	  the	  	  tens	  	  of	  	  thousands24.	  	  A	  	  monitoring	  	  strategy	  	  that	  	  would	  	  objectively	  	  measure	  	  response	  would	  	  be	  	  useful	  	  for	  	  better	  	  decisions	  	  regarding	  	  changes	  	  of	  	  treatment	  	  in	  	  non-­‐-­‐-­‐responding	  patients	  or	  to	  justify	  ongoing	  therapy	  in	  those	  with	  objective	  indicators	  of	  benefit.	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Finally,	  the	  development	  of	  appropriate	  outcome	  measures	  can	  prove	  valuable	  in	  the	  field	  of	  new	  	  drug	  	  development.	  	  There	  	  is	  	  a	  	  growing	  	  pipeline	  	  of	  	  candidate	  	  drugs	  	  in	  	  IBD25,	  	  and,	  	  	  as	  	  a	  result,	  	  	  a	  	  	  great	  	  	  need	  	  	  for	  	  	  suitable	  	  	  biomarkers,	  	  	  which	  	  	  are	  	  	  reproducible,	  	  	  validated	  	  	  and	  responsive	  to	  change.	  These	  can	  enhance	  the	  efficacy	  of	  enrolment,	  by	  ensuring	  recruitment	  of	  patients	  with	  objective	   activity	   rather	   than	   functional	   symptoms,	   a	  well-­‐-­‐-­‐highlighted	   issue	  in	  past	   studies26.	  As	  biomarkers	  become	  more	   sophisticated,	   the	   selection	   can	  become	  even	  more	  	  	  focused,	  	  	  to	  	  	  include	  	  	  patients	  	  	  with	  	  	  a	  	  	  certain	  	  	  phenotype	  	  	  or	  	  	  a	  	  	  specific	  	  	  dominant	  inflammatory	  	  pathway	  	  targeted	  	  by	  	  the	  	  corresponding	  	  drug.	  	  Just	  	  as	  	  importantly,	  	  they	  	  can	  enable	  the	  tracking	  of	  the	  biologic	  effects	  of	  new	  agents,	  and	  even	  act	  as	  benchmarks	  for	  the	  definition	  of	  response	  and	  remission27.	  	  	   The	  following	  review	  critically	  assesses	  monitoring	  tools,	  which	  either	  have	  an	  established	  clinical	  role,	  or	  show	  some	  potential	  in	  research	  studies.	  	  	  
1.2.1 Symptoms	  and	  clinical	  scores	  as	  monitoring	  instruments	  in	  CD	  
	  
	  
	   A	  number	  of	  symptom-­‐-­‐-­‐based	  scoring	  systems	  have	  been	  developed	  for	  the	  monitoring	  of	  CD	  activity	  	  both	  	  in	  	  clinical	  	  practice	  	  and	  	  in	  	  the	  	  context	  	  of	  	  clinical	  	  trials.	  	  The	  	  Crohn’s	  	  Disease	  Activity	  	  	  Index	  	  	  (CDAI)	  	  	  combines	  	  	  8	  	  	  independent	  	  	  factors,	  	  	  which	  	  	  correlate	  	  	  best	  	  	  to	  	  	  the	  physician’s	  	  overall	  	  evaluation	  	  of	  	  clinical	  	  activity28.	  	  The	  	  simpler	  	  Harvey	  	  Bradshaw	  	  Index	  (HBI)	  	  was	  	  proposed	  	  shortly	  	  afterwards29	  	  	  and	  	  was	  	  shown	  	  to	  	  have	  	  an	  	  excellent	  	  correlation	  with	  	  CDAI30.	  	  	  	  These	  	  scores	  	  provide	  	  a	  	  gauge	  	  for	  	  general	  	  wellbeing	  	  along	  	  with	  	  common	  	  GI	  symptoms,	  as	  well	  as	  extra-­‐-­‐-­‐intestinal	  manifestations	  and	  complications.	  While	   they	  are	  very	  simple	  tools,	  which	  offer	  themselves	  for	  serial	  monitoring	  of	  the	  condition,	  the	  main	  point	  of	  criticism	  	  is	  	  that	  	  of	  	  their	  	  inherent	  	  subjectivity.	  	  This	  	  is	  	  of	  	  vital	  	  importance	  	  when	  	  a	  	  clinical	  symptom	  	  score	  	  provides	  	  the	  	  only	  	  benchmark	  	  of	  	  success	  	  in	  	  assessing	  	  new	  	  therapies	  	  in	  clinical	   trials.	  Also,	   in	  keeping	  with	   the	  empirical	  disconnect	  between	  symptomatology	  and	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inflammatory	  activity,	  recent	  studies	  demonstrate	  a	  lack	  of	  correlation	  between	  clinical	  scores	   and	   more	   robust	   endpoints	   of	   inflammatory	   activity	   such	   as	   endoscopic	   or	  histological	   assessments.	   	   A	   study	   testing	   agreement	   between	   CDAI	   and	   endoscopic	  scores	   12	   months	   following	   ileo-­‐caecal	   resections	   reported	   a	   very	   poor	   relationship	  (r=0.12,	  p=0.68)31.	  In	  a	  different	  context	  following	  anti-­‐TNFα	  therapy,	  a	  separate	  group	  from	   Scandinavia	   examined	   the	   relationship	   between	   endoscopy	   and	   clinical	   scores	  (HBI	  and	  CDAI),	  and	  reported	  positive	  but	  modest	  correlations32.	  	  Common	  symptoms	  in	  IBD	  are	  non-­‐pathognomonic,	  and	  shared	  with	  a	  variety	  of	  gastro-­‐intestinal	  conditions.	  According	  to	  a	  recent	  population-­‐based	  study	  in	  over	  700	  people	  with	  established	  IBD,	  diarrhoea	  is	  the	  most	  common	  complaint	  in	  CD	  (63%)	  followed	  by	  fatigue	   (54%),	   abdominal	   pain	   (47%)	   and	   arthralgia	   (42%)	   while	   symptoms	   like	  bleeding,	  which	  are	  more	  suggestive	  of	  ongoing	  inflammatory	  activity,	  are	  experienced	  by	  a	  minority	  of	  patients	  (17%)	  33.	  	  A	   well-­‐recognised	   phenomenon	   in	   clinical	   practice	   is	   the	   ongoing	   reporting	   of	   GI	  symptoms	  in	  patients	  despite	  the	   lack	  of	  evidence	  of	  disease	  activity.	  These	  symptoms	  are	  then	  commonly	  attributed	  to	  a	  functional	  origin.	  A	  well-­‐designed,	  exhaustive	  meta-­‐analysis	  of	  11	  studies	  collectively	  examined	  a	  cohort	  of	  patients	  with	  IBD	  in	  documented	  remission	   for	   functional	   symptoms,	   which	   were	   strictly	   defined	   by	   validated	   criteria.	  This	  reports	  a	  prevalence	  of	  35%	  for	  such	  symptoms	  in	  IBD	  patients.	  	  When	  CD	  patients	  were	  looked	  at	  in	  isolation,	  the	  percentage	  was	  higher	  at	  46%.	  Moreover,	  the	  two	  case-­‐control	  studies	  comparing	  264	  CD	  patients	  with	  414	  non-­‐IBD	  controls	  revealed	  irritable	  symptom	  prevalence	  of	  26.4%	  vs.	  6.3%	  respectively	  34.	  	  At	   the	  other	  end	  of	   the	  spectrum	  there	   is	   increasing	  evidence	  that	  patients	  who	  are	   in	  clinical	   remission	   may	   continue	   to	   have	   progressive	   subclinical	   bowel	   inflammation,	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which	   ultimately	   culminates	   to	   the	   formation	   of	   a	   stricture	   or	   fistula.	   Recent	  epidemiological	  studies	  independently	  demonstrated	  that	  this	  paradigm	  of	  (often	  silent)	  disease	   evolution	   from	   pure	   inflammatory	   to	   a	   stricturing	   or	   fistulising	   phenotype	   is	  applicable	  to	  the	  majority	  of	  patients	  over	  time8,15.	  	  	  	  In	  summary,	  the	  achievement	  of	  adequate	  symptom	  control	  is	  crucial	  in	  terms	  of	  patient	  care.	   However,	   poor	   association	   between	   symptomatology	   and	   underlying	   activity	   or	  even	   bowel	   damage8	   is	   becoming	   increasingly	   recognised.	   Consequently,	   the	   use	   of	  symptoms	   in	   isolation	   to	  monitor	   disease	   activity	   is	   inaccurate	   and	   ineffective.	  Major	  effort	   has	   therefore	   been	   directed	   in	   the	   development	   of	   alternative	   biomarkers	   to	  monitor	  disease	  activity.	  This	  will	  facilitate	  both	  the	  optimisation	  of	  patient	  care	  as	  well	  as	  the	  assessment	  of	  therapeutic	  efficacy	  and	  safety	  in	  the	  context	  of	  clinical	  trials.	  
	  
1.2.2	  C-­‐Reactive	  Protein	  
	  C-­‐Reactive	  protein	   is	   a	  non-­‐specific	  marker	  of	   inflammation,	   infection	  or	   tissue	   injury.	  Its	  name	  derives	  from	  the	  observation	  that	  it	  reacted	  with	  the	  cell	  wall	  C	  polypeptide	  of	  Streptococcus	   35,	   before	   its	   cross-­‐reactivity	   with	   a	   	   wide	   range	   of	   antigens	   was	  subsequently	  demonstrated.	  It	  is	  predominantly	  produced	  by	  the	  liver	  and	  its	  short	  half-­‐life	  of	  only	  19	  hours	  makes	  it	  a	  very	  responsive	  tool	  in	  monitoring	  disease	  activity.	  	  	  In	   CD	  management,	   CRP	   has	   been	   shown	   to	   be	   useful	   in	   variety	   of	   contexts.	   	   At	   first	  presentation,	   an	  elevated	  CRP	  has	   some	  potential	   in	  making	  a	  differentiation	  between	  IBD	   and	   other	   functional	   bowel	   disorders36.	   It	   has	   very	   little	   accuracy	   however	   in	  differentiating	  IBD	  from	  other	  causes	  of	  colitis37.	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Several	   studies	   have	   been	   performed	   to	   assess	   the	   capacity	   of	   CRP	   to	   monitor	   disease	  activity.	   Some	   investigators	   have	  used	   the	  marker	   in	   parallel	  with	   a	   clinical	   activity	   score	  such	  as	  CDAI	  or	  HBI,	  and	  the	  correlation	  has	  been	  moderate	  at	  best	  (summarised	  in38).	  One	  explanation	   of	   this	   is	   that	   clinical	   indices	   are	   frequently	   elevated	  by	   functional	   symptoms	  and	  do	  not	  always	  represent	  increased	  inflammatory	  activity.	  	  	   Other	   studies	   have	   attempted	   to	   correlate	   CRP	   levels	   with	   a	   more	   objective	   marker	   of	  inflammation	   such	   as	   endoscopic	   activity,	   or	   radiological	   parameters,	   and	   the	   results	   are	  again	  very	  inconsistent.	  A	  typical	  result	  is	  from	  a	  study	  in	  Belgium,	  in	  which	  28	  consecutive	  patients	   with	   a	   high	   CDAI	   and	   normal	   CRP	   underwent	   colonoscopy,	   which	   demonstrated	  that	  92%	  had	   lesions	  on	  endoscopy,	  albeit	  predominantly	  mild39.	   In	  a	  similar	  study	  by	  the	  Mayo	   clinic	  on	  a	   larger	   cohort	  of	  104	  patients,	  62%	  of	  patients	  with	   raised	   clinical	   scores	  and	  a	  normal	  CRP	  had	  active	  disease	  on	  endoscopy40	  .	  These	  studies	  suggest	  a	  low	  sensitivity	  of	  CRP	  in	  predicting	  endoscopically	  active	  disease.	  	  	   More	  recently,	  studies	  have	  hinted	  towards	  a	  significant	  correlation	  between	  mesenteric	  fat	  hyperplasia	  on	  imaging	  and	  CRP	  levels.	  A	  group	  from	  France	  in	  a	  recently	  published	  	   series	  of	  elegant	  experiments	  confirmed	  that	  mesenteric	  adipocytes	  are	  a	  significant	  source	  of	  CRP	  in	   response	   to	   bacterial	   translocation	   and	   local	   cytokines41.	   This	   could	   potentially	   explain	  the	   discrepancies	   between	   CRP	   levels	   in	   CD	   and	   UC,	   as	   well	   as	   the	   variable	   correlations	  between	  mucosal	  activity	  and	  CRP	  levels.	  This	  study	  has	  opened	  a	  significant	  avenue	  of	  new	  research,	  to	  establish	  the	  significance	  of	  mesenteric	  fat	  involvement	  in	  triggering	  raised	  CRP	  levels	   in	  CD.	  However,	   at	   present,	   the	   frequency	  of	   the	  observed	  disconnect	  between	  CRP	  and	  endoscopic	  or	  radiological	  reference	  standards	  suggests	   that	   the	  marker	   is	  not	  robust	  enough	  to	  be	  used	  in	  isolation	  for	  the	  monitoring	  of	  activity.	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1.2.3 Faecal	  markers	  of	  activity	  
	  
	  
	   Faecal	  	  biomarkers	  	  have	  	  recently	  	  been	  	  introduced	  	  in	  	  the	  	  diagnosis	  	  and	  	  monitoring	  	  of	  	  IBD.	  These	   rely	   on	   the	   fact	   that	   in	   active	   IBD,	   there	   is	   a	   10-­‐-­‐-­‐fold	   increase	   in	  neutrophil	  migration	  towards	  	  the	  	  diseased	  	  intestinal	  	  wall	  	  and	  	  subsequent	  	  shedding	  	  into	  	  the	  	  lumen42.	  	  Faecal	  Calprotectin	  (FC),	  the	  most	  effective	  of	  these,	  was	  first	  isolated	  by	  Fagerhol	  in	  1980.	  It	  is	  one	  of	  	  the	  	  major	  	  components	  	  of	  	  neutrophils,	  	  accounting	  	   for	  	  more	  	   than	  	  60%	  	  of	  	  their	  	   total	  cytosolic	  	  	  protein,	  	  	  and	  	  	  has	  	  	  a	  	  	  role	  	  	  as	  	  	  one	  	  	  of	  	  	  the	  	  	  phagocytic	  	  	  S100	  	  	  proteins.	  	  	  These	  	  	  are	  endogenous	  	  molecules	  	  released	  	  by	  	  activated	  	  or	  	  damaged	  	  cells	  	  under	  	  conditions	  	  of	  	  cell	  stress43.	  As	  	  such,	   it	  	  can	  	  be	  	  obtained	  	  and	  	  measured	  	  in	  	  stool	   specimens	  	  from	  	  patients	  	  with	  	  a	  variety	  	  	  of	  	  	  intestinal	  	  	  inflammatory	  	  	  disorders	  	  	  including	  	  	  IBD,	  	  	  neoplastic	  	  	  conditions,	  	  	  GI	  infections	  and	  others.	  	   Its	  stability	  at	  room	  temperature	  for	  up	  to	  a	  week,	  small	   intra-­‐-­‐-­‐subject	  variability	  and	  its	  resistance	  to	  metabolism	  by	  gut	  microflora	  render	  it	  a	  suitable	  test	  from	  a	  practical	  perspective44.	  	  	   Tibble	  et	  al.	  produced	  the	  seminal	  paper	  on	  its	  use	  in	  IBD,	  demonstrating	  good	  correlation	  of	  FC	  with	   111Indium-­‐-­‐-­‐labeled	  white	   cell	   excretion	  over	  4	  days,	   and	   significant	  differences	   in	  FC	  concentrations	  	  between	  	  CD	  	  patients	  	  and	  	  normal	  	  subjects.	  	  	  The	  	  group	  	  went	  	  on	  	  to	  	  examine	  602	  consecutive	  patients	  with	  abdominal	  symptoms	  and	  found	  that	  a	  cut-­‐-­‐-­‐off	  of	  50µg/g	  has	  a	  sensitivity	  of	  89%	  and	  specificity	  of	  79%	  in	  detecting	  organic	  disease45.	  Several	  more	  studies	  placed	  its	  positive	  predictive	  value	  (PPV)	  and	  negative	  predictive	  value	  (NPV)	  in	  that	  context	  between	  	  70-­‐-­‐-­‐100%	  	  and	  	  70-­‐-­‐-­‐90%	  	  respectively,	  	  and	  	  in	  	  a	  	  large	  	  meta-­‐-­‐-­‐analysis	  	  which	  	  included	  over	  1200	   IBD	  patients	  and	  3300	  controls,	  a	  cut-­‐-­‐-­‐off	  value	  of	  100µg/g	  of	  stool	  was	  proposed	  as	  more	  optimal	  in	  differentiating	  IBD	  from	  IBS	  at	  first	  presentation46.	  	  	   Having	  successfully	  overcome	  the	  first	  hurdle	  of	  identifying	  IBD,	  FC	  was	  then	  assessed	  as	  a	  quantitative	  tool.	  Initially,	  the	  lack	  of	  correlation	  between	  FC	  and	  clinical	  scores,	  a	  	  	  common	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theme	  with	  most	  biomarkers,	  was	  demonstrated	  by	  a	  group	  from	  Finland,	  who	  reported	  that	  as	  many	  as	  56%	  of	  patients	   in	  clinical	  remission	  had	  a	  persistently	  elevated	  FC.	  A	  much	  better	  correlation	  with	  endoscopic	  and	  histologic	  scores	  severity	  was	  shown32.	  In	  addition,	   several	   studies	   have	   examined	   the	   role	   of	   FC	   in	   monitoring	   response	   to	  therapy	   in	   CD.	   The	   same	   research	   group	   reported	   significantly	   larger	   reductions	   in	  responders	  versus	  non-­‐responders	  in	  a	  small	  cohort	  (n=19)	  treated	  with	  corticosteroids	  and	  a	  group	  (n=15)	  treated	  with	  anti-­‐TNFα,	  findings	  which	  were	  corroborated	  by	  other	  studies47.	  	  While	  these	  demonstrate	  significant	  differences	  in	  FC	  levels	  before	  and	  after	  therapy	  in	  responders,	   they	   also	   reveal	   the	   biomarker’s	  main	  weaknesses	   in	  monitoring	   disease	  progress.	  Firstly,	  despite	  the	  significantly	  different	  post-­‐treatment	  values	  in	  responders,	  there	   is	   still	   a	   large	   inter-­‐subject	   variability,	   with	   several	   subjects	   in	   this	   cohort	  exceeding	   the	   threshold	   for	   remission,	   which	   in	   itself	   varies	   from	   study	   to	   study.	  Moreover,	   an	   unequivocal	   inferiority	   in	   the	   test’s	   accuracy	   in	   quantifying	   ileal	   versus	  colonic	   inflammation	   has	   also	   been	   demonstrated32.	   As	   ileal	   Crohn’s	   is	   mostly	  inaccessible	   to	   colonoscopic	   monitoring,	   it	   is	   the	   subset	   that	   is	   most	   in	   need	   of	   an	  alternative	  reliable	  biomarker,	  and	  these	  data	  suggest	  that	  FC	  is	   likely	  not	  sufficient	   in	  filling	  that	  gap	  in	  this	  subgroup.	  	  Lactoferrin	   is	   an	   iron-­‐binding	   protein	   also	   present	   in	   neutrophil	   cytoplasm,	   which	  appears	   to	   have	   bacteriostatic	   properties48.	   Increased	   concentrations	   of	   faecal	  lactoferrin	   (FL)	   in	   stool	   samples	   was	   first	   demonstrated	   in	   relation	   to	   shigellosis	   49.	  Similar	  to	  FC,	  several	  studies	  have	  since	  appeared	  that	  demonstrate	  the	  ability	  of	  FL	  to	  differentiate	   between	   IBD	   and	   functional	   bowel	   disease	   50–52.	   Moreover,	   FL	   has	   also	  demonstrated	  significant	  correlations	  with	  clinical,	  endoscopic,	  and	  histologic	  markers	  of	  disease	  severity	  (reviewed	  in	  53).	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Studies	  examining	  FC	  and	  FL	  show	  comparable	  diagnostic	  accuracy	  and	  disease	   monitoring	  potential	   for	  the	  two	  markers	  54.	  As	  FC	  has	  been	  more	  extensively	   investigated	  it	  has	  been	  preferentially	   adopted	   in	   clinical	   guideline	   protocols	   pending	   larger	   studies	   comparing	  directly	  these	  and	  other	  newer	  faecal	  markers.	  	  	  
1.2.4 Endoscopic	  Assessment	  
	  
	  
	   Ileo-­‐-­‐-­‐colonoscopy	   and	   biopsy	   has	   been	   a	   long	   established	   diagnostic	   and	   assessment	   tool	   in	  the	  	  management	  	  of	  	  CD55.	  	  25	  	  years	  	  ago	  	  the	  	  CDEIS	  	  score	  	  was	  	  put	  	  forward	  	  by	  	  the	  	  GETAID	  group	   in	  an	  attempt	   to	  standardise	  endoscopic	  reporting,	  and	   introduce	   it	  as	  an	  endpoint	   in	  clinical	  	  trials56.	  	  Initial	  	  uptake	  	  of	  	  CDEIS	  	  was	  	  significant,	  	  but	  	  following	  	  some	  	  criticism	  	  on	  	  its	  reproducibility,	  	  	  	  other	  	  	  	  more	  	  	  	  simplified	  	  	  	  indices	  	  	  	  were	  	  	  	  proposed57.	  	  	  	  Currently,	  	  	  	  formal	  endoscopic	  scoring	  systems	  are	  not	  widely	  used	  outside	  a	  clinical	  trial	  context.	  	  	   More	  	  recently,	  	  mucosal	  	  healing	  	  (MH)	  	  has	  	  been	  	  described	  	  by	  	  several	  	  studies	  	  as	  	  a	  	  robust	  surrogate	  marker	  of	  successful	  therapy.	  It	  was	  first	  proposed	  a	  decade	  ago	  as	  a	  new	  marker	  of	  	  	  efficacy	  	  	  in	  	  	  scheduled	  	  	  anti-­‐-­‐-­‐TNF	  	  	  therapy58.	  	  	  Several	  	  	  large	  	  	  studies	  	  	  assessed	  	  	  it	  	  	  both	  retrospectively,	  prior	  to	  the	  anti-­‐-­‐-­‐TNF	  era59	  	  as	  well	  as	  prospectively	  in	  the	  setting	  of	  anti	  TNF	  therapy19,60,61	  	  ,62.	  All	  these	  studies	  converge	  on	  the	  conclusion	  that	  MH	  is	  a	  very	  powerful	  tool	  in	  	  assessing	  	  response	  	  to	  	  treatment,	  	  and,	  	  to	  	  that	  	  end,	  	  it	  	  has	  	  acted	  	  as	  	  a	  	  benchmark	  	  for	  	  the	  validation	  of	  several	  other	  disease	  assessment	  instruments	  mainly	  from	  the	  field	  of	  imaging.	  	  	   As	  	  compelling	  	  as	  	  the	  	  evidence	  	  in	  	  support	  	  of	  	  MH	  	  may	  	  be,	  	  there	  	  are	  	  three	  	  major	  	  limitations	  preventing	  	  it	  	  from	  	  standing	  	  alone	  	  as	  	  a	  	  gold-­‐-­‐-­‐standard	  	  reference	  	  in	  	  the	  	  monitoring	  	  of	  	  CD.	  Firstly,	  most	  of	   the	   small	  bowel	   is	  beyond	   the	   reach	  of	  a	   conventional	   colonoscope,	  while	   it	  very	  	  often	  	  harbours	  	  the	  	  majority	  	  of	  	  disease	  	  bulk.	  	  Moreover,	  	  in	  	  cases	  	  of	  	  stricturing	  	  disease	  within	  the	  colon	  or	   ileo-­‐-­‐-­‐caecum,	  proximal	  segments,	  which	  are	  normally	  within	  range,	  may	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be	  	  inaccessible	  	  to	  	  endoscopic	  	  assessment.	  	  Secondly,	  	  a	  	  key	  	  pathologic	  	  hallmark	  	  of	  	  CD	  	  is	  	  its	  trans-­‐-­‐-­‐mural	  	  	  nature,	  	  	  and	  	  	  indeed	  	  	  several	  	  	  characteristics	  	  	  such	  	  	  as	  	  	  oedema,	  	  	  fibrosis	  	  	  and	  fistulisation	  	  involve	  	  deeper	  	  layers	  	  on	  	  which	  	  colonoscopy	  	  cannot	  	  inform63.	  	  Finally,	  	  poor	  patient	  	  tolerability	  	  is	  	  another	  	  major	  	  drawback	  	  that	  	  limits	  	  the	  	  role	  	  of	  	  colonoscopy	  	  as	  	  a	  monitoring	  instrument.	  
1.2.5 Imaging	  
1.2.5.1 Traditional	  Imaging	  –	  Barium	  studies	  
Small	   bowel	   follow	   through	   (SBFT)	   following	   ingestion	  of	   a	   barium	  meal,	   or	   enteroclysis	   of	  barium	  and	  air,	  have	  been	  the	  mainstay	  of	  small	  bowel	  assessment	  in	  CD	  for	  several	  decades.	  Excellent	  	  visualisation	  	  of	  	  the	  	  bowel	  	  mucosa	  	  is	  	  achieved.	  	  Moreover,	  	  the	  	  relative	  	  position	  	  of	  bowel	  loops	  can	  also	  provide	  some	  limited	  information	  on	  mesenteric	  changes,	  although	  the	  latter	  	  cannot	  	  be	  	  directly	  	  observed64.	  	  In	  	  recent	  	  years	  	  however,	  	  newer	  	  techniques	  	  such	  	  as	  computerized	  	   tomography	  	  (CT)	  	  and	  	  magnetic	  	  resonance	  	   imaging	  	  (MRI)	  	  have	  	  gradually	  superseded	  	  	  	  barium	  	  	  	  studies,	  	  	  	  mainly	  	  	  	  due	  	  	  	  to	  	  	  	  their	  	  	  	  higher	  	  	  	  sensitivity	  	  	  	  extra-­‐-­‐-­‐luminal	  complications	  such	  as	  abscesses	  and	  fistulae65,66
1.2.5.2 Magnetic	  Resonance	  Imaging	  
Magnetic	  Resonance	  Imaging	  (MRI)	  has	  gradually	  been	  introduced	  as	  an	  assessment	  tool	  in	  Crohn’s	  disease	  over	  the	   last	  20	  years67,68.	   It	  rapidly	  gained	  popularity	  and	   found	  a	  role	   in	  clinical	   practice,	   due	   to	   its	   two	   obvious	   major	   advantages	   over	   	   competing	   imaging	  modalities	   such	  as	  CT	  and	  SBFT.	  Firstly,	   it	  does	  not	   involve	   ionising	   radiation,	  which	   is	  of	  vital	  	  	  importance	  	  	  in	  	  	  young	  	  	  patient	  	  	  cohorts	  	  	  with	  	  	  chronic	  	  	  illness	  	  	  requiring	  	  	   recurrent	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assessments.	  	  Secondly,	  	  it	  	  has	  	  the	  	  potential	  	  of	  	  providing	  	  information	  	  on	  	  the	  	  entirety	  	  of	  	  the	  bowel	  wall	  thickness,	  as	  well	  as	  mesenteric	  and	  extra-­‐-­‐-­‐intestinal	  tissues	  in	  one	  sitting.	  
Initial	  	  	  studies	  	  	  examined	  	  	  the	  	  	  modality’s	  	  	  accuracy	  	  	  in	  	  	  segments	  	  	  previously	  	  	  identified	  	  	  as	  diseased,	  	  and	  	   looked	  	  at	  	  correlations	  	  between	  	  MRI	  	  and	  	  other	  	  clinical,	  	  pathological	  	  and	  endoscopic	  	  	  markers	  	  	  of	  	  	  disease.	  	  	  One	  	  	  of	  	  	  the	  	  	  first	  	  	  such	  	  	  studies	  	  	  was	  	  	  by	  	  	  Koh	  	  	  et	  	  	  al.	  	  	  who	  investigated	  23	  patients	  with	  active	  and	  7	  patients	  with	  quiescent	  disease	  and	  demonstrated	  a	  	  	  ‘per	  	  	  patient’	  	  	  sensitivity	  	  	  and	  	  	  specificity	  	  	  values	  	  	  of	  	  	  91%	  	  	  and	  	  	  71%	  	  	  respectively	  	  	  when	  compared	  	  	  	  to	  	  	  	  an	  	  	  	  endoscopic	  	  	  	  or	  	  	  	  a	  	  	  	  histo-­‐-­‐-­‐pathological	  	  	  	  reference.	  	  	  The	  	  	  	  sensitivity	  	  	  	  was	  significantly	  	  lower	  	  on	  	  a	  	  ‘per	  	  segment’	  	  analysis	  	  at	  	  59%.	  	  This	  	  study	  	  described	  	  bowel	  	  wall	  thickness	  	  	  over	  	  	  4mm,	  	  	  bowel	  	  	  wall	  	  	  hyper-­‐-­‐-­‐enhancement	  	  	  and	  	  	  focal	  	  	  mesenteric	  	  	  vascularity	  (Comb	  sign)	  as	  distinguishing	  factors	  between	  normal	  and	  diseased	  bowel	  69.	  These	  findings	  were	  subsequently	  replicated	  by	  other	  groups:	  
Ajaj	  W	   et	   al.	   focused	  on	   colonic	   segments	   in	   23	  patients	  with	   IBD	   and	  15	   controls	   having	  endoscopic	  and	  histological	  assessment.	  They	  demonstrated	   that	  simultaneously	  assessing	  bowel	  wall	  thickness	  and	  enhancement,	  loss	  of	  mucosal	  haustrations	  and	  mesenteric	  lymph	  node	  enlargement	  can	  identify	  abnormal	  segments	  with	  a	  sensitivity	  of	  87%	  and	  specificity	  of	  100%.	  These	  observations	  have	  not	  yet	  been	  externally	  validated70.	  
A	  sound	  argument	  was	  subsequently	  put	  forward	  that	  since	  MRI	  is	  capable	  of	  visualising	  the	  whole	  	  thickness	  	  of	  	  the	  	  bowel	  	  wall,	  	  or	  	  even	  	  beyond	  	  it,	  	  an	  	  endoscopic	  	  reference	  	  standard	  	  is	  not	  	  an	  	  adequate	  	  benchmark	  	  for	  	  the	  	  assessment	  	  of	  	  its	  	  performance.	  	  On	  	  that	  	  basis,	  	  three	  studies	  	  	  from	  	  	  London,	  	  	  Paris	  	  	  and	  	  	  Amsterdam	  	  	  published	  	  	  a	  	  	  more	  	  	  robust	  	  	  methodology	  	  	  of	  assessing	  MRI	   endpoints	  which	   involved	   their	   correlation	   to	   full-­‐-­‐-­‐thickness	  histopathological	  indices,	  obtained	  on	  surgical	  resection	  specimens	  from	  patients	  with	  CD71–73.	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The	  	  first	  	  such	  	  study,	  	  produced	  	  by	  	  the	  	  University	  	  College	  	  London	  	  group71	  	  	  prospectively	  examined	  	  18	  	  consecutive	  	  	  	  	  CD	  	  patients	  	  with	  	  MRI,	  	  prior	  	  to	  	  scheduled	  	  resective	  	  surgery.	  Resected	   specimens	   were	   re-­‐-­‐-­‐imaged	   ex	   vivo,	   to	   facilitate	   precise	   co-­‐-­‐-­‐localisation	   of	   recorded	  radiological	  	  features	  	  and	  	  histo-­‐-­‐-­‐pathological	  	  scoring	  	  of	  	  activity.	  	  Important	  	  findings	  	  of	  	  this	  study	  	  include	  	  a	  	  significant	  	  correlation	  	  between	  	  bowel	  	  wall	  	  thickness	  	  as	  	  well	  	  as	  	  a	  	  mural	  signal	   intensity	  on	  fat-­‐-­‐-­‐suppressed	  T2	  	  images	  (proposed	  to	  represent	  mural	  oedema),	  and	  the	  acute	   inflammatory	   score	   (AIS),	  which	  quantifies	   elements	   such	   as	  mucosal	  ulceration,	  wall	  oedema	  	  and	  	  neutrophilic	  	   infiltration	  	  across	  	   the	  	  whole	  	   thickness	  	  of	  	   the	  	  bowel	  	  wall.	  	   In	  addition,	  	  a	  	  layered	  	  pattern	  	  of	  	  mural	  	  enhancement,	  	  seen	  	  in	  	  segments	  	  with	  	  the	  	  highest	  	  AIS,	  was	  	  contrasted	  	  to	  	  a	  	  limited	  	  mucosal	  	  contrast	  	  enhancement	  	  or	  	  homogeneous	  	  uptake	  	  of	  	  the	  intravenous	  	  gadolinium,	  	  observed	  	  in	  	  segments	  	  with	  	  lower	  	  inflammatory	  	  activity.	  	  Layered	  enhancement	  	  was	  	  also	  	  the	  	  only	  	  marker	  	  associated	  	  with	  	  fibrostenosis	  	  in	  	  this	  	  cohort,	  	  which	  reflects	  	  an	  	  increasingly	  	  prevalent	  	  hypothesis	  	  that	  	  the	  	  two	  	  entities	  	  of	  	  inflammation	  	  and	  fibrosis	  	  co-­‐-­‐-­‐exist	  	  in	  	  the	  	  most	  	  severe	  	  of	  	  lesions,	   rather	  	  than	  	  occurring	  	  independently	  	  of	  	  each	  other.	  
Zappa	  et	  al.	  published	  a	  similar	  study	  correlating	  MRI	  features	  with	  semi-­‐-­‐-­‐quantitative	  scores	  of	  	  inflammation	  	  and	  	  fibrosis	  	  performed	  	  on	  	  resected	  	  intestinal	  	  specimens	  	  on	  	  53	  	  patients.	  Each	  segment	  was	  classified	  as	  containing	  no	  or	  mild,	  moderate,	  or	  severe	  inflammation	  and	  fibrosis	   respectively.	   Interestingly,	   there	  was	   a	   good	   correlation	   between	   the	   inflammatory	  and	  	  fibrosis	  	  scores	  	  in	  	  each	  	  patient	  	  (r=0.63	  	  p=0.0001),	  	  supporting	  	  the	  	  above	  	  hypothesis.	  Several	  	  significant	  	  correlations	  	  between	  	  MR	  	  markers	  	  and	  	  histo-­‐-­‐-­‐pathologic	  	  parameters	  	  of	  inflammation	  	  	  were	  	  	  demonstrated,	  	  	  including	  	  	  bowel	  	  	  wall	  	  	  thickness,	  	  	  retained	  	  	  contrast	  enhancement	  	  in	  	  the	  	  delayed	  	  phase,	  	  layered	  	  enhancement	  	  in	  	  the	  	  early	  	  phase	  	  and	  	  mural	  oedema	  	  on	  	  T2	  	  	  (exclusively	  	  seen	  	  at	  	  the	  	  severe	  	  end	  	  of	  	  the	  	  inflammation	  	  spectrum).	  	  MRI	  features	  associated	  with	  fibrostenosis	  were	  bowel	  thickness,	  blurred	  wall	  enhancement,	  and	  mural	  	  	  	  oedema	  	  	  	  on	  	  	  	  T2	  	  	  	  	  (also	  	  	  	  seen	  	  	  	  exclusively	  	  	  	  in	  	  	  	  severe	  	  	  	  fibrostenosis).	  	  	  	  In	  	  	  	  addition,	  
28	  	  
extraintestinal	  findings	  including	  mesenteric	  hypervascularity,	  abscesses	  and	  fistulae	  were	  also	   independent	   predictors	   of	   severe	   inflammation,	   the	   latter	   also	   being	   associated	  with	  fibrosis72.	  	  	   Finally,	  	  a	  	  group	  	  from	  	  Amsterdam	  	  retrospectively	  	  examined	  	  MRI	  	  data	  	  on	  	  39	  	  segments	  	  (25	  patients),	  	  which	  	  had	  	  been	  	  scored	  	  using	  	  the	  	  AIS.	  	  Photographs	  	  of	  	  resected	  	  specimens	  	  were	  used	  to	  co-­‐-­‐-­‐localise	  the	  histo-­‐-­‐-­‐pathological	  findings	  to	  the	  MRI	  images.	  	  Once	  again,	  bowel	  wall	  thickness	  was	   correlated	  with	  AIS.	   In	   contrast	   to	   other	  published	  work	  however,	   endpoints	  such	  	  as	  	  maximal	  	  bowel	  	  wall	  	  enhancement,	  	  enhancement	  	  layering,	  	  mural	  	  oedema	  	  and	  	  the	  presence	  of	  ulcerations	  did	  not	  reach	  statistical	  significance	  73.	  	  	   In	  summary,	  these	  three	  studies	  by	  Punwani,	  Zappa	  and	  Ziech	  converged	  on	  bowel	  thickness	  as	  	  	  	  the	  	  	  	  most	  	  	  	  important	  	  	  	  marker	  	  	  	  of	  	  	  	  inflammation.	  	  	  	  Mural	  	  	  	  oedema	  	  	  	  and	  	  	  	  layered	  	  	  	  wall	  enhancement	  	  only	  	  reached	  	  statistical	  	  significance	  	  in	  	  two	  	  of	  	  the	  	  three	  	  studies.	  	  Predictors	  	  of	  fibrostenosis	  	  were	  	  less	  	  consistent,	  	  with	  	  one	  	  study	  	  which	  	  assessed	  	  these	  	  proposing	  	  layered	  enhancement	  	  and	  	  the	  	  other	  	  bowel	  	  wall	  	  thickness	  	  and	  	  mural	  	  oedema.	  	  Interestingly,	  	  pre-­‐-­‐-­‐	  stenotic	  	  dilatation	  	  empirically	  	  believed	  	  to	  	  signify	  	  the	  	  presence	  	  of	  	  fibrostenosis	  	  in	  	  clinical	  practice,	  did	  not	  correlate	  to	  the	  degree	  of	  fibrosis	  observed	  within	  pathological	  specimens.	  	  	   As	  	  investigators	  	  strived	  	  to	  	  obtain	  	  maximal	  	  benefit	  	  from	  	  these	  	  various	  	  observations	  	  on	  	  the	  relative	  	  weighting	  	  of	  	  each	  	  individual	  	  endpoint	  	  in	  	  reflecting	  	  the	  	  inflammatory	  	  burden,	  	  they	  started	  	  organising	  	  them	  	  together,	  	  by	  	  applying	  	  statistical	  	  modelling,	  	  in	  	  order	  	  to	  	  construct	  quantitative	  	  scores.	  	  These	  	  can	  	  aid	  	  in	  	  the	  	  better	  	  characterisation	  	  of	  	  disease	  	  burden	  	  at	  	  a	  particular	   time-­‐-­‐-­‐point,	   but	   also	   in	   the	  monitoring	   of	   the	   therapeutic	   effects	   of	   various	   drugs	  either	  in	  clinical	  practice	  or	  in	  the	  field	  of	  drug	  development.	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The	  	  most	  	  thoroughly	  	  validated	  	  score	  	  is	  	  the	  	  Magnetic	  	  Resonance	  	  Index	  	  of	  	  Activity	  	  (MaRIA),	  introduced	  	  by	  	  the	  	  Barcelona	  	  group	  	  in	  	  2009.	  	  50	  	  patients	  	  with	  	  known	  	  CD	  	  underwent	  	  ileo-­‐-­‐-­‐	  colonoscopy	  	  	  and	  	  	  estimation	  	  	  of	  	  	  segmental	  	  	  as	  	  	  well	  	  	  as	  	  	  global	  	  	  CDEIS	  	  	  as	  	  	  a	  	  	  reference	  investigation.	  Of	   the	  213	  segments	  examined	  endoscopically,	  130	  were	  normal,	  43	  had	  mild	  lesions	  and	  40	  contained	  superficial	  or	  deep	  ulcers.	  	  	  This	  was	  compared	  to	  T2	  	  weighted	  and	  pre	   and	   post	   contrast	   T1	  	  weighted	  MR	   sequences,	   obtained	  within	   24	   hours.	   Binary	   logistic	  regression	  	  	  was	  	  	  used	  	  	  to	  	  	  identify	  	  	  the	  	  	  MR	  	  	  parameters	  	  	  that	  	  	  correlated	  	  	  independently	  	  	  to	  endoscopic	   findings.	  The	  model	   revealed	   that	  wall	   thickness,	   relative	   contrast	  enhancement	  (RCE)	  and	  identification	  of	  ulcers	  at	  MRI	  were	  all	  independent	  predictors	  of	  finding	  ulcers	  at	  endoscopy.	   In	   terms	  of	  predicting	   the	  CDEIS,	   bowel	  wall	   oedema	  on	  T2	  	  weighted	   sequences	  was	  	  	  added	  	  	  to	  	  	  the	  	  	  above	  	  	  three	  	  	  parameters.	  	  	  The	  	  	  resultant	  	  	  MaRIA	  	  	  index	  	  	  had	  	  	  a	  	  	  highly	  significant	  	  correlation	  	  with	  	  both	  	  segmental	  	  (r=0.81)	  	  and	  	  global	  	  CDEIS	  	  (r=0.78)	  	  as	  	  well	  	  as	  HBI	  	  (r=0.56)	  	  and	  	  CRP	  	  (r=0.42)74.	  	  The	  	  same	  	  group	  	  successfully	  	  validated	  	  this	  	  score	  	  in	  	  an	  independent	  cohort	  of	  48	  patients	  with	  very	  similar	  results75.	  	  	   Taking	  	  into	  	  account	  	  both	  	  these	  	  well-­‐-­‐-­‐designed	  	  studies	  	  there	  	  is	  	  little	  	  doubt	  	  that	  	  the	  	  MaRIA	  score	  	  can	  	  accurately	  	  reflect	  	  the	  	  state	  	  of	  	  the	  	  mucosa	  	  in	  	  direct	  	  comparison	  	  to	  	  endoscopic	  scoring,	  and	   it	  could	  potentially	  replace	  endoscopic	  examinations	  to	  assess	  mucosal	  activity.	  One	  	  major	  	  criticism	  	  of	  	  this	  	  method,	  	  however,	  	  is	  	  that	  	  it	  	  excludes	  	  findings	  	  which	  	  are	  	  well	  within	  	  the	  	  scope	  	  of	  	  MR	  	  imaging,	  	  though	  	  not	  	  directly	  	  linked	  	  to	  	  mucosal	  	  disease.	  	  By	  	  its	  	  very	  nature	  	  Crohn’s	  	  is	  	  a	  	  transmural	  	  process	  	  and,	  	  often,	  	  the	  	  condition	  	  of	  	  the	  	  mucosa	  	  does	  	  not	  reflect	   the	  	  disease	  	  burden	  	  in	  	  deeper	  	  layers.	  On	  	  the	  	  other	  	  hand,	   there	  	  is	  	  evidence	  	  that	  deep	  bowel	  layers	  can	  themselves	  act	  as	  drivers	  of	  the	  inflammatory	  process	  independently	  of	  the	  epithelial	  activity76	  	  and,	  moreover,	   they	  certainly	  contain	  targets	   for	  effective	  therapies	  such	  as	   anti-­‐-­‐-­‐TNF	   biologics77.	  Markers	   such	   as	   perimural	   oedema,	  mesenteric	   vascularity,	   fistulae	  and	  	  lymph	  	  nodes	  	  are	  	  readily	  	  identifiable	  	  on	  	  MR	  	  sequences	  	  and,	  	  in	  	  combination	  	  with	  	  the	  mucosal	  	  markers,	  	  can	  	  provide	  	  a	  	  more	  	  global	  	  overview	  	  of	  	  disease	  	  burden	  	  and	  	  intestinal	  
30	  	  
damage	  that	  MaRIA	  does	  in	  isolation.	  Furthermore,	  a	  careful	  look	  at	  the	  MaRIA	  score	  makes	  is	  obvious	  that	  disease	  extent	  does	  not	  feature	  as	  one	  of	  the	  parameters.	  There	  is	  evidence,	  however,	  that	  the	  length	  of	  affected	  bowel	  has	  considerable	  bearing	  on	  long	  term	  morbidity	  associated	  with	  CD78.	  An	  alternative	  score,	  therefore,	  which	  incorporates	  features	  across	  the	  bowel	   thickness	   as	  well	   as	   on	   disease	   extent	   could	   be	  more	   representative	   of	   the	   overall	  disease	  burden	  and	  act	  as	  a	  better	  benchmark	  for	  therapeutic	  monitoring.	  	  	   Makanyanga	  	  et	  	  al.	  	  recently	  	  published	  	  a	  	  study	  	  on	  	  the	  	  significantly	  	  more	  	  inclusive	  	  Magnetic	  Enterography	  	  Global	  	  Score	  	  (MEGS).	  	  MEGS	  	  was	  	  produced	  	  by	  	  the	  	  expansion	  	  of	  	  MRI	  	  Crohn’s	  Disease	  	  Activity	  	  Score	  	  (CDAS)	  	  produced	  	  by	  	  the	  	  same	  	  group,	  	  which	  	  had	  	  been	  	  validated	  against	  histology79.	   It	   assesses	  wall	   thickness,	  T2	  	  signal,	  peri-­‐-­‐-­‐mural	  mesenteric	  oedema,	  post	  contrast	  T1	  	  enhancement	   level	  and	  pattern,	  colonic	  haustral	   loss	  as	  well	  as	   length	  of	  disease	  in	  each	  segment.	  Fistulae,	  lymphadenopathy,	  comb	  sign	  and	  abscesses	  are	  also	  evaluated.	  71	  patients	  	  were	  	  assessed	  	  using	  	  MEGS,	  	  which	  	  was	  	  compared	  	  to	  	  FC,	  	  CRP	  	  and	  	  HBI,	  	  showing	  	  a	  positive	  	  correlation	  	  with	  	  the	  	  first	  	  two	  	  (r=46	  	  p<0.001,	  	  r=0.39	  	  p=0.002	  	  respectively).	  	  MEGS	  incorporates	  	  	  a	  	  	  variety	  	  	  of	  	  	  non-­‐-­‐-­‐mucosal	  	  	  factors	  	  	  including	  	  	  peri-­‐-­‐-­‐mural	  	  	  and	  	  	  extra-­‐-­‐-­‐enteric	  complications	  which	  partially	   justifies	   the	   lack	  of	   attempted	   correlation	  with	   an	   endoscopic	  gold	  standard.	  Had	  this	  been	  demonstrated,	  however,	  it	  would	  further	  strengthen	  its	  validity	  as	   a	  marker	  of	   inflammatory	  burden.	   In	   contrast	   to	   the	  MaRIA,	  which	  probably	   attempts	   to	  substitute	  	  endoscopy	  	  in	  	  the	  	  monitoring	  	  of	  	  CD	  	  patients,	  	  an	  	  absolute	  	  indication	  	  for	  	  MEGS	  	  is	  not	  directly	  obvious,	  but	  intuitively	  it	  is	  more	  relevant	  to	  the	  newly	  proposed	  natural	  history	  paradigm	  	  of	  	  accumulating	  	  bowel	  	  damage80.	  	  Once	  	  it	  	  has	  	  undergone	  	  external	  	  validation,	  	  it	  could	  potentially	  serve	  as	  a	  tool	  to	  trace	  its	  progression	  or	  regression	  in	  response	  to	  disease-­‐-­‐-­‐	  modifying	  therapy.	  	  	   In	  addition	   to	   the	  various	  MRI	  endpoints	  described	  above,	  novel	  endpoints	  of	   inflammatory	  activity	  such	  as	  assessment	  of	  small	  bowel	  motility,	  dynamic	  contrast-­‐-­‐-­‐enhanced	  (DCE)	  MRI	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and	  	  	  	  diffusion-­‐-­‐-­‐weighted	  	  	  	  imaging	  	  	  	  (DWI)	  	  	  	  have	  	  	  	  also	  	  	  	  been	  	  	  	  investigated	  	  	  	  as	  	  	  	  markers	  	  	  	  of	  inflammatory	  activity	  in	  CD.	  	  	   Small	  bowel	  motility	  can	  be	  assessed	  and	  quantified	  by	  MRI	  using	  dynamic	   ‘cine’	   sequences	  and	  	  	  	  appropriate	  	  	  	  software.	  	  	  	  Briefly,	  	  	  	  an	  	  	  	  optic	  	  	  	  flow	  	  	  	  registration	  	  	  	  algorithm	  	  	  	  estimates	  deformation	  	  of	  	  each	  	  frame	  	  of	  	  a	  	  given	  	  cine	  	  loop	  	  relative	  	  to	  	  an	  	  initial	  	  target	  	  frame.	  	  The	  standard	  	  deviation	  	  of	  	  the	  	  Jacobian	  	  determinant	  	  of	  	  this	  	  deformation	  	  acts	  	  as	  	  a	  	  measure	  	  of	  intestinal	  	  motility,	  	  and	  	  it	  	  is	  	  expressed	  	  in	  	  arbitrary	  	  units	  	  (AU).	  	  The	  	  first	  	  report	  	  correlating	  motility	  	  with	  	  histological	  	   inflammation	  	  was	  	  published	  	   in	  	  2012	  	  by	  	   the	  	  UCL	  	  group.	  	  The	  hypothesis	  was	   that	  diseased	  bowel	  motility	   is	   reduced	  due	   to	   the	  effect	  of	   fibrosis,	   chronic	  inflammatory	  	  cellular	  	  infiltrate	  	  and	  	  perhaps	  	  myenteric	  	  plexitis,	  	  commonly	  	  seen	  	  in	  	  small	  bowel	  resection	  specimens81.	  The	  authors	  reported	  on	  28	  patients	  with	  known	  terminal	  ileal	  disease	  who	  underwent	   ileoscopy	  and	  biopsy,	   scored	  using	   the	  AIS,	  as	  well	  as	  MRI	  within	  4	  days.	  	  A	  	  significant	  	  difference	  	  in	  	  the	  	  motility	  	  indices	  	  in	  	  inflamed	  	  and	  	  un-­‐-­‐-­‐inflamed	  	  TIs	  	  were	  demonstrated	  	  (p=0.002)	  	  as	  	  well	  	  as	  	  a	  	  moderate	  	  negative	  	  correlation	  	  between	  	  AIS	  	  and	  	  the	  motility	  	  index	  	  (r=-­‐-­‐-­‐0.57)82.	  	  These	  	  results	  	  were	  	  corroborated	  	  by	  	  a	  	  very	  	  similar	  	  study	  	  from	  Switzerland	  published	  a	  year	   later83.	  More	  recently,	   reproducibility	  data	  on	  MRI-­‐-­‐-­‐determined	  small	   bowel	  motility	   in	   20	   healthy	   volunteers	   demonstrated	  wide	   inter-­‐-­‐-­‐segmental	   variation	  and	  	  poor	  	  repeatability	  	  over	  	  a	  	  four-­‐-­‐-­‐week	  	  interval.	  	  The	  	  significance	  	  of	  	  this	  	  in	  	  small	  	  bowel	  segments	  affected	  by	  CD	  however	  is	  still	  unknown	  but	  it	  suggests	  a	  possible	  limitation	  of	  the	  method84.	  	  	   DCE	  MRI	  is	  a	  tool	  that	  assesses	  perfusion,	  by	  measuring	  the	  rate	  as	  well	  as	  the	  magnitude	  of	  relative	   contrast	   uptake	   by	   various	   tissues.	   The	   rationale	   behind	   its	   application	   in	  inflammatory	   imaging	   is	   that	   chronic	   inflammation	   is	   typically	   associated	   with	   various	  degrees	  of	  angiogenesis.	  Angiogenesis,	  the	  process	  of	  new	  capillary	  formation	  from	  existing	  vasculature,	   has	   been	   shown	   to	   be	   a	   central	   process	   in	   a	   range	   of	   chronic	   inflammatory	  
32	  	  
conditions	   such	   as	   psoriasis,	   rheumatoid	   arthritis,	   atherosclerosis	   etc85.	   Proposed	   functions	  for	  	  	  this	  	  	  altered	  	  	  microvasculature	  	  	  in	  	  	  the	  	  	  immune	  	  	  process	  	  	  are	  	  	  the	  	  	  increased	  	  	  influx	  	  	  of	  inflammatory	  	  cells,	  	  enhanced	  	  nutrient	  	  supply	  	  to	  	  a	  	  metabolically	  	  active	  	  tissue	  	  and	  	  local	  production	  	  	  of	  	  	  cytokines	  	  	  and	  	  	  other	  	  	  pro-­‐-­‐-­‐inflammatory	  	  	  molecules	  	  	   through	  	  	  endothelial	  activation	  86,87.	  	  	   The	   evidence	   base	   on	   aberrations	   in	   the	   microvasculature	   of	   IBD	   tissue	   is	   scarce	   and	  equivocal.	  On	  the	  one	  hand,	  there	  are	  investigators	  which	  suggest	  there	  is	  relative	  reduction	  in	   perfusion	   in	   segments	   with	   active	   CD	   as	   assessed	   by	   various	   techniques	   such	   as	  endoscopic	   or	   intraoperative	   Doppler	   88,89,	   or	   paucity	   in	   end	   vessels90.	   Other	   studies	  demonstrate	   increased	  blood	   flow	   in	  active	   tissue91.	  A	  group	   from	  Cleveland	  carried	  out	  a	  comprehensive	   study	   on	   microvascular	   changes	   in	   IBD.	   They	   demonstrated	   increased	  microvascular	   density	   (MVD)	   through	   immunohistochemical	   expression	   of	   the	   CD31	   and	  von	   Willebrand/factor	   VIII	   markers	   of	   endothelium	   in	   8	   control	   and	   17	   IBD	   colonic	  specimens.	   Moreover,	   CD31+ve	   capillaries	   were	   shown	   to	   express	   αVβ3,	   a	   	   specific	  endothelial	  marker	  of	  angiogenic	  endothelium92	  	  	   In	  	  another	  	   landmark	  	  study	  	  Taylor	  	  et	  	  al.	  	  recruited	  	  11	  	  patients	  	  scheduled	  	   for	  	   intestinal	  resection,	  	  	  	  	  who	  	  	  	  	  underwent	  	  	  	  	  prospective	  	  	  	  	  DCE	  	  	  	  	  imaging	  	  	  	  	  of	  	  	  	  	  the	  	  	  	  	  relevant	  	  	  	  	  segment.	  Histopathological	  	  assessment	  	  included	  	  quantification	  	  of	  	  vascular	  	  elements	  	  using	  	  a	  	  CD34	  ligand,	  	  as	  	  well	  	  as	  	  the	  	  estimation	  	  of	  	  AIS.	  	  The	  	  authors	  	  demonstrate	  	  significant	  	  differences	  	  in	  the	  DCE	  parameters	   in	  normal	  versus	  abnormal	  regions	  of	   interests.	  Surprisingly,	   there	  was	  a	  	  strong	  	  negative	  	  correlation	  	  between	  	  the	  	  MVD	  	  and	  	  the	  	  slope	  	  of	  	  enhancement	  	  (r=-­‐-­‐-­‐0.86),	  which	  	  the	  	  authors	  	  justified	  	  by	  	  the	  	  hypothesis	  	  of	  	  predominant	  	  ischaemia	  	  in	  	  CD,	  	  i.e.	  	  MVD	  occurs	   in	  response	   to	   limited	   tissue	   flow	  secondary	   to	  arteriolar	  stenosis.	  None	  of	   the	  other	  DCE	  	  endpoints	  	  correlated	  	  to	  	  any	  	  of	  	  the	  	  histopathological	  	  markers	  	  of	  	  vascular	  	  density	  	  or	  inflammation93.	  
33	  	  
	   Despite	  these	  uncertainties	  in	  the	  pathophysiology	  of	  the	  haemodynamics	  in	  diseased	  tissue,	  and	  a	  knowledge	  gap	  concerning	  the	  relative	  significance	  of	   increased	  MVD	  on	  the	  one	  hand	  and	  probable	   reduced	  perfusion	   at	   the	  pre-­‐-­‐-­‐capillary	   level	   on	   the	   other,	   several	   groups	  have	  taken	   the	  step	   to	  evaluate	  DCE	  endpoints	  as	  a	  quantitative	  assessment	   tool	   in	  patients	  with	  Crohn’s	  disease.	  	  	   Most	  	  of	  	  the	  	  early	  	  studies	  	  examine	  	  the	  	  correlation	  	  of	  	  DCE	  	  endpoints	  	  to	  	  a	  	  clinical	  	  index	  	  of	  activity	  	  rather	  	  than	  	  a	  	  more	  	  robust	  	  marker	  	  of	  	  inflammation94,95,96.	  	  	  	  A	  	  group	  	  from	  	  Chicago	  examined	  	  51	  	  bowel	  	  segments	  	  (19	  	  with	  	  inflammation	  	  and	  	  32	  	  normal	  	  as	  	  assessed	  	  by	  	  ileo-­‐-­‐-­‐	  colonoscopy	  and	  histology	  or	  surgery)	  from	  11	  patients	  and	  reported	  statistically	  significant	  differences	  	  in	  	  a	  	  comprehensive	  	  list	  	  of	  	  parameters.	  	  	  	  	  The	  	  role	  	  of	  	  the	  	  histological	  	  reference	  standard	  	  was	  	  merely	  	  to	  	  differentiate	  	  between	  	  abnormal	  	  and	  	  normal	  	  segments,	  	  and	  	  there	  was	  no	  attempt	  to	  correlate	  kinetic	  parameters	  with	  histologic	  or	  endoscopic	  activity	  97.	  	  	   This	  	  	  was	  	  	  partially	  	  	  addressed	  	  	  by	  	  	  Rottgen	  	  	  and	  	  	  his	  	  	  group	  	  	  who	  	  	  examined	  	  	  several	  	  	  DCE	  parameters	  	  in	  	  a	  	  larger	  	  cohort	  	  of	  	  26	  	  patients98.	  	  The	  	  slope	  	  of	  	  enhancement	  	  (r=0.59)	  	  but	  	  not	  the	  area	  under	  the	  enhancement	  curve	  nor	  the	  peak	  maximum	  were	  shown	  to	  correlate	  with	  endoscopic	  	  	  severity	  	  	  in	  	  	  this	  	  	  retrospective	  	  	  study.	  	  	  More	  	  	  recently	  	  	  the	  	  	  Amsterdam	  	  	  group	  evaluated	  	  DCE	  	  parameters	  	  in	  	  correlation	  	  to	  	  AIS	  	  and	  	  FS	  	  in	  	  50	  	  intestinal	  	  sections	  	  from	  	  20	  patients	  	  	  undergoing	  	  	  surgical	  	  	  intestinal	  	  	  resection.	  	  	  There	  	  	  were	  	  	  moderate	  	  	  correlations	  between	  	  	  the	  	  	  AIS	  	  	  and	  	  	  the	  	  	  maximal	  	  enhancement	  	  	  as	  	  	  well	  	   as	  	  	  slope	  	  	  of	  	  	  enhancement.	  	  As	  predicted	  by	  the	  hypothesis	  that	  inflammation	  will	  co-­‐-­‐-­‐exist	  with	  fibrosis	   in	  the	  same	  lesions,	  significant	  	  correlations	  	  were	  	  also	  	  observed	  	  when	  	  the	  	  FS	  	  was	  	  assessed	  	  against	  	  the	  	  DCE	  measures99.	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In	   summary,	   even	   though	   the	   pathophysiological	   basis	   underpinning	   the	   technique	   still	  remains	  dubious,	  DCE	  MRI	  is	  emerging	  as	  a	  new	  tool	  to	  assess	  disease	  activity.	  This	  is	  due	  to	  several	  studies	  demonstrating	  that	  iv	  contrast	  appears	  to	  be	  handled	  differently	  by	  inflamed	  versus	   normal	   intestinal	  wall,	   a	   discrepancy	  which	   can	   be	   formally	   quantified.	  How	   these	  measures	   will	   perform	   longitudinally,	   and,	   in	   particular,	   how	   illustrative	   they	   will	   be	   of	  change	  achieved	  with	  therapy	  remains	  to	  be	  elucidated.	  	  	   Diffusion-­‐-­‐-­‐Weighted	   Imaging	   (DWI)	   is	   a	  MRI	  method	  which	   allows	  mapping	   of	   the	   diffusion	  of	  	  	  molecules,	  	  	  predominantly	  	  	  water,	  	  	  within	  	  	  biological	  	  	  tissues.	  	  	  The	  	  	  movement	  	  	  of	  	  	  water	  molecules	  	  between	  	  the	  	  intracellular,	  	  interstitial	  	  and	  	  intravascular	  	  compartments	  	  normally	  occurs	   freely,	   in	  a	  random	  manner,	  but	   it	   is	  restricted	  by	  obstacles	  such	  as	  macromolecules,	  membranes	  and	  fibre.	  DWI	  is	  a	  technique	  that	  assesses	  the	  rate	  of	  this	  movement,	  ultimately	  producing	  a	  map	  of	  average	  diffusion	  per	  voxel	  of	   tissue.	   In	  pathological	   states	  where	   there	  is	  	  increased	  	  cellular	  	  density	  	  (e.g.	  	  malignancy	  	  or	  	  inflammation),	  	  or	  	  cellular	  	  swelling	  	  (e.g.	  cytotoxic	  	  oedema),	  	  this	  	  free	  	  movement	  	  of	  	  water	  	  molecules	  	  is	  	  reduced100.	  	  DWI	  	  was	  	  first	  introduced	  in	  the	  mid-­‐-­‐-­‐1980s	  finding	  applications	   in	  the	  acute	   imaging	  of	  stroke,	   followed	  by	  a	  	  wide	  	  range	  	  of	  	  oncological	  	  indications	  	  and	  	  others101.	  	  Two	  	  properties	  	  which	  	  make	  	  it	  	  an	  attractive	  modality	  are	  its	  quantitative	  nature	  and	  the	  lack	  of	  need	  for	  intravenous	  contrast.	  	  	   Soon	   after	   these	   reports,	   several	   groups	   examined	   DWI	   in	   the	   context	   of	   inflammatory	  imaging.	  Nogushi	  et	  al.	  demonstrated	  the	  techniques	  potential	  to	  distinguish	   inflammatory	  from	  malignant	  processes	  in	  the	  brain102.Other	  investigators	  have	  introduced	  its	  application	  in	  imaging	  of	  hepatic	  inflammation	  and	  fibrosis	  103,104.	  	  	   The	  first	  report	  of	  DWI	  in	  CD	  was	  by	  Oto	  et	  al.	  who	  retrospectively	  assessed	  53	  segments	  	   in	  	   11	  	  	  patients	  	  	  	  	  subsequently	  	  	  	  	  undergoing	  	  	  	  	  ileo-­‐-­‐-­‐colonoscopy	  	  	  	  	  or	  	  	  	  	  resection.	  	  	  	  	  The	  	  	  	  	  group	  demonstrated	  	  	  significant	  	  	  differences	  	  	   in	  	  	  the	  	  	  Apparent	  	  	  Diffusion	  	  	  Coefficient	  	  	  (ADC),	  	  	  a	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quantitative	   measure	   of	   water	   diffusivity,	   between	   normal	   and	   abnormal	   segments105.	  Shortly	  afterwards,	  a	  report	  from	  Tokyo	  on	  a	  larger	  cohort	  of	  31	  patients	  in	  whom	  DWI	  was	  compared	   to	   a	   barium	   study	   or	   surgical	   pathology	   revealed	   strikingly	   similar	   results.	  Moreover,	  the	  authors	  hinted	  on	  possible	  differences	  between	  small	  bowel	  and	  colonic	  ADCs	  requiring	  further	  exploration106.	  	  	   Oussalah	  	  and	  	  his	  	  group	  	  from	  	  Nancy,	  	  reported	  	  clinical–radiological	  	  results	  	  obtained	  	  with	  DW-­‐-­‐-­‐MRI	  in	  35	  patients	  with	  UC	  and	  61	  with	  CD.	  A	  segmental	  magnetic	  resonance	  score	  (MR-­‐-­‐-­‐	  score-­‐-­‐-­‐S)	  	  based	  	  on	  	  DWI	  	  values	  	  and	  	  other	  	  MRI	  	  parameters	  	  was	  	  much	  	  more	  	  successful	  	  in	  detecting	  	  endoscopic	   inflammation	  	  in	  	  UC,	  	  	  (sensitivity	  	  89%	  	  and	  	  specificity	  	  of	  87%)	   than	  	  in	  CD	  (sensitivity	  58	  %	  and	  specificity	  of	  84	  %).	  	  	  The	  authors	  attributed	  the	  differences	   to	   the	  segmental	  nature	  of	  the	  latter107.	  	  	   More	  	  recently,	  	  a	  	  different	  	  group	  	  in	  	  France	  	  performed	  	  DWI	  	  imaging	  	  in	  	  31	  	  ileal	  	  segments	  using	  	  the	  	  MaRIA	  	  score	  	  as	  	  a	  	  standard	  	  of	  	  reference	  	  for	  	  the	  	  first	  	  time	  	  after	  	  its	  	  validation,	  	  and	  reported	  	  a	  	  good	  	  correlation	  	  between	  	  it	  	  and	  	  ADC.	  	  ROC	  	  analysis	  	  was	  	  also	  	  performed,	  	  and	  	  a	  cut-­‐-­‐-­‐off	  ADC	  value	  of	  1.6mm/s2	  	  for	  active	   ileitis	  was	  proposed,	  with	  a	   sensitivity	  of	  83%	  and	  specificity	  	  of	  	  100%	  	  (area	  	  under	  	  ROC	  	  curve	  	  0.96).	  	  The	  	  same	  	  unit’s	  	  extended	  	  experience	  	  on	  130	  	  patients,	  	  inclusive	  	  of	  	  both	  	  small	  	  bowel	  	  and	  	  colonic	  	  data	  	  was	  	  presented	  	  in	  	  a	  	  separate	  paper.	  Once	  again	  MaRIA	  was	  used	  as	  a	  comparator,	   to	  determine	   the	  175	  out	  of	  848	  active	  bowel	  segments,	  and	  per	  segment	  sensitivity	  and	  specificity	  figures	  were	  proposed,	  all	  being	  well	  	  	  over	  	  	  90%.	  	  	  The	  	  	  ADC	  	  	  threshold	  	  	  was	  	  	  revised	  	  	  to	  	  	  1.9mm/s2,	  	  	  and,	  	  	  challenging	  	  	  the	  conclusions	  of	  Nancy’s	  group,	  they	  advocate	  the	  use	  of	  DWI	  in	  colonic	  as	  well	  as	  ileal	  Crohn’s	  monitoring108.	  	  	   In	  conclusion,	  most	  conducted	  studies	  on	  DWI	  in	  CD	  have	  supported	  the	  hypothesis	  that	  the	  focal	  hyper-­‐-­‐-­‐cellularity	  arising	  from	  inflammatory	  cell	  influx,	  and	  perhaps	  also	  the	  fibrogenic	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process,	  do	  result	  in	  a	  measurable	  reduction	  in	  water	  diffusivity	  in	  the	  affected	  tissue.	  In	  the	  largest	  of	   these	  cohorts	  MaRIA	  has	  been	  used	  as	   the	  as	  a	  gold-­‐-­‐-­‐standard,	  or	  more	  accurately,	  a	  	  variant	  of	   the	  score	  proposed	  	  by	  	  its	   inventors	  which	  	  does	  not	   involve	  bowel	  preparation	  and	  	  colonic	  	  distension,	  	  a	  	  strategy	  	  which	  	  has	  	  left	  	  the	  	  study	  	  open	  	  to	  	  some	  	  criticism.	  	  	  	  Once	  again	  	  the	  	  performance	  	  of	  	  DWI	  	  as	  	  a	  	  monitoring	  	  tool,	  	  in	  	  terms	  	  of	  	  its	  	  responsiveness	  	  and	  	  its	  reliability	  remains	  undetermined.	  	  	  
1.2.5.2.1	  MRI	  in	  monitoring	  disease	  progress	  in	  CD	  
	  
	  
	   Whilst	  	  there	  	  is	  	  an	  	  increasing	  	  evidence	  	  base	  	  suggesting	  	  that	  	  several	  	  modalities	  	  within	  	  MRI	  have	  a	  high	  diagnostic	  accuracy	  in	  demonstrating	  active	  segments	  in	  patients	  with	  CD,	  only	  a	  small	  	  number	  	  of	  	  studies	  	  have	  	  assessed	  	  the	  	  responsiveness	  	  of	  	  MRI	  	  qualitative	  	  endpoints	  	  or	  quantitative	  	  scores	  	  over	  	  time	  	  in	  	  such	  	  patients.	  	  The	  	  first	  	  study	  	  included	  	  8	  	  patients	  	  with	  follow-­‐-­‐-­‐up	  	  MRI	  	  at	  	  variable	  	  times	  	  after	  	  initiation	  	  of	  	  therapy	  	  (11	  	  days	  	  to	  	  4	  	  months),	  	  and	  	  the	  authors	   reported	   significant	   changes	   in	  T2	  	  wall	   signal	   intensity,	  T1	  	  contrast	   enhancement	  as	  well	  	  	  as	  	  	  bowel	  	  	  wall	  	  	  thickness109	  	  	  	  The	  	  	  prospective	  	  	  multi-­‐-­‐-­‐centric	  	  	  ACTIF	  	  	  trial	  	  	  exclusively	  examined	  	  terminal	  	  ileal	  	  segments	  	  in	  	  15	  	  patients	  	  with	  	  active	  	  CD	  	  prior	  	  to,	  	  and	  	  at	  	  two	  	  time-­‐-­‐-­‐	  points	  after	  the	  introduction	  of	  infliximab.	  The	  MRE	  score	  of	  severity	  in	  Ileal	  Disease	  (MCID),	  a	  	  composite	  	  score	  	  consisting	  	  of	   inflammatory,	  obstructive	  	  and	  	  extra-­‐-­‐-­‐intestinal	   components	  (range	   1-­‐-­‐-­‐14),	  was	   assessed,	  which	   to	   date	   lacks	   external	   validation.	   The	   primary	   endpoints	  were	  a	  drop	  in	  MCID	  by	  2	  points	  at	  week	  26	  in	  combination	  with	  a	  decrease	  in	  inflammatory	  sub-­‐-­‐-­‐score	  	  of	  	  at	  	  least	  	  50%.	  These	  	  were	  	  met	  	  by	  	  40%	  	  of	  	  patients.	  The	  	  authors	  	  emphasise	  	  the	  fact	  	  that	  	  complete	  	  resolution	  	  of	  	  transmural	  	  inflammatory	  	  features	  	  was	  	  rarely	  	  encountered	  at	  6	  	  months,	  despite	   several	  participants	  enjoying	  	  full	   clinical	   remission	  	  at	   that	   time-­‐-­‐-­‐point.	  They	  	  	  	  	  propose	  	  	  	  	  however	  	  	  	   further	  	  	  	  prospective	  	  	  	  	  studies	  	  	  	  	  to	  	  	  	  	  establish	  	  	  	  	  the	  	  	  	  	  modality’s	  responsiveness	  in	  monitoring	  the	  effects	  of	  treatment.	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In	  	  	  a	  	  	  recent	  	  	  landmark	  	  	  paper,	  	  	  Ordas	  	  	  et	  	  	  al.	  	  	  explored	  	  	  the	  	  	  potential	  	  	  of	  	  	  the	  	  	  MaRIA	  	  	  score,	  previously	  	  	  proposed	  	  	  and	  	  	  validated	  	  	  by	  	  	  their	  	  	  group,	  	  	  to	  	  	  monitor	  	  	  Crohn’s	  	  	  patients	  	  	  with	  endoscopic	  evidence	  of	  activity	  and	  mucosal	  ulceration,	  after	   introduction	  of	  corticosteroids	  or	  	  	  anti-­‐-­‐-­‐TNF	  	  	  therapy.	  	  	  48	  	  	  patients	  	  	  were	  	  	  recruited	  	  	  prospectively	  	  	  before	  	  	  treatment,	  	  	  and	  received	  	  	  an	  	  	  MRI	  	  	  and	  	  	  an	  	  	  ileo-­‐-­‐-­‐colonoscopy,	  	  	  which	  	  	  were	  	  	  repeated	  	  	  12	  	  	  weeks	  	  	  following	  introduction	  	  of	  	  therapy.	  	  The	  	  aim	  	  of	  	  this	  	  study	  	  was	  	  to	  	  report	  	  on	  	  the	  	  responsiveness	  	  and	  reliability	  	  	  of	  	  	  MRE	  	  	  as	  	  	  a	  	  	  monitoring	  	  	  tool,	  	  	  using	  	  	  the	  	  	  colonoscopy	  	  	  as	  	  	  the	  	  	  gold	  	  	  standard.	  Appropriately,	   the	  primary	  objective	  was	   to	   investigate	   the	   accuracy	   in	   the	   identification	  of	  ulcer	  resolution,	  as	   the	  reference	   investigation	  can	  only	  provide	   information	  on	  the	  mucosa.	  Other	  	  	  components	  	  	  of	  	  	  the	  	  	  MaRIA	  	  	  score	  	  	  were	  	  	  examined,	  	  	  alongside	  	  	  morphological	  	  	  MRE	  endpoints,	  	  	  	  however,	  	  	  	  including	  	  	  	  bowel	  	  	  	  wall	  	  	  	  thickness,	  	  	  	  oedema	  	  	  	  and	  	  	  	  wall	  	  	  	  contrast	  enhancement.	  Using	  robust	  statistical	  methods,	  the	  authors	  demonstrated	  several	   important	  findings:	  	  On	  	  a	  	  ‘per	  	  patient	  	  analysis’	  	  it	  	  was	  	  found	  	  that	  	  a	  	  global	  	  MaRIA	  	  score	  	  of	  	  <50	  	  was	  predictive	  of	  ulcer	  healing	  	  with	  	  sensitivity	  	  and	  	  specificity	  	  of	  75%	  	  and	  	  80%	  	  respectively,	  as	  well	  	  as	  	  of	  	  mucosal	  	  healing	  	  (by	  	  CDEIS	  	  criteria),	  	  with	  	  sensitivity	  	  and	  	  specificity	  	  of	  	  83%	  	  and	  84%	  	  respectively.	  	  Furthermore,	  	  the	  	  authors	  	  report	  	  good	  	  agreement	  	  between	  	  MRE	  	  and	  endoscopy	  in	  diagnosing	  MH	  (κ	  =0.71).	  	  For	  the	  	   ‘per	  segment	  analysis’	  111	  of	  265	  segments	  had	   ulcers	   at	   index	   endoscopy,	   of	  which	   73	   had	   healed	   on	   follow-­‐-­‐-­‐up.	   In	   these,	  mean	   CDEIS	  and	  	  MaRIA	  	  were	  	  significantly	  	  different.	  	  In	  	  the	  	  30	  	  segments	  	  without	  	  ulcer	  	  healing,	  	  neither	  CDEIS	  	  nor	  	  MaRIA	  	  had	  	  changed	  	  significantly.	  	  A	  	  MaRIA	  	  of	  	  <11	  	  was	  	  sensitive	  	  (94%)	  	  but	  moderately	  	  specific	  	  for	  	  ulcer	  	  healing	  	  whereas	  	  a	  	  MaRIA	  	  of	  	  <7	  	  had	  	  a	  	  high	  	  sensitivity	  	  (85%)	  and	   specificity	   (78%)	   for	  MH.	   Segments	  which	  demonstrated	  ulcer	  healing	  on	   the	   follow-­‐-­‐-­‐up	  scan,	  	  also	  	  had	  	  significantly	  	  higher	  	  rates	  	  of	  	  resolution	  	  of	  	  qualitative	  	  MRI	  	  endpoints	  	  such	  	  as	  oedema,	  	   lymphadenopathy,	  	  peri-­‐-­‐-­‐enteric	  	  vascularisation,	  	  and	  	   fat	  	   stranding,	  	  compared	  	   to	  those	  	  that	  	  did	  	  not	  	  demonstrate	  	  ulcer	  	  healing.	  	  The	  	  score’s	  	  responsiveness,	  	  according	  	  to	  	  the	  formulas	  	  described	  	  previously	  	  was	  	  calculated	  	  as	  	  1.10	  	  (responsiveness	  	  ratio	  	  of	  	  Guyatt)	  	  and	  1.72	  (standardised	  effect	  size	  ratio),	  with	  values	  over	  0.80	  signifying	  good	  responsiveness.	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Finally,	  	  Intra-­‐-­‐-­‐class	  	  correlation	  	  coefficient	  	  was	  	  calculated	  	  as	  	  0.56	  	  in	  	  the	  	  subset	  	  of	  	  segments	  without	  	  	  ulcer	  	  	  healing,	  	  	  suggesting	  	  	  a	  	  	  good	  	  	  reliability	  	  	  of	  	  	  the	  	  	  score	  	  	  in	  	  	  addition	  	  	  to	  	  	  good	  responsiveness110.	  	  	   These	   data	   support	   the	   use	   of	   MaRIA	   in	   monitoring	   primarily	   the	   mucosal,	   but	   also	   the	  transmural	   effects	   of	   therapy.	   One	   important	   issue	   about	   the	   methodology	   of	   the	   MaRIA	  score	   is	   that	   it	   involves	   both	   bowel	   cleansing	  with	   polyethylene	   glycol	   as	  well	   as	   passive	  colonic	  distension	  with	  rectal	  catheterisation	  performed	  before	  the	  exam,	  a	  practice	  which	  other	  groups	  have	  been	  reluctant	  to	  reproduce	  because	  it	  makes	  the	  procedure	  substantially	  more	   invasive,	   and	   less	   acceptable	   to	   patients.	  While	   the	   score	   seems	   to	   be	   a	   promising	  monitoring	   tool,	   its	   assessment	   without	   the	   colonic	   cleansing	   and	   subsequent	   distension	  component	  is	  warranted	  before	  it	  can	  find	  a	  role	  in	  clinical	  practice.	  	  	   Similar	   studies	   are	   also	   required	   to	   assess	   reliability	   and	   responsiveness	   of	   several	   other	  quantitative	  endpoints	  of	  MRI	  enterography,	  which	  appear	  to	  measure	  accurately	  different	  components	   of	   the	   inflammatory	   process	   on	   ‘snapshot’	   observations,	   such	   as	   the	   MEGS	  score,	  Apparent	  Diffusion	  Coefficient	  and	  DCE	  MRI	  parameters.	  	  	  
1.2.5.3 CT	  Enterography	  
	  
	  
	   Computed	  Tomographic	  (CT)	  enterography	  has	  also	  been	  shown	  to	  detect	  disease	  activity	  in	  CD	   with	   accuracy	   very	   comparable	   to	   MRI.	   Endpoints	   which	   have	   been	   highlighted	   	   by	  clinical	   studies	   as	   the	   most	   representative	   of	   inflammatory	   activity	   are,	   perhaps	  unsurprisingly,	  very	  similar	  to	  MRI	  and	  are	  summarised	  in	  Table	  1.1	  111,112,113,114,115.	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Radiology	  2006	  	   	   Correlation	  	  	  between	  	  	  thickness	  	  	  and	  	  endoscopic	  activity	  (p<0.001)	  and	  histologic	  activity	  (p=0.01)	  	  	  












	   Booya	  
Radiology	  2006	  	   Normal	  jejunum	  enhancement	  >	  Normal	  ileal	  enhancement	  (p=0.001)	  TI	  hyper-­‐-­‐-­‐enhancement	   in	  pts	  with	  definite	  CD	  vs.	  controls	  (119	  vs.	  96	  HU	  p<0.001)	  	  	  
	   Bodily	  
Radiology	  2006	  	  
TICONTROL=	  96±23HU	  TIPROBABLE	  CD=114±28HU	  TIDEFINITE	  	  CD	  	  =127±15HU	  	  	  Control	  vs.	  Probable	  p=0.02	  Control	  vs.	  Definite	  p<0.001	  	  
	   Colombel	  
Gut	  2006	  	   TI	   attenuation	   +	   Ratio	   of	   ileal/control	   ileal	   loop	  attenuation	   were	   significantly	   correlated	   to	  histological	  score	  (r=	  0.34–38;	  p<0.001)	  	  
	   Chiorean	  






(layered	  /	  diffuse)	  
	   Choi	  
Clin	  Radiol	  2003	  	   	   Layering	   enhancement	   associated	   with	   activity	  and	   homogeneous	   enhancement	  with	   quiescence	  p<0.05	  	  
	   Chiorean	  








	   Bodily	  
Radiology	  2006	  	   	   Sensitivity	  29-­‐-­‐-­‐35%	  Specificity	  93%	  	  Booya	  
Radiology	  2006	  	   	   Sensitivity	  53-­‐-­‐-­‐67%	  Specificity	  89-­‐-­‐-­‐100%	  	  Colombel	  
Gut	  2006	  	   Significantly	  correlates	  with	  histological	  score	  (r=0.29	  p=0.002)	  	  








	   Bodily	  
Radiology	  2006	  	   	  	  Low	  sensitivity	  (10%)	  but	  high	  specificity	  for	  activity	  (93%)	  	  
	   Booya	  
Radiology	  2006	  	   	   Low	  	  sensitivity	  	  (40%)	  	  but	  	  high	  	  specificity	  	  (93-­‐-­‐-­‐	  96%)	  for	  activity	  	  
	   Colombel	  
Gut	  2006	  	   	   Modest	  correlation	  between	  fat	  density	  and	  histological	  score	  	  (r=0.22	  p=0.016)	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A	  	  major	  	  limitation	  	  in	  	  the	  	  application	  	  of	  	  this	  	  modality	  	  as	  	  a	  	  monitoring	  	  instrument	  	  is	  	  the	  patient	  	  	  exposure	  	  	  to	  	  	  ionising	  	  	  radiation.	  	  	  A	  	  	  team	  	  	  from	  	  	  Ireland	  	  	  showcased	  	  	  the	  	  	  issue	  	  	  by	  investigating	  	  	  retrospectively	  	  	  the	  	  	  cumulative	  	  	  effective	  	  	  doses	  	  	  (CED)	  	  	  of	  	  	  radiation	  	  	  in	  	  	  354	  patients	  	  with	  	  CD	  	  over	  	  3	  	  5-­‐-­‐-­‐year	  	  periods	  	  between	  	  1992	  	  and	  	  2007,	  	  aiming	  	  to	  	  quantify	  	  the	  proportion	  of	   these	   that	  received	  a	  CED	  over	  a	   threshold	  of	  75mSv.	  This	  has	  been	  shown	  to	  be	  associated	  with	  an	  absolute	  risk	  of	   lifetime	  all-­‐-­‐-­‐cancer	  mortality	  	  	  >7%	  in	  a	   large	  definitive	  epidemiological	  study116.	  	  	  The	  authors	  report	   that	  more	   than	  15%	  of	  patients	  had	  exceeded	  that	  	  threshold	  	  at	  	  a	  	  mean	  	  age	  	  of	  	  39	  	  years.	  	  Risk	  	  factors	  	  associated	  	  with	  	  increased	  	  CED	  	  were	  young	   age	   at	   diagnosis,	   ileo-­‐-­‐-­‐colonic	   distribution	   and	   the	   requirement	   for	   steroids,	   anti-­‐-­‐-­‐TNF	  and	  	  immune-­‐-­‐-­‐modulators117.	  	  	  	  	  As	  	  MRI	  	  availability	  	  is	  	  expanding	  	  (data	  	  from	  	  the	  	  centre	  	  of	  disease	  	  control	  	  and	  	  prevention),	  	  and	  	  clinical	  	  guidelines	  	  supporting	  	  its	  	  use	  	  over	  	  CT	  	  are	  propagated118,	   it	   is	   likely	   that	   the	  role	  of	  CT	   in	   the	  management	  of	  CD	  will	   rapidly	  diminish,	  sparing	  patients	  from	  the	  burden	  of	  excessive	  ionising	  radiation.	  	  	  
1.2.5.4 Functional	  Imaging	  
	  
	  
	   Molecular	  imaging	  has	  been	  defined	  as	  “the	  visualisation,	  characterisation	  and	  measurement	  of	  	  biological	  	  processes	  	  at	  	   the	  	  molecular	  	  and	  	  cellular	  	   level	  	   in	  	  humans	  	  and	  	  other	  	   living	  systems.”119	  	  It	  typically	  includes	  2-­‐-­‐-­‐3	  dimensional	  imaging	  as	  well	  as	  quantification	  over	  time	  
119.	   The	   techniques	   involve	   the	   incorporation	  of	   a	   radionuclide,	   detectable	  by	   the	   imaging	  modality,	  onto	  a	  biologically	  active	  molecule	  which	  has	  a	  known	  role	  in	  the	  pathway	  under	  investigation.	   The	   studying	   of	   the	   resulting	   radioligands’	   rate	   and	   degree	   of	   specific	  accumulation,	   as	   well	   as	   rate	   of	   metabolism,	   can	   provide	   valuable	   information	   on	   the	  abundance	  and	  kinetics	  of	  the	  biological	  process.	  	  	   By	  far	  the	  most	  broadly	  studied	  ligand,	  with	  a	  wide	  range	  of	  established	  clinical	  applications	  is	  	  18F-­‐-­‐-­‐Fluorodeoxyglucose	  	  (FDG),	  	  an	  	  analogue	  	  of	  	  glucose	  	  in	  	  which	  	  an	  	  18F	  	  molecule	  	  has	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replaced	  	  	  the	  	  	  naturally	  	  	  occurring	  	  	  hydroxyl	  	  	  group	  	  	  in	  	  	  the	  	  	  2’	  	  	  position.	  	  	  After	  	  	  intravenous	  administration,	  	  FDG	  	  is	  	  transported	  	  intracellularly	  	  by	  	  the	  	  GLUT	  	  family	  	  of	  	  transporters,	  	  at	  	  a	  rate	   proportional	   to	   each	   cell’s	   glycolysis,	   and	   phosphorylated	   by	   hexokinase	   into	   	  18F-­‐-­‐-­‐FDG-­‐-­‐-­‐	  phosphate.	   18F-­‐-­‐-­‐FDG-­‐-­‐-­‐phosphate	   is	   trapped	   intra-­‐-­‐-­‐cellularly,	  which	   gives	   rise	   to	   the	   hypothesis	  that	   the	   great	  majority	   FDG	   signal	   originates	   intra-­‐-­‐-­‐cellularly,	   after	   sufficient	   time	   is	   allowed	  for	  the	  intravascular	  reserves	  to	  be	  taken	  up	  by	  cells120.	  	  	   It	  	  has	  	  long	  	  been	  	  known	  	  that	  	  malignant	  	  cells	  	  utilise	  	  glucose	  	  more	  	  rapidly	  	  than	  	  surrounding	  tissue.	  	  This	  	  is	  	  a	  	  result	  	  of	  	  an	  	  increased	  	  metabolic	  	  rate	  	  in	  	  these	  	  cells,	  	  in	  	  combination	  	  with	  	  a	  shift	  	  of	  	  the	  	  energy-­‐-­‐-­‐producing	  	  pathway,	  	  from	  	  oxidative	  	  phosphorylation	  	  to	  	  the	  	  less	  	  oxygen-­‐-­‐-­‐	  dependent	  	  	  glycolysis,	  	  	  as	  	  	  cells	  	  	  adapt	  	  	  to	  	  	  the	  	  	  relative	  	  	  hypoxic	  	  	  conditions	  	  	  within	  	  	  solid	  tumours121.	   This	   property	   of	  malignant	   cells	   has	  been	   the	  basis	   of	   development	  of	   FDG-­‐-­‐-­‐PET	  scanning	  	  as	  	  a	  	  diagnostic,	  	  and	  	  subsequently,	  	  a	  	  monitoring	  	  and	  	  prognostic	  	  tool	  	  for	  	  a	  	  wide	  range	  of	  cancers	  over	  the	  last	  30	  years122.	  	  	   Shortly	  after	  the	  potential	  of	  FDG-­‐-­‐-­‐PET	  in	  oncological	  imaging	  began	  to	  be	  realised,	  a	  group	  in	  Japan,	  	  through	  	  a	  	  series	  	  of	  	  elegant	  	  experiments,	  	  proposed	  	  its	  	  use	  	  for	  	  the	  	  identification	  	  of	  benign	  	  	  	  inflammatory	  	  	  	  foci.	  	  	  	  Stimulated	  	  	  	  by	  	  	  	  reports	  	  	  	  of	  	  	  	  increased	  	  	  	  glucose	  	  	  	  uptake	  	  	  	  by	  inflammatory	  	  tissue123,	  	  and	  	  incidental	  	  FDG	  	  foci	  	  found	  	  within	  	  abscesses124,	  	  	  	  Kubota	  	  et	  	  al.	  transplanted	  syngeneic	  FM3A	  tumour	  cells	  in	  mice,	  and	  followed	  them	  up	  until	  tumours	  had	  fully	  	  developed.	  The	  	  animals	  	  were	  	  then	  	  injected	  	  with	  	  FDG	  	  and	  	  shortly	  	  afterward	  	  sacrificed	  and	  	  	  	  the	  	  	  	  tumours	  	  	  	  were	  	  	  	  examined	  	  	  	  using	  	  	  	  macro	  	  	  	  and	  	  	  	  micro-­‐-­‐-­‐autoradiography,	  	  	  	  which	  demonstrated	  	  that	  	  the	  	  majority	  	  of	  	  the	  	  injected	  	  FDG	  	  had	  	  accumulated	  	  in	  	  macrophage-­‐-­‐-­‐rich	  areas	  as	  well	  as	  young	  granulation	   tissue	  within	   the	   tumours125.	   	   	  This	  was	  corroborated	  by	  another	  group	  performing	  a	  set	  of	  murine	  studies	  which	  showed	  differential	  FDG	  activity	   in	  immuno-­‐-­‐-­‐competent	  	  	  	  versus	  	  	  	  immune-­‐-­‐-­‐deficient	  	  	  	  mice	  	  	  	  after	  	  	  	  xenografting	  	  	  	  them	  	  	  	  with	  	  	  	  an	  experimental	  	  	  	  tumour	  	  	  	  model	  	  	  	  126.	  	  	  	  The	  	  	  	  Kyoto	  	  	  	  group	  	  	  	  then	  	  	  	  used	  	  	  	  turpentine-­‐-­‐-­‐induced	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inflammation,	  	  	  a	  	  	  chronic	  	  	  inflammatory	  	  	  model	  	  	  of	  	  	  granulation	  	  	  tissue	  	  	  in	  	  	  mice	  	  	  to	  	  	  also	  demonstrate	  	  increased	  	  FDG	  	  affinity	  	  in	  	  such	  	  tissue127,	  	  which	  	  was	  	  completely	  	  devoid	  	  of	  	  a	  malignant	  component.	  Finally,	   in	  a	  similar	  experiment	   in	  a	  model	  of	  concanavalin-­‐-­‐-­‐A	   induced	  lymphoid	  	  activation,	   increased	  	  FDG	  	  affinity	  	  was	  demonstrated	  	  in	  	  lymphocytes	  both	  	  in	  	  vivo	  and	   in	  vitro,	   implicating	   these	   cells	   as	   a	   source	  of	  FDG	  signal	   in	   inflammation128.	  This	   latter	  study	  	  	  also	  	  	  demonstrated	  	  	  that	  	  	  18F-­‐-­‐-­‐FDG	  	  	  binding	  	  	  in	  	  	  splenocytes	  	  	  of	  	  	  mice	  	  	  that	  	  	  had	  	  	  been	  inoculated	  at	  a	   remote	   site	  with	   the	  concanavalin-­‐-­‐-­‐A	  30	  minutes	  previously,	  was	  higher	   than	  splenocytes	  of	  untreated	  animals.	  This	  suggests	  that	  the	  FDG	  signal	  is	  not	  exclusively	  related	  to	  an	  increased	  cellular	  density	  that	  results	  from	  cell	  migration	  at	  the	  site	  of	  inoculation,	  but	  it	  also	  reflects	  a	  state	  of	  activation	  of	  the	  immune	  lineages.	  	  	   These	   reports	   gave	   rise	   to	   a	   large	  number	  of	   studies,	  which	   examined	   the	  potential	   of	   FDG-­‐-­‐-­‐	  PET	  	  to	  	  identify	  	  the	  	  inflammatory	  	  lesions,	  	  and	  	  measure	  	  the	  	  inflammatory	  	  load	  	  in	  	  a	  	  wide	  range	   of	   conditions.	   This	   has	   been	   achieved	   successfully	   in	   atherosclerosis,	  where	   FDG	  	  has	  been	  used	   to	  quantify	   the	  macrophage	  content	   in	  vessel	  plaques,	   inflammatory	  vasculitides,	  and	  rheumatoid	  arthritis	  among	  others	  129–132.	  	  	  
1.2.5.4.1 18F-­‐-­‐-­‐FDG-­‐-­‐-­‐PET	  in	  CD	  
	  
	  
	   The	   first	   report	   on	   FDG-­‐-­‐-­‐PET	   in	   IBD	  was	   published	   in	   the	   Lancet	   in	   1997,	  where	  Bicik	   et	   al.	  performed	  	  FDG	  	  PET	  	  alongside	  	  ileo-­‐-­‐-­‐colonoscopy	  	  and	  	  histology,	  	  describing	  	  good	  	  correlation	  between	   the	   two,	   as	  well	   as	   between	  PET	  and	   clinical	   scores	   for	  CD	   and	  UC	   respectively133.	  Two	  years	   later,	  a	  Canadian	  paediatric	  study	  was	  published	   in	  which	  69	   intestinal	  segments	  in	  25	  children	  undergoing	  FDG-­‐-­‐-­‐PET	  alongside	  colonoscopy	  and	  biopsy	  or	  small	  bowel	  follow	  through	  	  as	  	  the	  	  reference	  	  gold	  	  standard.	  	  The	  	  investigators	  	  report	  	  an	  	  overall	  	  ‘per	  	  patient’	  sensitivity	  of	  81%	  and	  specificity	  of	  85%,	  having	  set	  the	  threshold	  for	  a	  positive	  gut	  segment	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at	   signal	  higher	   than	   that	   in	   the	   spine.	  The	  group’s	   ‘per	   segment’	  analysis	  demonstrated	  a	  sensitivity	  of	  71%	  and	  specificity	  of	  81%134.	  	  	   Neurath	  	  et	  	  al.	  published	  	  a	  	  larger	  	  study	  	  of	  	  59	  	  patients	  	  with	  	  established	  	  CD	  	  comparing	  	  FDG-­‐-­‐-­‐	  PET	  with	  MR	  enterography,	  and,	   in	  a	  subset,	  granulocyte	  scintigraphy.	  The	  authors	  report	  a	  higher	  	  incidence	  	  of	  	  ‘pathological’	  	  segments	  	  identified	  	  by	  	  FDG-­‐-­‐-­‐PET	  	  compared	  	  to	  	  the	  	  other	  two	  	  	  modalities.	  	  	  In	  	  	  addition,	  	  	  for	  	  	  the	  	  	  45	  	  	  segments	  	  	  where	  	  	  endoscopic	  	  	  verification	  	  	  was	  available,	  this	  corresponded	  to	  sensitivities	  of	  85%	  for	  PET	  versus	  41%	  for	  MR	  and	  67%	  for	  granulocyte	  scintigraphy,	  whereas	  the	  specificities	   for	  all	  3	  modalities	  were	  over	  89%.	  	  This	  study	   introduced	   several	   parameters	   in	   the	   field	   of	   FDG-­‐-­‐-­‐PET	   imaging	   in	   CD:	   The	   use	   of	   the	  liver	  signal	  as	  a	   threshold,	  above	  which	  any	  bowel	  signal	  was	  considered	  relevant,	  was	   first	  described	  	  in	  	  this	  	  paper,	  	  supported	  	  by	  	  the	  	  fact	  	  that	  	  11	  	  of	  	  12	  	  IBS	  	  controls	  	  as	  	  well	  	  as	  	  20	  controls	  	  with	  	  no	  	  GI	  	  pathology,	  	  had	  	  no	  	  bowel	  	  FDG	  	  accumulation	  	  above	  	  that	  	  threshold.	  	  This	  study	  was	  also	  the	  first	  to	  provide	  quantitative	  Standardised	  Uptake	  Values	  (SUVs)	  for	  those	  bowel	  	  segments	  	  described	  	  as	  	  abnormal.	  	  SUV	  	  was	  	  henceforth	  	  adopted	  	  as	  	  a	  	  measure	  	  of	  activity	  by	  the	  majority	  of	  studies	  in	  the	  area	  135.	  	  	   Two	  similar	  studies	  from	  India	  136	  	  and	  Wisconsin	  137,	  published	  simultaneously	  in	  2007	  were	  the	  first	  to	  introduce	  the	  combination	  of	  FDG-­‐-­‐-­‐PET	  with	  CT	  in	  17	  and	  12	  patients	  respectively	  patients	  	  with	  	  known	  	  IBD.	  	  The	  	  authors	  	  describe	  	  sensitivities	  	  and	  	  specificities	  	  similar	  	  to	  previous	  	  studies,	  	  but	  	  the	  	  added	  	  benefit,	  	  if	  	  any,	  	  of	  	  the	  	  CT	  	  component	  	  on	  	  the	  	  scan	  	  was	  	  not	  specifically	  mentioned.	  	  	   One	  	  of	  	  the	  	  landmark	  	  papers	  	  in	  	  the	  	  literature	  	  was	  	  published	  	  by	  	  Edward	  	  Louis	  	  et	  	  al138.	  	  The	  authors	  	  	  	  prospectively	  	  	  	  recruited	  	  	  	  22	  	  	  	  consecutive	  	  	  	  patients	  	  	  	  with	  	  	  	  known	  	  	  	  CD	  	  	  	  having	  colonoscopies	  	  for	  	  clinical	  	  reasons	  	  and	  	  performed	  	  FDG-­‐-­‐-­‐PET/	  	  CT	  	  scanning	  	  as	  	  well	  	  as	  	  faecal	  calprotectin	  assay	  and	  CRP	  within	  1	  week	  of	  the	  endoscopy.	  The	  sensitivity	  of	  FDG-­‐-­‐-­‐PET	  for	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the	  detection	  of	  endoscopic	   lesions	  was	  73%	  and	   the	  specificity	  of	  55%.	  The	  group	  was	   the	  first	  	  to	  	  demonstrate	  	  a	  	  positive	  	  correlation	  	  between	  	  SUV	  	  and	  	  endoscopic	  	  severity	  	  of	  	  the	  lesions.	  This	   is	  a	  crucial	   finding	  as	   the	  principal	  purpose	  of	  FDG	  PET	  scanning	   in	  CD,	  and	   its	  proposed	  	  advantage	  	  over	  	  conventional	  	  modalities,	  	  is	  	  the	  	  ability	  	  to	  	  meaningfully	  	  quantify,	  measure	  	  and	  	  monitor	  	  the	  	  inflammatory	  	  load	  	  at	  	  a	  	  particular	  	  time-­‐-­‐-­‐point.	  	  	  	  The	  	  concept	  	  of	  expressing	  SUV	  as	   a	   ratio	  over	   the	  value	   in	   liver	  parenchyma	   (RSUV)	  was	   introduced	  and	  a	  ROC	  	  analysis	  	  was	  	  produced,	  	  which	  	  demonstrated	  	  a	  	  predictive	  	  value	  	  of	  	  RSUV	  	  ≥	  	  1.47	  	  as	  having	  	  100%	  	  sensitivity	  	  in	  	  identifying	  	  severely	  	  inflamed	  	  segments	  	  on	  	  endoscopy.	  	  Finally,	  the	  	  study	  	  explicitly	  	  addresses	  	  the	  	  21	  	  of	  	  95	  	  segments	  	  which	  	  were	  	  positive	  	  on	  	  FDG	  	  PET	  	  but	  negative	  on	  endoscopy	  and	  demonstrates	  either	  CT	  or	  histologic	   features	  of	  disease	   in	  16	  of	  them,	  	  suggesting	  	  that	  	  FDG	  	  PET	  	  can	  	  reveal	  	  disease	  	  better	  	  than	  	  that	  	  achieved	  	  by	  	  endoscopic	  mucosal	  	  	  	  visualization.	  	  	  	  This	  	  	  	  latter	  	  	  	  observation	  	  	  	  also	  	  	  	  highlights	  	  	  	  the	  	  	  	  shortcomings	  	  	  	  of	  endoscopic	  assessment	  as	  an	  ultimate	  gold	  standard	  of	  disease	  activity.	  	  	   Another	  	   important	  	  study	  	  which	  	  significantly	  	  contributed	  	  to	  	  current	  	  knowledge	  	  was	  	  by	  Jacene	  et	  al.	  who	  prospectively	  recruited	  12	  patients	  scheduled	  to	  have	  resective	  surgery	  for	  Crohn’s	  	  disease,	  	  and	  	  carried	  	  out	  	  FDG-­‐-­‐-­‐PET/CT	  	  scanning	  	  before	  	  correlating	  	  the	  	  findings	  	  to	  histological	  	  assessment	  	  of	  	  inflammation,	  	  fibrosis	  	  and	  	  muscle	  	  hypertrophy	  	  within	  	  resected	  segments.	  	  The	  investigators	  demonstrated	  that	  the	  majority	  of	  lesions	  contained	  features	  of	  both	  inflammation	  and	  fibrosis-­‐-­‐-­‐hypertrophy.	  They	  also	  showed	  that	  a	  SUVMAX	  	  ≥8.0	  can	  select	  predominantly	   inflammatory	   lesions	  with	  a	  sensitivity	  of	  60%	  but	  a	  specificity	  of	  100%	  and	  a	  	  negative	  	  predictive	  	  value	  	  (NPV)	  	  of	  	  78%.	  	  This	  	  has	  	  significant	  	  clinical	  	  implications	  	  in	  	  the	  context	  	  of	  	  a	  	  notorious	  	  clinical	  	  conundrum	  	  in	  	  IBD	  	  practice,	  	  of	  	  patients	  	  presenting	  	  with	  symptomatic	   stricturing	   necessitating	   a	   choice	   of	   either	   an	   aggressive	  medical	   approach	   or	  an	  	  operation	  	  in	  	  the	  	  first	  	  instance.	  	  The	  	  other	  	  important	  	  contribution	  	  of	  	  this	  	  study	  	  was	  	  the	  proposition	  	  of	  	  Total	  	  Inflammatory	  	  Volume	  	  (TIV)	  	  of	  	  a	  	  lesion	  	  as	  	  a	  	  valuable	  	  endpoint.	  	  TIV	  	  or	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Total	  Lesion	  Glycolysis	  (TLG)	  is	  calculated	  as	  the	  product	  of	  SUVMEAN	  of	  a	  lesion	  x	  Volume	  of	  signal	  and	  has	  widespread	  applications	  in	  oncologic	  monitoring139.	  	  	   In	  	  2010,	  	  a	  	  group	  	  of	  	  investigators	  	  from	  	  Florida	  	  published	  	  a	  	  very	  	  interesting	  	  study	  	  which	  examined	  	  the	  	  potential	  	  of	  	  a	  	  single	  	  FDG	  	  PET/CT	  	  to	  	  predict	  	  response	  	  to	  	  medical	  	  therapy	  	  in	  patients	  with	  CD140.	   41	  patients	  were	   included	  and	  30/41	  who	  demonstrated	  abnormalities	  either	  	  on	  	  the	  	  CT	  	  or	  	  PET	  	  component	  	  of	  	  the	  	  scan	  	  were	  	  subsequently	  	  analysed.	  	  These	  	  were	  divided	  into	  a	  group	  of	  23	  who	  eventually	  responded	  and	  7-­‐-­‐-­‐strong	  group	  who	  failed	  medical	  therapy	  ultimately	  requiring	  surgical	  intervention.	  48	  abnormal	  segments	  were	  identified	  on	  CT,	   38	  of	  which	   also	   showed	   increased	  FDG	  uptake	  with	   a	  mean	   SUVMAX	  of	   4.8.	  The	   authors	  identified	  	  CT	  	  positive	  	  segments	  	  without	  	  FDG	  	  activity	  	  as	  	  a	  	  risk	  	  factor	  	  for	  	  failing	  	  medical	  therapy,	  	  found	  	  in	  	  6/7	  	  patients	  	  of	  	  that	  	  group	  	  and	  	  only	  	  in	  	  1/23	  	  responders,	  	  a	  	  finding	  	  that	  reached	   significance	   in	   their	   performed	   logistic	   regression	   analysis.	   The	   authors	   concluded	  that	  	  while	  	  these	  	  findings	  	  are	  	  encouraging,	  	  adequately	  	  powered	  	  studies	  	  will	  	  be	  	  required	  	  to	  establish	  the	  predictive	  role	  of	  the	  investigation.	  	  	   A	  	  recent	  	  study	  	  by	  	  Saboury	  	  et	  	  al.,	  	  similar	  	  in	  	  design	  	  to	  	  several	  	  previous	  	  ones	  	  inasmuch	  	  as	  	  it	  correlates	  	  FDG-­‐-­‐-­‐PET	  	  endpoints	  	  with	  	  clinical,	  	  laboratory	  	  and	  	  endoscopic	  	  results	  	  in	  	  patients	  with	  	  established	  	  CD,	  	  was,	  	  however,	  	  the	  	  study	  	  with	  	  the	  	  most	  	  comprehensive	  	  assessment	  	  of	  quantitative	  endpoints	  of	  PET	  activity.	  Data	   from	  22	  patients	  undergoing	  CDAI	  scoring,	  CRP,	  faecal	  calprotectin	  and	  ileo-­‐-­‐-­‐colonoscopy,	  was	  categorized	  into	  segmental	  and	  ‘per	  patient’.	  In	  the	   former,	   segmental	   SUVMAX,	   SUVMEAN	  	  and	  TLG	  were	   correlated	  with	   segmental	   CDEIS,	   the	  first	  	  two	  	  reaching	  	  statistical	  	  significance.	  	  In	  	  order	  	  to	  	  derive	  	  a	  	  meaningful	  	   ‘per	  	  patient’	  assessment	  of	  FDG	   signal,	   they	  proposed	   the	  Global	   SUVMAX	  (Average	  SUVMAX	  in	   all	   abnormal	  segments),	   the	  Global	  Lesion	  Glycolysis	   (GLG),	   calculated	  as	   the	   sum	  of	  TLG	   in	  all	   abnormal	  segments	  	  	  and	  	  	  the	  	  	  Global	  	  	  SUVMEAN,	  	  	  calculated	  	  	  as	  	  	  the	  	  	  ratio	  	  	  of	  	  	  GLG/	  	  	  Sum	  	  	  of	  	  	  volumes	  	  	  of	  abnormal	  	  	  segments.	  	  	  While	  	  	  all	  	  	  of	  	  	  the	  	  	  ‘per	  	  	  patient’	  	  	  scores	  	  	  correlated	  	  	  with	  	  	  CDAI,	  	  	  GLG	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correlated	   positively	   with	   calprotectin	   only,	   Global	   SUVMAX	   and	   SUVMEAN	   demonstrated	   a	  positive	  correlation	  with	  CRP	  and	  CDEIS	  141.	  	  	   These	   important	  clinical	   studies	  have	  also	  been	  supplemented	  by	  basic	  science	  experiments	  in	  	  relevant	  	  animal	  	  models,	  	  which	  	  further	  	  support	  	  the	  	  role	  	  of	  	  FDG-­‐-­‐-­‐PET	  	  as	  	  a	  	  quantitative	  measure	  	  of	  	  inflammatory	  	  burden	  	  in	  	  IBD.	  	  Sarah	  	  Brewer	  	  and	  	  her	  	  colleagues	  	  performed	  	  a	  series	  	  	  of	  	  	  experiments	  	  	  in	  	  	  a	  	  	  range	  	  	  of	  	  	  murine	  	  	  models	  	  	  of	  	  	  mild	  	  	  and	  	  	  severe	  	  	  IBD.	  	  	  	  	  	  She	  demonstrated	  	  that	  	  FDG	  	  signal	  	  in	  	  Gαi2-­‐-­‐-­‐/-­‐-­‐-­‐	  	  	  mice,	  	  a	  	  model	  	  of	  	  severe	  	  colitis,	  	  was	  	  significantly	  higher	   than	   in	   heterozygote	   Gαi2+/-­‐-­‐-­‐	  littermates,	  which	  was	   replicated	   on	   IL10-­‐-­‐-­‐/-­‐-­‐-­‐,	   a	  model	   of	  milder	  colitis.	  Moreover,	  by	  using	  piroxicam	  to	  augment	   the	   inflammation	   in	  a	  subset	  of	   the	  IL10-­‐-­‐-­‐/-­‐-­‐-­‐	  	  	  	  animals,	  	  	  she	  	  	  demonstrated	  	  	  the	  	  	  responsiveness	  	  	  of	  	  	  the	  	  	  FDG	  	  	  PET	  	  	  signal,	  	  	  which	  increased	  significantly	  on	   follow-­‐-­‐-­‐up	  scanning	   in	   treated	  mice	  against	  controls.	   In	  an	  attempt	  to	  	  determine	  	  the	  	  cellular	  	  source	  	  of	  	  the	  	  FDG	  	  signal,	  	  the	  	  investigators	  	  tried	  	  correlating	  	  the	  latter	  	  	  	  with	  	  	  	  populations	  	  	  	  of	  	  	  	  specific	  	  	  	  immune	  	  	  	  cells,	  	  	  	  without	  	  	  	  result.	  	  	  	  When	  	  	  	  individual	  mononuclear	  	  cells	  	  were	  	  stained	  	  for	  	  the	  	  Glut-­‐-­‐-­‐1	  	  receptor	  	  and	  	  subset	  	  markers,	  	  and	  	  examined	  by	  	  flow	  	  cytometry,	  	  it	  	  was	  	  revealed	  	  that	  	  Glut-­‐-­‐-­‐1	  	  expression	  	  was	  	  similar	  	  in	  	  macrophages	  	  and	  CD8+	  cells	   in	   colitic	  versus	  non-­‐-­‐-­‐colitic	  mice.	  CD4+	  cells	  expressed	  significantly	  higher	  Glut-­‐-­‐-­‐1	  expression	   in	  all	  colitic	  mice.	  This	  Glut-­‐-­‐-­‐1	  expression	   in	  CD4+	  T-­‐-­‐-­‐cells	  correlated	  with	   the	  FDG	  signal	  in	  two	  independent	  experiments	  using	  the	  IL10-­‐-­‐-­‐/-­‐-­‐-­‐	  	  model	  142.	  	  	   Yamato	  	  	  et	  	  	  al.	  	  	  performed	  	  	  FDG	  	  	  PET	  	  	  scanning	  	  	  in	  	  	  an	  	  	  indomethacin-­‐-­‐-­‐induced	  	  	  small	  	  	  bowel	  ulceration	  model,	   in	  which	   indomethacin	  or	  vehicle	  solution	  was	   injected	  subcutaneously	   in	  male	  	  Sprague-­‐-­‐-­‐Dawley	  	  rats,	  	  resulting	  	  in	  	  ulceration	  	  within	  	  1	  	  day,	  	  granulation	  	  tissue	  	  at	  	  the	  ulcer	  	  edges	  	  by	  	  day	  	  4,	  	  and	  	  re-­‐-­‐-­‐epithelialisation	  	  and	  	  repair	  	  by	  	  day	  	  7.	  	  This	  	  time	  	  course	  	  was	  shown	  	  to	  	  be	  	  mirrored	  	  by	  	  myeloperoxidase	  	  activity	  	  in	  	  intestinal	  	  mucosa,	  	  an	  	  assay	  	  which	  quantifies	  	  	  neutrophilic	  	  	  infiltration,	  	  as	  	  	  well	  	  as	  	  	  intestinal	  	  FDG	  	  	  signal	  	  with	  	  	  foci	  	  observed	  exclusively	  	  in	  	  the	  	  indomethacin-­‐-­‐-­‐treated	  	  rodents.	  The	  	  investigators	  	  attempted	  	  to	  	  determine	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the	  	  	  cellular	  	  	  source	  	  	  of	  	  	  the	  	  	  signal	  	  	  by	  	  	  performing	  	  	  macro	  	  	  and	  	  	  micro-­‐-­‐-­‐autoradiography	  	  	  in	  sacrificed	  	  	  animals	  	  	  shortly	  	  	  after	  	  	  FDG	  	  	  administration.	  	  	  Macro-­‐-­‐-­‐autoradiography	  	  	  revealed	  discontinuous,	   dot-­‐-­‐-­‐like	   accumulations	   on	   the	  mesenteric	   side	   of	   the	   ileal	  mucosa,	  which	   co-­‐-­‐-­‐	  localised	  	  with	  	  the	  	  ulcerations.	  	  18F-­‐-­‐-­‐FDG	  	  micro-­‐-­‐-­‐autoradiography	  	  in	  	  combination	  	  with	  	  H&E	  staining	  localized	  the	  activity	  in	  the	  ulcer	  margins,	  within	  the	  mucosa	  but	  also	  in	  submucosal	  and	  	  smooth	  	  muscle	  	  layers.	  	  In	  	  contrast	  	  to	  	  the	  	  Brewer	  	  indirect	  	  experiments,	  	  which	  	  revealed	  CD4+	  T	  helper	  cells	  as	  the	  probable	  sole	  source	  of	  the	  FDG	  signal,	  Yamato’s	  group	  performed	  co-­‐-­‐-­‐staining	  	  and	  	  direct	  	  visualization	  	  revealing	  	  a	  	  much	  	  broader	  	  range	  	  of	  	  cells	  	  containing	  	  18F.	  On	  	  day	  	  1,	  	  the	  	  majority	  	  of	  	  cells	  	  containing	  	  the	  	  radioactivity	  	  were	  	  myeloperoxidase-­‐-­‐-­‐positive	  neutrophils	  	  and	  	  macrophages,	  	  whereas	  	  on	  	  day	  	  4	  	   the	  	   foci	  	  were	  	  mainly	  	  α-­‐-­‐-­‐SMA	  	  positive	  myofibroblasts,	  	  	  CD31-­‐-­‐-­‐positive	  	  	  endothelial	  	  	  cells	  	  	  and	  	  	  some	  	  	  ED-­‐-­‐-­‐2	  	  	  positive	  	  	  macrophages.	  Moreover,	  abundant	  FDG	  also	  accumulated	  in	  Ki67	  stem	  cells	  deep	  inside	  the	  crypts143.	  	  	   Finally,	  	  a	  	  research	  	  group	  	  from	  	  Germany	  	  carried	  	  out	  	  a	  	  series	  	  of	  	  experiments	  	  using	  	  the	  Dextran	  	  Sulfate	  	  Sodium	  	  (DSS)	  	  model	  	  of	  	  colitis	  	  in	  	  C57BL/6	  	  wild	  	  type	  	  mice.	  	  All	  	  the	  	  animals	  exposed	  	  	  to	  	  	  DSS	  	  	  for	  	  	  7	  	  	  days	  	  	  had	  	  	  an	  	  	  elevated	  	  	  FDG	  	  	  signal	  	  	  compared	  	  	  to	  	  	  control	  	  	  mice,	  predominantly	  	  in	  	  the	  	  medial	  	  and	  	  distal	  	  colon.	  	  Histological	  	  activity	  	  in	  	  the	  	  various	  	  regions	  correlated	  	  very	  	  well	  	  with	  	  a	  	  change	  	  in	  	  signal	  	  before	  	  and	  	  after	  	  DSS,	  	  with	  	  areas	  	  of	  	  superficial	  erosion	  	  	  or	  	  	  deep	  	  	  ulceration	  	  	  demonstrating	  	  	  an	  	  	  up	  	  	  to	  	  	  400%	  	  	  increase	  	  	  of	  	  	  tracer	  	  	  uptake.	  Moreover,	  	  	   colonic	  	  	  	  FDG	  	  	  	  signal	  	  	  had	  	  	  	  dropped	  	  	  	  substantially	  	  	  	  at	  	  	  day	  	  	  	  10,	  	  	  	  3	  	  	  	  days	  	  	  	  after	  discontinuation	  	  	  of	  	  	  DSS,	  	  	  suggesting	  	  	  good	  	  	  responsiveness	  	  	  of	  	  	  the	  	  	  test	  	  	  in	  	  	  reflecting	  	  	  the	  inflammatory	   changes.	   	   	  In	   addition	   to	   the	   intestinal	   signal,	   the	  authors	   identified	  an	  almost	  3.5-­‐-­‐-­‐fold	  	  	  increase	  	  	  of	  	  	  FDG	  	  	  uptake	  	  	  in	  	  	  large	  	  	  joints	  	  	  of	  	  	  exposed	  	  	  mice	  	  	  and	  	  	  suggested	  	  	  the	  possibilities	  	  of	  	  a	  	  colitis-­‐-­‐-­‐associated	  	  arthropathy	  	  versus	  	  bone	  	  marrow	  	  hyperactivation.	  	  In	  	  an	  attempt	  	  to	  	  differentiate	  	  between	  	  the	  	  two,	  	  several	  	  joints	  	  were	  	  examined	  	  histologically,	  	  and	  there	  	  were	  	  no	  	  features	  	  of	  	  immune	  	  cell	  	  infiltrates	  	  or	  	  cartilaginous	  	  damage.	  	  Bone	  	  marrow	  histology	  	  	  	  revealed	  	  	  	  significant	  	  	  	  hyperproliferation	  	  	  	  in	  	  	  	  keeping	  	  	  	  with	  	  	  	  pro-­‐-­‐-­‐inflammatory	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activation.	  This	   finding	  was	  corroborated	  with	  flow	  cytometry	  of	  bone	  marrow	  and	  spleen	  extracts,	  which	  demonstrated	  a	  substantial	  increase	  in	  granulocyte	  precursors144.	  	  	   In	  	  	  summary,	  	  	  knowledge	  	  	  in	  	  	  the	  	  	  field	  	  	  of	  	  	  FDG-­‐-­‐-­‐PET	  	  	  scanning	  	  	  in	  	  	  CD	  	  	  has	  	  	  moved	  	  	  forward	  significantly	   over	   recent	   years.	   Starting	   from	   initial	   reports	   qualitatively	   demonstrating	   co-­‐-­‐-­‐	  localisation	  of	  intestinal	  FDG	  foci	  and	  endoscopic	  features	  of	  disease,	  we	  have	  now	  identified	  tools	  	  which	  	  we	  	  can	  	  use	  	  to	  	  measure	  	  the	  	  signal	  	  both	  	  in	  	  a	  	  single	  	  segment	  	  as	  	  well	  	  as	  	  in	  	  the	  entirety	  of	  bowel	   in	  each	  patient.	   It	  has	  also	  been	  demonstrated	  with	  reasonable	  confidence	  that	  	  	  higher	  	  	  FDG	  	  	  activity	  	  	  mirrors	  	  	  more	  	  	  significant	  	  	  inflammation,	  	  	  as	  	  	  measured	  	  	  by	  	  	  the	  currently	  	  accepted	  	  gold	  	  standards.	  	  Evidence	  	  from	  	  animal	  	  experiments	  	  suggests	  	  that	  	  the	  origin	  of	  the	  FDG	  signal	  can	  be	  pinpointed	  in	  inflammatory	  but	  also	  endothelial	  and	  resident	  intestinal	  	  stem	  	  cells.	  	  Moreover,	  	  murine	  	  experiments	  	  demonstrate	  	  that	  	  FDG	  	  signal	  	  intensity	  readily	  	   fluctuates	  	   in	  	  keeping	  	  with	  	  the	  	  underlying	  	   inflammatory	  	  cell	  	  burden	  	   in	  	  affected	  segments	  	  in	  	  animal	  	  studies.	  	  For	  	  FDG-­‐-­‐-­‐PET	  	  to	  	  have	  	  a	  	  role	  	  in	  	  the	  	  longitudinal	  	  monitoring	  	  of	  patients	  with	  CD	  in	  clinical	  practice,	  or	  as	  an	  endpoint	  of	  demonstrating	  early	  efficacy	  in	  the	  context	  	  	  	  of	  	  	  	  new	  	  	  	  drug	  	  	  	  development,	  	  	  	  it	  	  	  	  is	  	  	  	  important	  	  	  	  for	  	  	  	  this	  	  	  	  responsiveness	  	  	  	  to	  	  	  	  be	  demonstrated	  	  in	  	  a	  	  human	  	  study.	  	  Lessons	  	  from	  	  the	  	  rheumatological	  	  literature	  	  are	  	  certainly	  encouraging	  to	  that	  end,	  but	  prospective	  data	  with	  early	  follow-­‐-­‐-­‐up	  are	  still	  scarce132.	  	  	  
1.2.5.4.2 Alternative	  targets	  in	  inflammatory	  imaging	  
	  
	  
	   The	   inflammatory	   process	   is	   triggered,	   and,	   subsequently	   propagated,	   by	   a	   variety	   of	  mediators	   which	   include	   cytokines,	   chemokines	   and	   other	   small	   molecules,	   produced	   by	  endothelium	   and	   resident,	   as	   well	   as	   newly	   recruited	   inflammatory	   cells.	   This	   cascade	   is	  commonly	  accompanied	  by	  increased	  vascular	  permeability	  and	  terminated	  by	  mediators	  of	  apoptosis	  of	  dominant	  cells.	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All	   of	   these	   key	   cellular	   components	   and	   mediator	   molecules	   can	   potentially	   function	   as	  targets	   for	   radiotracers	   aimed	   at	   the	   imaging	   of	   the	   inflammatory	   process.	   The	   following	  section	  summarises	  current	  evidence	  and	  potential	  applications	  appearing	  in	  the	   literature	  for	  several	  such	  targets.	  To	  date,	  all	  of	  the	  agents	  outlined	  below	  are	  purely	  research	  tools	  which	  have	  not	  progressed	  through	  to	  clinical	  translation,	  some	  of	  them	  however	  hold	  great	  potential	  of	  finding	  a	  clinical	  niche	  in	  the	  near	  future.	  	  	  
1.2.5.4.2.1 Membrane	  markers	  of	  inflammatory	  cells	  -­‐-­‐-­‐TSPO	  
	  
	  
	   Translocator	  	  Protein	  	   (TSPO),	  	  previously	  	  known	  	  as	  	  Peripheral	  	  Benzodiazepine	  	  Receptor	  (PBR)	  	  is	  	  a	  	  18kDa	  	  trans-­‐-­‐-­‐membrane	  	  receptor	  	  consisting	  	  of	  	  169	  	  amino	  	  acids145.	  	  It	  	  is	  	  most	  commonly	  	  	  expressed	  	  	  on	  	  	  the	  	  	  outer	  	  	  mitochondrial	  	  	  membrane,	  	  	  while	  	  	  some	  	  	  studies	  	  	  have	  demonstrated	  the	  presence	  of	  TSPO	  on	  erythrocytes	  which	  are	   free	  of	  mitochondria,	  as	  well	  as	  	  plasma	  	  membranes	  	  of	  	  peripheral	  	  cells	  	  such	  	  as	  	  hepatocytes146.	  	  TSPO	  	  has	  	  been	  	  shown	  	  to	  express	  	  throughout	  	  the	  	  body	  	  and	  	  brain.	  	  	  	  Concentrations	  	  are	  	  relatively	  	  higher	  	  in	  	  steroid-­‐-­‐-­‐	  producing	  	  endocrine	  	  tissues,	  	  as	  	  opposed	  	  to	  	  brain,	  	  liver	  	  and	  	  breast.	  	  In	  	  peripheral	  	  blood	  TSPOs	  are	  most	  commonly	  found	  in	  monocytes	  and	  PMNs147	  	  	   The	  	  reason	  	  TSPO	  	  has	  	  been	  	  extensively	  	  studied	  	  in	  	  the	  	  context	  	  of	  	  inflammatory	  	  molecular	  imaging	  is	   its	   increased	  expression	  in	  macrophages,	  neutrophils	  and	  lymphocytes.	   In	  human	  atherosclerosis,	  	  it	  	  has	  	  been	  	  shown	  	  that	  	  macrophages	  	  express	  	  binding	  	  sites	  	  for	  	  PK11195,	  	  a	  selective	  	  TSPO	  	  ligand,	  	  20	  	  times	  	  more	  	  abundantly	  	  than	  	  vascular	  	  smooth	  	  muscle	  	  cells,	  	  and	  autoradiographic	  	  	  	  experiments	  	  	  	  demonstrated	  	  	  	  co-­‐-­‐-­‐localisation	  	  	  	  of	  	  	  	  this	  	  	  	  ligand	  	  	  	  with	  	  	  	  the	  macrophage-­‐-­‐-­‐specific	  	  CD68148.	  	  	  	  These	  	  findings	  	  have	  	  found	  	  applications	  	  in	  	  in	  	  vivo	  	  carotid	  atherosclerotic	  	  PET	  	  imaging	  	  with	  	  PK11195,	  	  with	  	  a	  	  high	  	  tissue-­‐-­‐-­‐to-­‐-­‐-­‐background	  	  signal	  	  being	  associated	  with	   symptomatic	   stenoses149.	   Similar	   increases	   have	   also	   been	   demonstrated	   in	  imaging	  of	  synovial	   inflammation	  in	  patients	  with	  rheumatoid	  arthritis,	   in	  whom	  the	  signal	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was	  also	   correlated	   to	  an	   influx	  of	  macrophages	  within	  diseased	   synovium150.	  Other	   studies	  have	  demonstrated	   the	   efficacy	  of	  TSPO	  PET	   imaging	   in	   inflammatory	  models	   of	   acute	   lung	  injury151,	  as	  well	  as	  non-­‐-­‐-­‐alcoholic	  fatty	  liver	  disease	  (NAFLD)	  152,	   implicating	  other	  cells	  such	  as	  neutrophils	  and	  lymphocytes	  as	  having	  a	  role	  for	  the	  increased	  tracer	  uptake	  .	  
There	   is	   an	   even	  more	   extensive	   body	   of	   evidence	   supporting	   the	   use	   of	   TSPO	   tracers	   in	  imaging	   of	   brain	   disease,	   which	   is	   underpinned	   by	   a	   combination	   of	   low	   background	  expression,	   which	   increases	   sharply	   in	   activated	   microglia,	   which	   hold	   key	   roles	   in	   the	  pathophysiology	  in	  a	  large	  array	  of	  CNS	  conditions153.	  
In	   addition	   to	   TSPO,	   alternative	   examples	   of	   membrane	   markers	   are	   the	   somatostatin	  receptor	   (sst2)	   and	   cortistatin	   receptor	   (cst)	   with	   applications	   in	   the	   imaging	   of	  atherosclerosis	   154,	   and	   the	   type	  2	   cannabinoid	   receptor	  CB2R	  which	  holds	  promise	   in	   the	  field	  of	  CNS	  inflammation	  155.	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   Interleukin-­‐-­‐-­‐2	  	  (IL-­‐-­‐-­‐2)	  	  is	  	  a	  	  pro-­‐-­‐-­‐inflammatory	  	  cytokine	  	  produced	  	  by	  	  activated	  	  Th1-­‐-­‐-­‐cells	  	  and	  	  it	  promotes	  	  	  further	  	  	  T-­‐-­‐-­‐cell	  	  	  proliferation,	  	  	  differentiation	  	  	  of	  	  	  B-­‐-­‐-­‐cells	  	  	  and	  	  	  Natural	  	  	  Killer	  	  	  and	  macrophage	  activation.	  The	  effects	  of	  IL-­‐-­‐-­‐2	  are	  mediated	  through	  binding	  to	  the	  IL-­‐-­‐-­‐2	  receptor	  (IL-­‐-­‐-­‐2R),	  a	  heterotrimeric	  receptor	  comprising	  of	  a	  α	  (CD25),	  β	  and	  γ	  subunits	  156,157.	  	  	   There	  	  	  have	  	  	  been	  	  	  several	  	  	  studies	  	  	  over	  	  	  the	  	  	  last	  	  	  two	  	  	  decades	  	  	  on	  	  	  applications	  	  	  of	  	  	  IL-­‐-­‐-­‐2	  scintigraphy	  	   in	  	  the	  	  diagnosis	  	  and	  	   follow-­‐-­‐-­‐up	  	  of	  	  a	  	  variety	  	  of	  	  conditions	  	  underpinned	  	  by	  abnormal	  	  monocytic	  	   infiltration	  	   in	  	   tissue:	  	  Signore	  	  et	  	  al.	  	  demonstrated	  	   the	  	  potential	  	  of	  
123Iodine-­‐-­‐-­‐labelling	  	  	  of	  	  	  the	  	  	  IL2	  	  	  molecule	  	  	  and	  	  	  subsequent	  	  	  tracing	  	  	  of	  	  	  its	  	  	  accumulation	  	  	  by	  analysing	  	  pancreatic	  	  tissue	  	  both	  	  in	  vivo	  	  and	  	  ex-­‐-­‐-­‐vivo	  	  in	  	  a	  	  murine	  	  model	  of	  diabetes	  	  158.	  	  	  In	  	  a	  different	  	  study	  in	  diabetic	  patients	  the	  same	  group	  used	  a	  different	  radioligand,	  99Tc-­‐-­‐-­‐IL2,	  	  to	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longitudinally	  	  assess	  	  newly	  	  diagnosed	  	  Type	  	  I	  	  diabetics	  	  before	  	  and	  	  after	  	  treatment	  	  with	  nicotinamide	  	  (NA).	  	  IL2	  	  radio-­‐-­‐-­‐labeling	  	  was	  	  successful	  	  in	  	  selecting	  	  the	  	  subgroup	  	  of	  	  patients	  with	  	  active	  	  insulitis	  	  at	  	  onset,	  	  who	  	  benefited	  	  from	  	  NA	  	  therapy	  	  as	  	  evidenced	  	  by	  	  significantly	  lowered	  insulin	  requirements	  at	  one	  year159.	  	  	   Several	  	  other	  	  human	  	  studies	  	  on	  	  IL-­‐-­‐-­‐2	  	  radiolabeling	  	  in	  	  a	  	  variety	  	  of	  	  auto-­‐-­‐-­‐immune	  	  conditions	  had	  	  been	  	  carried	  	  out	  	  by	  	  the	  	  same	  	  group	  	  in	  	  the	  	  interim.	  	  	  	  One	  	  such	  	  study	  	  compared	  	  10	  patients	  	  with	  	  celiac	  	  disease,	  	  7	  	  of	  	  which	  	  were	  	  re-­‐-­‐-­‐investigated	  	   following	  	  gluten-­‐-­‐-­‐free	  	  diet	  (GFD),	  	  	  with	  	  	  10	  	  	  normal	  	  	  controls.	  	  	  Radiographic	  	  	  analysis	  	  	  showed	  	  	  significant	  	  	  differences	  between	  	  untreated	  	  coeliacs	  	  and	  	  coeliacs	  	  post	  	  GFD	  	  in	  	  5/6	  	  regions	  	  analysed,	  	  as	  	  well	  	  as	  between	  coeliacs	  and	  normal	  controls	   in	  6/6	  regions	  analysed.	   Importantly,	  despite	  clusters	  of	  	  CD25	  	  +ve	  	  cells	  	  being	  	  demonstrated	  	  in	  	  normal	  	  individuals,	  	  these	  	  did	  	  not	  	  lead	  	  to	  	  any	  appreciable	  	  uptake	  	  of	  	  the	  	  radio-­‐-­‐-­‐ligand	  	  to	  	  trigger	  	  positivity	  	  in	  	  planar	  	  or	  	  tomographic	  	  γ-­‐-­‐-­‐	  camera	  	  	  	  imaging.	  	  	  	  Histological	  	  	  	  data,	  	  	  	  obtained	  	  	  	  only	  	  	  	  in	  	  	  	  patients	  	  	  	  with	  	  	  	  coeliac	  	  	  	  disease	  demonstrate	  	  a	  	  changing	  	  prevalence	  	  of	  	  CD25	  	  positive	  	  mononuclear	  	  cells	  	  pre	  	  and	  	  post	  	  GFD	  (P<0.0001),	  	  	  	  which	  	  	  	  is	  	  	  	  in	  	  	  	  keeping	  	  	  	  with	  	  	  	  the	  	  	  	  difference	  	  	  	  of	  	  	  	  radio-­‐-­‐-­‐active	  	  	  	  signals.	  	  	  	  No	  immunological	  	  marker	  	  (e.g.	  	  anti-­‐-­‐-­‐gliadin	  	  antibody	  	  or	  	  serum	  	  soluble	  	  IL2-­‐-­‐-­‐R)	  	  correlated	  	  with	  
123I-­‐-­‐-­‐IL2	  	  	  	   signal.	  	  	  	  	  	  	  	  	  Finally,	  	  	  	   immunohisto-­‐-­‐-­‐staining	  	  	  	   for	  	  	  	  CD25	  	  	  	  and	  	  	  	  concurrent	  	  	  	  micro-­‐-­‐-­‐	  autoradiography	  of	  biopsied	   tissue	   confirms	   that	   the	   123I-­‐-­‐-­‐IL-­‐-­‐-­‐2	   signal	   is	   actually	  derived	   from	  binding	  to	  CD25	  cells	  rather	  than	  non-­‐-­‐-­‐specific	  binding	  160.	  	  	   A	  	  similar	  	  study	  	  on	  	  carotid	  	  atherosclerosis	  	  using	  	  the	  	  99Tc	  	  ligand	  	  on	  	  IL2	  	  showed	  	  similar	  results	  	  with	  	  good	  	  correlation	  	  between	  	  signal	  	  and	  	  CD25+ve	  	  cells	  	  on	  	  histology.	  	  However,	  	  on	  this	  	  occasion,	  	  monocytes	  	  accounted	  	  for	  	  only	  	  a	  	  proportion	  	  of	  	  CD25+	  	  cells	  	  which	  	  in	  	  their	  majority	  	  were	  	  activated	  	  smooth	  	  muscle	  	  cells	  	  (SMCs).	  	  This	  	  was	  	  justified	  	  by	  	  a	  	  ‘synthetic	  plaque’	  	  paradigm	  	  where	  	  there	  	  is	  	  excessive	  	  interaction	  	  between	  	  immune	  	  and	  	  non-­‐-­‐-­‐immune	  cells	  	  with	  	  a	  	  trophic	  	  effect	  	  in	  	  the	  	  latter.	  	  Regardless	  	  of	  	  the	  	  exact	  	  aetio-­‐-­‐-­‐pathogenesis	  	  of	  	  CD25	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positivity	  	   in	  	  SMCs,	  	   it	  	  highlights	  	  the	  	  observation	  	  that	  	  IL-­‐-­‐-­‐2	  	  radio-­‐-­‐-­‐ligands	  	  are	  	  not	  	  strictly	  immune-­‐-­‐-­‐cell	  selective,	  in	  conditions	  studied	  161.	  	  	   The	  	  	  	  same	  	  	  	  group	  	  	  	  has	  	  	  	  also	  	  	  	  performed	  	  	  	  123I-­‐-­‐-­‐IL-­‐-­‐-­‐2	  	  	  	  Single	  	  	  	  Photon	  	  	  	  Emission	  	  	  	  Computed	  Tomography	  (SPECT)	  scanning	  in	  Crohn’s	  disease.	  	  The	  study	  group	  comprised	  of	  10	  healthy	  controls	   and	  15	   subjects	  with	   ileal	   CD,	   confirmed	  by	   conventional	  measures,	  who	  were	  not	  on	  	  steroid	  	  or	  	  immunosuppressive	  	  therapy.	  	  10	  	  had	  	  active	  	  disease	  	  and	  	  5	  	  were	  	  in	  	  remission	  based	  	  on	  	  CDAI.	  	  Of	  	  the	  	  10	  	  patients	  	  with	  	  active	  	  disease,	  	  6	  	  were	  	  re-­‐-­‐-­‐examined	  	  following	  	  a	  	  12-­‐-­‐-­‐	  week	  	  	  interval	  	  	  of	  	  	  treatment	  	  	  with	  	  	  corticosteroids.	  	  	  There	  	  	  were	  	  	  statistically	  	  	  significant	  differences	  	  both	  	  in	  	  SPECT	  	  and	  	  planar	  	  data	  	  between	  	  all	  	  3	  	  groups	  	  (healthy,	  	  CD	  	  in	  	  remission	  and	   active	   CD).	   There	  was	   also	   a	   correlation	   between	   activity	   on	   IL-­‐-­‐-­‐2	   scanning	   and	   clinical	  deterioration	  	  or	  	  relapse	  	  of	  	  disease	  	  (r=0.49	  	  P=0.03).	  	  Interestingly,	  	  there	  	  was	  	  no	  	  attempt	  	  to	  correlate	  	  the	  	  location	  	  of	  	  IL-­‐-­‐-­‐2	  	  accumulation	  	  with	  	  that	  	  of	  	  active	  	  disease	  	  established	  	  with	  conventional	  	  methods	  	  i.e.	  	  the	  	  study	  	  does	  	  not	  	  inform	  	  if	  	  the	  	  IL-­‐-­‐-­‐2	  	  probe	  	  reveals	  	  the	  	  active	  segments	   or	   sub-­‐-­‐-­‐clinical	   inflammation	   elsewhere.	   On	   a	   micro-­‐-­‐-­‐autoradiography	   assay	   which	  was	   performed	  on	   bowel	   resected	   shortly	   after	   administration	   of	   the	   radio-­‐-­‐-­‐ligand,	   some	   co-­‐-­‐-­‐	  localisation	  	  between	  	  the	  	  radio-­‐-­‐-­‐activity	  	  and	  	  CD-­‐-­‐-­‐25	  	  +ve	  	  lineages	  	  was	  	  demonstrated,	  	  as	  	  was	  the	  case	  in	  the	  coeliac	  study.	  162.	  	  	   Finally,	  the	  same	  group	  investigated	  the	  prognostic	  potential	  of	  both	  99Tc-­‐-­‐-­‐IL2	  as	  well	  as	  99Tc-­‐-­‐-­‐	  HMPAO	  	  WBC	  	  scintigraphy,	  	  in	  	  a	  	  cohort	  	  of	  	  10	  	  controls	  	  and	  	  29	  	  CD	  	  patients	  	  in	  	  deep,	  	  long-­‐-­‐-­‐	  standing	  remission	  of	  over	  12	  months	   in	  duration.	  Subjects	  underwent	  both	  diagnostic	  tests	  at	  	  	  entry,	  	   and	  	  	  subsequently	  	  	  clinical	  	   and	  	  	  laboratory	  	  	  parameters	  	  	  were	  	  	  monitored	  	  	  for	  	  	  12	  months.	  	  	  	  Several	  	  interesting	  	  points	  	  arise	  	  from	  	  this	  	  study.	  	  Firstly,	  	  concordance	  	  in	  	  the	  	  two	  scans	  was	   seen	   in	  17	  of	  29	  patients	   (12	  positive	   and	  5	  negative)	  whereas	   in	   the	   remainder	  the	  	  results	  	  were	  	  discordant.	  	  In	  	  addition,	  	  out	  	  of	  	  12	  	  patients	  	  with	  	  concordant	  	  results,	  	  only	  	  1	  patient	  showed	  co-­‐-­‐-­‐localisation	  of	  monocytic	  and	  neutrophilic	   infiltrates	  suggesting	  that	  the	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techniques	  	  may	  	  be	  	  capturing	  	  sub-­‐-­‐-­‐clinical	  	  disease	  	  at	  	  different	  	  stages	  	  of	  	  its	  	  natural	  	  history.	  Finally,	   both	   tests	   had	   an	   excellent	  NPV	  >90%	  whereas	   the	  Positive	  Predictive	  Value	   (PPV)	  was	  	  around	  	  40%	  	  161.	  	  Importantly,	  	  a	  	  complete	  	  lack	  	  of	  	  adverse	  	  effects	  	  was	  	  reported	  	  by	  	  the	  authors	  	  	  on	  	  	  all	  	  	  of	  	  	  the	  	  	  aforementioned	  	  	  studies.	  	  The	  	  	  study	  	  	  dose	  	  	  is	  	  	  less	  	  	  than	  	  	  1%	  	  	  of	  	  	  the	  therapeutic	   dose	   of	   IL2	   immunotherapy,	   licensed	   for	   use	   in	   end-­‐-­‐-­‐stage	  metastatic	  melanoma	  and	  renal-­‐-­‐-­‐cell	  carcinoma,	  and	  therefore	  no	  biologic	  effects	  were	  anticipated.	  	  	   While	  	  IL-­‐-­‐-­‐2	  	   is	  	  a	  	  well-­‐-­‐-­‐studied	  	  cytokine	  	  system	  	  in	  	  the	  	  context	  	  of	  	   inflammatory	  	  molecular	  imaging,	  	  there	  	  are	  	  several	  	  studies	  	  of	  	  key	  	  molecules	  	  in	  	  alternative	  	  inflammatory	  	  pathways.	  Interestingly,	   the	  	  majority	  	  of	   the	  	  probes	  	  put	  	  forward	  	  in	  	  this	  	  category	  	  comprise	  	  of	  	  selective	  medications	  	  already	  	  in	  	  use	  	  in	  	  routine	  	  clinical	  	  practice,	  	  with	  	  established	  	  selectivity	  	  profiles,	  which	   have	   been	  modified	   by	   the	   tagging	   of	   appropriate	   radionuclides	  which	   renders	   them	  detectable	  by	  imaging	  devices.	  	  	   One	  of	   these	   is	   cyclo-­‐-­‐-­‐oxygenase	  2	   (COX-­‐-­‐-­‐2),	   an	   enzyme	   that	   transforms	   arachidonic	   acid	   into	  prostaglandins	  	  	  	  in	  	  	  	  inflamed	  	  	  	  tissues.	  	  	  	  Celecoxib	  	  	  	  is	  	  	  	  an	  	  	  	  established	  	  	  	  non-­‐-­‐-­‐steroidal	  	  	  	  anti-­‐-­‐-­‐	  inflammatory	  	   selective	  	   for	  	  COX-­‐-­‐-­‐2,	  	  and	  	   several	  	   investigators	  	  have	  	  produced	  	   radioligand	  versions	  of	  celecoxib,	  which	  until	  recently	  had	  rather	  poor	  signal	  to	  noise	  ratios	  163.	  A	  recent	  
18F-­‐-­‐-­‐	  	  celecoxib	  	  derivative	  	  is	  	  likely	  	  more	  	  specific	  	  than	  	  its	  	  predecessors,	  	  which	  	  holds	  	  some	  promise	  as	  an	  early	  marker	  of	  pre-­‐-­‐-­‐malignant	  lesions.	  	  	   Another	  	  key	  	  cytokine	  	  in	  	  both	  	  acute	  	  as	  	  well	  	  as	  	  chronic	  	  inflammatory	  	  cascades	  	  is	  	  Tumour	  Necrosis	  Factor-­‐-­‐-­‐alpha	  (TNFa),	  with	  chemotactic	  as	  well	  as	  anti-­‐-­‐-­‐apoptotic	  funtions164.	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1.2.5.4.2.3 Targets	  related	  to	  angiogenesis	  
	  
	  




	   The	  last	  two	  decades	  have	  seen	  major	  advances	  in	  the	  diagnostics	  of	  Crohn’s	  disease.	  Studies	  that	  demonstrate	   the	  dissociation	  between	  symptoms	  and	  clinical	  scores,	  and	  even	  between	  mucosal	  	  activity	  	  and	  	  underlying	  	  bowel	  	  damage	  	  have	  	  had	  	  a	  	  major	  	  impact	  	  on	  	  the	  	  way	  	  we	  program	  	  our	   therapeutic	  	  interventions	  and	  	  monitoring	  	  strategies.	  Moreover,	  as	   treatments	  become	  	  more	  	  sophisticated,	  	  as	  	  well	  	  as	  	  costly	  	  and	  	  potentially	  	  toxic,	  	  the	  	  lack	  	  of	  	  a	  	  gold-­‐-­‐-­‐	  standard	   instrument	  to	  quantify	  and	  monitor	  the	   inflammatory	   load	   is	  more	  important	  than	  ever	  before.	   	   	  The	  development	  of	   such	   a	   gold	   standard	   is	   required	   in	   order	   to	   fulfill	   unmet	  needs	   such	   as	   the	   timely	   escalation	   of	   therapy	   before	   irreversible	   damage	   occurs,	   the	   early	  identification	  	  	  of	  	  	  response	  	  	  to	  	  	  treatment	  	  	  as	  	  	  well	  	  	  as	  	  	  the	  	  	  more	  	  	  targeted	  	  	  recruitment	  	  	  of	  appropriate	  	  patients	  	  in	  	  clinical	  	  studies.	  	  Intense	  	  research	  	  effort	  	  has	  	  gone	  	  into	  	  thoroughly	  defining	  	  roles	  	  for	  	  existing	  	  modalities,	  	  while	  	  steps	  	  are	  	  also	  	  being	  	  made	  	  in	  	  investigating	  functions	  of	  novel	  tools	  such	  as	  molecular	  imaging	  in	  that	  arena.	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1.4.1 18F-­‐-­‐-­‐FDG	  	  Positron	  	  Emission	  	  Tomography	  	  outcome	  	  measures	  	  in	  	  the	  	  monitoring	  
of	  inflammatory	  activity	  in	  Crohn’s	  disease	  
	  
	  
	   The	  	  study	  	  described	  	  in	  	  Chapter	  	  2	  	  aimed	  	  to	  	  investigate	  	  the	  	  monitoring	  	  of	  	  inflammatory	  activity	  in	  Crohn’s	  disease	  with	  18F-­‐-­‐-­‐FDG-­‐-­‐-­‐PET,	  for	  the	  first	  time.	  	  	   i. 18F-­‐-­‐-­‐FDG	  	  has	  	  been	  	  shown	  	  to	  	  accumulate	  	  in	  	  areas	  	  of	  	  active	  	  inflammation	  	  in	  	  CD	  producing	  higher	   signal	   than	   in	  unaffected	   segments.	  This	   signal	   correlates	  with	  endoscopic	  and	  histopathological	  markers	  of	   severity	  and	   it	   can	  be	  quantified	   in	  terms	  of	   its	   intensity	   and	  extent.	   It	  was	  hypothesised	   that	   the	  magnitude	  of	   this	  signal	   in	  each	  affected	  bowel	  segment	  would	  remain	  unchanged	   in	  patients	  with	  stable	  disease	  and	  on	  stable	  therapy,	  over	  short	  periods	  of	  time.	  ii. It	  	  was	  	  hypothesized	  	  that	  	  several	  	  measures	  	  of	  	   this	  	   focal	  	  FDG	  	  activity	  	  would	  change	  over	  a	  12-­‐-­‐-­‐week	  interval	  in	  patients	  responding	  to	  anti-­‐-­‐-­‐TNFα	  therapy.	  iii. It	  	  was	  	  also	  	  hypothesized	  	  that	  	  several	  	  measures	  	  of	  	  the	  	  18F-­‐-­‐-­‐FDG	  	  signal	  	  would	  	  be	  correlated	  	  with	  	  clinical	  	  and	  	  biochemical	  	  markers	  	  of	  	  disease	  	  severity	  	  both	  	  at	  	  a	  single	  time-­‐-­‐-­‐point	  as	  well	  as	  longitudinally.	  	  
1.4.2 Magnetic	  Resonance	  Imaging	  outcome	  measures	  in	  the	  monitoring	  
of	  inflammatory	  activity	  in	  Crohn’s	  disease	  
	  
	   The	  study	  outlined	  in	  Chapter	  3	  aimed	  to	   investigate	  the	  role	  of	  MRI	  scores	  in	  monitoring	  inflammatory	  activity	  in	  Crohn’s	  disease.	  	  	   i. Several	  scores	  have	  been	  derived	  using	  MRI,	  which	  assess	  anatomical	  as	  well	  as	  functional	  aspects	  of	  disease	   severity	   in	  actively	   inflamed	  segments	   in	  patients	  with	   CD.	   These	   have	   been	   correlated	  with	   clinical,	   endoscopic	   and	   other	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biochemical	  	  markers	  	  of	  	  disease	  	  severity.	  	  Similarly	  	  to	  	  the	  	  18F-­‐-­‐-­‐FDG	  	  study,	  	  it	  	  was	  hypothesised	   that	   these	   scores	  would	   remain	   unchanged	   in	   patients	  with	   stable	  disease,	  and	  on	  stable	  therapy	  over	  short	  time	  periods.	  ii. It	  	  was	  	  hypothesised	  	  that	  	  anatomical	  	  and	  	  functional	  	  MRI	  	  scores	  	  representing	  disease	   activity	  would	   change	  over	   a	   12-­‐-­‐-­‐week	   interval	   in	  patients	   responding	   to	  anti-­‐-­‐-­‐TNFα	  therapy.	  iii. It	  	  	  was	  	  	  also	  	  	  hypothesized	  	  	  that	  	  	  anatomical	  	  	  and	  	  	  functional	  	  	  MRI	  	  	  scores	  	  	  would	  correlate	  	  with	  	  clinical	  	  and	  	  biochemical	  	  markers	  	  of	  	  disease	  	  severity	  	  both	  	  at	  	  a	  single	  time-­‐-­‐-­‐points	  as	  well	  as	  longitudinally.	  	  
1.4.3 Exploration	  of	  alternative	  targets	  for	  PET	  radioligands	  specific	  to	  
inflammatory	  pathways	  
	  
	   The	  study	  described	   in	  Chapter	  4	  aimed	   to	  assess	   the	  expression	  of	  TSPO	  and	   IL-­‐-­‐-­‐2	   receptor	  in	  	  normal	  	  versus	  	  inflamed	  	  bowel	  	  segments.	  	  Moreover	  	  it	  	  aimed	  	  to	  	  evaluate	  	  the	  	  binding	  properties	  of	  TSPO	  and	  IL-­‐-­‐-­‐2R	  specific	  radioligands	  in	  normal	  versus	  inflamed	  tissue.	  	  	   i. TSPO	  	  has	  	  been	  	  shown	  	  to	  	  over-­‐-­‐-­‐express	  	  in	  	  a	  	  variety	  	  of	  	  inflammatory	  	  conditions.	  Studies	  	  	  have	  	  	  shown	  	  	  that	  	  	  PET	  	  	  radioligands	  	  	  specific	  	  	  for	  	  	  TSPO	  	  	  can	  	  	  quantify	  inflammatory	  load	  in	  a	  variety	  of	  inflammatory	  conditions.	  Expression	  of	  the	  IL-­‐-­‐-­‐2	  receptor	  	  is	  	  also	  	  increased	  	  in	  	  Crohn’s	  	  mucosa.	  	  This	  	  has	  	  been	  	  used	  	  in	  	  the	  	  past	  	  in	  the	  assessment	  of	  activity	  in	  CD	  by	  SPECT	  imaging.	  ii. It	  was	  hypothesised	  that	  TSPO	  and	  IL-­‐-­‐-­‐2R	  will	  be	  over-­‐-­‐-­‐expressed	  in	  	  	  	  intestinal	  sections	  containing	  inflammation	  compared	  to	  uninvolved	  controls.	  iii. It	  was	  also	  hypothesised	  that	  this	  over-­‐-­‐-­‐expression	  will	  also	  represent	  	   an	  increase	  in	  specific	  binding	  sites	  for	  first	  and	  second	  generation	  	  TSPO	  as	  well	  as	  IL-­‐-­‐-­‐2	  radioligands.	  iv. Finally	  it	  was	  hypothesised	  that	  the	  dissociation	  constant	  (Kd)	  of	  PBR28,	  a	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second	  generation	   radioligand	   for	  TSPO,	  would	  be	   similar	   to	   that	  described	   in	  brain.	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   Recently,	  	  there	  	  has	  	  been	  	  a	  	  significant	  	  interest	  	  into	  	  the	  	  capabilities	  	  of	  	  the	  	  18F-­‐-­‐-­‐FDG	  	  PET	  	  to	  delineate	  Crohn’s	  lesions	  and	  quantify	  their	  metabolic	  activity.	  Early	  studies	  suggest	  that	  the	  technique	  	  	  has	  	  	  sensitivity	  	  	  and	  	  	  specificity	  	  	  in	  	  	  lesion	  	  	  identification	  	  	  comparable	  	  	  to	  	  	  other	  available	  modalities	   133,134	  	  .	  Methods	   of	   quantifying	   the	   signal	   intensity	   have	   been	   explored,	  with	  	  the	  	  majority	  	  of	  	  the	  	  early	  	  studies	  	  focusing	  	  on	  	  Standardised	  	  Uptake	  	  Values	  	  (SUV)	  	  136,138	  while	  more	  recent	  reports	  also	  used	  composite	  measures	  including	  signal	  volume,	  translated	  from	  the	  oncological	  literature	  141,168.	  Most	  of	  these	  endpoints	  correlate	  reasonably	  well	  with	  respective	  conventional	  markers	  of	  activity	  both	  on	  a	  segmental	  (e.g.	  CDEIS)	  as	  well	  as	  on	  a	  global	  level	  (clinical	  scoring,	  blood	  and	  faecal	  inflammatory	  markers).	  	  	   There	  	  are	  	  still	  	  several	  	  major	  	  unknown	  	  factors	  	  in	  	  the	  	  role	  	  of	  	  FDG-­‐-­‐-­‐PET	  	  in	  	  monitoring	  	  CD	  patients.	  There	  have	  been	  no	  published	  studies	  exploring	  the	  technique’s	  responsiveness	   i.e.	  the	  potential	  of	  FDG-­‐-­‐-­‐PET	  to	  demonstrate	  change	   in	   its	  outcome	  measures	  over	   time.	  Several	  well-­‐-­‐-­‐designed	  experiments	   in	  appropriate	  murine	  models,	  as	  well	  as	  human	  studies	   in	  other	  chronic	  	  inflammatory	  	  conditions	  	  have	  	  produced	  	  encouraging	  	  results,	  	  but	  	  a	  	   longitudinal	  study	  focused	  on	  CD	  is	  still	  lacking142–144.	  	  Moreover,	  there	  is	  a	  need	  for	  data	  on	  the	  reliability	  of	  	  18F-­‐-­‐-­‐FDG	  	  PET	  	  in	  	  CD,	  	  defined	  	  as	  	  a	  	  measure	  	  of	  	  the	  	  consistency	  	  of	  	  yielded	  	  results	  	  when	  	  the	  test	  is	  administered	  repeatedly	  in	  stable	  subjects.	  	  	   Finally,	  	  the	  	  origin	  	  of	  	  the	  	  FDG	  	  signal	  	  within	  	  intestinal	  	  segments	  	  has	  	  not	  	  been	  	  accurately	  ascertained:	  	  Murine	  	  studies	  	  have	  	  provided	  	  some	  	  evidence	  	  that	  	  the	  	  most	  	  FDG-­‐-­‐-­‐avid	  	  cellular	  populations	  	  	  in	  	  	  inflammatory	  	  	  foci	  	  	  are	  	  	  neutrophils,	  	  	  macrophages	  	  	  and	  	  	  lymphocytes,	  	  	  and	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   2.2.1 STUDY	  DESIGN	  -­‐-­‐-­‐	  PARTICIPANT	  SELECTION-­‐-­‐-­‐	  POWER	  CALCULATIONS	  	  	  	   To	  	  assess	  	  responsiveness,	  	  patients	  	  with	  	  active	  	  CD	  	  (HBI>4)	  	  were	  	  prospectively	  	  recruited,	  after	  	  a	  	  decision	  	  had	  	  been	  	  made	  	  by	  	  the	  	  IBD	  	  specialist	  	  supervising	  	  their	  	  care	  	  to	  	  commence	  anti-­‐-­‐-­‐TNF	   therapy.	   Two	   PET	   scans	  were	   performed	   under	   standardised	   conditions	   (outlined	  in	  	  detail	  	  in	  	  2.2.3),	  	  one	  	  baseline	  	  before	  	  and	  	  one	  	  follow-­‐-­‐-­‐up	  	  after	  	  anti-­‐-­‐-­‐TNF	  	  therapy,	  	  with	  	  a	  target	  	  	  interval	  	  	  of	  	  	  three	  	  	  months	  	  	  between	  	  	  the	  	  	  start	  	  	  of	  	  	  therapy	  	  	  and	  	  	  the	  	  	  follow-­‐-­‐-­‐up	  	  	  scan.	  Reference	  	  investigations	  	  performed	  	  on	  	  the	  	  day	  	  of	  	  the	  	  scanning	  	  included	  	  HBI	  	  scoring,	  	  CRP	  and	  calprotectin	  analysis	  as	  well	  as	  the	  Magnetic	  Resonance	  Index	  of	  Activity	  (MaRIA)	  score	  
74,75	  	  (obtained	  by	  MR	  enterography,	  see	  Chapter	  3)	  	  	   With	  	  regards	  	  to	  	  recruitment	  	  for	  	  the	  	  test-­‐-­‐-­‐retest	  	  reliability	  	  component	  	  of	  	  the	  	  study,	  	  the	  	  aim	  was	   to	   select	  patients	  with	  a	   variety	  of	  disease	  distributions,	   inclusive	  of	   small	   intestinal	   as	  well	  	  as	  	  colonic	  	  segments.	  	  We	  	  therefore	  	  prospectively	  	  enrolled	  	  patients	  	  with	  	  active	  	  CD	  (HBI>4,	  	  also	  	  deemed	  	  active	  	  by	  	  their	  	  IBD	  	  specialist	  	  on	  	  the	  	  basis	  	  of	  	  recent	  	  endoscopic/	  radiological	  	  examination).	  	  The	  	  target	  	  interval	  	  between	  	  the	  	  two	  	  scans	  	  was	  	  1	  	  week	  	  and	  	  a	  maximum	  	  permitted	  	  interval	  	  of	  	  2	  	  weeks.	  	  	  	  The	  	  HBI	  	  score,	  	  CRP	  	  and	  	  a	  	  MaRIA	  	  score	  	  were	  assessed	  on	  both	  visits,	  while	  a	  calprotectin	  assay	  was	  performed	  on	  one	  of	  the	  two	  visits	  as	  additional	  evidence	  of	  active	  disease.	  	  	   In	  addition	  to	  active	  CD	  at	  the	  outset,	  our	  inclusion	  criteria	  were	  a	  minimum	  age	  of	  18	  years,	  and	  	  a	  	  post-­‐-­‐-­‐menopausal	  	  status	  	  in	  	  females	  	  or	  	  willingness	  	  to	  	  adhere	  	  to	  	  contraception	  	  advice	  and	  avoid	  unprotected	  sexual	  intercourse	  for	  the	  duration	  of	  the	  study	  in	  both	  genders.	  This	  was	  to	  mitigate	  the	  radiation	  risks	  of	  18F-­‐-­‐-­‐FDG	  in	  insemination	  and	  early	  pregnancy.	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Participants	  with	   alternative	  GI	   pathologies,	  which	   could	   produce	   additional	   foci	   of	   signal	  (e.g.	   known	   polyps,	   malignancy,	   GI	   infection,	   coeliac	   disease)	   were	   excluded.	   We	   also	  excluded	  patients	  with	  physical	  disabilities	  precluding	  comfortable	  positioning	  on	   the	  PET	  scanner.	   In	  an	  order	   to	  minimise	   the	  risks	  of	   ionising	  radiation,	  we	  also	  excepted	  patients	  who	  were	  pregnant	  or	  who	  might	  become	  pregnant,	  a	  history	  of	  cancer,	  either	  personal	  or	  in	  a	   first	   degree	   relative	   at	   an	   age	   <55	   years,	   and	   also	   patients	   who	   had	   participated	   	   in	  research	  which	  involved	  ionising	  radiation	  in	  the	  previous	  3	  years.	  	  	   In	  	  order	  	  to	  	  estimate	  	  an	  	  appropriate	  	  number	  	  of	  	  participants	  	  the	  	  following	  	  were	  	  taken	  	  into	  consideration:	  	  This	  	  was	  	  a	  	  pilot	  	  study	  	  with	  	  numbers	  	  of	  	  subjects	  	  determined	  	  by	  	  feasibility.	  Within	  	  our	  	  Trust	  	  approximately	  	  25-­‐-­‐-­‐30	  	  patients/year	  	  are	  	  commenced	  	  on	  	  anti-­‐-­‐-­‐TNF	  	  therapy	  for	  	  Crohn’s	  	  disease.	  	  Assuming	  	  a	  	  similar	  	  prescription	  	  pattern	  	  by	  	  our	  	  specialists	  	  during	  	  the	  duration	  of	  the	  study,	  the	  aim	  was	  to	  recruit	  24	  patients	  (20	  for	  the	  longitudinal	  study	  and	  4	  for	  the	  test-­‐-­‐-­‐retest	  component)	  over	  18	  months.	  	  	   I	  	  examined	  	  studies	  	  where	  	  bowel	  	  segments	  	  affected	  	  by	  	  Crohn’s	  	  disease	  	  were	  	  assessed	  	  by	  SUVMAX	  	  and	   found	   that	   the	  average	  SUVMAX	  	  across	  all	   these	   segments	  was	  approx.	  5.0	  with	  a	  standard	  	  deviation	  	  of	  	  2.2.	  	  These	  	  figures	  	  were	  	  used	  	  to	  	  calculate	  	  the	  	  power	  	  of	  	  the	  	  study	  assuming	  an	  80%	  primary	  response	  rate,	  in	  keeping	  with	  published	  data170.	  The	  potential	  to	  detect	  an	  effect	  at	  12	  weeks	  over	  a	  range	  of	  marker	  sensitivities	  was	  estimated,	  with	  the	  use	  of	  projected	  SUVMAX	  	  drops	  between	  10-­‐-­‐-­‐50%	  (see	  Table	  2.1):	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(participants)	   n	  (responders)	   SD	   %	  drop	  in	  SUVmax	   Power	  10	   8	   2.2	   10	   0.08	  10	   8	   2.2	   20	   0.20	  10	   8	   2.2	   30	   0.38	  10	   8	   2.2	   40	   0.59	  10	   8	   2.2	   50	   0.79	  	   	   	   	   	  20	   16	   2.2	   10	   0.11	  20	   16	   2.2	   20	   0.33	  20	   16	   2.2	   30	   0.62	  
20	   16	   2.2	   40	   0.85	  20	   16	   2.2	   50	   0.99	  
	  
	   With	  these	  assumptions,	  it	  was	  estimated	  that	  studying	  20	  patients,	  (approx.	  16	  responders)	  should	  allow	  measurement	  of	  a	  significant	  decrease	   in	  signal	   in	   the	   follow-­‐-­‐-­‐up	  relative	   to	   the	  pre-­‐-­‐-­‐treatment	  scan.	  	  	   As	  the	  MRI	  component	  was	  optional,	  and	  radiation	  exposure	  the	  principal	  risk	  in	  this	   study,	  only	   the	   PET	   endpoints	   have	   been	   taken	   into	   account	   in	   the	   formulation	   of	   a	   power	  calculation	  for	  this	  study.	  	  	   2.2.2 SCREENING	  PROCESS	  -­‐-­‐-­‐	  PATIENT	  PREPARATION	  	  	  	   Formal	   approval	   by	   a	  Research	  Ethics	   Committee	   (REC),	  Research	   and	  Development	   (R&D)	  departments	  of	  participating	  hospitals	  and	  ARSAC	  had	  been	  granted	  before	  commencing	  the	  study	  	  (REC:	  	  South	  	  East	  	  Coast-­‐-­‐-­‐Surrey	  	  12/LO/1018,	  	  R&D:	  	  JRCOHH0453,	  	  ARSAC	  	  Certificate:	  RPC	  630/2892/28817).	   Informed	  consent	  was	  obtained	   from	  all	  participants.	   In	  addition	   to	  eligibility	   checks,	   screening	   assessment	   included	   a	   full	   physical	   examination	  with	   recording	  of	  	  the	  	  vital	  	  signs.	  	  Investigations	  	  included	  	  routine	  	  urine	  	  analysis	  	  and	  	  a	  	  pregnancy	  	  test	  	  in	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women	  of	  childbearing	  potential,	  as	  well	  as	  routine	  full	  blood	  count	  and	  biochemical	  profile	  performed	   in	  advance	  of	   the	  scanning.	   On	   the	  day	  of	   the	  scanning,	  participants’	  HBI	  score	  was	  assessed,	  and	  blood	  and	  stool	   samples	  were	  obtained	   for	  blood	  glucose	  and	  CRP,	  and	  faecal	  calprotectin	  measurements	  respectively.	  	  	   2.2.3 SCANNING	  PROCEDURE	  	  	  	   A	  20	  gauge	  intravenous	  cannula	  was	  placed	  and	  a	  target	  dose	  of	  185MBq	  of	  18F-­‐-­‐-­‐FDG	  in	  10ml	  of	  	  normal	  	  saline	  	  was	  	  administered	  	  intravenously,	  	  followed	  	  by	  	  a	  	  saline	  	  flush.	  	  The	  	  patients	  were	   then	   asked	   to	   rest	   semi-­‐-­‐-­‐recumbent	   in	   a	   quiet	   room,	   and	  were	   given	  between	  800	   and	  1200ml	  	  of	  	  2.5%	  	  mannitol	  	  orally	  	  for	  	  small	  	  bowel	  	  distention.	  	  At	  	  50	  	  minutes	  	  following	  	  FDG	  administration,	  	  patients	  	  were	  	  asked	  	  to	  	  void	  	  their	  	  bladders,	  	  and	  	  were	  	  positioned	  	  on	  	  the	  PET/CT	  	  scanner	  	  (Siemens	  	  Biograph	  	  6	  	  Truepoint,	  	  Siemens	  	  Healthcare,	  	  Enlargen,	  	  Germany).	  20mg	  	  of	  	   intravenous	  	  hyoscine	  	  butylbromide	  	  (Buscopan®)	  	  was	  	  administered	  	   to	  	  reduce	  motion	  artifact,	  and	  a	   low	  dose	  CT	  scan	  of	  the	  abdomen	  was	  obtained	  (130KV,	  30mAs,	  pitch	  1.5,	  6	  slice	  x	  3mm	  collimation).	  Subsequently,	  PET	  emission	  data	  from	  the	  gut	  were	  acquired	  in	   a	  3-­‐-­‐-­‐dimensional	  model.	  A	  maximum	  of	  3	  bed	  positions	  were	  used	   for	   this	   component	   for	  the	  baseline	  scan.	  The	  maximal	  total	  duration	  of	  scanning	  time	  was	  30	  minutes	  (10	  minutes	  per	  bed	  position).	  ImPACT	  dose	  calculator	  was	  used,	  a	  software	  for	  estimation	  of	  dose	  levels	  in	  	  X-­‐-­‐-­‐ray	  	  computed	  	  tomography	  	  using	  	  pre-­‐-­‐-­‐calculated	  	  tables,	  	  to	  	  estimate	  	  our	  	  average	  	  target	  effective	  dosage	  at	  11.2mSv,	  comprised	  of	  3.5mSv	   for	  each	  of	   the	  PET	  scans	  and	  2.1mSv	   for	  each	  of	   the	  CT	  scans).	  These	  procedures	  were	  standardised	  so	   that	   they	  could	  be	  accurately	  replicated	  on	  follow-­‐-­‐-­‐up	  scanning.	  
	  2.2.4	  PET	  SCAN	  ANALYSIS	  	  	  	  	   PET/CT	  	  	  images	  	  	  were	  	  	  analysed	  	  	  using	  	  	  Inveon	  	  	  Research	  	  	  Workplace	  	  	  (IRW,	  	  	  Siemens	  Healthcare,	  USA).	   Scans	  were	   reconstructed	   in	   both	  OSEM	   (Ordered	   Subset	   Expectation	  Maximisation,	  2	  iterations,	  8	  subsets)	  and	  FBP	  (Filtered	  Back	  Projection),	  but	  the	  former	  was	  used	   in	   the	  analysis.	   Scans	  were	   reconstructed	   in	  a	  	  256	  x	  	  256	  matrix	  and	  zoom	  of	  1.3	  and	  3D	  Gaussian	  image	  filter	  with	  5	  mm	  full-­‐-­‐-­‐width	  at	  half	  maximum	  (FWHM).	  	  	  	   The	  	  attenuation	  	  corrected	  	  (AC)	  	  CT	  	  sequence	  	  was	  	  fused	  	  with	  	  OSEM	  	  PET	  	  sequences.	  Volume	  	  of	  	  Interest	  	  (VOI)	  	  derivation	  	  and	  	  subsequent	  	  analysis	  	  were	  	  carried	  	  out	  	  by	  	  the	  author	  	  	  and	  	  	  a	  	  	  nuclear	  	  	  medicine	  	  	  expert	  	  	  fully	  	  	  blinded	  	  	  to	  	  	  all	  	  	  clinical	  	  	  data,	  	  	  working	  independently.	  	  In	  	  cases	  	  of	  	  discrepancy	  	  in	  	  VOI	  	  positioning	  	  and	  	  margins,	  	  these	  	  were	  reprocessed	   in	   	  tandem	   by	   both	   investigators	   until	   consensus	  was	   reached.	   A	   VOI	   of	   at	  least	  	  40cm3	  was	  	  created	  	  inside	  	  the	  	  liver	  	  parenchyma	  	  and	  	  the	  	  mean	  	  SUV	  	  (LivSUVMEAN)	  was	   recorded.	   In	   keeping	   with	   published	   literature134,137,	   	  the	   resulting	   LivSUVMEAN	   was	  used	  as	  a	   threshold	  above	  which	  GI	   signal	  was	  deemed	   	  abnormal.	  The	  entire	   fused	  3-­‐-­‐-­‐D	  sequence	  was	   adjusted	   to	   exclude	   signal	   of	   intensity	   lower	   than	   LivSUVMEAN.	   The	   bowel	  was	  	  then	  	  separated	  	  into	  	  seven	  	  segments	  	  (small	  	  bowel,	  	  terminal	  	  ileum,	  	  caecum	  	  and	  ascending	  	  	  colon,	  	  	  transverse	  	  	  colon,	  	  	  descending	  	  	  colon,	  	  	  sigmoid	  	  	  and	  	  	  rectum).	  	  	  The	  distinction	   between	   SB	   and	   TI	  was	  made	   functionally,	   with	   the	   latter	   consisting	   of	   	  the	  most	  distal	  unified	   focus	  of	  activity	   in	  small	  bowel	   irrespective	  of	   its	   length,	  and	  SB	  was	  classified	   as	   the	   collection	   of	   all	   foci	   corresponding	   to	   regions	   distal	   to	   the	   pylorus	   and	  proximal	  	  	  to	  	  	  TI.	  	  	  The	  	  	  remaining	  	  	  segments	  	  	  were	  	  	  defined	  	  	  anatomically,	  	  	  and	  	  	  special	  attention	  was	   focused	   on	   the	   precise	   replication	   of	   their	  margins	   between	  baseline	   and	  follow-­‐-­‐-­‐up	   scanning	   in	   each	   patient.	   Once	   segments	   had	   been	   identified,	   a	   crude	   ‘parent’	  VOI	  	  was	  	  drawn	  	  in	  	  those	  	  segments	  	  which	  	  contained	  	  visible	  	  signal.	  	  This	  	  parent	  	  VOI	  included	  	  	  individual	  	  	  voxels	  	  	  both	  	  	  above	  	  	  LivSUVMEAN,	  	  	  as	  	  	  well	  	  	  as	  	  	  adjacent	  	  	  ones	  	  	  below	  	  64	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Figure	  2.1:	  Methodology	  of	  VOI	  derivation	  
	  
A) Liver	  VOI	  drawn	  and	  LivSUVMEAN	  determined	  (red	  circle)	  
	  
	  
B) Sequence	  thresholded	  to	  exclude	  signal	  of	  SUV<	  LivSUVMEAN	  
	  
	  




D) ‘Daughter’	  VOI	  produced	  by	  software	  and	  Volume,	  SUVMEAN,	  and	  SUVMAX	  recorded	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Standardised	  Uptake	  Value	  (SUV)	  is	  the	  typical	  measure	  of	  PET	  signal	  and	  is	  defined	  as:	  SUV=	  r/(α’/w)	  where	   r	   is	   the	   radioactivity	   concentration	   in	   KBq/ml	   within	   a	   VOI,	   α’	   is	   the	   decay	  corrected	  amount	  of	  administered	  FDG	  and	  w	  is	  the	  weight	  of	  the	  patient	  170.	  For	   each	   ‘daughter’	   VOI	   the	   software	   provided	   the	   following	   endpoints:	   SUVMAXreflecting	   the	  SUV	  of	   the	   single	  voxel	  of	  highest	   intensity,	  SUVMEAN,	  which	   represented	  the	  average	  values	  of	  all	  SUVs	  in	  the	  VOI,	  and	  its	  Volume	  in	  cm3.	  From	  these	  three	  values	  a	  number	  of	  other	   endpoints	  were	  derived,	   as	  described	   in	   the	   literature140,	   on	  a	   ‘per	  segment’	  and	  ‘per	  patient’	  basis.	  All	  endpoints	  are	  defined	  in	  the	  tables	  below:	  
Table	  2.2:	  	  Segmental	  endpoints	  
Endpoint	   Definition	  SUVMAX The	  SUV	  of	  the	  voxel	  of	  highest	  intensity	  within	  the	  daughter	  VOI	  SUVMEAN The	  average	  SUV	  of	  all	  voxels	  within	  the	  daughter	  VOI	  V	   The	  volume	  of	  abnormal	  voxels	  in	  a	  daughter	  VOI	  (cm3)	  RSUVMAX SUVMAX	  expressed	  as	  a	  ratio	  over	  	  	   LivSUVMEANRSUVMEAN SUVMEAN	  expressed	  as	  a	  ratio	  over	  	  	   LivSUVMEANSLG	   Segmental	  Lesion	  Glycolysis	  	  =	  SUVMEAN	  x	  Volume	  of	  VOI	  RSLG	   SLG	  expressed	  as	  a	  ratio	  over	  LivSUVMEAN
Table	  2.3:	  Global	  (‘per	  patient’)	  endpoints	  
Endpoint	   Definition	  GSUVMAX Global	  SUVMAX:	  The	  average	  SUVMAX	  of	  all	  segments	  with	  abnormal	  signal	  RGSUVMAX GSUVMAX	  	  expressed	  as	  a	  ratio	  over	  	  	   LivSUVMEANTotal	  V	   Total	  Volume	  =	  Σ	  of	  segmental	  volumes	  TLG	   Total	  Lesion	  Glycolysis	  	  =	  Σ	  of	  SLGs	  in	  abnormal	  segments	  R-­‐-­‐-­‐TLG	   TLG	  expressed	  as	  a	  ratio	  over	  LivSUVMEANGSUVMEAN Global	  SUVMEAN:	  TLG	  /	  Σ	  Volumes	  of	  all	  abnormal	  segments	  R-­‐-­‐-­‐GSUVMEAN GSUVMEAN	  	  expressed	  as	  a	  ratio	  over	  	  	   LivSUVMEAN
Most	  	  endpoints	  	  were	  	  expressed	  	  as	  	  absolute	  	  values	  	  as	  	  well	  	  as	  	  tissue-­‐-­‐-­‐to-­‐-­‐-­‐background	  ratios	  	  (TBR)	  	  over	  	  LivSUVMEAN	  	  as	  	  the	  	  liver	  	  is	  	  always	  	  in	  	  the	  	  field	  	  of	  	  view	  	  and	  	  it	  	  has	  	  been	  shown	  to	  have	   low	  within-­‐-­‐-­‐patient	  variability171.	   	   	  Therefore	   it	  was	  chosen	  as	  a	  reference	  organ	  for	  normal	  tissue	  activity.	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PET	  endpoints	  such	  as	  SUVMAX	  and	  SUVMEAN	  in	  a	  segment	  (either	  as	  absolutes	  or	  as	  ratios	  over	   LivSUVMEAN)	   reflect	   disease	   severity	   in	   that	   segment,	   and	   GSUVMAX	  and	   GSUVMEAN represent	   global	   disease	   severity	   in	   each	   patient.	   Each	   daughter	   VOI’s	   Volume	   (V)	   as	  well	  as	  the	  Total	  V	  are	  measures	  of	  disease	  extent.	  SLG	  and	  TLG	  are	  composite	  measures	  designed	  to	  reflect	  the	  metabolic,	  and	  as	  such,	  the	  inflammatory	  activity	  more	  globally	  in	  each	  segment	  or	  patient	  respectively.	  
There	  were	  several	   instances	  when	  a	  segment	  only	  expressed	  signal	  above	  threshold	  on	  either	  the	  baseline	  or	  the	  follow-­‐-­‐-­‐up	  scan.	  In	  those	  instances,	  endpoints	  for	  the	  scan	  with	  the	  	  	  active	  	  	  segment	  	  	  were	  	  	  derived	  	  	  as	  	  	  described,	  	  	  but	  	  	  when	  	  	  analysing	  	  	  the	  	  	  scan	  	  	  that	  contained	   the	   segment	   with	   no	   activity,	   an	   anatomical	   VOI	   of	   equal	   volume	   was	   placed	   on	  	  that	  	  ‘normal’	  	  segment	  	  matching	  	  the	  	  location	  	  of	  	  the	  	  corresponding	  	  daughter	  	  VOI	  	  on	  the	  ‘abnormal’	  segment	  as	  closely	  as	  possible.	  All	  PET	  endpoints	  were	  then	  calculated	  as	  described	  above.	  
The	  	  	  data	  	  	  analysis	  	  	  outlined	  	  	  above	  	  	  was	  	  	  conducted	  	  	  twice	  	  	  in	  	  	  the	  	  	  cohort	  	  	  undergoing	  longitudinal	  	  	  pre	  	  	  and	  	  	  post-­‐-­‐-­‐treatment	  	  	  PET.	  	  	  The	  	  	  first	  	  	  time,	  	  	  all	  	  	  intestinal	  	  	  segments	  expressing	  	  FDG	  	  signal	  	  above	  	  the	  	  prer r r defined	  	  threshold	  	  were	  	  included.	  	  In	  	  the	  	  second	  analysis,	  	  	  I	  	  	  excluded	  	  	  all	  	  	  segments	  	  	  which	  	  	  on	  	  	  the	  	  	  concurrent	  	  	  MR	  	  	  enterography	  	  	  had	  segmental	  MaRIA	  scores	  <7.073,74	  	  or,	  in	  the	  case	  of	  small	  bowel,	  had	  normal	  appearances	  as	  judged	  by	  an	  experienced	  MR	  radiologist.	  This	  allowed	  us	  to	  exclude	  segments	  where	  potentially	  the	  FDG-­‐-­‐-­‐PET	  signal	  did	  not	  specifically	  represent	  Crohn’s	  disease	  activity.	  
2.2.5 DATA	  ANALYSIS	  
Correlation	  between	  clinico-­‐-­‐-­‐pathological	  markers	   (HBI,	  CRP	  and	  FC)	  and	  PET	  endpoints	  using	  	  the	  	  baseline	  	  PET	  	  scan	  	  for	  	  each	  	  participant	  	  from	  	  both	  	  cohorts	  	  were	  	  performed	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using	  Spearman	  rank	  coefficients.	  p<0.05	  was	  the	  threshold	  of	  significance.	  This	  was	  not	  corrected	   for	  multiple	   comparisons.	   It	  was	  hypothesised	   that	   in	   active	  CD,	   the	   clinical	  score,	  CRP	  and	  FC	   can	  be	   accounted	   for	  by	   (or	  be	   representative	  of)	   either	   the	   global	  inflammatory	   activity,	   or	   activity	   within	   the	   worst	   affected	   bowel	   segments,	   so	   	   the	  above	   correlations	   were	   performed	   using	   global	   as	   well	   as	   segmental	   PET	   endpoints	  respectively.	  The	  most	  abnormal	  segment	  in	  each	  patient	  was	  determined	  on	  the	  basis	  of	  its	  SUVMEAN.	  
Subsequently	  	  I	  	  focused	  	  on	  	  subjects	  	  who	  	  completed	  	  the	  	  longitudinal	  	  component	  	  of	  	  the	  study	  	  	  by	  	  	  having	  	  	  FDG-­‐-­‐-­‐PET	  	  	  scanning	  	  	  before	  	  	  and	  	  	  after	  	  	  the	  	  	  introduction	  	  	  of	  	  	  anti-­‐-­‐-­‐TNF	  therapy.	  	  	  I	  	  	  assessed	  	  	  correlations	  	  	  between	  	  	  the	  	  	  absolute	  	  	  differences	  	  	  (Δ)	  	  	  in	  	  	  clinico-­‐-­‐-­‐	  pathological	   endpoints	   and	  with	   those	  of	   corresponding	  PET	  endpoints172.	  The	  Δ-­‐-­‐-­‐values	  for	  each	  endpoint	  were	  defined	  as	  follows	  (exemplified	  by	  SUVMAX):	  ΔSUVMAX=	  SUVMAX(POST-­‐-­‐-­‐TREATMENT)	  	  –	  SUVMAX(PRE-­‐-­‐-­‐TREATMENT)For	  all	  these	  correlations,	  the	  Spearman	  rank	  correlation	  coefficient	  was	  also	  used.	  
I	  	  then	  	  segregated	  	  the	  	  patients	  	  into	  	  responders	  	  and	  	  non-­‐-­‐-­‐responders	  	  on	  	  the	  	  basis	  	  of	  	  a	  clinically	  demonstrable	  response	  3	  months	   into	  therapy.	  This	  was	  defined	  as	  a	  decrease	  on	  the	  HBI	  scale	  of	  3	  points	  or	  more	  in	  line	  with	  previous	  studies173.	  Baseline	  and	  follow-­‐-­‐-­‐	  up	  	  PET	  	  measures	  	  were	  	  compared	  	  for	  	  responders	  	  and	  	  non-­‐-­‐-­‐responders.	  This	  	  distinction	  between	  	  responders	  	  and	  	  non-­‐-­‐-­‐responders	  	  was	  	  used	  	  to	  	  calculate	  	  the	  	  Responsiveness	  ratio	  	  of	  	  Guyatt	  	  (RRG)174,	  	  as	  	  well	  	  as	  	  the	  	  standardized	  	  size	  	  effect	  	  (SES)	  	  109.	  	  RRG	  	  for	  	  each	  endpoint	  	  is	  	  defined	  	  as	  	  the	  	  	  	  (mean	  	  Δ	  	  endpoint	  	  in	  	  responders	  	  /Standard	  	  deviation	  	  of	  endpoint	  	  	  	  in	  	  	  	  non-­‐-­‐-­‐responders).	  	  	  	  The	  	  	  	  SES	  	  	  	  is	  	  	  	  defined	  	  	  	  as	  	  	  	  (mean	  	  	  	  Δ	  	  	  	  endpoint	  	  	  	  in	  responders/Standard	  	  deviation	  	  of	  	  endpoint	  	   in	  	  responders).	  	  These	  	  two	  	  values	  	  were	  calculated,	  	  	  	  	  as	  	  	  	  	  they	  	  	  	  	  constitute	  	  	  	  	  direct	  	  	  	  	  statistical	  	  	  	  	  measures	  	  	  	  	  of	  	  	  	  	  an	  	  	  	  	  endpoint’s	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responseveness.	   A	   value	   greater	   than	   0.80	   in	   these	   parameters	   is	   suggestive	   of	   a	   high	  responsiveness.	  
To	  	  assess	  	  test-­‐-­‐-­‐retest	  	  reliability	  	  of	  	  PET-­‐-­‐-­‐endpoints	  	  I	  	  measured	  	  the	  	  %	  	  variability	  	  (%VAR)	  for	  	  	  each	   	   	   	  endpoint	   	   	   	  using	   	   	   	  all	   	   	   	  segments	   	   	   	  with	   	   	   	  signal	   	   	   	  >	   	   	   	  LivSUVMEAN	  	  	  	  as	   	   	   	  previously	  described175.	   %VAR	  =	  Value(2)-­‐-­‐-­‐Value(1)/	  Value(1)	  x100%	  
2.2.6 WORKLOAD	  DISTRIBUTION	  –	  PERSONAL	  INVOLVEMENT	  
Sequential	  	  drafts	  	  of	  	  the	  	  study	  	  protocol	  	  were	  	  produced	  	  by	  	  me	  	  and	  	  amended	  	  following	  consultation	  with	  my	  supervisors	  and	  the	  multi-­‐-­‐-­‐disciplinary	  team	  at	  the	  Imaging	  Centre.	  I	  subsequently	  	  defended	  	  the	  	  protocol	  	  at	  	  a	  	  REC	  	  meeting,	  	  and	  	  drafted	  	  and	  	  submitted	  	  all	  subsequent	  amendments.	  I	  also	  carried	  out	  participant	  recruitment,	  including	  obtaining	  informed	  	  consent,	  	  by	  	  attending	  	  IBD	  	  clinics	  	  at	  	  participating	  	  hospitals.	  	  During	  	  scanning	  visits,	  I	  acted	  as	  Study	  Physician,	  which	  involved	  the	  preparation	  and	  administration	  of	  oral	  	  contrast,	  	  administration	  	  of	  	  the	  	  radio-­‐-­‐-­‐pharmaceutical,	  	  and	  	  ensuring	  	  patient	  	  safety	  from	  admission	  to	  discharge.	  For	  the	  purposes	  of	  the	  analysis,	  I	  was	  trained	  on	  the	  IRW	  software	  by	  a	  PET	  physicist,	   following	  which	  I	  produced	  all	  VOIs	  on	  all	  38	  scans.	  These	  were	  	  	  individually	  	  	  corroborated	  	  	  or	  	  	  amended	  	  	  by	  	  	  a	  	  	  PET	  	  	  radiologist.	  	  	  Finally,	  	  I	  	  	  also	  performed	  statistical	  analysis	  and	  interpretation.
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2.3.RESULTS	  2.3.1	  DEMOGRAPHICS	  
22	  patients	   (13	  male)	  with	  a	  mean	  age	  of	  40	  years	   (range	  22-­‐-­‐-­‐59)	  were	   recruited,	  17	  for	  the	  	  	  longitudinal	  	   component	  	  	  and	  	  	  5	  	  	  for	  	  	  the	  	  	  test-­‐-­‐-­‐retest	  	  	  reliability	  	  	  arm	  	  	  of	  	  	  this	  	  study.	  Demographic	  	  details	   	  and	  	  disease	  	  characteristics	   	  of	   	  these	  	  two	  	  cohorts	  	  are	  outlined	  	  in	  Table	  2.4.	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  Table	  2.4A:	  Demographic	  data	  and	  disease	  characteristics	  in	  the	  LONGITUDINAL	  cohort	  
Patient	   Sex	   Age	   Disease	  duration	  (years)	   Disease	  Distribution* Previous	  resections	   HBI	  baseline	   HBI	  follow-­‐up	   Response(by	  HBI	  criteria)	   CRP	  baseline	  (mg/L)	  
CRP	  follow-­‐up	  (mg/L)	  
FC	  baseline	  (mcg/g)	  
FC	  follow-­‐up	  (mcg/g)	   Anti-­‐TNF	   Completed	  F/U	  
Treatment	  onset-­‐	  F/U	  scan	  interval	  (weeks)	   Reason	  for	  not	  completing	  1	   M	   25	   4	   L3	   No	   4	   1	   Y	   3.4	   0.5	   934	   23	   IFX	   Y	   11	  2	   F	   57	   30	   L1	   2	   7	   8	   N	   0.9	   0.2	   74	   33	   ADA	   Y	   10	  3	   M	   36	   4	   L3	   No	   7	   6	   N	   34.5	   42.5	   1340	   850	   ADA	   Y	   12	  4	   M	   54	   14	   L1	   No	   5	   4	   N	   6.2	   2.9	   173	   116	   IFX	   Y	   13	  5	   F	   39	   13	   L3	   1	   5	   -­‐-­‐-­‐	   -­‐-­‐-­‐	   5.3	   -­‐-­‐-­‐	   -­‐-­‐-­‐	   -­‐-­‐-­‐	   ADA	   N	   -­‐-­‐-­‐	   Discontinued	  anti-­‐TNF	  after	  1	  dose	  6	   F	   53	   11	   L1	   1	   11	   -­‐-­‐-­‐	   -­‐-­‐-­‐	   2.6	   -­‐-­‐-­‐	   75	   -­‐-­‐-­‐	   -­‐-­‐-­‐	   N	   -­‐-­‐-­‐	   Ca	  diagnosis	  during	  screening7	   M	   41	   4	   L3	   1	   8	   2	   Y	   7.8	   2.2	   443	   59	   ADA	   Y	   11	  8	   F	   40	   13	   L1	   1	   10	   7	   Y	   1.6	   0.2	   178	   33	   ADA	   Y	   12	  9	   F	   47	   3	   L1	   1	   6	   4	   N	   5.7	   10.3	   237	   595	   IFX	   Y	   18	  10	   F	   22	   1	   L3	   No	   14	   6	   Y	   51	   0.4	   252	   33	   ADA	   Y	   12	  11	   M	   40	   2	   L1	   No	   8	   2	   Y	   17.6	   3.5	   2100	   850	   ADA	   Y	   11	  12	   M	   27	   3	   L1	   1	   10	   -­‐-­‐-­‐	   -­‐-­‐-­‐	   0.3	   -­‐-­‐-­‐	   -­‐-­‐-­‐	   -­‐-­‐-­‐	   -­‐-­‐-­‐	   N	   -­‐-­‐-­‐	   Lost	  to	  F/U	  13	   M	   51	   1	   L3	   1	   9	   4	   Y	   5	   6.9	   91	   6	   IFX	   Y	   13	  14	   F	   30	   2	   L2	   No	   5	   -­‐-­‐-­‐	   -­‐-­‐-­‐	   0.2	   -­‐-­‐-­‐	   89	   -­‐-­‐-­‐	   ADA	   N	   -­‐-­‐-­‐	   Lost	  to	  F/U	  15	   F	   32	   26	   L1	   1	   5	   1	   Y	   1.6	   1.0	   70	   64	   IFX	   Y	   12	  16	   M	   44	   13	   L3	   No	   13	   5	   Y	   6.4	   2.5	   186	   1515	   IFX	   Y	   10	  17	   M	   36	   5	   L1	   No	   9	   6	   Y	   46.4	   13.8	   377	   -­‐-­‐-­‐	   IFX	   Y	   11	  





Table	  2.4B:	  Demographic	  data	  and	  disease	  characteristics	  in	  the	  TEST-­‐RETEST	  cohort	   	  	  	  	  
	  
	  
*Disease	  distribution:	  L1:	  small	  bowel	  only	  L2:	  colonic	  only	  L3:ileo-­‐colonic7	  	  
	  Patient	   	  Sex	   	  Age	   Disease	  duration	  (years)	   Disease	  Distribution*	   Previous	  resections	   HBI	  baseline	   HBI	  follow-­‐up	   CRP	  baseline	  (mg/L)	  
CRP	  follow-­‐up	  (mg/L)	   FC	  	  (mcg/g)	  
	  Completed	  both	  scans	  
Baseline-­‐	  F/U	  	  scan	  interval	  (days)	  
	  Reason	  for	  not	  completing	  1	   M	   55	   22	   L1	   2	   6	   7	   14.8	   7.9	   655	   Y	   7	   Declined	  MRI	  on	  repeat	  visit	  2	   M	   41	   12	   L3	   No	   5	   5	   5.8	   10.3	   325	   Y	   7	   	  3	   F	   59	   23	   L3	   No	   10	   -­‐-­‐	   22.5	   -­‐-­‐-­‐	   839	   N	   -­‐-­‐-­‐	   Declined	  repeat	  scanning	  4	   M	   24	   3	   L3	   No	   7	   7	   13.5	   8.2	   257	   Y	   12	   	  5	   M	   31	   11	   L3	   No	   10	   10	   2.8	   1.7	   346	   Y	   4	   	  
	  2.3.2	  SEGMENT	  ANALYSIS	  	  	  	  	   145	   segments	   were	   assessed	   by	   PET	   with	   MaRIA	   score,	   which	   was	   obtained	   on	   MRI	  enterography	  performed	  on	   the	   same	  day,	   as	   a	   	   reference	   	   standard.	  This	  was	  on	   	   the	  basis	  of	   its	  close	  correlation	  with	  endoscopic	  disease	  scores74,75.	  The	   	  MaRIA	   threshold	  for	   a	   bowel	   segment	   to	   be	   deemed	   inflamed	   was	   >7.0.	   Since	   MaRIA	   has	   not	   been	  validated	  in	  small	  bowel	  disease,	  presence	  of	  activity	  in	  small	  bowel	  proximal	  to	  the	  TI	  was	   assessed	   on	   the	   basis	   of	   an	   expert	   opinion	   by	   an	   MR	   radiologist	   with	   10	   years	  experience	  in	  abdominal	  MR,	  blinded	  to	  the	  clinical	  details	  of	  the	  patients.	  Of	  these	  145	  segments,	  MaRIA	   (or	  MR	   enterography	   in	   the	   case	   of	   small	   bowel)	  was	   positive	   in	   51	  and	   negative	   in	   94.	   Segmental	   FDG	   signal	   equal	   or	   higher	   than	   LivSUVMEAN	  correctly	  identified	   47	   of	   51	   segments	   resulting	   in	   a	   sensitivity	   of	   92%.	   67	   of	   the	   94	   negative	  segments	  had	  signal	  of	  intensity	  less	  than	  LivSUVMEAN,	  therefore	  the	  specificity	  was	  71%.	  Figure	   2.2	   outlines	   the	   various	   segments	   and	   their	   MRI	   and	   PET	   positivity	   on	   the	  baseline	  scan.	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  2.3.3	  	  ‘SNAPSHOT’	  CORRELATION	  OF	  BASELINE	  PET	  ENDPOINTS	  WITH	  CLINICO-­‐-­‐-­‐	  	  	  	  	  	  	  	  	  	  	  	  PATHOLOGICAL	  SCORES	  	  	   Spearman	   rank	   correlation	   coefficients	   were	   performed	   to	   assess	   the	   degree	   of	   correlation	  between	  	  each	  	  of	  	  the	  	  clinico-­‐-­‐-­‐pathological	  	  variables	  	  and	  	  the	  	  FDG-­‐-­‐-­‐PET	  	  endpoints.	  	  These	  	  are	  reviewed	  	   in	  	  Tables	  	  2.4A-­‐-­‐-­‐D.	  	  The	  	  closest	  	  and	  	  more	  	  consistent	  	  correlations	  	  are	  	  observed	  between	  	  CRP	  	  and	  	  FDG-­‐-­‐-­‐PET	  	  measures	  	  of	  	   intensity.	  	   	  	  HBI	  	  and	  	  FC	  	  correlations	  	  with	  	  PET	  endpoints	  were	  weaker	  and	  less	  consistent.	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Tables	  2.5A,	  2.5B,	  2.5C,	   and	  2.5D:	  Correlations	  between	   clinico-­‐-­‐-­‐pathological	   (Harvey	  Bradshaw	  
Index,	  CRP	  and	  Faecal	  Calprotectin)	  and	  PET	  endpoints	  (segmental	  and	  global	  SUVMAX,	  SUVMEAN	  
and	  lesion	  glycolysis).	  Statistical	  significance	  highlighted	  in	  pink.	  	  
	  	  
A)	  All	  PET-­‐-­‐-­‐positive	  segments,	  absolute	  values	  	  
	  
Endpoint	  	   SUVMAX	  	   SUVMEAN	  	   SLG	  	   GSUVMAX	  	   GSUVMEAN	  	   TLG	  	  














r=-­‐-­‐-­‐0.01	  p=0.95	   r=0.37	  p=0.10	  
	  
B)	  All	  PET-­‐-­‐-­‐positive	  segments,	  TBR	  	  
	  
Endpoint	  	   RSUVMAX	  	   RSUVMEAN	  	   RSLG	  	   RGSUVMAX	  	   RGSUVMEAN	  	   RTLG	  	  
















r=0.46	  p=0.04	  	  
C)	  PET-­‐-­‐-­‐positive	  MRI-­‐-­‐-­‐positive	  segments,	  absolute	  values	  	  
	  
Endpoint	  	   SUVMAX	  	   SUVMEAN	  	   SLG	  	   GSUVMAX	  	   GSUVMEAN	  	   TLG	  	  
HBI	  	   r=0.36	  p=0.10	  
R=0.40	  P=0.064	   R=0.35	  P=0.11	  
R=0.46	  P=0.031	   R=0.38	  P=0.08	  
R=0.46	  P=0.031	  
CRP	  	   r=0.49	  p=0.019	  
R=0.48	  P=0.024	   R .0	  P=0.64	  
R=0.56	  P=0.007	   R .50	  P=0.017	   R=0.49	  P=0.022	  
FC	  	   R=0.41	  P=0.070	   R=0.17	  P=0.46	  
R -­‐-­‐-­‐0.05	  P=0.85	   R=0.29	  P=0.22	  
R=0.02	  P=0.93	  
R=0.34	  P=0.15	  	  
	  
D)	  PET-­‐-­‐-­‐positive	  MRI-­‐-­‐-­‐positive	  segments,	  TBR	  	  
	  
Endpoint	  	   RSUVMAX	  	   RSUVMEAN	  	   RSLG	  	   RGSUVMAX	  	   RGSUVMEAN	  	   RTLG	  	  










r=0.41	  p=0.06	  FC	  	   0=0.47	  p=0.035	  
R=0.39	  P=0.085	   R=0.25	  P=0.29	  
R=0.41	  P=0.071	   R=0.24	  P=0.31	  
P=0.41	  P=0.07	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2.3.4 LONGITUDINAL	  ASSESSMENT	  -­‐-­‐-­‐	  RESPONSIVENESS	  2.3.4.1 CLINICO-­‐-­‐-­‐PATHOLOGICAL	  –PET	  ENDPOINT	  CORRELATIONS	  
The	   strongest	   and	  most	   consistent	   longitudinal	   correlations	  were	   between	   segmental	   and	  global	   SUVMAX	  and	   ΔHBI	   and	   ΔCRP	   and	   both	   segmental	   and	   global	   ΔSUVMAX.	   These	   were	  present	   but	   less	   strong	   with	   ΔSUVMEAN	   /ΔGSUVMEAN.	   Similarly	   to	   the	   static	   relationships	  outlined	   above,	   there	  was	  no	   correlation	  between	  ΔHBI	   and	  ΔCRP	   and	   lesional	   glycolysis,	  while	   ΔFC	   correlated	   with	   none	   of	   the	   PET	   endpoints.	   These	   observations	   changed	   little	  whether	  values	  were	  absolute	  (Tables	  2.5A,	  2.5C)	  or	  expressed	  as	  TBR	  (Tables	  2.5B,	  2.5D)	  or	  whether	   all	   PET+ve	   segments	   (Tables	   2.5A,	   2.5B)	   or	   PET+ve	   /	   MRI	   +ve	   subsets	   were	  examined	  (Tables	  2.5C,	  2.5D).	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Tables	  	  2.6A,	  2.6B,	  2.6C,	  2.6D:	  Correlations	  	  between	  	  Δclinico-­‐-­‐-­‐pathological	  and	  	  ΔPET	  	  endpoints	  
(statistical	   significance	   highlighted	   in	   pink	   if	   corresponding	   snap-­‐-­‐-­‐shot	   correlation	   in	   Table	   2.4	  
was	  not	  significant	  or	  purple	  if	  snapshot	  correlation	  was	  also	  significant)	  
	  
A) All	  PET-­‐-­‐-­‐positive	  segments,	  absolute	  values	  
	  
Endpoint	   Δ	  SUVMAX	   Δ	  SUVMEAN	   Δ	  SLG	   Δ	  GSUVMAX	   Δ	  GSUVMEAN	   Δ	  TLG	  









r=0.71	  p=0.009	   r=0.51	  p=0.08	  Δ	  FC	   r=-­‐-­‐-­‐0.25	  p=0.43	   r=0.06	  p=0.85	  
r=-­‐-­‐-­‐0.02	  p=0.96	   r=0.06	  p=0.87	  
r=-­‐-­‐-­‐0.05	  p=0.89	   r=-­‐-­‐-­‐0.17	  p=0.60	  
	  
	  
B) All	  PET-­‐-­‐-­‐positive	  segments,	  TBR	  
	  
Endpoint	   Δ	  RSUVMAX	   Δ	  RSUVMEAN	   ΔR	  SLG	   Δ	   RGSUVMAX	   Δ	   RGSUVMEAN	   Δ	  RTLG	  
Δ	  HBI	   r=0.60	  p=0.03	  
r=0.67	  p=0.01	   r=0.24	  p=0.42	  
r=0.77	  p=0.003	  
r=0.55	  p=0.06	  









r=-­‐-­‐-­‐0.01	  p=0.97	   r=-­‐-­‐-­‐0.10	  p=0.76	  
	  
C) PET-­‐-­‐-­‐positive	  MRI-­‐-­‐-­‐positive	  segments,	  absolute	  values	  
	  
Endpoint	   Δ	  SUVMAX	   Δ	  SUVMEAN	   Δ	  SLG	   Δ	  GSUVMAX	   Δ	  GSUVMEAN	   Δ	  TLG	  
Δ	  HBI	   r=0.75	   r=0.79	   r=0.57	   r=0.83	   r=0.63	  p=0.02	   r=0.48	  p=0.10	  p=0.005	   p=0.002	   p=0.045	   p=0.0007	  Δ	  CRP	   r=0.74	   r=0.45	  p=0.12	   r=0.54	  p=0.6	   r=0.79	   r=0.52	  p=0.07	   r=0.53	  p=0.06	  p=0.005	   p=0.002	  Δ	  FC	   r=0.28	  p=0.38	   r=0.08	  p=0.80	   r .12	  p=0.72	   r=0.08	  p=0.80	   r=-­‐-­‐-­‐0.20	  p=0.53	   r=-­‐-­‐-­‐0.18	  p=0.57	  	  
D) PET-­‐-­‐-­‐positive	  MRI-­‐-­‐-­‐positive	  segments,	  TBR	  
	  
Endpoint	   Δ	  RSUVMAX	   Δ	  RSUVMEAN	   ΔR	  SLG	   Δ	   RGSUVMAX	   Δ	   RGSUVMEAN	   Δ	  RTLG	  














r=-­‐-­‐-­‐0.13	  p=0.70	   r=-­‐-­‐-­‐0.18	  p=0.57	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2.3.4.2 PERFORMANCE	  OF	  FDG-­‐-­‐-­‐PET	  ENDPOINTS	  IN	  RESPONDERS	  VERSUS	  NON-­‐-­‐-­‐RESPONDERS	  	  	  	   9	  of	  the	  13	  patients	  that	  completed	  PET	  scanning	  before	  and	  3	  months	  after	  treatment	  had	  a	  clinically	  demonstrable	  response,	  as	  demonstrated	  by	  a	  ΔHBI	  ≥	  3.	  The	  median	  (range)	  ΔHBI	  in	  	  responders	  	  was	  	  5	  	  (3-­‐-­‐-­‐9)	  	  and	  	  in	  	  non-­‐-­‐-­‐responders	  	  was	  	  1(-­‐-­‐-­‐1-­‐-­‐-­‐2).	  	  While	  	  this	  	  dichotomy	  	  was	  made	  	  on	  	  clinical	  	  criteria,	  	  tracking	  	  CRP	  	  and	  	  FC	  	  between	  	  the	  	  two	  	  visits	  	  largely	  	  corroborates	  the	  	  allocation	  	  of	  patients	  	  in	  	  each	  	  group.	  CRP	  	  was	  	  abnormal	   (>5.0mg/L)	   in	  	  5/9	  	  responders,	  and	  	  normalized	  	  in	  	  4,	  	  and	  	  in	  	  3/4	  	  non-­‐-­‐-­‐responders	  	  and	  	  it	  	  increased	  	  in	  	  2.	  	  FC	  	  was	  	  abnormal	  (>100mcg/g)	  	   in	  	  7/9	  	  responders	  	  and	  	  normalized	  	   in	  	  5,	  	  and	  	   in	  	  3/4	  	  non-­‐-­‐-­‐responders	  	  and	  normalized	  in	  none	  (Table	  2.3A)	  	  	   Differences	  	  before	  	  and	  	  after	  	  treatment	  	  were	  	  statistically	  	  significant	  	  in	  	  all	  	  PET	  	  endpoints	  	  in	  responders	  versus	  non-­‐-­‐-­‐responders	   (Table	  2.6	  A).	  Shifting	   the	   focus	   to	   segments	  which	  were	  also	  	  MRI	  	  +ve	  	  did	  	  not	  	  have	  	  a	  	  significant	  	  impact	  	  except	  	  for	  	  a	  	  non-­‐-­‐-­‐significant	  	  result	  	  for	  	  TLG	  (Table	  	  2.6B).	  	  This	  	  was	  	  also	  	  the	  	  case	  	  when	  	  values	  	  were	  	  expressed	  	  as	  	  TBR	  	  (results	  	  not	  shown).	  	  	  Figure	  	  2.3	  	  shows	  	  characteristic	  	  appearances	  	  of	  	  baseline	  	  and	  	  follow-­‐-­‐-­‐up	  	  segmental	  signal	  in	  responders	  and	  non-­‐-­‐-­‐responders.	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Figure	  	  2.3	  	  (A)	  	  Characteristic	  	  PET	  	  signal	  	  in	  	  a	  	  terminal	  	  ileal	  	  segment	  	  of	  	  a	  	  non-­‐-­‐-­‐responder	  	  at	  
baseline	  	  (top)	  	  and	  	  follow-­‐-­‐-­‐up	  	  (bottom).	  	  (B)	  	  Typical	  	  PET	  	  signal	  	  in	  	  a	  	  descending	  	  colon	  	  of	  	  a	  




Table	  2.7:	  Magnitude	  of	  change	   for	  each	  endpoint	   in	  PET	  +ve	  (Table	  2.7	  A)	  and	  PET+ve	  MRI	  
+ve	  	  	  segments	  	  	  (Table	  	  	  2.7	  	  	  B).	  	  	  The	  	  	  number	  	  	  of	  	  	  segments	  	  	  or	  	  	  patients	  	  	  showing	  	  	  a	  	  	  reduction	  
(improvement)	  	  of	  	  the	  	  endpoint	  	  in	  	  each	  	  of	  	  the	  	  responder	  	  and	  	  non-­‐-­‐-­‐responder	  	  groups	  	  is	  	  shown.	  
The	  mean	   absolute	   reduction	   and	   a	  mean	  %	  	  reduction	   between	   index	   and	   follow-­‐-­‐-­‐up	   scan	   are	  
also	  given.	  Finally	   the	  p-­‐-­‐-­‐value	   from	  Mann-­‐-­‐-­‐Whitney	  test	  comparisons	   for	  each	  ΔPET	  endpoint	   in	  






All	  PET	  	  +ve	  Segments	  
Δ	  in	  responders	  
(n=9	  patients,	  26	  segments)	   Δ	  in	  Non-­‐-­‐-­‐responders	  (n=4	  patients,	  14	  segments)	   	   p-­‐-­‐-­‐value	  
n	  










All	  PET	  	  +ve	  MRI	  +ve	  segments	  
Δ	  in	  responders	  
(n=9	  pts,	  26	  segments)	   Δ	  in	  Non-­‐-­‐-­‐responders	  (n=4	  pts,	  14	  segments)	   	   p-­‐-­‐-­‐value	  
n	  
improving	   Absolute	  Δ	   %	  Δ	   n	  improving	   Absolute	  Δ	   %	  Δ	  ΔSUVMAX	   18/20	   -­‐-­‐-­‐3.6	   -­‐-­‐-­‐39%	   1/8	   1.8	   22%	   <0.0001	  ΔSUVMEAN	   18/20	   -­‐-­‐-­‐1.2	   -­‐-­‐-­‐25%	   2/8	   0.2	   6.4%	   0.0005	  ΔSLG	   17/20	   -­‐-­‐-­‐94	   -­‐-­‐-­‐54%	   3/8	   113	   133%	   0.006	  ΔGSUVMAX	   8/9	   -­‐-­‐-­‐3.2	   -­‐-­‐-­‐39%	   1/4	   1.2	   16%	   0.006	  ΔGSUVMEAN	   8/9	   -­‐-­‐-­‐1.1	   -­‐-­‐-­‐32%	   1/4	   0	   0.6%	   0.036	  ΔTLG	   8/9	   -­‐-­‐-­‐210	   -­‐-­‐-­‐52%	   2/4	   227	   49%	   0.07	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Figure	  2.4:	  Baseline	  and	  follow-­‐up	  values	  of	  all	  PET	  endpoints	  in	  all	  PET+ve	  segments.	  	  	  
ΔPET	   endpoints	   in	   responders	   vs.	   non-­‐responders:	  A)SUVMAX/	  GSUVMAX	   	  B)SUVMEAN/	  GSUVMEAN	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 Responders vs Non-Responders 
p=0.033 *
C	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Figure	  2.5:	  Baseline	  and	  follow-­‐up	  values	  of	  all	  PET	  endpoints	  in	  all	  PET+ve	  MRI+ve	  segments.	  	  	  
ΔPET	   endpoints	   in	   responders	   vs.	   non-­‐responders:	  A)SUVMAX/	  GSUVMAX	   	  B)SUVMEAN/	  GSUVMEAN	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2.3.4.3	  RESPONSIVESS	  RATIOS	  	  RRG	  and	  SES,	  for	  each	  outcome	  measure	  are	  summarised	  in	  Table	  2.7.	  Values	  over	  0.80	  are	  considered	  as	  indicative	  of	  good	  responsiveness	  for	  an	  evaluative	  instrument	  162.	  
	  
	  
Table	  2.7:	  Responsiveness	  ratios	  for	  FDG-­‐PET	  outcome	  measures	  





















+ve	  Segs	  SUVMAX	   	  0.85	   0.95	   0.87	   0.98	  SUVMEAN	   1.14	   1.63	   0.87	   1.02	  SLG	   0.27	   0.59	   0.62	   0.75	  GSUVMAX	   1.29	   1.20	   1.06	   1.06	  GSUVMEAN	   3.22	   2.35	   0.89	   1.08	  TLG	   	  0.21	   0.49	   0.90	   1.01	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2.3.5	  TEST-­‐RETEST	  RELIABILITY	  	  	  5	   patients	   (1	   female)	   with	   active	   CD	   were	   recruited	   for	   this	   arm	   of	   the	   trial,	   and	   4	  completed	   the	   two	   scans	  within	   a	  median	  of	   7	  days	   (range	  4-­‐12	  days).	  Demographics	  and	  clinico-­‐pathological	  scores	  are	  listed	  in	  Table	  	   2.1B.	  	  %Variability	   for	   each	   endpoint	   was	   measured	   using	   segments	   with	   a	   signal	   focus	   >	  LivSUVMEAN.	  Results	  are	  summarised	  in	  Table	  2.8.	  	  
	  
Table	  2.8:	  %	  Variabilities	  in	  SEGMENTAL	  and	  GLOBAL	  endpoints	  of	  FDG-­‐PET	  scanning	  in	  
CD	  
	  	  	  	  	  
	  




	   Mean	  	  %VAR	  	   St.	  dev	  
SUVMAX	   20	   16.6	  
RSUVMAX	   20	   15.8	  
	   	   	  
SUVMEAN	  	   9	   	  RSUVMEAN	   9	   6.0	  
	   	   6.9	  Volume	   64	   	  
	   	   54.4	  
SLG	   66	   	  
RSLG	   67	   55.5	  
Global	  





GSUVMAX	   13	   20.7	  
RGSUVMAX	   14	   15.9	  
	   	   	  GSUVMEAN	   2	   2.3	  
RGSUVMEAN	  	   4	   4.6	  
	   	   	  
TLG	   51	   45.3	  
RTLG	   56	   41.7	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Figure	  2.6:	  An	  example	  of	  18F-­‐FDG	  PET	  signal	  in	  the	  neo-­‐terminal	  ileum	  of	  patient	  5	  of	  the	  
test-­‐retest	  cohort,	  receiving	  baseline	  (left)	  and	  follow-­‐up	  (right)	  scans	  4	  days	  apart.	  SUVMAX	  
and	  SUVMEAN	  were	  similar	  between	  the	  two	  scans	  while	  Volume	  (and	  SLG)	  was	  significantly	  
more	  variable.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	   Baseline	   Follow-­‐up	  SUVMAX	   5.9	   4.3	  SUVMEAN	   2.6	   2.3	  Volume	   87	  cm³	   43	  cm³	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Figure	   2.7:	   As	   signal	   threshold	   was	   increased	   (red	   circles),	   the	   voxels	   of	   highest	   signal	  
(yellow	  areas)	  concentrated	  in	  the	  centre	  of	  the	  VOI	  which	  overlaid	  the	  intestinal	  lumen.	  	  
A:	  Longitudinal	  section	  B:	  Transverse	  section.	  
	  
	  
	  We	  therefore	  set	  out	  to	  differentiate	  the	  mural	  and	  luminal	  components	  of	  the	  signal	  in	  three	   subjects	   with	   recto-­‐sigmoid	   disease	   having	   a	   scan	   as	   part	   of	   the	   pre	   and	   post	  treatment	   arm	   of	   our	   study.	   Our	   hypothesis	  was	   that	  we	   can	   eliminate	   recto-­‐sigmoid	  luminal	   radioactivity	   by	   means	   of	   a	   phosphate	   enema,	   and	   we	   can	   quantify	   it	   as	   a	  proportion	  of	  the	  total	  radioactivity	  of	  the	  segment.	  	  	  
A	  
B	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  After	   completing	   the	   original	   30-­‐minute	   period	   of	   PET	   signal	   acquisition,	   the	   images	  were	  reconstructed	  and	  qualitatively	  reviewed	  for	  the	  presence	  of	  a	  signal	  focus	  in	  the	  recto-­‐sigmoid	   region.	   Once	   this	   was	   visually	   confirmed,	   and	  without	   any	   quantitative	  measurements	  being	  obtained	  at	   that	  stage,	   the	  patient	  was	  administered	  a	  phosphate	  enema,	   and	   following	   evacuation	   of	   bowel	   contents,	   he	   was	   asked	   to	   return	   on	   the	  scanner.	  A	  repeat	  limited	  low-­‐dose	  CT	  scan	  of	  the	  pelvis,	  using	  the	  parameters	  described	  above,	   followed	   by	   an	   additional	   10-­‐minute	   PET	   acquisition	   over	   a	   single	   pelvic	   bed	  position	  was	  obtained	  (patient	  1).	  For	  the	  latter	  two	  patients,	  we	  measured	  directly	  the	  radioactivity	  (RA)	  in	  the	  eliminated	  bowel	  contents,	  instead	  of	  performing	  a	  repeat	  scan,	  and	  following	  decay	  correction,	  expressed	   it	  as	  a	  proportion	  of	   the	  original	   total	  RA	  in	  the	  recto-­‐sigmoid.	  	  The	  total	  radioactivities	  (RA)	   in	  KBqs	   in	   the	  whole	  of	   the	  recto-­‐sigmoid	   in	  the	  pre	  and	  post	  enema	  scans	  were	  compared.	  In	  addition,	  in	  the	  latter	  two	  subjects,	  the	  eliminated	  bowel	   contents	   were	   also	   placed	   in	   the	   scanner	   for	   10	   minutes	   and	   their	   total	  radioactivity	  quantified.	  All	  measured	  radioactivities	  for	  the	  post	  enema	  scan	  and	  bowel	  contents	  were	  decay-­‐corrected	  to	  the	  time	  of	  the	  pre-­‐enema	  PET	  acquisition.	  	  	  
Table	  2.9:	  Rectosigmoid	  radioactivities	  pre	  and	  post	  PO4	  enema	  and	  faecal	  radioactivities	  
Patient	   Rectosigmoid	  RA	  




RA	  (KBq)	  in	  
bowel	  
contents	  
%	  of	  RA	  in	  
bowel	  
contents	  1	   568	   	  467	   Not	  measured	   Estimated	  17.8%	  2	   989	   Not	  measured	   300	  	   30.3	  3	   373	   Not	  measured	   38.9	   10.4	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2.4.DISCUSSION	  	  
	   2.4.1	  SUMMARY	  OF	  FINDINGS	  	  Key	  results	  from	  this	  study	  are	  the	  following:	  
• CRP	   closely	   correlates	   with	   FDG-­‐PET	   endpoints	   of	   intensity	   (segmental	   and	   global	  SUVMAX	  and	  SUVMEAN)	  both	  in	  the	  static	  as	  well	  as	  the	  longitudinal	  assessment.	  	  
• There	  was	  no	  correlation	  between	  faecal	  calprotectin,	  a	  marker	  of	  intestinal	  neutrophil	  migration,	  and	  FDG-­‐PET	  outcome	  measures.	  
• Segmental	  and	  Global	  SUVMAX	  and	  SUVMEAN	  are	  significantly	  more	  responsive	  than	  SLG	  and	   TLG	   in	   demonstrating	   change	   in	   patients	   responding	   to	   anti-­‐TNFα	   within	   12	  weeks.	  	  
• Segmental	  and	  Global	  SUVMAX	  and	  SUVMEAN	  are	  significantly	  more	  reliable	  than	  SLG	  and	  TLG	  on	  test-­‐retest	  assessments	  in	  stable	  patients	  at	  short	  time	  intervals	  
• A	  significant	  proportion	  of	   intestinal	  FDG	  signal	   appears	   to	  originate	   intra-­‐luminally,	  rather	  than	  trapped	  intra-­‐cellularly	  in	  cells	  within	  the	  bowel	  wall.	  
• If	   the	   significant	   presence	   of	   luminal	   FDG	   is	   not	   confirmed	   in	   larger	   studies,	   then	  (G)SUVMAX	   and	   (G)SUVMEAN	   should	   be	   taken	   forward	   with	   larger	   studies	   confirming	  their	  suitability	  as	  early	  monitoring	  markers	  in	  Crohn’s	  disease.	  
	   2.4.2	  DISCUSSION	  OF	  FINDINGS	  	  FDG-­‐PET	   is	   a	   non-­‐invasive	   method	   of	   quantifying	   inflammatory	   activity	   both	   on	   a	  segmental	  as	  well	  as	  a	  global	  level	  in	  patients	  with	  CD,	  and	  it	  has	  previously	  shown	  good	  correlation	  with	   endoscopic	   and	  histo-­‐pathological	   reference	   standards	   133–135,138,141,168.	  Little	   is	   known	   however	   on	   the	   technique’s	   potential	   to	   monitor	   the	   inflammatory	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lesions	   over	   time.	   To	  my	   knowledge	   this	   is	   the	   first	   prospective	   study	   that	   evaluates	  comprehensively	   the	   entirety	   of	   proposed	   FDG-­‐PET	   endpoints’	   responsiveness	   and	  reliability	  in	  demonstrating	  the	  variations	  in	  disease	  activity.	  	  
Twenty-­‐two	   patients	   had	   at	   least	   1	   PET	   scan	   and	   simultaneous	   clinical	   (HBI)	   and	  biochemical	  markers	  of	  severity	  (CRP	  and	  faecal	  calprotectin).	  These	  baseline	  data	  were	  used	  for	  correlations	  of	  PET	  with	  clinico-­‐pathological	  outcome	  measures.	  In	  the	  case	  of	  segmental	  PET	  endpoints	   it	  was	  hypothesised	   that	   the	  most	   inflamed	  segment,	   judged	  on	  the	  basis	  of	   its	  SUVMEAN	  value,	  will	  have	  the	  highest	  contribution	  towards	  symptoms	  (HBI)	  and	  CRP	  and	  FC	  rise,	  so	  it	  was	  used	  for	  the	  correlation.	  	  
SUVMAX	  correlated	   significantly	  with	  CRP,	  whereas	  when	  expressed	  as	   a	  TBR,	  RSUVMAX,	  the	  correlation	  was	  significant	  with	  all	  three	  clinico-­‐pathologic	  markers.	  Its	  longitudinal	  performance	   was	   also	   satisfactory	   as	   both	   responsiveness	   ratios	   were	   consistently	  above	   the	   pre-­‐defined	   threshold	   of	   0.80.	   The	   effect	   was	   maintained	   when	   PET+ve	   -­‐	  MRI+ve	   segments	   were	   examined.	   This	   observation	   was	   further	   strengthened	   by	   the	  fact	   that	   ΔSUVMAX	   in	   responders	   was	   significantly	   larger	   than	   in	   non-­‐responders.	   In	  addition	  to	  the	  significant	  responsiveness	  figures,	  the	  test-­‐retest	  %variability	  of	  20%	  is	  favourable,	   especially	  when	   considering	   the	   significant	   difference	   between	   that	   figure	  obtained	   in	   the	   test-­‐retest	   cohort,	   with	   a	  %	   change	   of	   -­‐32%	   in	   responders.	   GSUVMAX,	  which	  represents	  the	  average	  SUVMAX	  in	  all	  PET+ve	  segments	  performed	  very	  similarly	  to	  its	  segmental	  counterpart	  both	  in	  its	  static	  correlations	  with	  HBI	  and	  CRP,	  as	  well	  as	  in	   its	   longitudinal	   performance.	   Importantly	   all	   9	   responders	   had	   reductions	   in	   their	  GSUVMAX	  between	  baseline	  and	  follow-­‐up	  scans	  (average	  %	  change	  -­‐40%)	  versus	  only	  1	  of	  4	  non-­‐responders.	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It	  is	  important	  to	  consider	  that	  SUVMAX	  only	  reflects	  activity	  in	  a	  single	  voxel	  within	  the	  entire	  segment,	  and	  may	  not	  be	  representative	  of	   the	   totality	  of	   inflammatory	  activity.	  Intuitively	   therefore,	   more	   inclusive	   endpoints	   such	   as	   SUVMEAN	   should	   offer	   more	  confidence	   that	   a	   true	   picture	   of	   the	   whole	   lesion	   is	   being	   obtained.	   Despite	   this	  theoretical	   limitation,	   SUVMAX	   has	   had	   an	   excellent	   track	   record	   of	   providing	   valuable	  diagnostic	  as	  well	  as	  prognostic	  information	  in	  oncological	  practice	  122,	  and	  its	  certainly	  biologically	   plausible	   that	   this	   will	   also	   be	   the	   case	   in	   inflammatory	   monitoring	   as	   a	  reduction	   in	   the	   peak	   of	   metabolic	   activity	   suggests	   a	   decrease	   in	   	   the	   degree	   of	  inflammatory	  cell	  activation.	  
SUVMEAN	  and	  GSUVMEAN,	  similarly	  to	  SUVMAX,	  were	  also	  shown	  to	  be	  responsive	  outcome	  measures.	  In	  addition,	  they	  demonstrated	  good	  correlation	  to	  CRP,	  and,	  when	  expressed	  as	  TBR,	  also	   to	  HBI.	  Highly	   significant	  differences	  were	   shown	   in	  ΔSUVMEAN,	   as	  well	   as	  ΔGSUVMEAN,	  between	  responders	  and	  non-­‐responders.	  Moreover,	  the	  within-­‐patient	  test-­‐retest	  %	  variabilities	  were	  very	  low	  at	  9%	  and	  2%,	  indicating	  excellent	  reliability	  of	  the	  measure.	  
The	  above	  results	  on	  (G)SUVMAX	  and	  (G)SUVMEAN	  are	  in	  	  contrast	  with	  the	  performance	  of	  SLG	   and	   TLG	   as	   monitors	   of	   CD	   activity:	   The	   snapshot	   assessment	   in	   all	   22	   patients	  revealed	  a	  modest	  correlation	  between	  TLG	  only	  and	  clinico-­‐pathological	  parameters.	  In	  the	  majority,	  these	  were	  not	  maintained	  in	  the	  longitudinal	  assessment	  where	  there	  was	  a	   profound	   lack	   of	   correlation	   between	   the	   evolution	   of	   CRP	   and	   FC	   compared	   to	  SLG/TLG	   over	   time.	   The	   ΔSLG	   were	   statistically	   significant	   between	   responders	   and	  non-­‐responders,	  whereas	   ΔTLGs	  were	   only	   different	  when	   all	   PET+ve	   segments	  were	  assessed.	  Moreover,	  the	  responsiveness	  markers	  for	  these	  two	  endpoints	  were	  low.	  On	  test-­‐retest	  analysis,	  the	  volume	  of	  signal	  in	  each	  segment	  and,	  as	  a	  consequence,	  SLG	  and	  TLG	   had	   much	   more	   pronounced	   variabilities	   of	   66%	   and	   51%	   respectively.	   The	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thorough	   standardization	   of	   scanning	   parameters,	   bowel	   distention	   protocols	   and	   the	  significantly	  better	  performance	  of	  SUVMAX	  and	  SUVMEAN	  in	  that	  assessment	  suggest	  that	  this	  was	  not	  due	  to	  methodological	   factors	  that	  can	  be	  improved	  in	  obvious	  ways.	  One	  explanation	  is	  that	  Crohn’s	  lesions	  are	  more	  dynamic	  than	  originally	  believed,	  with	  the	  cellular	  inflammatory	  influx	  changing	  significantly	  even	  within	  days.	  If	  these	  cells	  have	  a	  relatively	   uniform	   glucose	  metabolism,	   and	   therefore	   FDG	   uptake,	   this	   would	   explain	  the	   lower	   variability	   in	   SUVMEAN	   between	   the	   two	   assessments	   as	   well	   as	   the	   large	  variability	  in	  the	  volume	  of	  segmental	  signal.	  An	  alternative	  reason	  for	  this	  phenomenon	  could	   be	   an	   intra-­‐luminal	   ‘escape’	   of	   a	   proportion	   of	   FDG,	   variable	   from	   visit	   to	   visit.	  This	   is	   less	   probable	   as	   a	   dilution	   of	   the	   signal	   resulting	   from	   FDG	   escape	   into	   free	  luminal	   space,	   would	   also	   have	   an	   effect	   on	   SUVMEAN	  values,	   which	  was	   not	   observed.	  Until	   these	   variations	   are	   better	   understood,	   given	   the	   poor	   reliability	   of	   these	   two	  endpoints	  as	  demonstrated	  by	  the	  test-­‐retest	  component	  of	  the	  analysis,	  these	  results	  do	  not	   support	   clinical	   applications	   of	   volume-­‐dependent	   PET	   endpoints	   in	   the	  quantification	  and	  monitoring	  of	  CD	  activity.	  	  The	  existing	  evidence	  base	  also	  concurs	  with	   the	  conclusion	   that	  SLG	  and	  TLG	  are	  not	  likely	  to	  be	  suitable	  assessment	  tools	  in	  CD.	  SLG	  was	  first	  introduced	  by	  Jacene	  et	  al.	  who	  attempted	   to	   correlate	   several	   FGD-­‐PET	   endpoints	   obtained	   pre-­‐operatively	   with	  histopathological	  scores	  of	  inflammation	  in	  the	  resected	  intestinal	  specimen	  in	  a	  cohort	  of	  12	  CD	  patients.	  That	  group	  also	  pointed	  out	  the	  large	  inter-­‐subject	  variability	  of	  SLG	  and	   its	   lack	  of	   correlation	   to	   lesional	   inflammatory	   scores	   168.	   In	  a	  more	   recent	  paper,	  Saboury	   et	   al.	   also	   assessed	   regional	   and	   global	   lesion	   glycolysis	   and	   demonstrated	  modest	   correlations	   between	   the	   latter	   and	   CDAI	   as	   well	   as	   FC,	   but	   not	   with	   CRP	   or	  more	  robust	  endoscopic	  scores	  of	  severity	  141.	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The	  demonstration	  of	  an	  intra-­‐luminal	  component	  of	  the	  signal	  is	  potentially	  important	  in	   interpretations	  of	  bowel	  FDG-­‐PET.	  There	  are	  at	   least	  two	  hypotheses	  to	  explain	  this	  finding.	   It	   is	   already	   known	   that	   epithelial	   tight	   junctions	   are	   disturbed	   in	   active	  inflammatory	  bowel	  disease	  lesions.	  	  While	  this	  has	  been	  studied	  more	  in	  the	  context	  of	  bacterial	   translocation	   and	   immune	   sensitisation	   177,	   barrier	   impairment	   could	   also	  result	   in	   intra-­‐luminal	   FDG	   escape	   from	   the	   extracellular	   space.	   	   The	   impact	   for	  quantitative	   interpretation	   arises	   despite	   the	   fact	   that	   this	   would	   be	   a	   direct	  consequence	  of	  the	  disease	  process.	  This	  is	  because	  the	  luminal	  FDG	  does	  not	  represent	  an	   increased	   metabolic	   activity,	   which	   underpins	   the	   use	   of	   the	   technique	   in	  inflammatory	   imaging,	   and	   thus	   it	   may	   reduce	   the	   accuracy	   of	   quantification.	   An	  alternative	   explanation	   for	   the	   intra-­‐luminal	   component	   could	   be	   the	   shedding	   of	  mucosal	  intestinal	  cells	  occurring	  in	  the	  interval	  between	  FDG	  administration	  and	  image	  acquisition.	  	  	  Moreover,	  while	  studies	  on	  murine	  models	  of	  IBD	  are	  suggestive	  that	  a	  very	  significant	  component	  of	  the	  signal	  is	  produced	  by	  inflammatory	  cell	  lineages	  in	  affected	  segments	  
142,144,	  similar	  studies	  in	  humans	  are	  still	  lacking.	  A	  potential	  direct	  way	  of	  testing	  this	  in	  humans	   would	   be	   to	   administer	   FDG	   immediately	   pre-­‐operatively	   in	   subjects	  undergoing	   intestinal	   resection,	   and	   then	   performing	   a	   combination	   of	   micro-­‐autoradiography	   and	   immunohistochemistry	   in	   several	   sections	   of	   the	   resected	  specimen.	  	  	   2.4.3.	  METHODOLOGICAL	  CONSIDERATIONS	  	  As	  discussed	  extensively	   in	   the	   introduction	   to	   this	   thesis,	   selecting	   suitable	   reference	  comparators	  to	  correlate	  to	  FDG-­‐PET	  was	  a	  challenging	  process,	  as	  is	  the	  case	  with	  most	  studies	  assessing	  novel	  monitoring	  markers	  in	  CD.	  HBI	  CRP	  and	  FC	  all	  have	  favourable	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profiles	   in	   demonstrating	   active	   disease	   20,38,47,	   but	   none	   can	   be	   considered	   as	   gold-­‐standard	   in	   the	   context	  of	   this	   study,	  due	   to	   a	   combination	  of	   suboptimal	   sensitivities	  and	  specificities,	  and	   lack	  of	  validation	  as	  monitoring	   tools.	  Quantitative	  MaRIA	  scores	  and	  CDEIS	  analysis	  are	  significantly	  more	  robust	  endpoints	  to	  use	  for	  this	  purpose,	  and	  recent	   studies	   suggest	   that	   the	   two	   are	   closely	   correlated	   74,75.	   As	   MRI	   was	   routinely	  performed	   in	   patients	   in	   this	   cohort,	   it	   was	   decided	   to	   use	   MaRIA	   scores	   as	   a	  determinant	   of	   normal	   versus	   abnormal	   segments.	   Encouragingly,	   a	   large	   study	  attributing	   a	   similar	   role	   to	   MaRIA	   has	   since	   been	   published	   108	   :	   Hordonneau	   et	   al.	  compared	   diffusion	   weighting	   in	   848	   bowel	   segments	   from	   130	   CD	   patients	   defining	  	  normal	  versus	  active	  segments	  on	  the	  basis	  of	  their	  MaRIA	  score.	  	  The	  methodology	   around	   the	   use	   of	   reference	   standard	   had	   some	   limitations.	   MaRIA	  was	   solely	   used	   as	   a	   surrogate	   for	   endoscopy	   to	   differentiate	   ‘true’	   from	   ‘false’	   PET-­‐positive	  segments	  on	  the	  baseline	  scan.	  At	  the	  time	  of	  study	  design,	  MaRIA	  had	  not	  been	  validated	   as	   a	   measure	   of	   treatment	   response	   110	   so	   it	   was	   not	   used	   as	   a	   way	   of	  differentiating	   responders	   from	   non-­‐responders	   in	   the	   relevant	   analysis.	   Moreover,	  even	  though	  MaRIA	  is	  expressed	  as	  a	  continuous	  variable,	   in	  my	  view	  it	  behaves	  more	  like	  a	  categorical	  one,	  with	  distinct	  clustering	  of	  the	  values	  around	  4-­‐5	  in	  the	  absence	  of	  disease,	   11-­‐13	   in	   diseased	   but	   non-­‐ulcerated	   segments	   and	   23-­‐30	   in	   segments	   with	  visible	   ulcerations.	   For	   that	   reason,	   a	   direct	   correlation	   between	   quantitative	   PET	  endpoints	  and	  MaRIA	  scores	  in	  each	  segment	  was	  not	  deemed	  appropriate.	  For	  lack	  of	  an	   alternative	   gold-­‐standard	   monitoring	   measure	   it	   was	   decided	   that	   the	   most	  appropriate	  way	  of	  making	   that	  distinction	  was	  on	   the	  basis	  of	  a	   clinically	  meaningful	  response,	   i.e.	   an	   HBI	   drop	   of	   3	   or	   more	   between	   the	   baseline	   and	   follow-­‐up	   visit	   as	  defined	  in	  the	  methods	  of	  large	  clinical	  trials174.	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When	  patients	  are	  introduced	  to	  anti-­‐TNF	  biologics,	  this	  is	  described	  to	  them	  as	  a	  novel,	  potent	  and,	  in	  most	  countries,	  end-­‐of-­‐the-­‐line	  therapy.	  Moreover,	  due	  to	  cost	  limitations,	  only	   primary	   responders	   are	   entered	   into	   a	   maintenance	   phase	   of	   therapy.	   This	   is	   a	  potential,	  but	  non-­‐circumventable	  source	  of	  bias	  in	  this	  study,	  as	  it	  is	  likely	  to	  have	  led	  to	   an	   over-­‐estimation	   or	   over-­‐reporting	   of	   the	   therapy’s	   symptomatic	   benefit	   by	  participants,	   resulting	   in	   larger	   ΔHBI	   between	   pre	   and	   post-­‐therapy	   assessments.	  Inevitably,	   this	  would	  unduly	  class	  more	  of	   them	  as	  responders.	  Had	  a	  more	  objective	  measure	   of	   treatment	   response	   been	   available,	   the	   measured	   differences	   in	   PET	  endpoints	   between	   responders	   and	   non-­‐responders	   may	   have	   been	   even	   more	  pronounced.	  	  	  The	   main	   aim	   of	   this	   study	   was	   not	   to	   assess	   FDG-­‐PET	   scanning	   exclusively	   in	   the	  context	   of	   monitoring	   the	   effects	   of	   anti-­‐TNF	   therapy,	   rather	   to	   assess	   the	  responsiveness	   of	   the	   test	   in	   reflecting	   disease	   modification	   at	   ‘per	   patient’	   and	  segmental	   level.	   	   A	   closer	   look	   on	   the	   proposed	   mode	   of	   action	   of	   anti-­‐TNF	   agents	  provide	  rationale	  why	  the	  particular	  patient	  group	  was	  selected	  at	  the	  particular	  time-­‐point.	  TNFα	  suppression	  is	  not	  the	  only	  effector	  mechanism	  of	  anti-­‐TNFα	  monoclonals,	  as	  evidenced	  by	   lack	  of	  efficacy	  of	  anti-­‐TNF	  agents	  directed	  against	   soluble	  TNFα	  (e.g.	  etanercept)	   178,179.	   The	   likely	   predominant	   mechanism	   of	   action	   is	   the	   induction	   of	  apoptosis	   of	   lamina	   propria	   T-­‐lymphocytes	   180	   and	   monocytes	   181	   via	   binding	   of	  membrane-­‐bound	  TNFα	  (mTNFα),	   	  antibody-­‐dependent	  cell-­‐mediated	  cytotoxicity,	  and	  complement-­‐	   dependent	   cytotoxicity	   182.	   Regulatory	   macrophages	   have	   also	   been	  demonstrated	  to	  contribute	  to	  mucosal	  healing	  in	  vitro	  and	  in	  vivo.	  These	  cells	  have	  been	  shown	   to	   inhibit	   proliferation	   of	   activated	   T	   cells,	   produce	   IL-­‐10,	   and	   express	   the	  regulatory	   macrophage	   marker	   CD206	   183,184.	   It	   was	   presumed	   therefore	   that	  performing	   the	  scanning	  around	  a	  period	  of	   these	  major	  cellular	  events,	  which	  should	  occur	   preferentially	   in	   responding	   patients,	   would	   give	   us	   the	   highest	   chance	   of	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demonstrating	   measurable	   signal	   changes	   both	   in	   individual	   segments	   as	   well	   as	  globally	  in	  each	  patient.	  	  	  Determining	  a	  working	  level	  of	  FDG	  signal	  to	  define	  the	  	  threshold	  for	  PET+ve	  segments	  was	  an	  additional	   significant	   challenge	   in	   the	  design.	  One	  option	   that	  was	  entertained	  was	   to	   not	   use	   a	   threshold	   and	   to	   obtain	   measurements	   from	   all	   segments	   in	   all	  participants.	  However,	  a	  degree	  of	  FDG	  accumulation	  in	  the	  intestine,	  and	  in	  particular	  the	  colon,	  is	  very	  frequent	  and	  not	  always	  pathological.	  Several	  studies	  in	  the	  literature	  have	  demonstrated	  the	  phenomenon	  of	  physiological	  (“artefactual”)	  FDG	  accumulation	  in	  the	  gut.	  A	  number	  of	  mechanisms	  have	  been	  proposed	  including	  uptake	  by	  intestinal	  smooth	  muscle,	  the	  swallowing	  of	  saliva	  and	  uptake	  by	  glucose-­‐metabolising	  microbial	  flora.	   In	   addition,	   the	   dense	   population	   of	   lymphocytes	   in	   the	   caecum	   and	   ascending	  colon	  may	  also	   justify	  some	  of	   the	  uptake	   in	  these	  regions	   185,	  and	   in	   this	  cohort	   these	  segments	   were	   certainly	   the	   ones	   with	   the	   highest	   ‘false	   positive’	   rates	   (Figure	   2.2).	  While	  the	  estimation	  of	  segmental	  SUVMAX	  in	  each	  segment	  would	  have	  been	  possible,	  as	  it	   represents	   the	   single	   voxel	   of	   maximal	   signal,	   any	   further	   measurements	   such	   as	  determination	   of	   SUVMEAN,	   without	   a	   thresholding	   activity	   to	   distinguish	   physiological	  from	  pathological	   signal	  would	  have	  been	  practically	   impossible.	   I	   therefore	  examined	  the	   literature	  for	  cut-­‐offs	  used	  by	  other	  groups.	  One	  study	  defined	  abnormal	  segments	  as	   those	   with	   an	   intestine-­‐to-­‐liver	   signal	   of	   >1.2186,	   while	   the	   most	   widely	   employed	  strategy,	  which	  I	  also	  used,	  was	  to	  quantify	  signal	  that	  appeared	  equal	  to	  or	  larger	  than	  the	  liver	  136,137,138.	  	  Radiation	  burden	  to	  participants,	  as	  well	  as	  funding	  and	  time	  constraints,	  were	  the	  main	  reasons	   that	  dictated	  optimisation	  of	  participant	  numbers	   in	  each	  of	   the	   two	  principal	  arms	  of	  the	  study.	  As	  the	  test-­‐retest	  variability	  of	  most	  of	   the	  PET	  endpoints	  had	  been	  predicted	  to	  be	  low	  in	  stable	  active	  patients,	  and	  considering	  the	  fact	  that	  each	  patient	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can	   contribute	   data	   on	   up	   to	   seven	   bowel	   segments,	   it	   was	   determined	   that	   a	   small	  number	  of	  5	  patients	  would	  be	  sufficient	  for	  this	  arm	  of	  the	  study.	  	  In	  determining	  a	  suitable	  target	  number	  of	  patients	  to	  be	  recruited	  for	  the	  longitudinal	  arm	  of	  the	  study	  several	  factors	  were	  considered.	  Firstly,	  this	  was	  a	  pilot	  observational	  study	   with	   numbers	   of	   subjects	   determined	   by	   feasibility.	   Within	   our	   Trust,	  approximately	  25-­‐30	  patients	  are	  commenced	  on	  anti-­‐TNF	  therapy	  for	  Crohn’s	  Disease	  each	   year.	   Assuming	   a	   similar	   prescription	   pattern	   by	   our	   specialists	   during	   the	  recruitment	  period,	  and	  an	  uptake	  rate	   in	   the	  region	  of	  50%,	   I	  estimated	  to	  recruit	  20	  patients	  over	  18	  months.	  	  As	   FDG-­‐PET	   scanning	   is	   not	   performed	   routinely	   for	   IBD,	   there	  was	   no	   alternative	   to	  prospectively	   recruiting	   subjects.	   Target	   intervals	   between	   scans	   were	   decided	   on	  appropriateness	   relevant	   to	   the	   indication.	   Cellular	   composition,	   and	   therefore	  metabolic	   activity,	   was	   expected	   to	   remain	   largely	   unchanged	  within	   an	   interval	   of	   1	  week	  in	  patients	  with	  chronic	  active	  disease	  who	  have	  had	  no	  changes	  to	  their	  therapy.	  For	   the	   longitudinal	   cohort	   a	   period	   of	   3	   months	   was	   selected,	   as	   by	   that	   time	   the	  patients	  have	  been	  established	  on	  therapy	  past	  the	  loading	  phase,	  and	  any	  effect	  at	  the	  cellular	   level	   within	   the	   lesions	   will	   have	   materialised	   and,	   furthermore,	   it	   is	   a	  reasonable	   juncture	   at	  which	   to	  make	   a	   differentiation	   between	   responders	   and	   non-­‐responders	  using	  clinical	  criteria.	  	  	  There	   were	   several	   reasons	   why	   I	   decided	   against	   the	   use	   of	   ileo-­‐colonoscopy	   as	   an	  additional	   assessment	   of	   activity	   and	   response.	   Firstly,	   the	   technique	   only	   provides	  information	   on	   mucosal	   activity,	   whereas	   PET	   can	   measure	   signal	   through	   each	  segments	  wall	  (and	  perhaps	  even	  the	  lumen).	  Moreover,	  it	  was	  decided,	  that	  proposing	  to	  perform	  ileo-­‐colonoscopies	  on	  both	  occasions,	   in	  addition	  to	  FDG-­‐PET	  and	  MRI	  was	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going	  to	  act	  as	  a	  deterrent,	  having	  a	  critical	  negative	  impact	  on	  recruitment	  rates,	  and,	  more	  importantly,	  it	  would	  cause	  considerably	  more	  inconvenience	  in	  patients	  with	  an	  already	  significant	  disease	  burden	  so	  it	  was	  not	  included	  in	  this	  study.	  	  The	   selected	   dose	   of	   185MBq	  was	   selected	   as	   the	   lowest	   dose	   of	   FDG	   through	  which	  meaningful	  data	  were	  obtained	  in	  a	  CD	  study	  187.	  Optimisation	  of	  radiation	  exposure	  was	  the	  reasoning	  behind	  the	  use	  of	  a	   low-­‐dose	  CT	  for	  attenuation	  correction	  and	  segment	  localization,	   instead	  of	  a	  full-­‐dose	  CT	  enterography	  protocol.	  If	  FDG-­‐PET	  scanning	  does	  find	   a	   clinical	   niche	   in	   the	   monitoring	   of	   CD	   patients,	   then	   more	   research	   will	   be	  required	  in	  an	  attempt	  to	  further	  reduce	  the	  FDG	  dosage.	  There	  is	  also	  a	  suggestion	  that	  the	  CT	  tube	  current	  can	  be	  reduced	  to	  10mA	  in	  follow-­‐up	  studies	  without	  compromising	  detection,	  and	  while	  this	  seems	  plausible	  it	  is	  not	  as	  yet	  supported	  by	  data	  188.	  	  	  This	  study	  has	  several	  strengths.	  It	  is	  the	  first	  study	  that	  focuses	  on	  the	  responsiveness	  and	   reliability	   of	   FDG-­‐PET	   for	   the	   purposes	   of	   monitoring	   inflammatory	   activity	   in	  patients	  with	  Crohn’s	  disease.	  Moreover,	  it	  is	  the	  first	  attempt	  to	  systematically	  dissect	  the	  origin	  of	  the	  signal	  in	  each	  segment.	   	  Patient	  preparation,	  scanning	  procedures	  and	  scanning	  intervals	  were	  meticulously	  standardised.	  In	  addition,	  a	  comprehensive	  range	  of	  FDG-­‐PET	  endpoints	  proposed	  in	  the	  literature	  on	  the	  modality’s	  use	  in	  inflammatory	  imaging	  was	  evaluated.	  	  The	  longitudinal	  data	  on	  a	  cohort	  of	  13	  patients	  completing	  the	  pre	  and	  post-­‐treatment	  scans	   of	   my	   protocol	   would	   benefit	   from	   external	   validation	   in	   a	   larger	   group	   of	  patients.	  Each	  individual	  endpoint’s	  performance	  can	  be	  further	  probed	  by	  ROC	  analyses	  in	   larger	   cohorts,	   which	   can	   determine	   sensitivity	   and	   specificity	   values	   in	  demonstrating	   a	   response.	   In	   addition,	   a	   longer	   follow-­‐up	   and	   accumulation	   of	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additional	   data	   after	   the	   follow-­‐up	   scan	   could	   help	   establish	   the	   potential	   of	   these	  endpoints	  in	  predicting	  longer	  term	  therapeutic	  outcomes.	  	  	  	  	  
2.5.	  CONCLUSION	  	  This	   study	   confirms	   good	   sensitivity	   and	   specificity	   for	   18F-­‐FDG-­‐PET	   in	   distinguishing	  inflamed	  from	  normal	  bowel	  segments	  compared	  to	  a	  recently	  validated	  MRI	  index	  used	  as	   gold	   standard.	   	   A	   thorough	   assessment	   of	   all	   outcome	   measures	   proposed	   in	   the	  literature	   demonstrated	   a	   superiority	   of	   (G)SUVMAX	   	   and	   (G)SUVMEAN	   	   compared	   to	  endpoints	  that	  depend	  on	  the	  volume	  of	  the	  signal	  (SLG	  and	  TLG)	  in	  terms	  of	  test-­‐retest	  reliability,	   static	   and	   longitudinal	   correlation	   with	   clinico-­‐pathological	   outcome	  measures	   and	   longitudinal	   responsiveness.	   More	   specifically	   in	   the	   context	   of	  responsiveness,	  highly	  significant	  differences	  in	  most	  parameters	  of	  the	  FDG	  signal	  were	  demonstrated	  between	  responders	  and	  non-­‐responders.	  	  	  However,	   the	   finding	   that	   a	   sizeable	   component	   of	   the	   signal	   originates	   in	   luminal	  contents	  is	  significant	  and	  merits	  further	  exploration	  as	  it	  can	  impact	  on	  the	  face	  validity	  of	  the	  technique	  as	  a	  molecular	  probe	  of	  activated	  inflammatory	  cells.	  	  Potential	  roles	  of	  FDG-­‐PET	  in	  the	  assessment	  of	  inflammatory	  activity	  of	  Crohn’s	  disease	  are	  further	  discussed	  in	  Chapter	  5.	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3.	  MAGNETIC	  RESONANCE	  IMAGING	  OUTCOME	  MEASURES	  IN	  THE	  MONITORING	  OF	  
INFLAMMATORY	  ACTIVITY	  IN	  CROHN’S	  DISEASE	  
	  
3.1.	  INTRODUCTION	  	  Magnetic	   Resonance	   Imaging	   (MRI)	   is	   an	   imaging	   modality	   that	   utilises	   the	  electromagnetic	   properties	   of	   protons	  within	   tissue.	   Protons	   are	   first	   stimulated	   by	   a	  constant	   strong	  magnetic	   field	   (B0),	  which	   causes	   them	   to	   align	  with	   that	   field.	   Their	  processing	   frequency	   is	   proportional	   with	   the	   strength	   of	   that	   field.	   Subsequently,	  radiofrequency	   pulses	   are	   emitted	   in	   a	   transverse	   direction	   to	   the	   original	   field,	  disrupting	  protons	  accordingly.	  Once	  these	  pulses	  are	  removed	  two	  relaxation	  times	  are	  described:	   T1	   measures	   the	   time	   taken	   for	   2/3	   of	   protons	   to	   revert	   to	   the	   natural	  longitudinal	   direction	   of	   B0,	   whereas	   T2	   measures	   the	   time	   taken	   for	   the	   transverse	  direction	  to	  decay	  in	  2/3	  of	  protons.	  	  T1-­‐weighted	  imaging	  is	  used	  for	  the	  differentiation	  of	  anatomical	  structures	  on	  the	  basis	  of	  T1	  values;	  i.e.	  the	  scanning	  parameters	  are	  set	  to	  minimize	  T2	  relaxation	  effects.	  Tissues	  with	  high	  fat	  content	  (e.g.	  white	  matter)	  appear	  bright	   and	   compartments	   filled	   with	   water	   (e.g.	   CSF)	   appear	   dark.	   This	   is	   good	   for	  demonstrating	  anatomy.	  T2-­‐weighted	  imaging,	  on	  the	  other	  hand,	  is	  used	  to	  differentiate	  structures	  on	  the	  basis	  of	  T2	  values.	  Water-­‐filled	  compartments	  	  	  appear	  bright	  and	  fat-­‐rich	   tissue	   appears	   dark.	   T2-­‐weighted	   imaging	   is	   useful	   for	   demonstrating	   pathology	  since	  most	  	  lesions	  are	  associated	  with	  an	  increase	  in	  water	  content.189.	  	  	  The	   applications	  of	  MRI	   in	  CD	   started	  being	   explored	  over	   two	  decades	   ago	   67,190,	   and	  	  research	   	   has	   since	   been	   carried	   out,	   providing	   evidence	   that	   the	   sensitivity	   and	  specificity	   of	   the	   modality	   are	   superior	   to	   more	   traditional	   imaging	   techniques	   191.	  	  Subsequently,	  important	  morphological	  characteristics	  were	  identified	  and	  grouped	  into	  quantitative	  scores	  (e.g.	  MaRIA,	  MEGS)	  which	  show	  good	  correlations	  with	  endoscopic	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3.2.METHODS	  	  3.2.1	  STUDY	  DESIGN	  -­‐	  PARTICIPANT	  SELECTION	  	  MRI	  scans	  was	  performed	  on	  the	  same	  patient	  cohort	  	  recruited	  for	  the	  PET	  study	  (see	  Table	  2.3	  for	  demographics).	  The	  MRI	  scan	  was	  performed	  on	  the	  same	  visit	  as	  the	  PET	  on	   all	   occasions.	   Patients	   that	   satisfied	   the	   inclusion	   criteria	   for	   that	   study	   were	  automatically	  eligible	  also	  to	  participate	  in	  the	  MRI	  study.	  Exceptions	  were	  patients	  with	  severe	   liver	   or	   kidney	   disease,	   documented	   allergic	   reactions	   to	   gadolinium,	   and	   the	  presence	  of	  metallic	  implants	  that	  were	  not	  MRI	  compatible.	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  Table	  3.1:	  MRI	  acquisition	  parameters	  
	  DCE	   oblique	   3D	   spoiled	   gradient	   echo	   (VIBE)	   images	  were	   acquired	   before	   and	   at	   11	  time-­‐points	  across	  6	  minutes	  after	  IV	  administration	  of	  a	  single-­‐dose	  (0.1mmol/kg)	  Gd-­‐chelate	   (Dotarem,	  Guerbet).	  Patients	   received	  a	   total	  of	  30mg	  of	   intravenous	  hyoscine	  butylbromide	  in	  two	  doses	  during	  each	  scan	  to	  reduce	  motion	  artifact.	  	  	  
	  
	  
	   	  	  	  	  	  	  










Slices	   Duration	  (s	  /	  BHs)	   iPAT	  
Additional	  
Info	  TrueFISP	   Coronal	   400	   1.8x1.7x5	   1.32	   669	   60	   36	   48	  /	  3	   1	   2	  NEX	  TrueFISP	   Coronal	   400	   3.1x2.5x5	   1.4	   242	   60	   12	   57	  /	  3	   2	   20	  CINE	  frames	  HASTE	   Coronal	   380	   2.1x1.5x4	   80	   1200	   -­‐	   4	   41	  /	  2	   3	   	  HASTE	   Coronal	   380	   2.1x1.5x4	   80	   1200	   -­‐	   4	   41	  /	  2	   3	   SPAIR	  HASTE	   Axial	   380	   1.5x1.5x4	   80	   1100	   -­‐	   69	   76	  /	  4	   2	   	  HASTE	   Axial	   380	   1.5x1.5x4	   80	   1100	   -­‐	   69	   76	  /	  4	   2	   SPAIR	  
DW-­‐EPI	   Axial	   350	   3.4x2.7x5	   71	   1120	   -­‐	   50	   5:36	  /	  free	  breathing	   2	  
3	  NEX,	  3	  Diffusion	  Directions,	  b=50,400,800	  mm2/s	  3D	  VIBE	   Coronal	   420	   1.9x1.9x4	   1.3	   3.0	   10	   60	   14	  BHs	   2	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3.2.3	  MRI	  SCAN	  ANALYSIS	  	  Analysis	   of	   the	  MRI	   scans	  was	   performed	  using	   open-­‐source	   image-­‐viewing	   and	  post-­‐processing	  software	  (OsiriX	  32-­‐bit,	  v5.6;	  Pixeo,	  Bernex,	  Switzerland).	  Initial	  analysis	  and	  ROI	  placement	  was	  performed	  by	  the	  author	  but	  all	  regions	  of	  interest	  (ROIs)	  and	  score	  calculation	  were	  corroborated	  by	  one	  of	  two	  radiologists	  with	  experience	  in	  abdominal	  MR	  imaging,	  who	  were	  blinded	  to	  clinical	  and	  PET	  data.	  	  	   3.2.3.1	  Magnetic	  Resonance	  Index	  of	  Activity	  (MaRIA)	  	  The	  MaRIA	   score	  was	   calculated	   as	   previously	   described	   74,75:	   The	   bowel	  was	   divided	  into	  six	  segments	  (terminal	  ileum,	  ascending,	  transverse,	  descending	  and	  sigmoid	  colon	  and	   rectum).	   The	   following	   parameters	   were	   recorded	   for	   each	   segment:	   bowel	   wall	  thickness	   (in	   mm),	   the	   presence	   of	   mural	   oedema	   (defined	   as	   hyperintensity	   of	   the	  bowel	  wall	   in	   comparison	   to	   the	   psoas	  muscle	   on	   T2	   sequences),	   and	   the	   presence	   of	  ulceration	  (defined	  as	  deep	  depressions	  of	  the	  mucosal	  surface).	  In	  addition,	  wall	  signal	  intensity	   (WSI)	  within	  ROIs	   in	  areas	  of	  maximal	  wall	   thickness	  before	  and	  70	  seconds	  after	  intravenous	  gadolinium	  was	  measured.	  Relative	  contrast	  enhancement	  (RCE)	  was	  then	  calculated	  as	  follows:	  	  RCE	   =	   ((WSIPOST-­‐GADOLINIUM–WSIPRE-­‐GADOLINIUM)/(WSIPRE-­‐GADOLINIUM))	   x	   100	   x	   (SDNOISE	   PRE-­‐
GADOLINIUM/SD	   NOISE	   POST-­‐GADOLINIUM),	   where	   SD	   noise	   pre-­‐gadolinium	   corresponds	   to	   the	  average	   of	   three	   standard	   deviations	   of	   the	   signal	   intensity	   measured	   outside	   of	   the	  body	   before	   gadolinium	   injection,	   and	   SD	   noise	   post	   gadolinium	   corresponds	   to	   the	  standard	   deviation	   of	   the	   same	   noise	   after	   gadolinium	   administration.	   Finally,	   the	  segmental	  MaRIA	  score	  was	  calculated	  using	  the	  following	  formula:	  	   MaRIAS=	  1.5	  x	  wall	  thickness	  +	  0.02	  x	  RCE	  +5	  x	  oedema	  +10	  x	  ulcers	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The	  global	  MaRIAG	  score	  was	  the	  sum	  of	  all	  MaRIAS	  in	  each	  patient.	  3.2.3.2	  Magnetic	  Enterography	  Global	  Score	  (MEGS)	  
To	   calculate	  MEGS	   score,	   the	   bowel	   was	   divided	   into	   nine	   segments	   (jejunum,	   ileum,	  terminal	  ileum,	  caecum,	  ascending,	  transverse,	  descending,	  sigmoid	  colon	  and	  rectum).	  The	  following	  MR	  features	  were	  scored	  from	  0-­‐3,	  as	  defined	  in	  the	  original	  paper192:	  wall	  thickness,	  mural	  and	  peri-­‐mural	  T2	  signal,	  post	  contrast	  T1	  enhancement	  level,	  contrast	  enhancement	   pattern	   (homogeneous,	   mucosal	   or	   layered)	   and	   loss	   of	   colonic	  haustrations.	  The	  total	  length	  of	  disease	  in	  each	  segment	  was	  measured	  using	  electronic	  calipers	  and	  was	  used	  as	  a	  multiplication	  factor	  for	  each	  individual	  segment	  score	  (x1	  if	  <5cm,	  x	  1.5	  if	  between	  5	  and	  15cm,	  x2	  if	  >15cm).	  Segmental	  scores	  were	  summed	  and	  then	   5	   points	  were	   added	   for	   each	   of	   lymph	  nodes	   (>1cm),	   abscesses,	   comb	   sign	   and	  fistulae	  respectively.	  
3.2.3.3	  Diffusion	  MRI	  
Diffusion	  sequences	  were	  first	  assessed	  visually	  and	  the	  region	  of	  highest	  signal	  in	  each	  intestinal	   segment	  was	   identified.	   ADCs	  were	   calculated	   twice	   for	   the	   23	   segments	   in	  patients	   participating	   in	   the	   test-­‐retest	   arm	   of	   the	   study.	   An	   ROI	   was	   placed	   on	   the	  bowel	   wall	   of	   relevant	   segments	   using	   b=800s/mm2	   sequence	   and	   then	   it	   was	  automatically	   propagated	   through	   to	   the	   b=50s/mm2	   and	   b=400s/mm2	   acquisitions.	  Occasionally,	  manual	   adjustment	  was	   required	   to	   correct	   for	  motion,	   in	   order	   for	   the	  ROI	   to	   be	   placed	   on	   the	   exact	   same	   part	   of	   wall	   in	   the	   latter	   two	   acquisitions.	   Two	  analysis	   approaches	   were	   explored:	   In	   the	   first,	   the	   ROI	   was	   1-­‐pixel	   wide,	   and	  positioned	   manually	   over	   the	   wall	   layer	   with	   the	   highest	   signal	   intensity	   within	   the	  bowel	   wall.	   Effort	   was	   made	   so	   that	   the	   ROI	   included	   only	   intestinal	   wall	   tissue,	  specifically	  aiming	   to	  exclude	   the	   lumen.	  The	  second	  set	  of	  measurements	  used	   larger	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ROIs,	  ranging	  between	  1	  and	  3cm2	  in	  surface	  area,	  as	  described	  previously	  105,108,194,195.	  The	  two	  types	  of	  ROI	  are	  illustrated	  in	  Figure	  3.1	  
Figure	   3.1:	   Examples	   of	   pixel-­‐sized	   (top,	   green)	   versus	   larger	   ROIs	   (bottom,	   red)	   in	   the	  
same	  segment	  
As	   normal	   segments	   were	   frequently	   not	   producing	   any	   signal	   on	   the	   b=800s/mm2	  image,	  ROI	  positioning	  on	  such	  segments	  was	  frequently	  not	  possible	  as	  the	  signal	  was	  too	   weak	   to	   discern	   any	   anatomical	   features.	   Therefore	   on	   some	   occasions	   (18/117)	  these	   segments	   had	   to	   be	   excluded	   from	   the	   analysis.	   Following	   analysis	   of	   the	   two	  alternative	  approaches	  (see	  results)	  the	  former	  approach	  was	  used	  for	  the	  remainder	  of	  the	  cohort.	  ADC	   was	   subsequently	   calculated	   using	   the	   ROI’s	   mean	   SI	   for	   each	   of	   the	   three	  acquisitions,	  using	  a	  simple	  mono-­‐exponential	  model:	  	  S(b)/S0=exp(-­‐bxADC)	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3.2.3.4	  Dynamic	  Contrast-­‐Enhanced	  (DCE)	  MRI	  
For	  DCE	  analysis,	  ROIs	  of	  at	  least	  one	  pixel	  in	  size	  were	  drawn	  on	  intestinal	  wall	  in	  all	  6	  segments	  used	   for	  MaRIA	   scoring,	   as	  well	   as	   in	   small	   bowel	   proximal	   to	  TI	  when	   this	  was	   thickened	   and	   abnormal.	   One	   previous	   study	   took	   a	   methodologically	   different	  approach,	   where	   larger	   VOIs	   covering	   the	   entirety	   of	   each	   segment	   within	   the	  sequence196.	   Replicating	   this	   method	   in	   a	   few	   segments	   produced	   significantly	   lower	  mean	   Slope	   of	   Enhancement	   	   (SoE),	  Maximal	   Enhancement	   (ME)	   and	   Area	   Under	   the	  enhancement	  Curve	  at	  300	  seconds	  (AUC300)	  as	  the	   lumen	  of	  the	  segments	  as	  well	  as	  peri-­‐enteric	   and	   mesenteric	   structures	   were	   also	   included,	   so	   this	   technique	   was	  abandoned.	  	  	  These	   ROIs	   were	   propagated	   across	   all	   14	   time-­‐points	   (3	   prior	   to	   and	   11	   post-­‐iv	  contrast)	   and	  manually	   adjusted	   to	   correct	   for	  motion	   between	   each	   sequence.	  Mean	  signal	  intensity	  (SI)	  in	  each	  time	  point	  was	  used	  to	  plot	  a	  time	  intensity	  curve	  (TIC).	  The	  derived	  curve	  parameters	  were	  calculated,	  using	  MatLab,	  (The	  MathWorks,	  Inc.,	  Natick,	  MA)	  as	  previously	  reported:	  
1) SoE	  is	  the	  gradient	  of	  the	  SI	  time	  curve	  between	  the	  last	  point	  of	  baseline	  SIand	  the	  inflexion	  point	  following	  initial	  rapid	  enhancement.
2) ME=(SIPEAK	   –	   SIBASELINE)/	   SIBASELINE,	   where	   SIPEAK	   is	   the	   peak	   signal	   intensityand	  SIBASELINE	  is	  the	  baseline	  signal	  intensity
3) Area	  under	  the	  TIC	  up	  to	  t=300s	  post	  contrast	  administration,
AUC300=	  0∫t=300(𝑡)
	   111	  
3.2.3.5	  Motility	  
	  Motility	   data	  were	   processed	   and	   quantified	   according	   to	   a	   previously	   published	   and	  validated	   method	   197.	   This	   uses	   an	   optic	   flow	   registration	   algorithm	   to	   estimate	  deformation	   of	   each	   frame	   of	   a	   given	   cine	   loop	   from	   an	   initial	   target	   frame,	   thereby	  serving	  as	  a	  measure	  of	  motility	  (since	  we	  expect	  deformation	  of	  images	  acquired	  in	  the	  same	  anatomical	  position	  to	  be	  primarily	  due	  to	  motion).	  Such	  motion	  can	  be	  quantified	  by	   taking	   the	   standard	   deviation	   of	   the	   Jacobian	   determinant	   of	   this	   deformation	  (quantified	   in	  arbitrary	  units,	  AU).	  To	   facilitate	   this	  analysis,	  a	  graphical	  user	   interface	  (GUI)	  developed	  using	  Matlab	  was	  used,	  which	  both	  displays	  the	  cine	  loops	  and	  permits	  the	  user	  to	  define	  which	  areas	  of	  small	  bowel	  should	  be	  subjected	  to	  motility	  analysis	  by	  encompassing	   them	   in	  a	   free	  hand	  ROI.	  The	  ROI	  was	  drawn	   to	   include	   the	  bowel	  wall	  and	   lumen	  but	  extra-­‐enteric	   tissues	  were	  excluded.	  This	  process	  was	   repeated	   for	   the	  post-­‐treatment	  MRE	  scans.	  Care	  was	   taken	   to	  match	  exactly	   the	  position	  of	   the	  ROI	   to	  that	  placed	  on	  the	  pre-­‐treatment	  images.	  	  
	   3.2.4	  STATISTICAL	  ANALYSIS	  	  Data	  was	  analysed	  using	  statistical	  software	  (Prism	  6.0,	  Graphpad,	  San	  Diego,	  CA,	  USA).	  Correlations	  between	  clinico-­‐pathological	  and	  MRI	  endpoints	  were	  performed	  using	  the	  index	   scan	   for	   all	   participants,	   with	   the	   Spearman	   rank	   coefficient.	   Subjects	   in	   the	  longitudinal	  arm	  of	  the	  study	  were	  then	  segregated	  into	  responders	  and	  non-­‐responders	  on	  the	  basis	  of	  a	  clinically	  significant	  response,	  described	  by	  a	  change	   in	  HBI	  of	  ≥3	  174.	  The	   difference	   in	   each	   endpoint	   between	   responders	   and	   non-­‐responders	   in	   the	  longitudinal	   arm	  was	   calculated	   using	   the	  Mann-­‐Whitney-­‐Wilcoxon	   rank	   sum	   test.	   All	  comparisons	   were	   deemed	   significant	   at	   a	   p-­‐value	   ≤0.05	   and	   correction	   for	   multiple	  comparisons	  was	  not	  performed.	  The	  responsiveness	  of	  each	  marker	  was	  then	  assessed	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by	  calculating	  the	  responsiveness	  ratio	  of	  Gyatt	  (RRG)	  and	  the	  standardized	  effect	  size	  (SES)	   as	   previously	   described	   175.	   	   Finally,	   test-­‐retest	   reliability	   was	   expressed	   as	  %variability	  in	  each	  outcome	  measure	  176.	  	   3.2.5	  WORKLOAD	  DISTRIBUTION	  –	  PERSONAL	  INVOLVEMENT	  	  	  Similar	  to	  the	  PET	  study,	  after	  receiving	  training	  on	  the	  Osirix	  software,	  I	  performed	  the	  MRI	  scan	  analysis,	  and	  designed	  all	  relevant	  VOIs.	  These	  were	  corroborated	  by	  an	  MRI	  radiologist	  at	  University	  College	  Hospital.	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3.3.RESULTS	  	  Data	  on	  the	  same	  22	  patients	  (14	  male)	  with	  a	  mean	  age	  of	  40	  years	  (range	  22-­‐59)	  who	  had	   participated	   in	   the	   PET	   study	   were	   acquired.	   17	   patients	   were	   recruited	   for	   the	  longitudinal	   arm	   and	   5	   for	   the	   test-­‐retest	   reliability	   component	   of	   the	   study.	  Of	   these	  13/17	   and	   3/5	   patients	   respectively	   completed	   both	   the	   baseline	   and	   the	   follow-­‐up	  scans.	  1	  of	   the	  17	  patients	   in	   in	   longitudinal	   arm	  did	  not	   receive	   intravenous	   contrast	  due	   to	   a	   borderline	   estimated	   Glomerular	   Filtration	   Rate	   (eGFR),	   and	   as	   such	   only	  contributed	  DWI	  data.	  	  	   3.3.1.	  ANATOMICAL	  SCORES	  	  3.3.1.1	  Magnetic	  Resonance	  Index	  of	  Activity	  (MaRIA)	  	  	  MaRIA	   was	   calculated	   in	   117	   segments	   from	   21	   patients.	   There	   were	   positive	  correlations	  between	  segmental	  MaRIAS	   (segment	  with	   the	  highest	   score)	  and	  CRP,	   as	  well	  as	  between	  global	  MaRIAG	  and	  CRP	  and	  FC.	  HBI	  did	  not	  significantly	  correlate	  with	  either	  the	  segmental	  or	  the	  global	  MaRIA	  scores.	  	  
Table	   3.2:	   Spearman	   rank	   correlations	   between	  MaRIAS	   and	  MaRIAG	  scores	   and	   clinico-­‐
pathological	  reference	  standards	  in	  21	  patients	  
	  These	  correlations	  were	  not	  maintained	  however	  when	  the	  differences	  in	  each	  marker	  between	  baseline	  and	  follow-­‐up	  scans	  were	  used	  (Table	  3.3).	  
	  
	   HBI	   CRP	   FC	  MaRIAS	   r=0.41	  p=0.07	   r=0.52	  p=0.01	   r=0.22	  p=0.36	  MaRIAG	   r=0.12	  p=0.61	   r=0.56	  p=0.007	   r=0.50	  p=0.02	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Table	   3.3:	   Spearman	   rank	   correlations	   between	   ΔMaRIAS	   and	   ΔMaRIAG	   scores	   and	   the	  
difference	  (Δ)	  of	  clinico-­‐pathological	  reference	  standards	  in	  13	  patients	  
	  
	   ΔHBI	   ΔCRP	   ΔFC	  ΔMaRIAS	   r=0.36	  p=0.22	   r=0.20	  p=0.50	   r=-­‐0.22	  p=0.50	  ΔMaRIAG	   r=0.53	  p=0.06	   r=0.29	  p=0.34	   r=-­‐0.03	  p=0.92	  	  The	  difference	  in	  MaRIAS	  and	  MaRIAG	  were	  compared	  between	  responders	  (22	  segments	  in	  9	   patients)	   and	   non-­‐responders	   (7	   segments	   in	   4	   patients)	   and	   were	   not	   statistically	  significant	  (Figure	  3.2).	  	  
Figure	  3.2:	  Baseline	  and	   follow-­‐up	  MaRIAS	  	  (top)	  and	  MaRIAG	  	  (bottom)	   in	  responders	  vs.	  non-­‐
responders.	  ΔMaRIAS	  (top)	  and	  ΔMaRIAG	  	  (bottom)	  in	  responders	  vs.	  non-­‐responders	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The	   observed	   change	   in	   MaRIAS	  in	   responders	   was	   modest	   (mean	   ΔMaRIAS	  was	   4.9).	  Oedema,	  which	  accounts	  for	  5	  points	  of	  the	  total	  segmental	  score,	  was	  observed	  in	  19	  of	  22	   segments	   in	   the	  baseline	   scan,	   and	   it	   had	  only	   resolved	   in	  2	  of	   these	  19	   segments.	  Ulcers,	  which	  account	  for	  10	  points,	  was	  present	  in	  11	  segments	  at	  baseline	  in	  the	  same	  group,	  and	  had	  only	  resolved	  in	  4	  of	  these	  in	  the	  follow-­‐up	  scanning.	  	  	  The	  responsiveness	  ratios	  of	  Gyatt	  and	  standardized	  effect	  size	  for	  MaRIAS	  and	  MaRIAG,	  and	  test-­‐retest	  variabilities	  are	  summarised	  in	  Table	  3.4.	  
	  
Table	  3.4:	  RRG,	  SES	  and	  %VAR	  for	  MaRIAS	  and	  MaRIAG	   	  	  	  	  3.3.1.2	  MEGS	  	  Subsequently,	  the	  MEGS	  was	  calculated	  in	  the	  21	  patients	  who	  had	  received	  IV	  contrast.	  There	  was	  a	  modest	  correlation	  between	  MEGS	  and	  CRP	  (r=0.37,	  p=0.04)	  but	  not	  with	  HBI	   (r=-­‐0.01	  p=0.67)	  or	  FC	   (r=0.37	  p=0.12).	  This	   significant	   correlation	  with	  CRP	  was	  not	  maintained	  when	  the	  differences	  in	  the	  two	  markers	  were	  examined	  over	  time.	  	  The	   longitudinal	  behaviour	  of	   the	  MEGS	   score	   in	   responders	   and	  non-­‐responders	  was	  subsequently	   assessed.	  The	   average	  ΔMEGS	   in	   responders	  was	  13.6.	  The	   two	  patients	  with	  the	  most	  profound	  drop	  in	  HBI	  between	  the	  two	  scans	  also	  had	  the	  highest	  drop	  in	  MEGS.	   	  Participants	  without	  a	  clinical	  response	  had	  lower	  changes	  in	  their	  MEGS	  score	  within	   that	   interval	   (ΔMEGS	   1.4).	   The	   ΔMEGS	   between	   the	   two	   groups	   did	   not	   reach	  statistical	  significance	  (Figure	  3.3)	  	  
	   RRG	   SES	   %VAR	  (STDEV)	  MaRIAS	   0.71	   0.87	   8.4	  (11.4)	  MaRIAG	   0.54	  	   0.58	  	   4.7	  (3.5)	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Figure	   3.3:	   Baseline	   and	   follow-­‐up	  MEGS	   score	   in	   responders	   and	  non-­‐responders.	   ΔMEGS	   in	  
responders	  vs	  non-­‐responders	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Table	   3.5:	   Relative	   %change	   in	   all	   components	   of	   the	   MEGS	   score	   in	   responders	   of	   the	  
longitudinal	  arm	  







Σ	  of	  scores	  in	  
baseline	  scan	  
(responders)	  
Σ	  of	  scores	  in	  F/U	  
scan	  
(responders)	  
%	  change	  Thickness	  score	   48	   40	   17%	  Mural	  oedema	  score	   50	   33	   34%	  Peri-­‐mural	   oedema	  score	   15	   8	   47%	  T1	   Enhancement	  score	   53	   38	   28%	  Enhancement	  pattern	  score	   20	   16	   20%	  Haustral	  loss	  score	   13	   10	   23%	  Length	   of	   disease	  score	   39.5	   34.5	   13%	  Lymph	  nodes	   0	   0	   n/a	  Comb	  sign	   40	   30	   25%	  Fistulae	  	   0	   0	   n/a	  Abscesses	   0	   0	   n/a	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Figure	  3.4:	  Correlation	  between	  ADC	  using	  pixel-­‐sized	  versus	  larger	  ROIs	  
	  
	  	  	  	  	  	  There	  were	  no	  significant	  correlations	  between	  the	  ADC	  of	  the	  most	  diseased	  segment	  and	  any	   of	   the	   clinico-­‐pathological	   parameters,	   either	   in	   the	   static	   or	   the	   longitudinal	  assessments.	  Furthermore,	  there	  was	  no	  statistically	  significant	  difference	  between	  ΔADC	  in	  segments	  from	  responders	  versus	  non-­‐responders.	  	  	  Of	  the	  117	  bowel	  segments	  that	  had	  been	  scored	  with	  MaRIAS,	  ADC	  analysis	  was	  feasible	  in	  99	  due	  to	  difficulties	  in	  creating	  ROI	  in	  18	  normal	  segments	  that	  did	  not	  produce	  any	  signal	  in	  the	  b=800s/mm2	  acquisition	  (described	  in	  the	  methods).	  I	  first	  compared	  the	  ADC	  values	  in	   53	   normal	   segments	   (MaRIAS	   <7.0)	   versus	   46	   abnormal	   segments	   (MaRIAS	  >7.0).	   The	  mean	  ADC	  in	  normal	  segments	  was	  2.18	  ±	  0.56	  x10-­‐3	  mm/s2,	  significantly	  higher	  than	  that	  in	  diseased	  segments	  (1.60	  ±0.49	  x10-­‐3	  mm/s2)	  (P<0.0001)	  (Figure	  3.5).	  	  
Figure	  3.5:	  Baseline	  ADC	  in	  normal	  versus	  abnormal	  (MaRIA+ve)	  intestinal	  segments	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ROC	  analysis	   revealed	   that	   an	  ADC<1.9	  mm/s2	  has	  85%	  sensitivity	   and	  75%	  specificity	   in	  revealing	  positive	  segments.	  	  Focusing	  on	  the	  longitudinal	  arm	  of	  the	  study,	  there	  was	  a	  significant	  difference	  in	  ΔADC	  in	  abnormal	   segments	   between	   responders	   and	   non-­‐responders.	   It	   is	   important	   to	   note	  however	   that	   in	   10	  of	   the	  22	   analysed	   segments	   in	   responders,	   there	  was	   an	   incremental	  drop	   of	   ADC	   (and	   therefore	   diffusivity)	   between	   the	   baseline	   and	   follow-­‐up	   scans.	   This	  meant	  that	  when	  responders	  were	  looked	  at	  in	  isolation,	  there	  was	  no	  statistical	  significance	  between	   the	  baseline	  and	   follow-­‐up	  scans	   (p=0.24).	  Despite	   this,	   the	  overall	  ΔADC	   in	  non-­‐responders	  was	  statistically	  lower	  than	  in	  responders	  (Figure	  3.6).	  
	  
Figure	   3.6:	   Baseline	   and	   follow-­‐up	  ADC	   in	   all	   abnormal	   (MaRIA+ve)	   segments	   in	   responders	  
and	  non-­‐responders.	  ΔADC	  in	  responders	  vs.	  non-­‐responders	  



































ΔADC in Responders vs Non-Responders
p=0.018 *
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3.3.2.2	  DCE	  All	   3	   DCE	   endpoints	   from	   115	   segments	   correlated	   moderately	   strongly	   with	   the	  corresponding	  MaRIAS	  (Table	  3.6)	  	  
Table	  3.6:	  Spearman	  rank	  correlation	  coefficients	  between	  MaRIAS	  and	  DCE	  endpoints	  
	  Moreover,	   there	   were	   statistically	   significant	   differences	   between	   DCE	   values	   of	   normal	  (MaRIAS	  <7.0)	  and	  abnormal	  segments	  (MaRIAS	  >7.0)	  illustrated	  in	  Figure	  3.7.	  	  
Figure	  3.7:	  DCE	  endpoints	  in	  normal	  and	  abnormal	  intestinal	  segments	  
	  The	  correlation	  between	  all	  three	  endpoints	  and	  disease	  duration	  (years)	  was	  also	  examined	  (Table	  3.7)	  
	  
Table	   3.7:	   Correlation	   between	   DCE	   MR	   endpoints	   in	   the	   most	   affected	   segment	   (highest	  
MaRIAS	  score)	  and	  disease	  duration	  (years)	  
	  
	   SoE	   ME	   AUC300	  MaRIAS	   r=0.63	  p<0.0001	   r=0.66	  p<0.0001	   r=0.65	  p<0.0001	  
	   SoE	   ME	   AUC300	  Disease	  duration	  (years)	   r=0.16	  p=0.50	   r=0.33	  p=0.14	   r=0.59	  p=0.005	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Once	  again,	  Spearman	  rank	  correlation	  coefficients	  between	  HBI,	  CRP	  and	  FC,	  and	  DCE	  endpoints	   were	   not	   significant	   (table	   3.8).	   Moreover,	   none	   of	   the	   three	   studied	  endpoints	  changed	  differently	  in	  responders	  and	  non-­‐responders	  over	  time	  (results	  not	  shown).	  	  
Table	  3.8:	  Correlations	  between	  DCE	  MR	  endpoints	  in	  the	  most	  diseased	  segment	  (highest	  
MaRIAS	  score)	  and	  clinico-­‐pathological	  markers	  of	  activity	  























	   HBI	   CRP	   FC	  SoE	   r=0.19	  p=0.40	   r=0.30	  p=0.18	   r=-­‐0.03	  p=0.91	  ME	  	   r=0.14	  p=0.55	   r=0.27	  p=0.23	   r=0.01	  p=0.98	  AUC300	   r=-­‐0.14	  p=0.55	   r=0.35	  p=0.12	   r=0.28	  p=0.25	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Figure	  3.8:	  Baseline	  and	   follow-­‐up	   SoE,	  ME	  and	  AUC300	   in	  MaRIA+ve	   segments	   in	   responders	  
and	  non-­‐responders.	  ΔSoE,	  ΔME,	  ΔAUC300	  in	  responders	  vs.	  non-­‐responders	  	  
	  
Table	  3.9:	  Responsiveness	  and	  test-­‐retest	  variability	  for	  SoE,	  ME	  and	  AUC300	  
DCE	  Endpoint	   Responsiveness	   Reliability	  
RRG	   SES	   %VAR	  
(STDEV)	  SoE	   0.21	  	   0.14	  	   76%	  (53)	  ME	   0.56	  	   0.31	  	   44%	  (39)	  AUC300	   0.47	  	   0.59	  	   52%	  (41)	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3.3.2.3	  Motility	  	  Small	   bowel	   motility	   quantitation	   was	   achieved	   in	   7	   of	   the	   9	   responders	   and	   all	   4	   non-­‐responders.	  Differences	  in	  motility	  at	  baseline	  versus	  follow-­‐up	  in	  diseased	  small	  intestinal	  segments,	   in	   responders	   only,	   were	   statistically	   significant	   (Figure	   3.9).	   However,	   the	  difference	   in	   motility	   between	   responders	   and	   non-­‐responders	   did	   not	   reach	   statistical	  significance	  (Figure	  3.10)	  	  
Figure	  3.9:	  Baseline	  and	  follow-­‐up	  motility	  in	  diseased	  small	  bowel	  segments	  in	  responders	  	  	  	  	  	  	  
	  
	  
Figure	   3.10:	   Baseline	   and	   follow-­‐up	  motility	   in	   responders	   and	   non-­‐responders.	   ΔMotility	   in	  
responders	  vs.	  non-­‐responders	  






































in Responders  vs Non-Responders
p=0.13
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3.4.	  DISCUSSION	  	  3.4.1	  SUMMARY	  OF	  FINDINGS	  	  Key	  results	  of	  this	  study	  were	  the	  following:	  
• MaRIA	   score	   shows	   a	   good	   static	   correlation	   with	   CRP	   but	   ΔMaRIA	   does	   not	  correlate	  with	  any	  of	  the	  clinico-­‐pathological	  markers	  of	  activity	  
• MaRIA	  had	  a	  high	  reproducibility	  but	  its	  responsiveness	  was	  lower	  in	  this	  cohort	  than	  that	  described	  in	  published	  literature	  110.	  	  
• Similar	   to	  MaRIA,	   the	  MEGS	   score	   correlates	   significantly	  with	   CRP	   in	   a	   single	  timepoint	  but	  not	  longitudinally.	  
• MEGS	   is	   a	   reproducible	   score,	   which	   however	   shows	   low	   responsiveness.	  Parameters	   such	   as	   oedema	   show	   greater	   change	   at	   3	   months	   compared	   to	  others	  e.g.	  length	  of	  disease	  in	  each	  segment	  
• ADC	   was	   significantly	   lower	   in	   abnormal	   versus	   normal	   bowel	   segments.	  However	   it	   did	   not	   correlate	   with	   any	   of	   the	   clinico-­‐pathological	   markers	   of	  severity	  
• ADC	   has	   a	   good	   reproducibility	   at	   test-­‐retest,	   but	   a	   low	   responsiveness	   score.	  This	   is	   because	   half	   the	   examined	   segments	   in	   responders	   demonstrated	   an	  unexpected	  reduction	  in	  water	  diffusivity	  within	  the	  three-­‐month	  interval.	  	  
• DCE	  endpoints	  seemed	  unsuitable	  tools	  for	  longitudinal	  assessment	  of	  disease	  in	  this	  cohort.	  
• Terminal	  ileal	  motility	  was	  significantly	  higher	  at	  follow-­‐up	  in	  responders.	  
• A	   3-­‐month	   interval	   was	   likely	   too	   short	   for	   any	   of	   the	   aforementioned	   MRI	  techniques	   to	   be	   utilised	   as	   monitoring	   instruments	   which	   assess	   transmural	  disease	   process.	  MaRIA,	  MEGS	   and	   small	   bowel	  motility	   should	   be	   tested	   over	  longer	  intervals	  in	  future	  studies.	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3.4.2	  DISCUSSION	  OF	  FINDINGS	  	  Magnetic	  Resonance	  Enterography	  is	  a	  non-­‐invasive	  method	  which	  aims	  to	  characterise	  inflammatory	  activity	   across	   the	   full	   thickness	  of	   affected	   segments	   in	   the	  bowel	  wall.	  Several	  studies	  have	  demonstrated	  positive	  correlations	  between	  anatomical	  as	  well	  as	  novel,	   functional	   MR	   endpoints,	   with	   endoscopic	   or	   histo-­‐pathological	   reference	  standards	  71–73.	  With	  the	  exception	  of	  MaRIA	  however,	  the	  literature	  on	  the	  longitudinal	  performance	   of	   these	   outcome	   measures	   is	   scarce.	   In	   this	   study,	   I	   examined	   a	  comprehensive	  range	  of	  quantitative	  MRI	  endpoints	  over	  time,	  assessing	  their	  potential	  of	  acting	  as	  monitoring	  tools	  in	  CD.	  	  	  The	   findings	   on	   the	   MaRIA	   score	   were,	   overall,	   not	   in	   keeping	   with	   those	   of	   the	  Barcelona	  group	  that	  introduced	  the	  score.	  Rimola	  et	  al.	  described	  a	  positive	  correlation	  between	  MaRIAG	  and	  HBI,	  as	  well	  as	  between	  MaRIAG	  and	  CRP	  in	  both	  their	  derivation	  as	   well	   as	   their	   validation	   cohorts	   74,75.	   In	   this	   study,	   only	   the	   latter	   result	   was	  corroborated.	   However,	   I	   identified	   a	   positive	   correlation	   between	  MaRIAG	   and	   faecal	  calprotectin,	  which	  had	  not	  been	  assessed	   in	   the	  group’s	  seminal	  papers.	  Validation	  of	  this	  observation	  through	  a	  larger	  study	  will	  be	  required.	  	  In	  the	  longitudinal	  arm	  of	  the	  study	  I	  assessed	  the	  change	  over	  time	  of	  both	  MaRIAS	  in	  all	  diseased	   segments	   in	   the	   baseline	   scan,	   as	   well	   as	   the	   MaRIAG	   in	   each	   participant,	  comparing	  responders	  with	  non-­‐responders.	  	  While	  there	  was	  a	  trend	  towards	  a	  larger	  decrease	  in	  MaRIAS	  	  between	  index	  and	  follow-­‐up	  scans	  in	  responders	  compared	  to	  non-­‐responders,	  this	  did	  not	  reach	  statistical	  significance	  (p=0.12).	  The	  observed	  change	  of	  MaRIAS	   in	   responders	  was	  modest	   (average	   absolute	   ΔMaRIAS	  was	   4.9)	  with	   the	   two	  major	  components,	  namely	  oedema	  and	  mucosal	  ulceration	  resolving	  only	  in	  a	  minority	  of	   segments,	   even	   in	   the	   responder	   group.	   This	   observation	   was	   in	   contrast	   to	   the	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Barcelona	   group’s	   longitudinal	   assessment	   of	   the	   MaRIA	   score	   who	   reported	   a	   mean	  ΔMaRIAS	  in	  responders	  of	  10.1.	  In	  order	  to	  put	  these	  interval	  differences	  into	  context,	  it	  is	   important	   to	   refer	   to	   the	   formula	   for	   the	   calculation	  of	   the	   segmental	  MaRIA	   score:	  The	  presence	  of	  any	  ulceration	  has	  the	  highest	  weighting	  (10	  points)	  and	  the	  presence	  of	   oedema	   is	   awarded	   half	   of	   this	   weight	   (5	   points).	   These	   are	   assessed	   in	   a	   binary	  fashion.	   The	   remaining	   two	   parameters,	   namely	   bowel	   wall	   thickness	   and	   RCE	   are	  continuous	   variables,	   and	   differences	   in	   these	   between	   the	   two	   scans	   contributed	   far	  less	  to	  the	  observed	  effect.	  	  	  The	   persistence	   of	   oedema	   and	   ulceration	   in	   participants	   with	   a	   clinical	   response	   is	  likely	   responsible	   for	   the	   responsiveness	   scores	   (RRG	   of	   0.5,	   SES	   of	   0.6)	   which	   are	  considerably	  more	  modest	   than	   the	   ones	   described	   by	   the	   Barcelona	   study	   (1.10	   and	  1.72	   respectively).	   Test-­‐retest	   variability	   measures	   in	   this	   cohort	   show	   an	   excellent	  reliability	  profile	  both	  for	  the	  segmental	  as	  well	  as	  the	  global	  MaRIA	  score.	  	  	  There	   were	   several	   methodological	   differences	   in	   the	   power	   and	   design	   of	   the	   two	  studies,	  which	  could	  potentially	  account	  for	  the	  differences	  in	  the	  measured	  effects.	  The	  original	  MaRIA	  score,	  as	  proposed	  and	  executed	  by	  the	  Barcelona	  group,	  involves	  rectal	  instillation	   of	   luminal	   contrast	   for	   colonic	   distension	   in	   addition	   to	   oral	   contrast	   for	  small	  bowel	  distension74,75,110.	  This	  has	  implications	  for	  the	  general	  acceptability	  of	  the	  test	   to	   patients.	   Hence	   other	   groups,	   including	   ours,	   have	   used	  MaRIA	  without	   rectal	  instillation	  of	  contrast	  in	  order	  to	  improve	  the	  tolerability	  of	  the	  test.108,194.	  However,	  it	  is	   possible	   that	   suboptimal	   distension	   of	   a	   colonic	   segment	   can	   give	   rise	   to	   mucosal	  invaginations	  in	  an	  otherwise	  healed	  mucosa,	  which	  can	  be	  misinterpreted	  as	  ulcers	  and	  in	   turn	   produce	   an	   over-­‐estimation	   of	   the	   MaRIA	   score	   in	   a	   given	   segment.	   I	  concentrated	  on	  terminal	   ilea	  of	  the	  responders,	  the	  distension	  of	  which	  should	  not	  be	  affected	  by	  rectal	  contrast,	  and	  found	  that	  7	  of	  the	  9	  had	  ulcerations	  at	  baseline,	  and	  3	  of	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these	  7	  had	  resolved	  at	  follow-­‐up.	  This	  further	  strengthens	  the	  hypothesis	  that	  colonic	  segments	   may	   have	   been	   ‘over-­‐read’	   as	   ulcerated,	   as	   it	   demonstrates	   that	   the	   three-­‐month	   scanning	   interval	   is	   adequate	   for	   a	   substantial	   proportion	   of	   ulcers	   to	   have	  healed.	  Moreover,	   in	  their	  responsiveness	  analysis,	  Ordas	  et	  al.	  only	  examine	  segments	  with	   endoscopic	   ulceration	   at	   baseline,	   while	   I	   included	   all	   segments	   with	   a	   baseline	  MaRIAS	  >7.0.	  This	  is	  because	  the	  Barcelona	  group	  aimed	  to	  assess	  the	  test	  as	  a	  surrogate	  examination	  for	  endoscopic	  mucosal	  healing,	  whereas	  my	  standpoint	  was	  one	  of	  a	  more	  inclusive	  analysis	  of	  all	   endpoints	   that	  assess	   the	   totality	  of	   intestinal	  damage.	  Finally,	  the	   Barcelona	   study	   was	   significantly	   larger	   with	   111	   ulcerated	   segments	   analysed,	  compared	   to	   29	   in	   this	   study,	   which	   may	   justify	   the	   lack	   of	   statistical	   significance	  between	  responders	  and	  non-­‐responders	  as	  well	  as	  the	  modest	  responsiveness	  scores.	  	  The	   MEGS	   score	   (the	   other	   anatomical	   score	   of	   disease	   activity)	   showed	   a	   weak	   but	  significant	  correlation	  with	  CRP,	  whereas	  the	  correlation	  with	  HBI	  and	  FC	  did	  not	  reach	  statistical	   significance.	   The	   latter	  was	   the	   reference	   standard	   in	   the	   score’s	   derivation	  study,	  where	  a	  positive	  and	  significant	  correlation	  was	  reported	  192.	  There	  was	  a	  definite	  observed	   trend	   towards	   a	   higher	   drop	   in	   MEGS	   score	   in	   responders	   versus	   non-­‐responders,	  which	  did	  not	  however	  reach	  statistical	  significance.	  As	  the	  number	  of	  non-­‐responders	  in	  this	  cohort	  was	  quite	  limited	  (n=4),	  the	  fact	  that	  only	  a	  minority	  of	  global	  endpoints	  reached	  statistical	  significance	  was	  probably	  anticipated.	  	  The	   responsiveness	  markers	   of	  MEGS	  were	   equally	  modest	   to	   the	  MaRIAG	  despite	   the	  fact	  that	  ulceration	  does	  not	  feature	  as	  a	  parameter	  on	  the	  MEGS	  score.	  A	  breakdown	  of	  the	   various	   constituents	   of	   MEGS	   and	   their	   %change	   in	   responders	   versus	   non-­‐responders	  (table	  3.5)	  reveals	  which	  of	  these	  are	  responsive	  and	  which	  are	  more	  rigid	  to	   change,	   at	   least	   within	   the	   three-­‐month	   interval.	   Mural	   and	   peri-­‐mural	   oedema	  appeared	  to	  be	  the	  most	  responsive	  endpoints.	  These	  are	  evaluated	  by	  the	  intensity	  of	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T2	  signal	  inside	  the	  bowel	  wall	  and	  peri-­‐mural	  tissue	  respectively,	  in	  comparison	  to	  the	  corresponding	   signal	   inside	   the	   psoas	   muscle.	   The	   higher	   the	   T2	   signal	   in	   these	  compartments,	  the	  greater	  the	  quantity	  of	  interstitial	  fluid	  within	  them.	  This	  is	  certainly	  biologically	   plausible	   as	   excess	   interstitial	   fluid	   is	   a	   central	   feature	   in	   both	   acute	   and	  chronic	   inflammation	   which	   reduces	   readily	   as	   the	   latter	   improves	   198.	   Bowel	   wall	  thickness	   and	   length	   of	   disease	   were	   the	   least	   responsive	   components	   of	   the	   MEGS	  score.	   If	   we	   refer	   to	   the	   original	   studies	   validating	   MRE	   endpoints	   against	  histopathology	  71–73,	  we	  see	  that	  bowel	  wall	  thickness	  correlates	  both	  with	  AIS	  as	  well	  as	  fibrostenosis,	   and	   that	   the	   two	   most	   commonly	   co-­‐exist	   within	   the	   same	   segments.	  Whilst	   the	   inflammatory	   infiltrate	   is	  expected	  to	  reduce	  upon	  introduction	  of	  anti-­‐TNF	  therapy,	  the	  fibrostenotic	  element	  remains	  unaffected	  and	  therefore	  a	  modest	  response	  of	  thickness	  scores	  to	  therapy	  is	  not	  surprising.	  Through	  the	  MEGS	  score	  a	  very	  low	  %	  reduction	  in	  overall	  disease	  length	  can	  be	  observed.	  To	  understand	  this,	  it	  is	  important	  to	  consider	  that	  full	  resolution	  of	  all	  the	  mucosal,	  mural	  and	  perimural	  signs	  had	  to	  take	  place	  for	  the	  lesion	  to	  be	  deemed	  shorter	  on	  the	  follow-­‐up	  scan.	  As	  it	  has	  already	  been	  demonstrated	  in	  the	  ACTIF	  study199,	  this	  is	  a	  rare	  occurrence	  even	  at	  26	  weeks	  following	  introduction	  of	  therapy.	  	  	  Analysis	   of	   DWI	   sequences	   also	   produced	   some	   interesting	   results.	   ADC	   values	   were	  significantly	  lower	  in	  diseased	  versus	  normal	  bowel	  segments.	  These	  differences	  would	  have	  been	  even	  more	  pronounced	   if	  ADC	  values	   could	  have	  been	  produced	   for	   the	  18	  normal	  segments	  	  which	  did	  not	  produce	  a	  signal	  at	  the	  b=800s/mm2,	  as	  ADCs	  in	  these	  would	   have	   been	   at	   the	   higher	   end	   of	   the	   spectrum,	   causing	   larger	   separation	   of	   the	  medians	  of	  the	  two	  groups.	   	  Moreover,	  ROC	  analysis	  revealed	  that	  an	  ADC	  value	  of	  1.9	  mm/s2	   is	   85%	   sensitive	   and	   75%	   specific	   in	   identifying	   bowel	   segments	   with	   a	  MaRIA>7.0,	   and	   an	   area	   under	   the	   curve	   of	   0.79.	   The	   largest	   study	   to	   date	   which	  examines	   ADC	   values	   in	   CD	   in	   a	   single	   time-­‐point	   proposed	   a	   similar	   figure	   as	   a	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threshold,	  but	   the	  resulting	  sensitivity	  and	  specificity	   figures	  were	   far	  superior	  at	  well	  over	   90%	   108.	   	   As	   the	   methodology	   of	   image	   acquisition	   between	   this	   and	   the	  Hordonneau	   study	   were	   very	   similar,	   this	   disparity	   likely	   arises	   form	   the	   tighter	  confidence	   intervals	   in	   the	   much	   larger	   French	   study	   (848	   versus	   117	   analysed	  segments).	  	  	  Despite	   this,	   correlation	   between	   ADC	   in	   the	   worst	   affected	   segment	   and	   clinico-­‐pathological	  parameters	  were	  all	  non-­‐significant.	   In	  the	  longitudinal	  arm	  of	  the	  study	  I	  identified	   increases	   in	   ΔADC	   in	   abnormal	   segments	   in	   responders,	   which	   reached	  statistical	  significance	  compared	  to	  non-­‐responders.	  There	  was	  a	  high	  variability	  in	  this	  response,	   with	   almost	   half	   of	   the	   affected	   segments	   in	   responders	   demonstrating	   a	  reduction	  in	  diffusivity.	  As	  a	  consequence,	  the	  responsiveness	  markers	  for	  this	  endpoint	  were	   modest.	   The	   combination	   of	   these	   with	   an	   appreciable	   test-­‐retest	   variability	   of	  21%	  render	  ADC	  a	  sub-­‐optimal	  monitoring	  tool	  for	  inflammatory	  load,	  at	  least	  for	  a	  12-­‐week	  interval.	  	  There	  are	  several	  methodological	  challenges	  presented	  by	  the	  DWI	  sequences	  that	  merit	  special	  mention.	  Even	  at	  a	  low	  b-­‐value	  of	  50s/mm2	  the	  image	  definition	  is	  significantly	  reduced	   compared	   to	   other	   T1	   or	   T2	   sequences.	   ROI	   position	   frequently	   required	   the	  simultaneous	  use	  of	  an	  anatomical	  sequence	  obtained	  several	  minutes	  earlier	  and	  hence	  any	   motion	   between	   the	   two	   could	   not	   be	   easily	   corrected	   for.	   Moreover,	   in	   poorly	  distended	  segments	  the	  interface	  between	  bowel	  wall	  and	  luminal	  content	  can	  be	  very	  hard	   to	   determine	   in	   DWI	   images,	   a	   problem	  most	   commonly	   encountered	   in	   normal	  segments.	  For	  that	  reason,	  ADC	  calculation	  was	  obtained	  in	  99	  out	  of	  the	  117	  segments	  that	  had	  been	  scored	  with	  MaRIA.	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While	  DWI	  has	  attracted	  an	   increasing	  amount	  of	   interest	   in	   the	   recent	  years,	   current	  knowledge	  on	  the	  causative	  factors	  that	  underpin	  the	  reduction	  of	  diffusivity	  in	  diseased	  segments	  is	  scarce	  and	  can	  permit	  at	  best	  a	  speculative	  discussion.	  The	  most	  commonly	  proposed	   element	   responsible	   for	   the	   reduction	   in	   diffusivity	   is	   the	   increased	   tissue	  density	   produced	   by	   the	   cellular	   influx	   associated	   with	   the	   inflammatory	   process.	  Lymphatic	   dilatation200	   and	   neuronal	   hypertrophy201	   occurring	   at	   later	   stages	   of	   the	  pathogenic	   process	   can	   further	   contribute	   to	   the	   contraction	   of	   extra-­‐cellular	   space.	  Moreover,	   the	   fibrogenic	   process	   has	   also	   been	   proposed	   as	   a	   causative	   agent	   in	   the	  reduction	   of	   free	   water	   movement,	   independently	   of	   inflammation.	   In	   a	   study	   of	   23	  patients	  with	   chronic	  hepatitis	   and	  7	   controls,	  Taouli	   et	   al.	   demonstrated	  a	   significant	  correlation	   between	   ADC	   and	   fibrotic	   score103.	   A	   similar	   study	   in	   IBD	   that	   focuses	  specifically	  on	   the	   role	  of	   fibrosis	   in	  ADC	   reduction	  has	  not	   yet	  been	  performed.	  With	  such	   a	   multifactorial	   aetio-­‐pathological	   profile	   for	   the	   reduction	   of	   diffusivity	   in	   CD-­‐affected	  gut	  tissue,	  the	  variable	  behaviour	  of	  this	  outcome	  measure	  in	  responders,	  non-­‐responders	   and	   test-­‐retest	   cohort	  was	   not	   unanticipated.	  More	  work	  will	   be	   required	  towards	   the	   dissection	   of	   the	   relative	   roles	   that	   cellularity,	   fibrosis	   and	   other	   less	  important	   elements	   of	   the	   chronic	   tissue	   injury	   play	   in	   ADC	   behaviour	   before	   the	  marker	  can	  be	  used	  with	  any	  confidence	  in	  the	  monitoring	  of	  CD	  activity.	  	  DCE	   endpoints	   seemed	   the	   least	   suitable	   for	   longitudinal	   monitoring	   of	   the	  inflammatory	  load,	  at	  least	  within	  my	  defined	  interval	  of	  three	  months.	  The	  correlations	  of	   all	   three	   endpoints	   in	   each	   segment	   with	   the	   reference	   standard,	   MaRIAS,	   were	  significant,	  and	  moderately	  strong.	  	  This	  is	  also	  demonstrated	  by	  significant	  differences	  in	   all	   three	   endpoints	   between	   normal	   (MaRIAS	   <	   7.0)	   and	   diseased	   (MaRIAS	   >7.0)	  segments.	  There	  was	  no	  correlation,	  however,	  between	  any	  of	  the	  DCE	  endpoints	  in	  the	  most-­‐diseased	  segment	   in	  each	  patient	  and	  HBI,	  CRP	  or	  FC.	   In	  addition,	  a	   focus	  on	  the	  longitudinal	  cohort	  reveals	  no	  differences	  in	  the	  evolution	  of	  these	  scores	  in	  responders	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versus	  non-­‐responders.	  This	  is	  also	  reflected	  in	  the	  low	  responsiveness	  ratio.	  Moreover,	  all	  of	  these	  endpoints	  showed	  very	  high	  test-­‐retest	  variabilities.	  	  	  There	   are	   two	   conclusions	   that	   can	   be	   drawn	   from	   the	   DCE	   data.	   Firstly,	   all	   three	  endpoints	   are	   extremely	   variable	   and	   their	   quantification,	   at	   least	   within	   pixel-­‐sized	  ROIs,	  is	  prone	  to	  a	  high	  degree	  of	  error.	  This	  is	  the	  first	  set	  of	  published	  data	  on	  the	  test-­‐retest	   reliability	   of	   these	   measures,	   and	   despite	   its	   limited	   size,	   the	   low	   reliability	   is	  quite	   convincing.	   Considering	   the	   fact	   that	   regional	   perfusion	   of	   a	   tissue	   segment	   is	  physiologically	  subject	  to	  a	  wide	  range	  of	  neuro-­‐humoral	  influences,	  all	  of	  which	  can	  be	  altered	  within	  a	  small	  period	  of	  time,	  the	  observed	  test-­‐retest	  reliability	  figures	  are	  not	  surprising.	  	  	  The	  second	  major	  conclusion	  is	  that	  even	  though	  there	  are	  undoubted	  differences	  in	  all	  three	  endpoints	  between	  normal	  and	  diseased	  segments,	  these	  do	  not	  demonstrate	  any	  signs	   of	   improvement	   within	   the	   three	   months	   of	   therapy.	   	   Referring	   back	   to	   the	  literature	   there	   is	   evidence	   that	   a	  major	   determinant	   of	   increases	   in	   DCE	   endpoint	   is	  disease	  chronicity93.	  This	  was	  corroborated	  by	  a	  second	  group,	  which,	  at	  the	  same	  time,	  found	  no	  correlation	  between	  DCE	  variables	  and	  endoscopic	  severity	  196.	  I	  found	  a	  highly	  significant	   correlation	   between	   disease	   duration	   and	   AUC300,	   a	   composite	   measure	  dependent	  on	  both	  the	  slope	  and	  maximal	  enhancement.	  There	  is	  limited	  evidence	  from	  the	   rheumatology	   literature	   that	   anti-­‐TNFα	   treatment,	   through	   the	   suppression	   of	  vascular	  endothelial	  growth	  factor	  (VGEF)	  has	  an	  effect	  solely	  on	  early	  immature	  blood	  vessels	  but	  not	  on	  mature	  established	  vasculature	  202.	  This	  may	  justify	  the	  lack	  of	  a	  clear	  response	  of	  DCE	  endpoints	  to	  3-­‐months	  of	  anti-­‐TNFα	  therapy	   in	  the	  subset	  of	  patients	  demonstrating	   an	   obvious	   benefit	   from	   the	   treatment	   as	   judged	   by	   clinical	   and	   other	  radiological	  markers.	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Results	  on	  small	  bowel	  motility	  were	  somewhat	  more	  encouraging.	  There	  seems	  to	  be	  a	  trend	  towards	   improved	  motility	  of	  small	  bowel	   in	  responders.	  This	   is	  reflected	   in	   the	  RRG,	  which,	  unlike	  all	  other	  outcome	  measures,	  was	  greater	  than	  the	  threshold	  of	  0.80.	  It	   is	   possible	   that	   a	  moderate	   increase	   in	   the	   scanning	   interval	  may	   have	   resulted	   in	  statistical	  significance	  between	  the	  two	  groups,	  as	  was	  a	  case	  in	  a	  separate	  retrospective	  cohort	  of	  35	  patients	  with	  a	  median	  scanning	  interval	  of	  55	  weeks	  (p	  =0.0002)	  (Plumb	  A,	  unpublished	  data).	  	  	  	  Reduction	   in	   intestinal	   motility	   has	   been	   well-­‐documented	   in	   CD	   82,83	   though	   the	  mechanism	  underpinning	   this	  pathophysiological	  phenomenon	   is	  not	  well	  understood.	  However,	  active	  CD	  is	  accompanied	  by	  inflammatory	  involvement	  of	  the	  submucosal	  or	  myenteric	  plexuses	  (i.e.	  plexitis)	  81	  which	  likely	  disrupts	  the	  normal	  neuronal	  control	  of	  gut	   motion.	   The	   natural	   history	   of	   this	   process	   and	   its	   potential	   for	   improvement	  following	   treatment	   or	   remission	   of	   CD,	   has	   not	   been	   investigated	   to	   date,	   partly	  because	   of	   the	   difficulty	   and	   inconvenience	   of	   taking	   such	   measurements	   using	  manometry.	   Available	   studies	   both	   on	   gastric	   emptying	   and	   intestinal	   motility	   offer	  comparisons	  between	  CD	  patients	  and	  controls	  rather	  than	  a	  longitudinal	  assessment	  of	  patients	  over	  time	  203–205.	  However,	  unlike	  manometry-­‐based	  techniques,	  MRE	  is	  widely	  available	  and	  better	  tolerated.	  Incorporating	  dynamic	  ‘cine’-­‐sequences	  in	  MRE	  protocols	  is	   not	   a	   considerable	   burden,	   as	   it	   requires	   no	   contrast	   and	   the	   scanning	   time	   is	  approximately	  3-­‐4	  minutes.	  Further	  studies	  on	  the	  evolution	  of	  this	  marker	  are	  feasible	  and	  pertinent.	  	  	  This	   study	   has	   several	   strengths.	   It	   is	   the	   first	   study	   that	   focuses	   on	   the	   longitudinal	  performance	  of	  a	  very	  comprehensive	  range	  of	  proposed	  quantitative	  MR	  endpoints	  that	  measure	   various	   aspects	   of	   disease	   activity	   in	   CD.	   The	   prospective	   design	   allowed	  optimal	  standardisation	  processes	  in	  patient	  preparation	  and	  MR	  acquisition	  protocols.	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  On	   the	   other	   hand,	   similarly	   to	   the	   PET	   study,	   the	   cohort	   of	   completed	   pre-­‐and	   post	  treatment	  scan	  pairs	  was	  quite	   limited,	  particularly	   for	  global	  or	   ‘per-­‐patient’	  outcome	  measures.	   Once	   again,	   the	   choice	   of	   MaRIAS	   instead	   of	   colonoscopy	   as	   a	   reference	  standard	  to	  classify	  segments	  into	  diseased	  and	  normal	  may	  invite	  some	  criticism.	  	  	  
	  
3.5	  CONCLUSION	  
	  Magnetic	   Resonance	   Enterography	   is	   becoming	   increasingly	   popular	   tool	   in	   the	  assessment	   of	   Crohn’s	   disease.	   This	   is	   a	   result	   of	   its	  widening	   availability,	   the	   lack	   of	  ionising	  radiation	  and	  an	  expanding	  evidence	  base	  supporting	   its	  potential	   to	  evaluate	  disease	   activity	   through	  measures	  which	   are	   in	   close	   correlation	  with	   endoscopic	   and	  histo-­‐pathological	  reference	  standards.	  	  	  Whilst	   scores	   such	   as	   MaRIA,	   MEGS	   and	   small	   bowel	   motility	   show	   good	   static	  correlation	  with	  disease	   activity,	   the	   longitudinal	   assessment	   suggests	   that	   a	   12-­‐week	  interval	   is	   probably	   too	   short	   even	   for	   those	   more	   strongly	   performing	   endpoints	   to	  track	   changes	   in	   disease	   load	   across	   the	   full	   thickness	   of	   the	   bowel	   wall.	   Larger	  longitudinal	   studies	  over	   longer	   follow-­‐up	   intervals	  will	   be	   required	   in	   the	   future	   and	  are	  discussed	  further	  in	  Chapter	  5	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4.	  THE	  EXPRESSION	  OF	  MOLECULAR	  TARGETS	  FOR	  NOVEL	  PET	  RADIOLIGANDS	  IN	  
CROHN’S	  LESIONS	  	  
4.1.	  INTRODUCTION	  In	  the	  previous	  chapters	  the	  potential	  of	  the	  most	  current	  FDG-­‐PET	  and	  MRI	  methods	  to	  quantify	  and	  monitor	   the	   inflammatory	   load	   in	  Crohn’s	  disease	  was	  explored.	  Some	  of	  the	   investigated	  endpoints,	  particularly	   from	  PET,	   show	  some	  promise	   in	   this	   context,	  but	  several	  limitations	  have	  been	  identified:	  Firstly,	  the	  presence	  of	  a	  significant	  amount	  of	   luminal	  FDG	  activity	  related	  to	   inflamed	  gut	  segments	  suggests	  that	  this	  signal	  does	  not	   reflect	   exclusively	   the	   inflammatory	   activity	   in	   the	   bowel	  wall.	  More	   importantly,	  while	   activated	   inflammatory	   cells	   are	   responsible	   for	   a	   proportion	   of	   FDG	   activity	   in	  tissue,	  the	  glycolytic	  activity	  in	  examined	  bowel	  segments	  can	  increment	  for	  a	  variety	  of	  reasons,	  with	   increased	  activity	  of	   leiomyocytes	  as	  well	  as	  relative	  stasis	  and	  bacterial	  overgrowth	  being	  prime	  examples	  169.	  	  As	  discussed	  in	  the	  introduction	  of	  this	  thesis,	  there	  have	  been	  significant	  advancements	  in	   the	   PET	   scanning	   of	   inflammatory	   tissue,	   with	   a	   focus	   on	   the	   development	   of	  radioligands	  more	   specific	   to	   the	   inflammatory	   pathway.	   Examples	   of	   such	   receptors	  that	   act	   as	   targets	   to	   novel	   radioligands	   are	   the	   Translocator	   Protein	   (TSPO)	   and	   the	  Interleukin-­‐2	  receptor	  (IL-­‐2R).	  	  	  The	   occurrence	   of	   TSPO	   in	   gut	   tissues	   has	   been	   assessed	   by	   Bribes	   et	   al.	   using	   an	  immunohistochemical	   probe,	   which	   showed	   heterogeneous	   expression.	   More	  specifically,	  expression	  seemed	  weak	   in	   the	  colon,	  and	  moderate	   in	   the	  small	   intestine	  
206.	  Han	  et	  al.	  demonstrated	  a	  significant	  and	  measurable	  difference	  of	  TSPO	  expression	  between	  malignant	  colorectal	   specimens	  and	  normal	  colonic	   tissue	   207.	   	  More	  recently,	  Ostuni	  et	  al.	   confirmed	  the	  distribution	  of	  TSPO	   in	  biopsies	  of	  normal	   ileum	  and	  colon	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and	   suggested	   an	   over-­‐expression	   in	   areas	   affected	   by	   Crohn’s	   disease	   and	   ulcerative	  colitis.	  The	  number	  of	  samples	  was	  not	  declared	  however,	  and	  there	  was	  no	  attempt	  to	  quantify	  this	  over-­‐abundance	  208.	  	  TSPO	  in	  being	  explored	  as	  a	  target	  in	  molecular	  imaging	  of	  inflammation	  as	  high	  levels	  have	   been	   demonstrated	   in	   activated	   macrophages	   sampled	   from	   a	   diverse	   range	   of	  peripheral	  inflammatory	  processes	  149,150,209,210.	  	  First	  generation	  TSPO	  radioligand	  PK11195	  has	  now	  been	  largely	  superseded	  by	  the	  far	  more	  specific	  PBR28	  and	  others	  211.	  	  While	  these	  have	  significantly	  better	  signal-­‐to-­‐noise	  profiles,	   they	   also	   exhibit	   significant	   between-­‐subject	   variability.	   This	   has	   been	  accounted	   for	   by	   a	   genetic	   polymorphism	   (rs6971)	   in	   the	   gene	   encoding	   TSPO212.	  	  Homozygote	  high-­‐affinity	  (HAB)	  and	  low-­‐affinity	  binders	  (LAB)	  as	  well	  as	  heterozygote	  mixed-­‐affinity	   binders	   (MAB)	   have	   been	   described,	   and	   the	   dissociation	   constant	   (Kd)	  has	  been	  estimated	   for	  each	  of	   the	   three	  phenotypes,	  at	   least	   for	  TSPO	  extracted	   from	  brain	   tissue	   213.	   Genotyping	   for	   binding	   status	   of	   subjects	   has	   been	   shown	   to	   form	   an	  integral	  part	  of	  the	  clinical	  scanning	  process	  using	  these	  ligands214.	  	  IL-­‐2	   is	   a	   pro-­‐inflammatory	   cytokine	   produced	   by	   activated	  Th1-­‐cells,	  which	   promotes	  further	  T-­‐cell	  proliferation,	  differentiation	  of	  B-­‐cells	  and	  NK	  and	  macrophage	  activation.	  The	   effects	   of	   IL-­‐2	   are	   mediated	   through	   binding	   to	   the	   IL-­‐2	   receptor	   (IL-­‐2R),	   a	  heterotrimeric	  	  receptor	  comprising	  of	  an	  α	  (CD25),	  β	  and	  γ	  subunits156	  .	  	  Several	  studies	  suggest	  a	  key	  role	  of	  IL-­‐2	  in	  the	  pathophysiology	  of	  CD.	  These	  show	  that	  patients	   with	   active	   Crohn’s	   	   disease	   have	   elevated	   serum	   IL-­‐2	   and	   soluble	   IL-­‐2R	  concentrations215.	   Moreover,	   patients	  with	   active	   disease	  who	   respond	   to	   cyclosporin	  and	  anti-­‐TNFα	  therapy	  are	  more	  likely	  to	  have	  decreases	  	  in	  serum	  IL-­‐2	  and	  soluble	  IL-­‐
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2R	   levels	   than	   are	   treatment-­‐refractory	   patients215,216.	   In	   addition,	   there	   have	   been	  reports	   of	   quiescent	   Crohn’s	   disease	   re-­‐activitation	   shortly	   after	   therapeutic	  administration	   of	   IL-­‐2	   in	   two	   patients	   with	   renal	   cell	   carcinoma217.	   More	   recently,	  genetic	   polymorphisms	   in	   the	   region	   of	   the	   Il2/IL21	   receptor	   have	   been	   linked	   with	  increased	   susceptibility	   to	   IBD218.	   Intestinal	   regional	   IL-­‐2R	   expression	   has	   also	   been	  investigated.	   In	   healthy	   controls	   there	   is	   very	   little	   expression	   on	   the	   lamina	   propria	  (LP),	   however,	   there	   is	   some	   CD25	   detected	   in	   Peyer’s	   patches.	   LP	   as	   well	   as	   sub-­‐epithelial	   segments	   from	   CD	   affected	   small	   and	   large	   bowel	   on	   the	   other	   hand,	  demonstrated	  abundant	  CD25	  219.	  	  	  	  Similarly	   to	   TSPO,	   the	   IL2R	   has	   found	   a	   role	   as	   an	   imaging	   target	   in	   a	   variety	   of	  conditions	   underpinned	   by	   a	   lymphocytic	   infiltrate	   in	   tissue.	   	   Most	   studies	   originate	  from	   the	   same	  group	   from	   the	  University	  of	  Rome,	   that	   investigated	   the	   receptor	  as	  a	  target	  for	  imaging	  using	  the	  SPECT	  technique.	  Following	  two	  seminal,	  proof	  of	  concept	  studies	   in	   a	   murine	   model	   of	   diabetes	   220,221,	   the	   group	   produced	   a	   series	   of	   papers	  correlating	  123I	  or	  99Tc	  –tagged	  IL2	  with	  clinical	  and	  histological	  markers	  of	  activity	  in	  a	  variety	   of	   conditions	   including	   coeliac	   disease160,	   atherosclerosis161	   and	   Crohn’s	  disease162,222.	  	  	  	  These	   studies	   are	   very	   suggestive	   that	   TSPO	   and	   IL-­‐2R	   are	   potentially	   suitable,	  receptors	  for	  use	  in	  inflammatory	  molecular	  imaging	  of	  Crohn’s	  disease.	  In	  the	  bench-­‐to-­‐bedside	  pathway	  of	  a	  new	  radioligand,	  or	  an	  established	  radioligand	  proposed	  for	  a	  new	  indication,	   several	   characteristics	  of	   its	   interaction	  with	   its	   target	   receptor	  need	   to	  be	  characterised.	   Key	   features	   of	   this	   interplay	   are	   the	   specificity	   of	   the	   tracer	   for	   its	  receptor,	   as	   well	   as	   the	   binding	   potential	   between	   the	   two.	   Specificity	   refers	   to	   the	  distribution	   of	   activity	   at	   target	   versus	   non-­‐target	   sites,	   or,	   also	   described	   as	   specific	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versus	  non-­‐specific	  binding.	  Binding	  potential	  is	  defined	  by	  the	  availability	  or	  density	  of	  the	  receptor	  (BMAX)	  and	  the	  affinity	  of	  the	  ligand	  towards	  that	  receptor	  (Kd)223.	  	  	  	  This	   study	   had	   two	   main	   purposes.	   Firstly,	   I	   set	   out	   to	   investigate	   the	   differential	  expression	   of	   the	   two	   target	   receptors,	   TSPO	   and	   IL2R	   in	   normal	   versus	   inflamed	  segments.	  Secondly,	  I	  wanted	  to	  examine	  such	  key	  characteristics	  of	  radioligand	  binding	  such	  as	  the	  density	  of	  available	  receptors	  (BMAX)	  and	  affinity	  of	  radioligand	  binding	  (Kd)	  in	  the	  inflamed	  versus	  normal	  gut.	  	  	  The	  hypotheses	  underpinning	   this	   study	  were	   that	   there	   is	  a	  measurable	  difference	   in	  TSPO	  and	  IL2-­‐R	  expression	  between	  inflamed	  and	  uninvolved	  segments	  in	  patients	  with	  CD.	  Moreover	  these	  differences	  will	  translate	  into	  increased	  binding	  of	  TSPO	  and	  IL-­‐2R	  specific	   radiotracers	   in	   the	   relevant	   segments.	   Finally,	   it	   was	   hypothesised	   that	   the	  binding	  affinity	  of	  the	  second-­‐generation	  TSPO	  radiotracer,	  PBR28,	  in	  peripheral	  tissue	  will	  be	  comparable	  to	  that	  described	  in	  brain	  specimens.	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4.2	  METHODS	  	   4.2.1	  PATIENT-­‐	  SPECIMEN	  SELECTION	  	  Two	  separate	  sources	  of	  specimens	  were	  used	  for	  this	  work	  and	  approval	  by	  Research	  Ethics	   Committees	   (REC)	   was	   obtained	   for	   both	   (South	   West	   London	   REC	   1,	   Ref	   No	  10/H0801/59	   and	   NRES	   Committee	   London-­‐Wandsworth	   Ref	   No	   11/LO/0380).	   The	  first	   study	   (immunohistochemical	   assessments	  of	   the	   two	   targets)	   involved	   the	  use	  of	  stored	   specimens,	   whereas	   the	   second	   (autoradiographic	   and	   homogenate	   binding	  studies)	  required	  prospective	  recruitment	  of	  patients	  undergoing	  intestinal	  resection.	  	  For	   immunohistochemical	   (IHC)	   analysis	   of	   TSPO	   and	   IL-­‐2R	   expression	   the	  histopathology	   database	   of	   St	  Mary’s	   hospital	   was	   searched	   and	   appropriate	  mucosal	  biopsies	   and	   resection	   specimens	   were	   retrieved.	   These	   met	   the	   following	   eligibility	  criteria:	  	  	  	  Inclusion	  criteria:	  1)	   Specimens	   from	   patients	   collected	   before	   September	   2006	   (for	   the	   purposes	   of	  compliance	  with	  the	  Human	  Tissue	  Act).	  2)	  Specimens	  from	  patients	  over	  18	  years	  of	  age	  at	  the	  time	  of	  endoscopy/	  surgery.	  3)	  Biopsies/	  resection	  specimens	  containing	  normal	  bowel.	  4)	  Biopsies/	  resection	  specimens	  containing	  quiescent	  Crohn's	  disease.	  5)	  Biopsies/	  resection	  specimens	  containing	  active	  Crohn's	  inflammation.	  	  Exclusion	  criteria	  1)	  Samples	  from	  patients	  with	  a	  diagnosis	  of	  gastro-­‐intestinal	  dysplasia	  or	  cancer.	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2)	   Samples	   derived	   from	   patients	   who	   meet	   inclusion	   criteria,	   but	   not	   adequately	  preserved	  or	  technically	  suitable	  for	  analysis.	  For	   the	   autoradiography	   and	   homogenate	   binding	   studies	   I	   prospectively	   recruited	  adult	   patients	   with	   proven	   Crohn’s	   disease	   who	   had	   failed	   medical	   therapy,	   and	   a	  decision	  had	  been	  made	  for	  intestinal	  resection	  to	  take	  place.	  The	  study	  was	  approved	  by	   the	  NIHR	  portfolio	   and	   recruitment	   took	  place	   in	   4	   hospitals.	   All	   participants	   gave	  informed	   consent,	   authorising	   the	   use	   of	   2	   tissue	   sections,	   one	   from	   the	   resection	  margin,	  which	  appeared	  disease-­‐free	  macroscopically	  at	  the	  time	  of	  operation,	  and	  one	  from	   the	   diseased	   area	   in	   the	   middle	   of	   the	   resected	   specimen,	   which	   the	   surgeon	  deemed	   abnormal	   intra-­‐operatively	   (Figure	   4.1).	   I	   excluded	   participants	   having	  intestinal	   resection	   for	   reasons	  other	   than	   symptomatic	  CD.	  Following	   the	  publication	  on	   the	   rs6971	  polymorphism	  ethical	  permission	  was	   sought	  and	   the	  binding	   status	  of	  the	  latter	  5	  participants	  was	  determined	  on	  a	  blood	  sample.	  	  
	  
Figure	  4.1:	  Schema	  representing	  the	  sites	  sampled	  following	  intestinal	  resection	  
	  
	  
	  	  	  	  	  
5mm-­‐thick	  ring	  cut	  from	  
the	  diseased	  core 
5mm-­‐thick	  ring	  cut	  
from	  the	  healthy	  edge 
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4.2.2	  TISSUE	  PREPARATION	  -­‐	  FREEZING	  
Stored	  tissue:	  Formalin-­‐fixed	  paraffin-­‐embedded	  (FFPE)	  mucosal	  biopsies	  and	  tissue	  blocks	  were	  used	  to	  produce	  sequential	  1μm-­‐thin	  sections,	  which	  were	  mounted	  onto	  glass	  slides.	  These	  were	   then	   stored	   at	   room	   temperature	   until	   staining.	   1	   section	   from	   each	   block	   was	  stained	  with	  Haematoxylin	  and	  Eosin	  (H&E)	  for	  histological	  assessment	  of	  inflammatory	  activity,	  and	  the	  others	  were	  stained	  with	  IHC	  probes.	  
Fresh	  tissue:	  Immediately	   following	   surgical	   resection,	   the	   specimen	   was	   transferred	   to	   the	  department	  of	  histopathology	  in	  each	  participating	  hospital	  and	  two	  5mm-­‐thick	  rings	  of	  tissue,	   one	   from	   the	   disease-­‐free	   edge,	   (acting	   as	   control)	   and	   one	   from	   the	   diseased	  segment	  were	  cut.	  The	  two	  specimens	  were	  washed	  in	  phosphate-­‐buffered	  saline	  (PBS),	  excess	  moisture	  was	  removed,	  and	  were	  snap-­‐frozen	  by	  immersion	  into	  a	  mixture	  of	  2-­‐methylbutane	  (Sigma	  Aldrich,	  Dorset,	  UK)	  at	  circa.	  -­‐30	  to	  -­‐400C.	  Snap-­‐frozen	  specimens	  were	  immediately	  stored	  at	  -­‐80°C	  until	  further	  use.	  
4.2.3	  HISTOLOGICAL	  ASSESSMENT	  
Following	   sectioning	   and	   H&E	   staining,	   stored	   formalin-­‐fixed	   paraffin	   embedded	   gut	  slides	   were	   assessed	   and	   Global	   Inflammatory	   Score	   (GIS)	   of	   each	   section	   was	  calculated168.	   This	   consisted	   of	   the	   sum	   of	   the	   acute	   neutrophilic	   and	   chronic	  lymphoplasmatocytic	  infiltrates,	  each	  being	  given	  a	  score	  of	  either	  0	  (absent),	  1	  (mild),	  2	  (moderate)	  or	  3	  (severe).	  The	  GIS	  on	  each	  section	  ranged	  from	  0	  to	  6.	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4.2.4	  IMMUNOHISTOCHEMISTRY	  	  Section	  staining	  was	  carried	  out	  at	  Pathology	  Diagnostics	  Ltd,	  Cambridge,	  UK.	  This	  was	  performed	  in	  3	  phases:	  	  	  Validation	   Phase	   1:	   Validation	   of	   staining	   using	   tissue	   samples	   or	   FFPE	   control	   tissue	  samples	   as	   appropriate	   and	   adapting	   the	   commercial	   antibody	   data	   sheet	   supplied	  method	  for	  use	  on	  the	  automated	  DAKO	  Autostainer-­‐Link	  platform.	  	  	  Analytical	  Phase	  2	  Staining	  on	  xenograft	  tumour	  samples	  to	  determine	  optimal	  antibody	  dilutions.	  The	  final	  optimised	  antibody	  dilutions	  were	  as	  follows:	  CD3	  (Dako,	  M7254,	  20007999):	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1:50	  CD25	  (Abcam,	  128955,	  YJ092903CS):	  	  	  	  	  	  	  	  	  	  	  1:100	  TSPO	  (Abcam,	  ab109497,	  GR113098-­‐6)	  	  	  	  	  	  	  1:400	  CD45	  (Dako	  15751,	  10005827):	  	  	  	  	  	  	  	  Ready	  to	  use	  CD68	  (Dako	  M0876,	  20002540):	  	  	  	  	  	  	  Ready	  to	  use	  	  Phase	  3	  Following	   completion	   of	   the	   validation	   phase,	   staining	   of	   all	   the	   tissue	   samples	   was	  performed	   using	   the	   method	   developed	   for	   each	   of	   the	   five	   markers	   from	   Phase	   1.	  Histological	   assessment	   and	   IHC	   scoring	  was	   performed	   by	   a	   histopathology	   research	  fellow	  with	  3	  years	  experience,	  and	  were	  corroborated	  by	  a	  senior	  histopathologist	  with	  more	  than	  30	  years	  experience	  in	  GI	  pathology.	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  4.2.4.1	  TSPO	  	  	  TSPO	  was	  assessed	  semi-­‐quantitatively	  with	  a	  score	  of	  0–9	  derived	  by	  the	  product	  of	  the	  increase	   in	   staining	   intensity	   compared	   with	   the	   negative	   controls	   (0,	   no	   labeling;	   1,	  faint	  staining;	  2,	  moderate	  staining;	  3,	  strong	  staining)	  and	  the	  frequency	  of	  stained	  cells	  (0:less	   than	  10%,	  1:10–25%,	  2:	  25–50%,	  3:	  more	   than	  50%)224.	   In	  a	   small	   subset	  of	  4	  sections,	   co-­‐staining	   with	   either	   a	   leukocyte-­‐common	   antigen	   CD45	   antibody	   or	   a	  macrophage-­‐specific	   CD68	   antibody	   was	   performed	   to	   qualitatively	   assess	   for	   co-­‐localisation	  with	  TSPO.	  	   4.2.4.2	  IL-­‐2RECEPTOR	  (CD25)	  	  CD25	  expression	   in	   the	  gut	  mucosa	  was	  quantified	  as	   follows:	   	  Using	   light	  microscopy	  the	   epithelium	  was	   identified	   and	  marked	  with	   1mm	  graduations.	   At	   each	   graduation	  high	  power	  fields	  (hpf,	  x400	  magnification)	  were	  sequentially	  examined	  and	  the	  number	  of	   CD25	   positive	   cells	   within	   the	   mucosa	   manually	   counted.	   The	   average	   number	   of	  CD25	  positive	  cells	  /hpf	  was	  recorded.	  To	  assess	  expression	  across	  the	  whole	  thickness	  of	   bowel	  wall	   on	   the	   other	   hand,	   light	  microscopy	  was	   used	   to	   select	  well-­‐orientated,	  full-­‐	  thickness	  sections	  of	  bowel	  wall,	  and	  1-­‐mm	  thick	  zones	  were	  marked.	  For	  each	  zone	  the	   whole	   of	   the	   mucosa,	   submucosa	   and	   muscularis	   propria	   were	   recorded	   using	   a	  Vernier	   scale.	   Expression	   was	   recorded	   as	   CD25+ve	   cells/mm2.	   	   Due	   to	   significant	  regional	  variability	  in	  CD25	  expression	  even	  within	  a	  single	  slide,	  more	  than	  one	  1mm-­‐wide,	  well-­‐orientated	  bowel	  wall	   regions	  were	  scored	  on	  each	  slide.	  Finally,	   in	  a	  small	  subset	  of	  4	  sections,	  co-­‐staining	  with	  a	  CD45	  antibody	  or	  a	  T-­‐cell	  specific	  CD3	  antibody	  was	  performed	  to	  qualitatively	  assess	  for	  co-­‐localisation	  with	  CD25.	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4.2.5	  AUTORADIOGRAPHY	  	  15μm-­‐thick	  sections	   from	  fresh	  gut	  specimens	  were	  serially	  sectioned	  using	  a	  cryostat	  microtome	   (Leica,	  Wetzlar,	   Germany;	   CM1900),	   and	   thaw-­‐mounted	   onto	   slides	   before	  being	  re-­‐stored	  at	  -­‐80°C.	  	  	  One	   the	  day	  of	   the	  bind,	   slides	  were	   thawed	   to	   room	   temperature	   and	  washed	   for	  15	  mins	   in	   assay	   buffer	   (50 mmol/L	   Tris	   Base,	   140 mmol/L	   NaCl,	   1.5 mmol/L	   MgCl2,	   5mmol/L	  KCl,	  1.5 mmol/L	  CaCl2,	  pH	  7.4,	   room	  temperature)	   to	  remove	   the	  endogenous	  ligand.	  	  	   4.2.5.1	  TSPO	  	  To	   determine	   the	   total	   binding	   signal,	   sections	   were	   incubated	   in	   assay	   buffer	  containing	   either	   [3H]PBR28	   (0.5 nmol/L)	   for	   60 minutes	   or	   [3H]PK11195	   (1	   nmol/L)	  for	   120 minutes.	   The	   non-­‐specific	   binding	   component	   was	   determined	   on	   adjacent	  sections	  by	  blocking	  TSPO	  receptors	  with	  unlabelled	  PK11195	  (10 μmol/L).	  	  	   4.2.5.2	  IL-­‐2R	  	  To	   determine	   the	   total	   binding	   signal,	   sections	   were	   incubated	   in	   assay	   buffer	  containing	  125I-­‐IL2	  (0.3nmol/L)(3	  x	  Kd	  of	  the	  high	  affinity	  CD25	  subunit)	  (PerkinElmer,	  Boston,	   MA,	   USA).	   The	   non-­‐specific	   binding	   component	   was	   determined	   on	   adjacent	  sections	  in	  the	  presence	  of	  100nmol/L	  of	  unlabelled	  human	  recombinant	  interleukin-­‐2	  (hr-­‐IL2)	   (Life	   Technologies,	   Paisley,	   UK)	   used	   to	   saturate	   all	   specific	   sites.	   The	   hr-­‐IL2	  concentration	  of	  100nM	  correlates	  with	  1000	  x	  Kd	  of	  the	  high-­‐affinity	  CD25	  subunit.	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Figure	  4.2:	  ROI	  placement	  on	  autoradiograms.	  4x10	  pixel	  –wide	  ROIs	  were	  positioned	  on	  
each	   of	   the	   three	   layers	   and	   their	   average	   was	   recorded	   (blue	   in	   mucosa,	   yellow	   in	  
submucosa	  and	  red	   in	  muscularis).	  Finally,	  a	   larger	  quadrangular	  ROI	  was	  placed	  across	  
the	  full	  thickness	  of	  the	  section	  (green),	  which	  represents	  average	  receptor	  density.	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4.2.6	  HOMOGENATE	  BINDING	  STUDIES	  	  Following	   slide	   sectioning,	   residual	   tissue	   (when	   available)	   was	   homogenised	   in	   10	  times	  weight	   for	  volume	  buffer	  (0.32 mmol/L	  sucrose,	  5 mmol/L	  Tris-­‐Base,	  1 mmol/L	  MgCl2,	  pH	  7.4,	  4°C)	  which	  contained	  protease	   inhibitor	  cocktail	   tablets	   (1	   tab/	  50ml	  of	  buffer)	   (Roche,	   Branford,	   CT,	   USA).	   Homogenates	   were	   centrifuged	   (1,000×	  g,	   20minutes,	   4°C)	   and	   the	   supernatant	   was	   removed	   and	   re-­‐centrifuged	   (32,000	   ×	  g,	   20minutes,	  4°C).	  High-­‐spin	  pellets	  were	  re-­‐suspended	  in	  at	  least	  10	  times	  w/v	  (weight	  for	  volume)	   buffer	   (50 mmol/L	  Tris-­‐Base,	   1 mmol/L	  MgCl2,	   pH	  7.4,	   4°C)	   followed	   by	   two	  washes	  by	  centrifugation	  (32,000	  ×	  g,	  20 minutes,	  4°C).	  Membranes	  were	  suspended	  in	  buffer	   (50 mmol/L	   Tris-­‐Base,	   1 mmol/L	  MgCl2,	   pH	   7.4,	   4°C).	   Protein	   concentration	   in	  homogenates	   (μg/mL)	   was	   determined	   using	   the	   bicinchoninic	   acid	   assay	   (BCA	   Kit,	  Sigma-­‐Aldrich,	   Gillingham,	   UK)	   and	   absorption	   was	   read	   at	   562nm.	   Membrane	  suspensions	  were	  finally	  stored	  at	  -­‐80°C	  until	  further	  use.	  	  	  Aliquots	   of	  membrane	   suspension	  were	  prepared	  using	   assay	  buffer	   (50mmol/L	  Tris-­‐Base.	   140mmol/L	   NaCl,	   1.5mmol/L	   MgCl2,	   5mmol/L	   KCl,	   1.5mmol/L	   CaCl2,	   pH	   7.4,	  37oC).	  This	  was	   incubated	  with	   [3H]PBR28	   in	   a	   final	   volume	  of	  500μL	   for	  60	  minutes.	  For	   the	   saturation	  binding	   analysis,	   triplicates	   of	   8	   concentrations	  of	   [3H]PBR28	  were	  used.	   In	   HABs,	   these	   ranged	   between	   100pM	   and	   300nM,	   and	   it	   MABs	   and	   LABs	   the	  range	  was	  between	  500pM	  and	  1μM.	  To	  calculate	  the	  non-­‐specific	  binding	  component	  of	  [3H]PBR28,	  unlabeled	  PK11195	  (100μM)	  was	  added	   in	  half	  of	   the	  binding	  wells.	  At	  60	  minutes,	  assays	  were	  terminated	  by	  filtration	  through	  Whatman	  GF/B	  filters	  (Whatman,	  Maidstone,	  UK),	  followed	  by	  3	  x	  1ml	  washes	  using	  ice-­‐cold	  buffer	  (50mml/L	  Tris-­‐Base,	  1.4mmol/L	  MgCl).	  During	  incubation,	  Whatman	  GF/B	  filters	  (Whatman,	  Maidstone,	  UK)	  were	  pre-­‐incubated	  in	  0.05%	  polyetheleneimine.	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The	  filters	  were	  then	  placed	  in	  scintillation	  vials	  and	  scintillation	  fluid	  (3mL/vial,	  Perkin	  Elmer	   Ultima	   Gold	   MV)	   was	   added,	   and	   were	   counted	   using	   a	   Perkin	   Elmer	   Tricarb	  liquid	  scintillation	  counter.	  	  	  	  The	  specific	  binding	  values	  were	  plotted;	  BMAX	  (fmol/mg	  protein)	  and	  Kd	  (nmol/L)	  were	  determined	   for	   each	   membrane	   preparation	   using	   GraphPad	   Prism	   6.0	   software	  (GraphPad	  Software,	  San	  Diego,	  CA,	  USA)	  by	  using	  a	  non-­‐linear	  regression	  fit	  for	  either	  one	  binding	  site	  or	  two	  binding	  sites.	  One	  site	  fit:	  	  	  	  Y=	  BMAX*X/(KD+X)	  Two-­‐site	  fit:	  Site	  1=	  BMAXHi*X/(KDHi+X)	  Site	  2	  =	  BMAXLow*X/(KDlow+X)	  	  Y=	  specific	  binding	  (fmol/mg	  protein)	  	  	  X	  =	  concentration	  of	  radioligand.	  	  I	  compared	  the	  Kd	  between	  normal	  and	  diseased	  sections	  from	  each	  patient	  to	  establish	  whether	   TSPO	   in	   inflamed	   tissue	   has	   different	   affinity	   towards	   its	   ligands.	   Moreover,	  affinities	   in	   low	   affinity	   binders	   and	   high	   affinity	   binders	   (and	   low	   and	   high	   affinity	  receptors	  in	  mixed	  affinity	  binders	  respectively)	  were	  compared	  with	  the	  ones	  reported	  in	  the	  published	  literature.	  	  	  4.2.7	  DATA	  ANALYSIS	  	  Distribution	   results	   are	   expressed	   diagrammatically	   as	   median±	   Inter	   Quartile	   Range	  (IQR).	   CD25	   expression	   between	   sections	   of	   different	   GIS	   was	   compared	   by	   Mann-­‐
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4.3.RESULTS	  4.3.1TSPO	  	  	  4.3.1.1	  HISTOLOGICAL	  ASSESSMENT	  OF	  SEVERITY	  	  33	  stored	  mucosal	  biopsies	  were	  obtained,	  5	  from	  normal	  controls	  and	  28	  from	  patients	  with	   CD.	   18	   transmural	   sections	   from	   7	   CD	   patients	   who	   had	   undergone	   intestinal	  resections	   were	   also	   assessed.	   H&E	   slides	   from	   each	   of	   these	   sections	   revealed	   the	  following	  distribution	  of	  Global	  Inflammatory	  Scores:	  	  
Table	  4.1:	  Distribution	  of	  GIS	   in	  mucosal	   biopsies	   and	   transmural	   sections	  assessed	  with	  
TSPO	  IHC	  
	  
	   	  Controls	  GIS	  0	   Crohn’s	  disease	   	  Total	  GIS	  0-­‐1	   GIS	  	  	  2-­‐4	   GIS	  5-­‐6	  Mucosal	  biopsies	   5	   13	   8	   7	   33	  	  Transmural	  sections	   	   GIS	  0-­‐2	   GIS	  3-­‐6	   	  0	   10	   8	   18	  	   4.3.1.2	  IMMUNOHISTOCHEMICAL	  EXPRESSION	  
Figure	   4.3:	  Mucosal	   TSPO	   expression	   index	   in	   normal	   controls	   and	   CD	  mucosal	   sections	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Figure	  4.4:	  Transmural	  TSPO	  index	  in	  sections	  with	  mild-­‐moderate	  (GIS	  0-­‐2)	  versus	  severe	  
(GIS	  3-­‐6)	  inflammation	  
	  	  	  	  	  	  	  	  
Figure	  4.5:	  Characteristic	  TSPO	  expression	  in	  (a)	  epithelial	  and	  (b)	  transmural	  specimens	  
in	  my	  cohort.	   	  The	  yellow	  circle	   in	  (a)	  corresponds	  to	  an	  area	  of	  epithelial	   inflammation,	  
which	  demonstrates	  similar	  expression	  to	  the	  rest	  of	  the	  un-­‐inflamed	  epithelium.	  The	  red	  
circle	   in	   (b)	   corresponds	   to	   an	   area	   of	   denser	   staining	   without	   any	   features	   of	  
inflammation.	  (c)	  shows	  the	  negative	  control	  slide.	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Figure	   4.6:	   Another	   example	   of	   TSPO	   expression	   across	   the	   full	   thickness.	   An	   area	   of	  
ulceration	  with	   inflammatory	  cell	   infiltrate	  also	   staining	   for	  TSPO	   is	  demonstrated	   (blue	  
arrow)	  	   	  	  	  	  	  	  	  	  	  	  	  When	   co-­‐staining	   for	  TSPO	  and	  CD45,	   as	  well	   as	  TSPO	  and	  CD68	  was	  performed,	   this	  demonstrated	  moderate-­‐strong	   TSPO	   staining	   throughout	   the	  mucosal	   glands	   in	   both	  the	   control	   and	   the	   inflamed	   slides	   and	   a	   lack	   of	   co-­‐localisation	   between	   TSPO	   and	  either	   of	   the	   two	   immune	   cell	   markers.	   More	   specifically,	   CD45	   was	   heavily	  concentrated	  within	  lymphoid	  aggregates	  in	  the	  diseased	  section,	  whereas	  some	  sparse	  transmural	   positivity	   was	   seen	   in	   the	   healthy	   section.	   CD68	   expression	   was	   also	  transmural	  and	  appeared	  more	  concentrated	  in	  the	  diseased	  section.	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4.3.1.3	  AUTORADIOGRAPHIC	  BINDING	  	  The	   12	   pairs	   of	   tissue	   which	   were	   collected	   prospectively	   from	   intestinal	   resection	  specimens	  were	   assessed	  qualitatively	  by	   consultant	  histopathologists	   at	  participating	  hospitals.	  Representative	  sections	  from	  the	  specimen	  edges	  were	  reported	  as	  normal	  in	  11/12	   specimens,	   with	   1/12	   showing	   evidence	   of	   quiescent	   ileitis.	   All	   12	   specimens	  from	  the	  diseased	  core	  contained	  inflammation	  and	  features	  of	  fibrosis.	  	   4.3.1.3.1	  3H-­‐PK11195	  	  
3H-­‐PK11195	   autoradiography	   was	   successfully	   performed	   on	   8	   sections	   from	  uninflamed	  margins	  and	  8	  sections	  from	  inflamed	  gut	  (6	  matched	  pairs	  from	  the	  same	  patients).	   Comparison	  was	   possible	   on	   a	   7th	   pair	   for	   submucosa	   and	  muscularis	   only.	  The	   remainder	  4	   and	  4	   specimens	   respectively	  were	  not	   examined	  due	   to	  poor	   tissue	  sectioning	  (see	  discussion).	  Specific	  binding	  achieved	  using	  1nM	  3H-­‐PK11195	  ligand	  and	  10μM	  unlabeled	  PK11195	  block	  was	  low	  (mean	  ±	  SD	  =	  41.5±17.5%)	  (Figure	  4.7)	  
	  
Figure	  4.7:	  Characteristic	  PK11195	  binding	  (a)	   total	  and	  (b)	  non-­‐specific	  binding.	  This	   is	  
illustrated	   in	   black-­‐white	   (top)	   and	   pseudo-­‐colour	   (bottom)	   modes.	   In	   the	   latter,	   high	  
radioactivity	   counts	   is	   represented	   by	   brown-­‐range	   whereas	   background	   staining	   is	  
represented	  by	  green.	  The	  non-­‐specific	  binding	  is	  obviously	  reduced,	  compared	  to	  the	  total,	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The	   differences	   in	   receptor	   density	   (specific	   binding,	   fmol/mg	   of	   tissue)	   between	   the	  normal	  and	  inflamed	  sections	  were	  not	  statistically	  significant	  (Figure	  4.8).	  
	  
Figure	  4.8:	  TSPO	  specific	  binding	  (SB)	  (fmol/mg	  or	  tissue)	  as	  determined	  by	  3H-­‐PK11195	  
autoradiography	   on	   normal	   un-­‐inflamed	   (blue)	   versus	   diseased	   sections	   (red).	  
Comparisons	  for	  each	  layer	  separately	  is	  shown	  in	  graphs	  (a),	  (b)	  and	  (c).	  Comparisons	  of	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4.3.1.3.2	  3H-­‐PBR28	  	  
3H-­‐PBR28	  autoradiography	  was	  successful	  on	  10	  sections	  from	  uninflamed	  margins	  and	  10	  sections	  from	  inflamed	  gut	  (8	  complete	  pairs).	  Comparison	  was	  possible	  for	  a	  9th	  pair	  for	   submucosa	   and	   muscularis	   only.	   The	   specific	   binding	   achieved	   using	   0.5nM	   of	  [3H]PBR28	  and	  41μM	  of	  unlabeled	  PK11195	  ligand,	  as	  a	  block	  to	  saturate	  specific	  sites,	  was	  high	  (mean	  ±	  SD	  91±11%)(Figure	  4.9).	  	  	  
	  
Figure	  4.9:	  Characteristic	  3H-­‐PBR28	  binding	  (a)	  total	  and	  (b)	  non-­‐specific	  binding	  shown	  
in	  pseudo-­‐colour	  mode.	  Non-­‐specific	   binding	   is	   far	   less	   prominent	   than	  with	  PK11195	   in	  
Figure	  4.7	  	  	  	  	  	  	  	  	  	  	  	  	  A	  trend	  was	  demonstrated	  towards	  a	  higher	  specific	  binding	  in	  diseased	  sections	  in	  the	  transmural	   and	   submucosal	  ROIs	  but	   this	  did	  not	   reach	   statistical	   significance	   (Figure	  4.10)	  	  	  	  
a	   b	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Figure	   4.10:	   TSPO	   specific	   binding	   (fmol/mg	   or	   tissue)	   as	   determined	   by	   3H-­‐PBR28	  
autoradiography	  on	  normal,	  un-­‐inflamed	  (blue)	  versus	  diseased	  sections	  (red).	  These	  are	  
compared	  with	  Wilcoxon	  rank	  sum	  test	  and	  p-­‐values	  are	  demonstrated.	  Comparisons	   for	  
each	   layer	   separately	   is	   shown	   in	   graphs	   (a),	   (b)	   and	   (c).	   Comparisons	   of	   transmural	  
expression	  are	  shown	  in	  (d)	  	  
	  	  Given	  the	  lack	  of	  statistical	  significance	  between	  specific	  binding	  in	  normal	  and	  diseased	  sections,	   I	   plotted	   all	   specific	   binding	   in	   LABs,	   MABs	   and	   HABs	   separately	   (when	  genotype	  was	  known)	  and	  observed	  the	  appropriate	  clustering	  both	  in	  each	  individual	  layer,	  as	  well	  as	  transmurally	  (Figure	  4.11).	  	  This	  observation	  confirms	  that	  the	  specific	  binding	  observed	  with	  LABs	  is	   lower	  than	  that	  seen	  in	  MABs	  and	  HABs.	   In	  a	  setting	  of	  























(a) Mucosal PBR28 Bmax 
in normal and diseased sections
p=0.64(ns)























 (b) Submucosal PBR28 Bmax 
in normal and diseased sections
p=0.10 (ns)























(c ) Muscularis PBR28 Bmax 
in normal and diseased section
p=0.50 (ns)























(d) Transmural PBR28 Bmax 
in normal and diseased sections
p=0.10 (ns)
	   157	  
human	  PET	  scanning	  with	  this	  radioligand,	  the	  subject	  genotype	  needs	  to	  be	  determined	  in	  advance	  and	  be	  factored	  in	  in	  the	  quantification	  of	  the	  PET	  signal.	  
	  
Figure	  4.11:	  Specific	  binding	  in	  LABs	  MABs	  and	  HABs	  in	  mucosa	  (top	  left)	  submucosa	  (top	  
middle)	  muscularis	  (top	  right	  )	  and	  transmurally	  (bottom).	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4.3.1.4	  HOMOGENATE	  BINDING	  STUDIES	  	  Tissue	   homogenates	   from	   5	   pairs	   of	   tissue	   from	   patients	   genotyped	   for	   the	   rs6971	  polymorphism	  (1	  LAB,	  2	  MABs,	  2	  HABs)	  were	  used	  to	  estimate	  the	  binding	  affinity	  (Kd)	  and	  density	  of	  available	  binding	  sites	  for	  PBR28.	  
	  
Figure	  4.12:	  Matched	  LAB	  and	  HAB	  binding	  affinities	   from	  membrane	  homogenates	   in	  5	  
subjects.	  There	  was	  no	  statistically	  significant	  difference	  between	  the	  Kd	  for	  LAB	  and	  HAB	  
sites	  from	  healthy	  and	  diseased	  specimens	  	  	  	  	  	  	  	  	  	  As	   there	  was	  no	   statistical	   significance	   in	  Kd	  in	  membranes	   from	  normal	   and	  diseased	  specimens,	  high	  affinity	  sites	  and	  low	  affinity	  sites	  were	  grouped	  from	  both	  normal	  and	  diseased	   specimens	   and	   measured.	   Low	   affinity	   Kd	   was	   68.7±16.5	   nmol/L	   and	   high	  affinity	  Kd	  was	  10.24±4.0	  nmol/L	  (Figure	  4.13)	  
	  
Figure	  4.13:	  Distribution	  of	  low	  affinity	  and	  high	  affinity	  Kd	  in	  gut	  tissue	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Figure	   4.14:	   Binding	   curves	   for	   the	   5	   pairs	   of	   normal	   and	   diseased	   membrane	  
preparations.	   (a)	  MAB	   (b)	  HAB	   (c)	   LAB.	   BMAX	  is	   denoted	   by	   the	   plateau	   of	   the	   signal.	   As	  
available	  receptors	  in	  membrane	  homogenates	  are	  much	  more	  concentrated	  than	  in	  whole	  
tissue	  laid	  on	  film,	  the	  resulting	  BMAX	  in	  fmol/mg	  is	  much	  greater	  than	  in	  autoradiography.	  
Moreover,	  the	  differences	  between	  healthy	  and	  diseased	  BMAX	  	  appear	  more	  pronounced.	  	  
	  	  
	  	  	  	  









































































































) HAB pair 2
Inflamed
Normal






























	   160	  
4.3.2 IL-­‐2	  RECEPTOR	  4.3.2.1	  HISTOLOGICAL	  ASSESSMENT	  OF	  SEVERITY	  	  25	  stored	  mucosal	  biopsies	  were	  obtained,	  2	  from	  normal	  controls	  and	  23	  from	  patients	  with	   CD.	   12	   transmural	   sections	   from	   5	   CD	   patients	   who	   had	   undergone	   intestinal	  resections	   were	   also	   assessed.	   H&E	   slides	   from	   each	   of	   these	   sections	   revealed	   the	  following	  distribution	  of	  Global	  Inflammatory	  Scores:	  	  
Table	  4.2:	  Distribution	  of	  GIS	   in	  mucosal	   biopsies	   and	   transmural	   sections	  assessed	  with	  
CD25	  IHC	  
	  
	   	  Controls	  GIS	  0	   Crohn’s	  disease	   	  Total	  	  GIS	  0-­‐1	   	  GIS	  	  	  2-­‐4	   	  GIS	  5-­‐6	  Mucosal	  biopsies	   2	   7	   10	   6	   25	  	   	   GIS	  0-­‐1	   GIS	  	  	  2-­‐4	   GIS	  5-­‐6	   	  Transmural	  sections	   0	   18	   12	   11	   41	  	   4.3.2.2	  IMMUNOHISTOCHEMICAL	  EXPRESSION	  
Figure	  4.15:	  Mucosal	  CD25+ve	   cells	   per	  hpf	  according	   to	  GIS.	  There	  were	  no	   statistically	  
significant	  differences	  between	  any	  of	  the	  groups.	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In	  order	  to	  assess	  CD25	  expression	  across	  the	  full	  thickness	  of	  the	  bowel	  wall,	  12	  sets	  of	  slides	  were	  produced	  from	  5	  resection	  specimens	  from	  patients	  with	  CD.	  A	  median	  of	  3	  (range2	   -­‐6)	  1	  mm-­‐wide,	  well-­‐orientated	  bowel	  wall	   regions	  were	  scored	  on	  each	  slide	  (total	  41)	  (see	  Methods	  4.2.4.2).	   	  Of	  these,	  18	  (44%)	  had	  no/mild	  inflammation	  (GIS	  0-­‐1),	   12	   (29%)	   showed	   moderate	   inflammation	   (GIS	   2-­‐4),	   and	   11	   (27%)	   had	   severe	  inflammation	  (GIS	  5-­‐6).	  	  	  
Figure	   4.16:	   Transmural	   CD25	   expression	   in	   the	   various	   groups.	   There	   was	   statistically	  
significant	   differences	   in	   CD25	   expression	   between	   mild	   and	   moderate,	   and	   mild	   and	  
severe	  GIS.	  Differences	  between	  moderate	  and	  severe	  GIS	  were	  borderline	  non-­‐significant.	  
Figure	  4.17:	  Area	  with	  significant	  lymphocytic	  infiltrate	  (a)	  H&E,	  circle,	  (b)	  CD25	  stain	  
(brown)	  


















a	   b	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Co-­‐localisation	  studies	  of	  CD25	  and	  CD3	  or	  CD45	  suggest	  that	  the	  majority,	  but	  not	  all	  CD25	  expression	  occurs	  on	  leukocytes	  (CD45	  positive	  cells)	  and	  specifically	  T-­‐lymphocytes	  (CD3	  positive	  cells).	  It	  was	  difficult	  to	  distinguish	  CD25	  staining	  in	  CD3	  stained	  cells	  due	  to	  strong	  intensity	  of	  staining.	  
4.3.2.3	  AUTORADIOGRAPHIC	  BINDING	  	  Several	   attempts	   were	   made	   to	   corroborate	   the	   immunohistochemical	   data,	   which	  suggested	   an	   enhanced	   expression	   of	   CD25	   in	   severely	   inflamed	   segments	   with	  autoradiography	  binding	  studies.	  A	  combination	  of	  125I-­‐	  IL-­‐2	  at	  a	  concentration	  of	  0.3nM	  (3	   x	   Kd	  of	   high	   affinity	   sites	   expressed	   on	   T-­‐cells)225	   and	   100nM	   of	   unlabeled	   human	  recombinant	   Interleukin-­‐2	   (hr-­‐IL2)	   to	   saturate	   specific	   sites	   failed	   to	   result	   in	   a	  significant	   specific	   binding	   (figure	   4.18).	   The	   mean±	   SD	   	   %	   specific	   binding	   was	  0±24.8%.	  	  	  
Figure	   4.18:	   Characteristic	   125I-­‐IL2	   binding	   (a)	   Total	   and	   (b)	   Non-­‐specific.	   The	   signal	   of	  
non-­‐specific	  binding	  is	  almost	  identical	  to	  the	  total.	  This	  signifies	  a	  failure	  to	  block	  specific	  
sites	  with	  the	  Hr-­‐IL2	  molecule,	  even	  at	  concentrations	  of	  1000x	  Kd	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4.4 DISCUSSION	  
4.4.1	  SUMMARY	  OF	  FINDINGS	  Key	  results	  of	  this	  study	  were	  the	  following:	  
• There	   is	   no	   difference	   in	   TSPO	   expression	   between	   normal	   gut	   tissue	   and	   CD	  segments.	  
• There	   is	   no	  difference	   in	  PK11195	  and	  PBR28	  binding	   in	  diseased	  versus	  normal	  gut	  segments	  from	  Crohn’s	  patients	  
• Clinical	  scanning	  with	  TSPO	  radioligands	  to	  delineate	  or	  monitor	  diseased	  segments	  in	  patients	  with	  Crohn’s	  disease	  is	  therefore	  not	  justified.	  
• Binding	   affinity	   of	   PBR28	   in	   gut	   is	   similar	   to	   previously	   published	   data	   on	   brain	  sections	  
• Severely	  inflamed	  gut	  sections	  have	  higher	  expression	  of	  the	  high	  affinity	  α	  subunit	  of	   the	   IL2-­‐R	   compared	   to	   moderately	   or	   mildly	   inflamed	   sections.	   This	   could	   be	  utilised	  in	  IL-­‐2	  based	  scanning	  in	  the	  future.	  
	   4.4.2 DISCUSSION	  OF	  FINDINGS	  	  
TSPO	  is	  a	  molecule	  that	  has	  been	  increasingly	  explored	  for	  its	  potential	  to	  act	  as	  a	  target	  in	  molecular	  imaging	  of	  inflammatory	  disorders.	  This	  data	  suggest	  that	  the	  background	  expression	  in	  normal	  intestine	  will	  likely	  prevent	  its	  use	  as	  a	  marker	  of	  inflammation	  in	  Crohn’s	  disease.	  	  The	   expression	   of	   the	   receptor	   was	   first	   assessed	   semi-­‐quantitatively	   with	  immunohistochemistry,	  using	  a	  previously	  employed	  composite	  score	  which	   factors	   in	  both	  the	  frequency	  and	  intensity	  of	  expression224.	  There	  was	  no	  appreciable	  difference	  either	   in	   the	  mucosa	   or	   across	   the	   full	   thickness	   of	   the	   bowel	  wall	   in	   specimens	  with	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histological	   features	  of	  moderate	  or	  severe	  inflammation	  compared	  to	  normal	  controls	  or	  mildly	  inflamed	  specimens.	  	  	  Several	  studies	  have	  shown	  the	  potential	  for	  TSPO	  probes	  to	  demonstrate	  and	  quantify	  inflammatory	  processes.	  A	  high	  expression	  of	  PBR	  on	  peripheral	  macrophages	  was	  first	  described	  three	  decades	  ago226.	  Since	  that	  time,	  several	  groups	  have	  demonstrated	  high	  TSPO	   expression	   in	   correlation	   with	   peripheral	   macrophage	   infiltrates.	   Bird	   et	   al.	  showed	  an	  abundance	  of	  PK11195	  –avid	  CD68	  +ve	  macrophages	  in	  in	  vitro	  specimens	  of	  carotid	   atherosclerotic	   plaques,	   which	   was	   20	   times	   higher	   than	   that	   in	   surrounding	  vascular	   smooth	   myocytes148.	   A	   group	   from	   Amsterdam	   performed	   TSPO	   and	   CD68	  immunohistochemistry	   in	   arthroscopically	   derived	   synovial	   specimens	   from	   patients	  with	   rheumatoid	   arthritis,	   as	   well	   as	   controls	   who	   underwent	   arthroscopy	   for	  mechanical	   knee	   injury.	   Their	   results	   demonstrate	   a	   relevant	   paucity	   of	   TSPO	  expression	  in	  control	  synovium,	  with	  increased	  expression	  in	  RA	  joints	  that	  closely	  co-­‐localises	   with	   CD68	   150.	   More	   recently,	   a	   Japanese	   group	   demonstrated	   high	   TSPO	  expression	   in	   a	   murine	   model	   of	   non-­‐alcoholic	   fatty	   liver	   disease	   (NAFLD).	   This	  correlated	  with	  C11b	  expression,	  a	  marker	  of	  macrophage	  and	  lymphocyte	  activation152.	  	  TSPO	   in	   IBD	   has	   been	   investigated	   by	   Ostuni	   et	   al.	   208.	   The	   group	   used	   an	  immunohistochemical	   probe	   to	   confirm	   diffuse	   TSPO	   expression	   in	   normal	   human	  intestinal	  epithelium.	  In	  epithelial	  biopsies	  from	  patients	  with	  small	  bowel	  CD,	  the	  TSPO	  distribution	  extended	  throughout	   the	   length	  of	   the	  villus.	  The	  authors	  did	  not	  disclose	  the	   exact	   numbers	   of	   control	   or	   IBD	   human	   biopsies	   analysed.	   These	   observations	   of	  isolated	  epithelial	  TSPO	  expression	  in	  healthy	  tissue,	  which	  extends	  deeper	  into	  the	  villi	  in	   the	   inflamed	   state,	   were	   also	   replicated	   using	   a	   DSS	   murine	   model	   of	   colitis.	   In	   a	  recent	   study,	   a	   French	   group	   performed	  microPET	   imaging	   using	   a	   TSPO	   radioligand	  (18F-­‐DPA-­‐714)	  on	  mice	  treated	  with	  DSS	  or	  2,4,6	  trinitrobenzenesulfonic	  acid	  (TNBS)	  to	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produce	  colonic	   inflammation.	  They	  report	  a	  significantly	  higher	  18F-­‐DPA-­‐714	  signal	   in	  both	   DSS	   and	   TNBS	   treated	   animals	   compared	   to	   controls.	   They	   also	   qualitatively	  demonstrate	   an	   increase	   on	   transmural	   colonic	   TSPO	   expression	   using	   an	  immunofluorescent	  probe	  227.	  	  This	  work	  confirms	  the	  observation	  that	  the	  background	  expression	  of	  TSPO	  in	  normal	  epithelium	  is	  significant.	  I	  attempted,	  for	  the	  first	  time,	  to	  compare	  semi-­‐quantitatively	  TSPO	   expression	   in	   normal	   specimens	   (mucosal	   and	   transmural)	   with	   that	   within	  sections	  containing	  active	  inflammation.	  The	  immunohistochemical	  data	  show	  that	  both	  in	   the	   mucosa	   as	   well	   as	   across	   the	   full	   thickness	   of	   the	   bowel	   wall,	   there	   is	   no	  appreciable	  increase	  in	  the	  TSPO	  expression.	  	  	  The	   main	   goal	   of	   this	   project	   was	   to	   examine	   the	   applicability	   of	   TSPO-­‐specific	  radioligands	  in	  clinical	  PET	  imaging	  of	  CD	  lesions.	  Current	  PET	  technology	  does	  not	  offer	  a	  high	  enough	  resolution	  to	  permit	  the	  differentiation	  between	  signal	  originating	  in	  the	  mucosa	  from	  that	  in	  deeper	  layers	  of	  the	  bowel.	  	  The	  transmural	  expression	  of	  TSPO	  (or	  any	   other	   target	   receptor)	   in	   inflamed	   versus	   normal	   samples	   has	   therefore	   more	  translational	  relevance	  than	  that	  in	  individual	  layers.	  While	  there	  may	  have	  been	  a	  trend	  towards	   a	   higher	   expression	   in	   grossly	   inflamed	   mucosal	   samples,	   the	   overall	  transmural	  expression	  was	  similar	  between	  sections	  of	  low	  and	  high	  GIS.	  	  	  The	  reason	  behind	  this	  over-­‐abundance	  of	  TSPO	  in	  normal	  gut	  has	  not	  been	  elucidated.	  Evidence	   suggests	   that	   the	   intestinal	   epithelium	   has	   an	   active	   role	   in	   maintaining	  immune	  homeostasis	  or	  a	  state	  of	   ‘controlled	   inflammation’.	  Firstly,	  epithelial	  cells	  are	  involved	  in	  MHC-­‐mediated	  antigen	  processing	  and	  presentation	  228.	  Secondly,	  they	  have	  been	   implicated	   in	   the	   production	   of	   chemokines	   in	   response	   to	   Toll-­‐like	   receptor	  ligation,	  which	  in	  turn	  leads	  to	  dendritic	  cell	  conditioning	  and	  migration	  229.	  In	  addition,	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they	  are	  capable	  of	  apoptosis	  following	  bacterial	  invasion	  230.	  All	  of	  the	  above	  are	  unique	  characteristics	   of	   the	   gut,	   in	   response	   to	   a	   constant	   and	   diverse	   antigenic	   load	   of	  resident	  microbes.	  These	  have	  not	  been	  observed	  in	  other	  relatively	  sterile	  tissues	  such	  as	  the	  vascular	  endothelium	  or	  the	  synovium.	  All	  these	  functions	  are	  in	  direct	  relevance	  with	  some	  of	  the	  key	  effector	  pathways	  linked	  to	  TSPO.	  Several	  studies	  have	  suggested	  an	   immune-­‐modulatory	   role	   for	   TSPO,	  which	   is	  modifiable	   by	   specific	   ligands	   such	   as	  PK11195	   231,232.	   It	   is	   therefore	   possible	   that	   the	   abundance	   of	   TSPO	   on	   intestinal	  epithelial	   cells	   reflects	   their	   status	   as	   key	   players	   in	   the	   paradigm	   of	   controlled	  inflammation.	  	  	  In	   addition,	   the	   double	   stains	   show	   that	   the	   majority	   of	   TSPO	   is	   not	   found	   in	  inflammatory	   cells.	   This	   was	   in	   contrast	   to	   synovium150,	   carotid	   atheroma148,	  steatohepatitis152,	   	   or	   neuro-­‐inflammatory	   disorders153,	   where	   TSPO	   expression	   in	  background,	  non-­‐inflammatory	  cells	   is	  very	   low.	   In	  order	   for	  molecular	   imaging	   in	   the	  gut	  to	  move	  forward	  from	  FDG,	  which	  is	  an	  inherently	  non-­‐specific	  ligand,	  the	  need	  is	  to	  identify	   radio-­‐tracers	   that	   selectively	   tag	   and	   quantify	   the	   inflammatory	   cells	   rather	  than	  rely	  on	  a	  relative	  increase	  in	  a	  receptor	  that	  is	  already	  abundant	  in	  normal	  state.	  	  Subsequently,	   I	   examined	   the	   binding	   potential	   of	   a	   first	   generation	   (PK11195)	   and	   a	  second-­‐generation	   ligand	   (PBR28).	   I	   was	   able	   to	   assess	   quantitatively	   the	   different	  receptor	  densities	   in	  ex-­‐vivo	   intestinal	  resection	  specimens	   from	  patients	  with	  Crohn’s	  disease,	   by	   performing	   saturation	   binding	   autoradiography	   in	   sections	   from	   the	  diseased	  core	  as	  well	  as	  the	  un-­‐inflamed	  margins	  of	  these	  specimens.	  A	  non-­‐significant	  trend	   towards	   a	   higher	   specific	   binding	   in	   inflamed	   sections	   was	   found,	   which	  corroborates	  the	  observations	  of	  immunohistochemistry.	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Each	   of	   the	   two	   techniques	   above	   has	   major	   benefits	   and	   drawbacks.	  Immunohistochemistry	   on	   the	   one	  hand	   is	  widely	   applicable,	   at	   low	   cost,	   	   and	   can	  be	  preformed	  on	  larger	  numbers	  of	  stored	  formalin-­‐fixed	  specimens.	  However,	  it	  can	  only	  offer,	  at	  best,	  a	  semi-­‐quantitative	  measure	  of	  the	  abundance	  of	   the	  TSPO	  receptor,	  and	  provide	   very	   limited	   information	   on	   its	   behaviour	   as	   a	   target	   for	   radioligands.	  Autoradiography,	  on	  the	  other	  hand,	  was	  performed	  with	  tritiated	  versions	  of	  the	  exact	  radioligands	  currently	  used	  for	   in-­‐vivo	  TSPO	  imaging,	  and	  as	  such,	  can	  provide	  a	  much	  more	   accurate	   representation	  not	   only	   of	   the	   location	   and	  density	   of	   receptors	   but	   of	  other	  parameters	   such	   as	   the	   signal-­‐to-­‐noise	   ratio	   in	   the	  binding.	   	   It	   too	  however	  has	  limitations:	   It	   has	   been	   shown	   that	   tissue	   fixation	   in	   (para)formaldehyde	   negatively	  impacts	   on	   the	   affinity	   of	   the	  majority	   of	   receptors233.	   	   Previous	   attempts	   to	   perform	  PBR28	   autoradiography,	   in	   particular	   on	   FFPE	   brain	   tissue	  were	   unsuccessful	   (Owen	  DR,	   personal	   communication).	   Therefore	   prospective	   recruitment	   with	   immediate	  processing	  of	  resected	  specimens	  was	  the	  only	  possible	  strategy	  of	  obtaining	  tissue	  for	  this	  project.	  This,	   in	   combination	  with	   the	   significant	   cost	  of	   re-­‐agents	  and	  equipment	  required,	   only	   allowed	   us	   to	   examine	   a	   limited	   number	   of	   specimens.	   The	   observed	  differences	  between	  the	  specific	  binding	  in	  un-­‐inflamed	  and	  diseased	  sections	  however	  were	  small,	  and	  hence	  larger	  numbers	  of	  tissue	  pairs	  would	  probably	  not	  have	  resulted	  in	  meaningful	  disparities.	  	  Another	   major	   limitation	   was	   the	   technical	   aspect	   of	   handling	   unfixed	   tissue.	   The	  maintenance	  of	  the	  tissue	  orientation	  during	  snap-­‐freezing	  was	  particularly	  challenging.	  It	   frequently	   resulted	   in	   significant	   distortion	   and	   malposition	   of	   the	   various	   layers	  (mucosa,	   submucosa,	   muscularis,	   serosa).	   In	   addition,	   the	   resulting	   tissue	   block	   was	  usually	   too	   large	   to	  be	   inserted	  whole	  onto	   the	  microtome	   for	   sectioning,	   and	   smaller	  fragments	  had	  to	  be	  produced.	  Commonly,	  these	  did	  not	  contain	  all	  layers	  of	  tissue,	  and,	  when	  they	  did,	  there	  was	  a	  variable	  degree	  of	  folding	  and	  superimposition.	  This	  was	  the	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main	  reason	  for	  failure	  to	  obtain	  paired	  autoradiograms	  for	  all	  12	  pairs	  of	  tissue.	  With	  experience,	   the	   integrity	   and	   orientation	   of	   tissue	   blocks	   during	   snap-­‐freezing	   and	  sectioning	   improved	   in	  sequential	   specimens.	  While	   this	   limits	   the	  statistical	  power	  of	  the	  observations,	  it	  is	  unlikely	  that	  it	  would	  have	  introduced	  any	  other	  type	  of	  bias	  in	  the	  measurements.	  	  	  It	  has	  been	  shown	   that	  PBR28	  and	  other	   second-­‐generation	  TSPO	  radioligands	  have	  a	  significantly	  improved	  signal-­‐to-­‐noise	  profile	  211,	  which	  was	  also	  evident	  on	  my	  samples	  They	   do,	   however,	   exhibit	   significant	   between-­‐subject	   variability,	   which	   has	   been	  accounted	   for	   by	   a	   genetic	   polymorphism	   (rs6971)	   in	   the	   gene	   encoding	   TSPO	   212.	  	  Homozygote	   high-­‐affinity	   and	   low-­‐affinity	   binders,	   as	   well	   as	   heterozygote	   mixed-­‐affinity	   binders	   have	   been	   described,	   and	   the	   dissociation	   constant	   (Kd)	   has	   been	  estimated	   for	   each	   of	   the	   three	   phenotypes,	   at	   least	   for	   TSPO	   extracted	   from	   brain	  tissue.	  	  	  	  I	   was	   only	   able	   to	   genotype	   a	   subset	   of	   issue	   donors	   as	   the	   discovery	   of	   the	   rs6971	  polymorphism	  was	  published	  while	  the	  recruitment	  was	  already	  in	  progress.	  Saturation	  binding	  was	   performed	  on	   the	   cell	  membrane	   fractions	   from	  homogenised	   specimens	  from	  1	  or	  2	  tissue	  pairs	  from	  each	  genotype	  (1	  LAB,	  2	  MAB,	  2	  HAB).	  To	  date,	  the	  affinity	  of	   PBR28	   on	   TSPO	   has	   only	   been	   described	   in	   receptors	   extracted	   from	   brain	  homogenates.	   Through	   this	   experiment	   I	   aimed	   to	   compare	   this	   to	   TSPO	   originating	  from	  peripheral	  tissue	  for	  the	  first	  time.	  	  	  The	  measured	  Kds	   from	  normal	  and	   inflamed	  gut	   tissue	  were	   statistically	   comparable.	  This	   suggests	   that	   while	   TSPO	   in	   inflamed	   tissue	   is	   relatively	   more	   abundant,	   its	  stereotactic	   conformation	   and	   binding	   properties	   remain	   stable	   in	   a	   diseased	   milieu.	  	  Moreover,	   the	   Kds	   for	   the	   high	   and	   low	   affinity	   states	   proposed	   the	   experiment	   on	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cellular	  membrane	  homogenates	  from	  intestinal	  tissue	  were	  similar	  to	  these	  described	  in	   the	  brain	   213,234.	  However,	  methodological	   limitations	  conferred	  a	  degree	  of	  error	   to	  the	  measurements	   of	   Kd	   in	   samples	   from	   the	   three	   phenotypes:	   Firstly,	   the	   proposed	  thickness	  of	  5mm	  for	  each	  of	   the	   two	  rings	  of	  gut	   tissue	  obtained	   from	  each	  resection	  specimen	  often	  was	  too	  limited	  to	  allow	  good	  quality	  sections	  as	  well	  as	  enough	  tissue	  for	  a	   triplicate	  of	   saturation	  curves	  per	   specimen	  (which	  would	  be	  standard	  practice).	  The	  tissue	  stores	  only	  allowed	  a	  single	  saturation	  curve	  for	  each	  specimen,	  significantly	  increasing	   error.	   Secondly,	   protein	   concentration	   in	   membrane	   fractions	   was	   limited	  and	   therefore,	   even	   though	   ligand	   depletion	   was	   not	   observed,	   a	   fixed	   membrane	  dilution	  had	  to	  be	  used,	  and	  applied	  to	  saturation	  curves	  retrospectively,	  which	  can	  also	  act	  as	  a	  source	  of	  error.	  	  	  Observation	  of	  the	  binding	  curves	  suggests	  that	  the	  BMAX	  in	  4	  of	  the	  5	  sets	  are	  higher	  in	  the	   diseased	   versus	   the	   normal	   specimens,	   which	   was	   not	   reflected	   in	   the	  autoradiograms.	  There	  are	  two	  possible	  explanations	  for	  this.	  Firstly,	  the	  tissue	  that	  was	  homogenised	  contained	  a	  significant	  proportion	  of	  mesentery,	  which	  was	  not	   included	  in	   the	   sections.	   A	   group	   from	   Berlin	   recently	   presented	   data	   suggesting	   that	   the	  mesenteric	  fat	  in	  CD	  is	  a	  rich	  source	  of	  macrophages	  235.	  It	  is	  possible	  therefore	  that	  this	  observed	   trend	   for	  higher	   receptor	  density	   in	  diseased	  homogenates	   results	   in	  higher	  densities	  of	  TSPO	  receptors	  obtained	  from	  that	  compartment.	   	  Secondly,	  the	  sequential	  centrifugation	   protocol	   ensures	   that	   the	   receptor	   concentration	   in	   homogenates	   is	   by	  definition	   higher	   than	   that	   of	   whole	   tissue	   sections	   used	   on	   autoradiograms.	  Homogenate	  binding	  studies	  are	   therefore	  more	   likely	   to	  reveal	   significant	  differences	  in	  available	  receptors	  between	  the	  healthy	  and	  inflamed	  compartments.	  The	  drawback	  of	  the	  technique	  is	  that	  the	  spatial	  localisation	  of	  these	  receptors	  is	  not	  possible.	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CD25	   (IL2R-­‐α)	   immunohistochemistry	   suggests	   that	   there	   are	   significant	   increases	   in	  CD25	   expression	   across	   the	   full	   thickness	   of	   the	   bowel	   wall,	   in	  moderate	   and	   severe	  inflammation	   compared	   to	   normal	   or	   mildly	   inflamed	   sections.	   	   By	   far	   the	   greatest	  increase	   in	  CD25	  expression	  was	  observed	   in	  specimens	  at	   the	  most	  severe	  end	  of	   the	  inflammation	  spectrum	  (GIS	  5-­‐6).	  These	  differences	  were	  not	  appreciable	  when	  mucosa	  biopsies	  were	  examined	   in	   isolation,	  but	  as	  discussed	  above,	  differences	   in	   transmural	  expression	  are	  more	   important	   	   	   in	   the	  context	  of	   the	  exploration	  of	  potential	   imaging	  probes.	  	  	  These	   findings	   are	   in	   agreement	   with	   a	   small	   number	   of	   early	   papers	   from	   several	  decades	  ago,	   on	   the	  expression	  of	   IL-­‐2,	   and	   its	   receptor,	   in	  CD:	  To	  assess	   the	  mucosal	  concentration	   of	   IL-­‐2	   amongst	   other	   cytokines,	   Brynskov	   et	   al.	   performed	   Enzyme-­‐Linked	  ImmunoSorbent	  Assays	  (ELISA)	  on	  supernatants	  following	  homogenisation	  of	  27	  colonic	   and	   4	   ileal	   biopsies	   from	   patients	   with	   IBD	   and	   19	   controls.	   He	   reports	   IL-­‐2	  detection	   in	  35%	  of	  the	  patient’s	  supernatants	  compared	  to	  0%	  from	  controls.	  A	  more	  detailed	  analysis	  of	  positive	  ELISAs	  revealed	  that	  IL-­‐2	  is	  more	  likely	  detected	  in	  lesions	  of	   higher	   histology	   score,	   and	   that	   none	   of	   4	   ileal	   CD	   biopsies	   revealed	   any	   IL-­‐2	  irrespective	  of	  the	  histology	  score236.	  	  	  	  Niessner	  et	  al.	  reports	  significantly	  higher	  IL-­‐2	  m-­‐RNA	  levels	  in	  biopsies	  with	  active	  CD	  compared	  with	  controls,	  as	  assessed	  by	  reverse	  transcriptase	  polymerase	  chain	  reaction	  (RT-­‐PCR).	  A	   comparison	  between	  active	   an	   inactive	   sites	   in	   the	   same	  patients	  did	  not	  reach	   significance237.	   	  Mullin	   GE	   et	   al.	   concurred	  with	   the	   above	   difference	   of	   IL-­‐2	  m-­‐RNA	   concentrations	   in	   CD	   colonic	   biopsies	   versus	   controls	   in	   a	   similarly	   designed	  experiment.	   In	   addition,	   he	   reported	   a	   significant	   difference	  when	   active	   and	   inactive	  sites	  were	   compared	   in	   5	   CD	   patients	   238.	   Desreumaux	   et	   al.	   went	   a	   step	   further	   and	  examined	   the	   difference	   of	   IL-­‐2	   expression	   in	   chronic	   ileal	   lesions	   versus	   early	   ileal	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recurrences	   and	   found	   a	   significantly	   higher	   expression	   in	   the	   former.	   This	   lead	   to	  suggestion	  of	  a	  shift	   in	   inflammatory	  type	  from	  Type	  2	  (IL-­‐4	  and	  IL-­‐5	  predominant)	   in	  early	  lesions	  to	  Type	  1	  later	  on	  in	  the	  disease’s	  natural	  history	  239.	  	  Two	  main	  studies	  focus	  on	  the	  expression	  of	  IL-­‐2	  receptors	  in	  active	  CD	  segments.	  Choy	  et	  al.	  examined	   the	  expression	  of	  CD25	   in	  resection	  specimens	   from	  patients	  with	   IBD	  and	  observed	   that	   in	  normal	   small	   and	   large	   intestinal	  mucosa	  CD25+	   cells	   are	   rarely	  seen.	   In	   ileal	   and	   colonic	   mucosa	   from	   CD	   patients,	   on	   the	   other	   hand,	   there	   were	  aggregated	   and	   scattered	   CD25+	   cells.	   The	   lymphoid	   follicles	   and	   submucosa/muscle	  layers	  also	  had	  abundant	  CD25+	  cells.	  Overall	  CD25+	  cells	  made	  up	  15-­‐64%	  of	   lamina	  propria	  nucleated	  cells	   in	  Crohn’s	  disease,	   the	  majority	  of	  which	  were	  CD3+CD4+CD8-­‐	  T-­‐cells.	  Most	  CD25+	  cells	  in	  sub-­‐epithelial	  aggregates,	  on	  the	  other	  hand,	  were	  identified	  as	  macrophages	  219.	  Mahida	  et	  al.	  performed	  comparative	  immunohistochemical	  staining	  for	   IL-­‐2	  R	   in	   tissue	   sections	   from	  CD	  patients	   and	  normal	   controls	   and	   confirmed	   the	  contrast	  between	  normal	  and	  diseased	  ileal	  mucosa,	  as	  well	  as	  CD25	  abundance	  in	  the	  Peyer’s	  patches.	  	  He	  also	  noted	  that	  macrophages	  from	  diseased	  tissue	  expressing	  IL-­‐2R	  had	  higher	  potential	  to	  undergo	  respiratory	  burst	  240.	  	  	  	  	  In	   addition	   to	   the	   aforementioned	   basic	   science	   papers	   on	   the	   abundance	   and	  distribution	   of	   IL-­‐2	   and	   its	   receptor	   in	   the	   context	   of	   Crohn’s	   disease,	   there	   is	   a	  significant	   body	   of	   literature	   from	   the	   field	   of	   SPECT	   imaging,	   which	   is	   suggests	  potential	  	  clinical	  applicability	  of	  an	  IL-­‐2	  based	  radio-­‐pharmaceutical	  to	  quantify	  as	  well	  as	  monitor	  inflammatory	  activity	  in	  CD	  (reviewed	  in	  the	  Introduction).	  	  The	   aim	   of	   the	   subsequent	   experiment	   was	   to	   confirm	   that	   these	   differences	   in	  transmural	   expression	  of	   the	   IL-­‐2R	  between	   inflamed	   and	  normal	   intestinal	   segments	  would	   also	   translate	   into	   preferential	   binding	   of	   IL-­‐2	   radioligands	   in	   these	   segments.	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Unfortunately,	   despite	   maximal	   efforts	   to	   optimise	   the	   binding	   parameters,	   the	   non-­‐specific	   component	   of	   125I-­‐IL2	   on	   tissue	   specimens	   was	   too	   high	   to	   permit	   any	  conclusions	  on	  the	  differential	  specific	  binding	  on	  un-­‐inflamed	  versus	  diseased	  sections.	  	  This	  study	  has	  many	  strengths.	  This	  is	  the	  first	  time	  quantification	  of	  TSPO	  expression	  in	  full-­‐thickness	   sections	   of	   CD	   tissue	  was	   attempted.	  Moreover,	   this	   is	   the	   first	   study	   to	  investigate	   the	   potential	   of	   first	   and	   second	   generation	   TSPO-­‐specific	   radioligands	   to	  delineate	   CD	   lesions	   and	   quantify	   the	   inflammatory	   activity	   within	   these.	   Finally,	   I	  attempt	  to	  quantify	  the	  affinity	  (Kd)	  of	  all	  three	  phenotypes	  of	  the	  binding	  status	  to	  2nd	  generation	   TSPO	   radio-­‐ligands	   in	   a	   peripheral	   tissue,	   demonstrating	   affinities	  comparable	   to	   those	   described	   in	   brain.	   With	   regards	   to	   the	   Interleukin-­‐2	   receptor,	  evidence	   was	   obtained	   that	   it	   is	   significantly	   over-­‐expressed	   in	   inflamed	   bowel	  segments,	  in	  proportion	  to	  the	  degree	  of	  the	  global	  inflammatory	  score.	  This	  renders	  it	  an	   attractive	   potential	   target	   for	   molecular	   imaging.	   This	   study	   however	   failed	   to	  elucidate	  useful	   characteristics	   of	   the	   radioligand-­‐IL2	   receptor	   interaction	   such	   as	   the	  anticipated	   signal-­‐to-­‐noise	   ratio	   and	   the	   density	   of	   available	   IL-­‐2	   receptors	   in	   normal	  versus	  diseased	  bowel.	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4.5	  CONCLUSION	  	  	  TSPO	   has	   a	   high	   background	   expression	   in	   normal	   gut	   epithelium	   and	   there	   was	   no	  obvious	   increase	   in	   transmural	   sections	   with	   significant	   inflammatory	   activity.	   In	  addition,	   the	   high	   expression	   in	   normal	   epithelial	   cells	   renders	   TSPO	   radioligands	  unsuitable	   as	   specific	   inflammatory	   tracers	   in	   CD.	   Full	   thickness	   autoradiograms	   and	  saturation	  binding	   studies	   from	   tissue	  homogenates	   suggested	   a	   non-­‐significant	   trend	  towards	   higher	   specific	   binding	   in	   diseased	   versus	   healthy	   sections	   from	   the	   same	  patients.	  	  	  Even	   though	   the	   IL-­‐2R	   is	   potentially	   a	   more	   promising	   target,	   due	   to	   its	   higher	  selectivity	   for	   activated	   T-­‐cells	   and	   its	   over-­‐expression	   in	   diseased	   versus	   normal	   gut	  tissue,	   there	   are	   still	   many	   unanswered	   questions	   on	   the	   specificity	   and	   binding	  potential	  of	  an	  IL2-­‐based	  radio-­‐pharmaceutical	   for	  the	   investigation	  of	  Crohn’s	  disease	  activity.	  	  The	  significance	  of	  these	  results	  and	  future	  studies	  that	  can	  originate	  from	  this	  work	  are	  further	  discussed	  in	  Chapter	  5.	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  5.DISCUSSION	  AND	  FUTURE	  DIRECTIONS	  
	  
	  
	   Crohn’s	  disease	   is	  a	   chronic	  disorder,	  with	  a	  highly	  variable	   impact.	  Some	  patients	  exhibit	  a	  benign	  	  phenotype,	  	  with	  	  localised	  	  disease	  	  that	  	  remains	  	  quiescent	  	  over	  	  long	  	  intervals,	  	  while	  others	  	  have	  	  extensive	  	  disease	  	  which	  	  evolves	  	  more	  	  rapidly	  	  to	  	  cause	  	  complications	  	  such	  	  as	  fistulae	  	  	  and	  	  	  fibrostenosis1.	  	  	  Large	  	  	  population-­‐-­‐-­‐based	  	  	  studies	  	  	  have	  	  	  shown	  	  	  that	  	  	  the	  	  	  latter	  phenotype	  	  	  with	  	  	  its	  	  	  accumulating	  	  	  complications	  	  	  is	  	  	  the	  	  	  commonest	  	  	  form	  	  	  1,15.	  	  	  Moreover,	  studies	  have	   shown	  a	   significant	   lack	  of	   association	  between	   the	   intestinal	  pathophysiology	  and	  	  	  	  symptom	  	  	  	  reporting	  	  	  	  by	  	  	  	  patients8,34.	  	  	  	  This	  	  	  	  suggests	  	  	  	  that	  	  	  	  exclusive	  	  	  	  reliance	  	  	  	  on	  symptomatology	  	  	  is	  	  	  not	  	  	  an	  	  	  ideal	  	  	  strategy	  	  	  for	  	  	  characterising	  	  	  disease	  	  	  activity	  	  	  in	  	  	  clinical	  practice.	  The	  need	  for	  objective	  markers	  of	  disease	  activity	  has	  therefore	  been	  highlighted.	  	  	   There	  	  are	  	  several	   instances	  	  in	  	  the	  	  natural	  history	  	  of	  CD	  	  when	  	  objective	  	  characterisation	  	  of	  disease	  	  burden	  	  and	  	  its	  	  change	  	  over	  	  time	  	  is	  	  needed.	  	  Firstly,	  	  at	  	  index	  	  presentation	  	  it	  	  is	  important	  	  to	  	  fully	  	  ascertain	  	  the	  	  extent	  	  and	  	  severity	  	  of	  	  the	  	   lesions.	  	  This	  	  will	  	  require	  	  a	  combination	  	  of	  	  several	  	  of	  	  the	  	  modalities	  	  currently	  	  available,	  	  which	  	  include	  	  imaging	  	  and	  endoscopic-­‐-­‐-­‐histological	  	  	  assessment,	  	  	   as	  	  	   these	  	  	  measures	  	  	  are	  	  	   complimentary.	  	  	  Such	  	  	  an	  approach	   is	   advocated	  by	   current	   international	  guidelines	   such	  as	   those	   from	   the	  European	  Crohn’s	  	  	  and	  	  	  Colitis	  	  	  Organisation	  	  	  (ECCO)241.	  	  	  	  	  Secondly,	  	  	  an	  	  	  assessment	  	  	  of	  	  	  inflammatory	  burden	  	  	  	  is	  	  	  	  important,	  	  	  particularly	  	  	  	  at	  	  	   times	  	  	  	  when	  	  	  	  escalation	  	  	  	  in	  	  	  	  medical	  	  	   therapy	  	  	  	  is	  contemplated.	  	  Finally,	  	  the	  	  evaluation	  	  of	  	  success	  	  of	  	  medical	  	  treatments	  	  also	  	  requires	  	  an	  objective	  	  parameter	  	  of	  	  disease	  	  activity.	  	  	  	  In	  	  view	  	  of	  	  the	  	  chronic	  	  and	  	  constantly	  	  evolving	  natural	  	  history	  	  of	  	  Crohn’s	  	  disease,	  	  it	  	  is	  	  therefore	  	  probable	  	  that	  	  each	  	  patient	  	  will	  	  require	  disease	  load	  monitoring	  at	  several	  time-­‐-­‐-­‐points	  in	  their	  illness.	  	  	   In	   addition	   to	   all	   these	   circumstances	   in	   which	   disease	  monitoring	   is	   clinically	   indicated,	  another	  	  major	  	  area	  	  of	  need	  	  for	  	  objective,	  reproducible	  	  outcome	  	  measures	  is	  that	  of	   drug	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development.	   Currently,	   clinical	   trials	   rely	   heavily	   on	   clinical	   scores,	   such	   as	   the	   CDAI,	   and,	  more	  	  	  recently,	  	  	  patient-­‐-­‐-­‐reported	  	  	  outcomes	  	  	  such	  	  	  as	  	  	  quality	  	  	  of	  	  	  life	  	  	  questionnaires	  	  	  and	  disability	  indices	  to	  assess	  the	  response	  of	  various	  therapies242.	  These	  ignore	  the	  suboptimal	  correlation	  	  between	  	  mucosal	  	  inflammation	  	  and	  	  symptoms,	  	  and	  	  thus	  	  lead	  	  to	  	  an	  	  over	  	  or	  underestimation	  	  of	  	  the	  	  therapeutic	  	  effect.	  	  	  	  This	  	  leads	  	  to	  	  high	  	  variance	  	  and	  	  the	  	  need	  	  for	  larger	  	  trials	  	  for	  	  longer	  	  periods,	  	  complicating	  	  particularly	  	  early-­‐-­‐-­‐stage	  	  development.	  	  While	  new	  approaches	  have	  been	  proposed,	  e.g.	  mucosal	  healing	  as	  assessed	  by	  endoscopy,	  (CDEIS	  and	   SES-­‐-­‐-­‐CD	   are	   the	   two	  most	   frequently	   used	   evaluative	   indices),	  more	   evidence	   is	   needed	  to	  assess	  its	  impact	  243.	  	  	   Moreover,	  	  over	  	  the	  	  last	  	  few	  	  years,	  	  there	  	  have	  	  been	  	  a	  	  large	  	  number	  	  of	  	  new	  	  therapies	  	  that	  have	  	  entered	  	  the	  	  therapeutic	  	  pipeline25	  	  and	  	  the	  	  need	  	  for	  	  new	  	  outcome	  	  measures	  	  has	  	  been	  increasingly	  	  vital.	  	  The	  	  roles	  	  that	  	  these	  	  new	  	  measures	  	  will	  	  be	  	  required	  	  to	  	  fulfill	  	  are	  	  to	  improve	  	  the	  	  definition	  	  of	  	  appropriate	  	  patient	  	  cohorts,	  	  and	  	  to	  	  reduce	  	  the	  	  rates	  	  of	  	  placebo	  response,	  which	  are	  currently	  high	   in	  studies	  relying	  on	  clinical	  scores	  and	  patient-­‐-­‐-­‐reported	  measures.	  	  There	  	   is	  	  an	  	  opinion	  	  that	  	  the	  	  practice	  	  of	  	  using	  	  of	  	  placebo	  	  arms	  	  is	  	  gradually	  becoming	  	  impractical	  	  and	  	  unethical,	  	  in	  	  this	  	  era	  	  of	  	  ever	  	  increasing	  	  availability	  	  of	  	  advanced	  effective	  	  therapies	  	  in	  	  CD.	  Finally,	   the	  	  use	  	  of	  	  robust	  	  endpoints	  	  can	  	  act	  	  to	  	  reduce	  	  the	  	  sample	  sizes	  required	  to	  measure	  the	  studied	  effects.	  	  	   The	   variability	   in	   disease	   phenotype,	   the	   disconnect	   between	   reported	   symptoms	   and	  ongoing	  bowel	  damage	  and	  the	  increasing	  throughput	  of	  costly	  and	  potentially	  toxic	  drugs	  currently	   in	   clinical	   practice	   or	   at	   various	   phases	   of	   development	   pose	   a	   currently	   unmet	  need	   for	   appropriate	   biomarkers	   that	   can	   assess	   disease	   burden	   in	   a	   variety	   of	  circumstances.	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A	  biomarker	   is	  defined	  as	   ‘a	   characteristic	   that	   is	  objectively	  measured	  and	  evaluated	  as	  an	  indicator	  of	  normal	  biological	   processes,	   pathogenic	  processes,	   or	  pharmacologic	   responses	  to	  	  	  a	  	  	  therapeutic	  	  	  intervention’	  	  	  244.	  	  	  Biomarkers	  	  	  can	  	  	  be	  	  	  subcategorised	  	  	  into	  	  	  prognostic,	  predictive,	  	  	  	  pharmacodynamic	  	  	  	  biomarkers	  	  	  	  and	  	  	  	  surrogate	  	  	  	  endpoints	  	  	  	  245.	  	  	  	  Prognostic	  biomarkers	  	  constitute	  	  of	  	  single	  	  or	  	  clusters	  	  of	  	  specific	  	  traits	  	  that	  	  separate	  	  the	  	  population,	  with	  respect	  to	  an	  outcome	  of	  interest,	  regardless	  of	  the	  type	  of	  therapy	  used.	  An	  example	  in	  CD	  would	  be	   an	   ileo-­‐-­‐-­‐colonic	   distribution	   compared	   to	   isolated	   ileal	   or	   colonic	   disease,	   and/	  or	  	   the	  	  presence	  	  of	  	  perianal	  	   lesions,	  	   traits	  	  which	  	  carry	  	  poorer	  	   long-­‐-­‐-­‐term	  	  outcomes	  	  246.	  Predictive	  	  biomarkers	  	  on	  	  the	  	  other	  	  hand	  	  constitute	  	  of	  	  baseline	  	  characteristics	  	  that	  	  can	  categorise	  patients	  by	  their	  degree	  of	  response	  to	  specified	  treatment	  247.	  To	  date,	   there	   is	  a	  distinct	  lack	  of	  predictive	  biomarkers	  in	  CD	  248.	  Pharmacodynamic	  biomarkers	  are	  those	  that	  are	   used	   to	   optimise	   drug-­‐-­‐-­‐dosing	   schedules.	   A	   classical	   example	   in	   CD	   is	   the	   assessment	   of	  thiopurine	  	  	  methyl-­‐-­‐-­‐transferase	  	  	  (TPMT)	  	  	  genotype	  	  	  to	  	  	  identify	  	  	  heterozygote	  	  	  patients	  	  	  with	  higher	  	  	  chances	  	  	  of	  	  	  myelotoxicity249	  	  	  	   .	  	  	  Finally,	  	  	  surrogate	  	  	  endpoints	  	  	  are	  	  	  intended	  	  	  to	  	  	  be	  substitutes	  	  of	  	  true	  	  clinical	  	  endpoints	  	  expected	  	  to	  	  predict	  	  clinical	  	  benefit	  	  (or	  	  harm)	  	  on	  	  the	  basis	  	  of	  	  epidemiologic	  	  therapeutic,	  	  pathophysiologic	  	  or	  	  other	  	  scientific	  	  correlations	  	  (FDA	  website).	   In	   the	   setting	  of	   clinical	   trials,	   surrogate	   endpoints	   are	  used	  as	  measures	  of	   effect	  on	  	  the	  	  basis	  	  of	  	  their	  	  correlation	  	  with	  	  true	  	  clinical	  	  endpoints250	  	  	  .	  	  For	  	  a	  	  biomarker	  	  to	  	  be	  deemed	  	  a	  	  surrogate	  	  endpoint,	  	  the	  	  corresponding	  	  clinical	  	  endpoint,	  	  population	  	  of	  	  interest	  and	  class	  of	  intervention	  must	  all	  be	  thoroughly	  defined.	  	  	  
5.1	  STATISTICAL	  ASSESSMENTS	  IN	  THE	  DEVELOPMENT	  OF	  BIOMARKERS	  	  	  	   The	  	  first	  	  step	  	  in	  	  the	  	  development	  	  of	  	  a	  	  biomarker	  	  is	  	  the	  	  determination	  	  of	  	  a	  	  normal	  	  cut-­‐-­‐-­‐off	  level.	  	  This	  	   is	  	  done	  	  by	  	  comparison	  	  of	  	  inactive	  	  and	  	  active	  	  cohorts	  	  as	  	  determined	  	  by	  	  an	  accepted	  	  	  gold-­‐-­‐-­‐standard	  	  	  investigation	  	  	  e.g.	  	  	  ileocolonoscopy.	  	  	  Biomarker	  	  	  values	  	  	  are	  	  	  then	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plotted	  	  for	  	  the	  	  two	  	  groups	  	  and	  	  ROC	  	  analysis	  	  is	  	  used	  	  to	  	  determine	  	  a	  	  normal	  cut-­‐-­‐-­‐off	   level	  as	  well	  as	  the	  sensitivity	  and	  specificity	  of	  the	  measure	  to	  determine	  disease	  status.	  	  	   From	  	  that	  point	   on,	   appropriate	   statistical	   assessments	   for	   awarding	  biomarker	   status	   to	   a	  measure	  depend	  on	  the	  exact	  roles	  a	  biomarker	   is	   intended	  to	   fulfill.	  Prognostic	  biomarkers	  are	  	  usually	  	  assessed	  	  through	  	  prospective	  	  randomised	  	  controlled	  	  trials.	  	  Biomarker-­‐-­‐-­‐positive	  patients	  	  are	  	  compared	  	  with	  	  biomarker-­‐-­‐-­‐negative	  	  controls	  	  matched	  	  for	  	  disease	  	  activity	  	  and	  demographics,	  	  and	  	  are	  	  followed-­‐-­‐-­‐up	  	  over	  	  a	  	  pre-­‐-­‐-­‐determined	  	  time	  	  interval.	  	  At	  	  the	  	  end	  	  of	  	  the	  study	  	  period,	  	  the	  	  two	  	  groups	  	  are	  	  compared	  	  for	  	  an	  	  event	  	  in	  	  question	  	  e.g.	  	  maintenance	  	  of	  remission	  	  or	  	  flare	  	  and	  	  compared	  	  by	  	  χ2	  	  	  test.	  	  p-­‐-­‐-­‐value	  	  between	  	  the	  	  two	  	  groups	  	  assesses	  	  the	  power	  of	  the	  biomarker	  to	  predict	  the	  specific	  outcome.	  	  	   Validation	  	  of	  	  an	  	  imaging	  	  biomarker	  	  in	  	  predicting	  	  therapeutic	  	  response	  	  involves	  	  a	  	  different	  methodology.	  A	  single	  cohort	  is	  commenced	  on	  a	  specified	  therapy	  and	  early	  re-­‐-­‐-­‐imaging	  visit	  is	  	  carried	  	  out.	  	  An	  	  ROC	  	  analysis	  	  can	  	  then	  	  be	  	  done	  	  to	  	  determine	  	  the	  	  degree	  	  of	  	  change	  	  in	  	  the	  biomarker	  that	   is	  associated	  with	  subsequent	  clinical	  response.	   	   Combination	  of	  biomarkers	  can	  often	  enhance	  the	  accuracy	  of	  early	  prediction	  of	  a	  clinical	  outcome.	  	  	   Finally,	   in	  order	   for	  a	  measure	   to	  be	  awarded	  “surrogate	  endpoint”	  status,	   several	  criteria	  have	   to	   be	  met.	   Firstly,	   proof	   of	   biological	   plausibility	   in	   the	   correlation	   of	   the	   biomarker	  with	   the	   corresponding	   clinical	   endpoint	   is	   essential.	   Plausibility	   building	   involves	   the	  accumulation	   and	   analysis	   of	   biochemical,	   tissue	   or	   animal	   data	   in	   order	   to	   describe	   a	  mechanism	  of	  action	  or	  to	  demonstrate	  the	  desired	  biological	  effect.	  Moreover,	  correlation	  statistics	   are	   used	   to	   show	   the	   degree	   of	   association	   between	   the	   surrogate	   and	   the	   true	  endpoint.	   Finally,	   additional	   important	   attributes	   of	   potential	   surrogate	   endpoints	   are	  reliability,	  validity	  and	  responsiveness,	  collectively	  termed	  clinimetrics251.	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A	  	  reliable	  	  measure	  	  is	  	  one	  	  that	  	  produces	  	  results	  	  that	  	  are	  	  consistent,	  	  accurate,	  	  stable	  	  over	  time	  	  and	  	  reproducible.	  	  The	  	  two	  	  most	  	  important	  	  components	  	  of	  	  reliability	  	  in	  	  the	  	  measures	  examined	  	  in	  	  this	  	  study	  	  are	  	  test-­‐-­‐-­‐retest,	  	  in	  	  other	  	  words	  	  the	  	  stability	  	  of	  	  an	  	  endpoint	  	  when	  assessed	  in	  the	  context	  of	  stable	  disease,	  and	  rater	  reliability	  i.e.	  the	  agreement	  of	  the	  results	  when	  a	  measure	  is	  assessed	  by	  independent	  observers.	  	  	   Validity,	  in	  general	  terms,	  refers	  to	  the	  degree	  to	  which	  an	  instrument	  actually	  measures	  the	  parameter	   it	   is	   intended	   to	  measure,	   in	  other	  words,	  whether	   it	   samples	   the	   relevant	   areas	  that	  	  are	  	  expected	  	  to	  	  be	  	  influenced	  	  by	  	  a	  	  certain	  	  intervention.	  	  Validity	  	  also	  	  examines	  	  the	  correlation	  	  it	  	  exhibits	  	  with	  	  an	  	  accepted	  	  gold	  	  standard,	  	  or	  	  other	  	  accepted	  	  measures	  	  of	  	  the	  disease	  	  process.	  	  In	  	  the	  	  case	  	  of	  	  an	  	  inflammatory	  	  condition	  	  such	  	  as	  	  CD,	  	  evidence	  	  must	  	  be	  provided	  	  that	  	  a	  	  measure	  	  is	  	  actually	  	  examining	  	  a	  	  component	  	  of	  	  the	  	  inflammatory	  	  burden,	  and,	  	  in	  	  the	  	  absence	  	  of	  	  an	  	  acceptable	  	  gold-­‐-­‐-­‐standard,	  	  that	  	  it	  	  correlates	  	  with	  	  other	  	  measures	  which	  	  have	  	  been	  	  validated	  	  to	  	  reflect	  	  disease	  	  activity	  	  e.g.	  	  clinical	  	  scores,	  	  blood	  	  and	  	  faecal	  biomarkers	  of	  inflammation,	  or	  endoscopic	  scores	  of	  activity.	  	  	   Finally,	  	  responsiveness	  	  is	  	  defined	  	  as	  	  the	  	  ability	  	  of	  	  an	  	  outcome	  	  measure	  	  to	  	  either	  	  detect	  	  a	  concurrent	  clinically	  meaningful	  change	  or	  predict	  one	  in	  the	  future.	  Gauging	  an	  appropriate	  time	  interval	   for	  taking	  the	  repeat	  measurement	   is	  a	  crucial	  step	   in	  the	  design	  of	  both	  these	  approaches.	   Ultimately,	   however,	   both	   short-­‐-­‐-­‐term	   as	  well	   as	   longer-­‐-­‐-­‐term	   endpoints	   have	   to	  be	  	  appropriate	  	  and	  	  clinically	  	  important.	  	  In	  	  CD,	  	  examples	  	  of	  	  the	  	  former	  	  usually	  	  include	  	  a	  measure	  	  of	  	  clinical	  	  response	  	  of	  	  remission,	  	  whereas	  	  endpoints	  	  of	  	  a	  	  longer	  	  horizon	  	  include	  hospitalisations,	  	  surgeries,	  	  steroid	  	  avoidance	  	  and	  	  quality	  	  of	  	  life.	  	  A	  	  further	  	  complication	  	  in	  CD,	  	  	  however,	  	  	  is	  	  	  the	  	  	  fact	  	  	  that	  	  	  clinical	  	  	  remission	  	  	  as	  	  	  an	  	  	  outcome	  	  	  does	  	  	  not	  	  	  guarantee	  	  	  a	  favourable	  	  medium	  	  term	  	  prognosis.	  	  Therefore	  	  biomarkers	  	  that	  	  predict	  	  progression	  	  and	  complications	  in	  the	  longer	  term	  would	  be	  very	  helpful.	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   The	   lack	  of	   suitable	  gold-­‐-­‐-­‐standard	  monitoring	   instruments	   for	  any	  of	   the	  situations	  outlined	  above	  	  has	  	  been	  	  discussed	  	  extensively	  	  earlier	  	   in	  	  this	  	  thesis.	  	  MRI	  	  has	  	  been	  	   increasingly	  evaluated	   for	   its	   potential	   to	   quantify	  disease	   activity,	   and	   several	   quantitative	  measures	  of	  inflammation	  have	   been	  proposed	   in	   recent	   years	   74,97,108,192,199.	   PET,	   on	   the	   other	   hand,	   has	  shown	  	  some	  	  promise	  	  through	  	  its	  	  static	  	  correlation	  	  with	  	  endoscopic	  	  138,141and	  	  histological	  markers	  	  of	  	  activity168.	  	  When	  	  this	  	  research	  	  was	  	  planned,	  	  evidence	  	  of	  	  the	  	  value	  	  of	  	  MRI	  	  as	  	  a	  monitoring	  tool	  was	  scarce	  in	  the	  case	  of	  MRI	  and	  was	  completely	  lacking	  for	  PET.	  	  	   This	  	  	   thesis	  	  	  makes	  	  	  a	  	  	   contribution	  	  	   to	  	  	   current	  	  	  knowledge	  	  	   through	  	  	   the	  	  	   simultaneous	  examination	  of	   a	   large	  number	   of	   outcome	  measures	   in	   a	  well-­‐-­‐-­‐characterised	  patient	   cohort.	  The	   future	  roles	  of	  some	  or	  all	  of	   these	  measures	   in	  disease	  monitoring	  and	  the	  proposition	  of	  	  further	  	  work	  	  required	  	  for	  	  their	  	  validation	  	  depend	  	  on	  	  drawing	  	  appropriate	  	  conclusions	  from	  	  the	  	  data.	  	  In	  	  order	  	  for	  	  this	  	  to	  	  be	  	  achieved,	  	  the	  	  aforementioned	  	  criteria	  	  on	  	  biomarker	  selection	  and	  assessment	  should	  be	  used	  as	  a	  benchmark	  against	  which	  each	  measure	  can	  be	  objectively	  scrutinised.	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5.2 18F-­‐-­‐-­‐FDG	  PET	  
	  
	  
	   The	  hypothesis	  that	  a	  reduction	  in	  inflammatory	  load	  corresponds	  to	  a	  decrease	  of	  glycolytic	  activity	  measured	  by	  18F-­‐-­‐-­‐FDG	  PET	  signal	  was	  tested	  in	  Chapter	  2.	  	  	   5.2.1 WHAT	  WAS	  ALREADY	  KNOWN	  	  	  	   A	  number	  of	  studies	  have	  already	  contributed	  towards	  our	  knowledge	  basis	  on	  the	  potential	  of	  	  18F-­‐-­‐-­‐FDG	  –PET	  	  to	  	  act	  	  as	  	  a	  	  biomarker	  	  in	  	  the	  	  assessment	  	  of	  	  CD.	  	  Bowel	  	  SUVMAX	  	  greater	  	  that	  that	   in	   the	   liver	  has	  been	   shown	   to	  be	   an	   accurate	   cut-­‐-­‐-­‐off	   to	   identify	   diseased	   segments	   135.	  Correlation	  	  	  of	  	  	  SUVMAX	  	  	  	  and	  	  	  SUVMEAN	  	  	  	  with	  	  	  several	  	  	  clinico-­‐-­‐-­‐pathological	  	  	  and	  	  	  endoscopic	  endpoints	  have	  also	  been	  demonstrated138,141.	  	  Evidence	  on	  the	  plausibility	  of	  the	  hypothesis	  that	  	  FDG	  	  signal	  	  represents	  	  inflammatory	  	  cell	  	  infiltrates	  	  in	  	  tissue	  	  can	  	  be	  	  found	  	  in	  	  animal	  studies	  142–144.	  	  	   5.2.2 CONTRIBUTION	  OF	  THIS	  PROJECT	  AND	  FUTURE	  DIRECTIONS	  	  	  	   Perhaps	  	  	  the	  	  	  most	  	  	  important	  	  	  finding	  	  	  of	  	  	  the	  	  	  PET	  	  	  study	  	  	  is	  	  	  the	  	  	  significant	  	  	  amounts	  	  	  of	  radioactivity	  	  	  within	  	  	  free	  	  	  faecal	  	  	  matter	  	  	  (10-­‐-­‐-­‐30%	  	  	  of	  	  	  the	  	  	  recto-­‐-­‐-­‐sigmoid	  	  	  activity)	  	  	  in	  	  	  the	  substudy	  of	  patients	  with	  distal	  colonic	  disease.	  This	  has	  a	  significant	  negative	  impact	  in	  the	  validity	  	  of	  	  the	  	  18F-­‐-­‐-­‐FDG	  	  PET	  	  as	  	  a	  	  method	  	  of	  	  monitoring	  	  lesional	  	  and	  	  global	  	  inflammatory	  change.	  This	   is	  because	   this	   luminal	  activity	  probably	  represents	  unbound	  FDG,	  which	   leaks	  or	  	  	  is	  	  	  secreted	  	  	  through	  	  	  extracellular	  	  	  space.	  	  	  Factoring	  	  	  it	  	  	  in	  	  	  as	  	  	  part	  	  	  of	  	  	  the	  	  	  total	  	  	  signal	  undermines	  	  the	  	  radioligand	  	  as	  	  a	  	  specific	  	  molecular	  	  marker	  	  of	  	  metabolic	  	  or	  	  inflammatory	  activity.	  This	   is	  because	   the	   free	  portion	  of	   the	   signal	   is	  more	  of	   a	  non-­‐-­‐-­‐specific	  noise,	   rather	  than	  	  a	  	  probe	  	  being	  	  traced	  	  through	  	  its	  	  physiological	  	  pathway.	  	  Dynamic	  	  PET	  	  sequences252,	  where	  a	  time	  series	  of	  images	  are	  obtained	  without	  any	  lag	  between	  injection	  and	  scanning	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could	  help	  demonstrate	  the	  path	  of	  FDG	  on	  its	  way	  to	  the	  lumen	  and	  allow	  the	  process	  to	  be	  modeled.	  	  My	  	  hypothesis	  	  is	  	  that	  	  this	  	  is	  	  likely	  	  a	  	  radial	  	  inward	  	  migration	  	  originating	  	  in	  	  the	  mesenteric	  	  vasculature	  	  upon	  	  delivery	  	  of	  	  the	  	  ligand.	  	  Other,	  	  less	  	  plausible	  	  explanations	  	  are	  that	  	  the	  	  signal	  	  follows	  	  a	  	  ‘downstream’	  	  migration	  	  pathway	  	  after	  	  being	  	  secreted	  	  at	  	  a	  	  remote	  site	  e.g.	  the	  biliary	  tree,	  or	  even	  that	  this	  is	  generated	  by	  epithelial	  cellular	  shedding	  into	  the	  lumen	  	  in	  	  the	  	  100-­‐-­‐-­‐minute	  	  interval	  	  between	  	  intravenous	  	  administration	  	  of	  	  FDG	  	  and	  	  bowel	  evacuation.	  This	  	  is	  	  not	  	  consistent	  	  however	  	  with	  	  the	  	  physiological	  	  transit	  	  time	  	  of	  	  small	  	  and	  large	  bowel.	  	  	   With	   regards	   to	   the	   individual	   endpoints,	   my	   study	   highlights	   the	   measures	   of	   signal	  intensity	  such	  as	  segmental	  or	  global	  SUVMAX	  and	  SUVMEAN,	  appeared	  much	  more	  reliable,	  had	  greater	  content	  validity	  reflected	  by	  their	  correlations	  with	  HBI,	  CRP	  and	  FC	  both	  statically	  and	  over	  time,	  and	  also	  significant	  responsiveness	  ratios.	  These	  should	  be	  explored	   further	  as	  possible	  biomarkers	  of	  disease	  activity	  	  	   In	   contrast	   to	   (G)SUVMAX	  and	   (G)SUVMEAN,	  measures	   that	   incorporate	   signal	   volume,	   SLG	  and	  TLG	  are	  far	  less	  likely	  candidates	  to	  act	  as	  biomarkers	  for	  inflammatory	  activity	  in	  CD.	  	  Test-­‐-­‐-­‐	  retest	  	  variability	  	  in	  	  these	  	  was	  	  of	  	  the	  	  order	  	  of	  	  67%,	  	  which	  	  is	  	  exclusively	  	  attributable	  	  to	  	  the	  variance	  	  of	   the	  	  collective	  	  volume	  	  of	  voxels	  	  in	  	  each	  	  segment	  exhibiting	  	  signal	  stronger	  	  than	  LivSUVMEAN.	  	  	  The	  	  positive	  	  correlations	  	  of	  	  SLG	  	  and	  	  TLG	  	  with	  	  clinico-­‐-­‐-­‐pathological	  	  markers	  confer	  	  some	  	  validity,	  	  and	  	  the	  	  responsiveness	  	  ratios	  	  were	  	  significant,	  	  but	  	  in	  	  the	  	  context	  	  of	  such	  poor	  reliability,	  these	  have	  little	  value	  in	  supporting	  the	  use	  of	  these	  two	  measures.	  The	  large	  	  test-­‐-­‐-­‐retest	  	  variability	  	  in	  	  the	  	  volume	  	  of	  	  lesional	  	  signal	  	  is	  	  an	  	  important	  	  observation,	  which	  	  should	  	  be	  	  corroborated	  	  with	  	  an	  	  independent	  	  study.	  	  	  This	  	  large	  	  variation	  	  cannot	  	  be	  justified	  	  	  by	  	  	  methodological	  	  	  shortfalls	  	  	  and	  	  	  it	  	  	  is	  	  	  conceivable	  	  	  that	  	  	  it	  	  	  reflects	  	  	  a	  	  	  genuine	  variability	   in	  the	  metabolic	  activity	  of	  a	   lesion	  even	  within	  an	   interval	  of	  7	  days.	  However,	   if	  it	  holds	  true,	  it	  is	  sufficient	  to	  render	  SLG	  and	  TLG	  unusable	  instruments	  to	  track	  change	  of	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disease	  activity.	  In	  addition,	  it	  would	  suggest	  that	  inflammatory	  activity	  in	  a	  lesion	  is	  a	  much	  more	  dynamic	  process	  than	  it	  is	  currently	  believed.	  This	  hypothesis	  cannot	  be	  readily	  tested	  in	  	  humans	  	  with	  	  current	  	   techniques,	  	  as	  	   it	  	  will	  	  require	  	  serial	  	   full-­‐-­‐-­‐thickness	  	  sampling	  	  of	  Crohn’s	  lesions,	  which	  would	  be	  prohibitively	  invasive.	  	  	   Three	   characteristics	   of	   the	  modality	   render	   it	   an	  unlikely	  	  candidate	   as	   a	   serial	  monitoring	  tool	  	  in	  	  clinical	  	  practice:	  	  	  Limited	  	  availability,	  	  high	  	  cost	  	  and	  	  radiation	  	  burden.	  	  However,	  	  the	  potential	   role	   of	   FDG-­‐-­‐-­‐PET	   in	   drug	   development	   is	  worthy	   of	   further	   study.	  Assuming	   that	   a	  large	   luminal	   component	  of	   the	   signal	   is	  not	   corroborated	   in	   larger	   studies,	   future	  work	  on	  FDG-­‐-­‐-­‐PET	   in	  CD	  should	  explore	   its	  potential	  as	  a	   surrogate	  endpoint	  of	   response	   in	  Phase	   III	  clinical	  trials.	   I	  would	  first	  propose	  a	  dual	  time-­‐-­‐-­‐point	  study	  on	  a	   larger	  cohort	  of	  CD	  patients	  before	  	  and	  	  after	  	  anti-­‐-­‐-­‐TNF	  	  therapy,	  	  with	  	  concurrent	  	  assessment	  	  of	  	  endoscopic	  	  activity	  	  by	  CDEIS	  at	   the	   time	  of	   the	  baseline	  and	   follow-­‐-­‐-­‐up	   scans.	  	   	  Subsequently,	  a	   study	  on	   the	   role	  of	  FDG-­‐-­‐-­‐PET	  	  as	  	  a	  	  predictive	  	  biomarker	  	  of	  	  response	  	  to	  	  biologics,	  	  similar	  	  in	  	  design	  	  to	  	  work	  published	  in	  rheumatoid	  arthritis	  132,253	  	  can	  also	  be	  useful.	  The	  follow-­‐-­‐-­‐up	  scan	  can	  take	  place	  as	   early	   as	   two	  weeks	   after	   treatment	   initiation,	   and	   the	  patients	   subsequently	   followed	  up	  for	  6	  months	  for	  clinical	  response	  and	  endoscopic	  mucosal	  healing.	  	  	   Finally,	  further	  studies	  to	  establish	  the	  specific	  cellular	  origins	  of	  the	  signal	  in	  humans	  are	  of	  scientific	   interest.	   It	   is	   possible	   that	   the	   increase	   in	   signal	   in	   inflamed	   segments	   is	  attributable	  both	  to	  the	  increased	  numbers	  of	  densely	  packed	  cells	  in	  the	  gut	  wall254,	  as	   well	  as	  the	  increased	  activation	  of	  various	  immune	  cell	  lineages	  126–128.	  Even	  if	  a	  focal	  increase	   in	  FDG	  uptake	  purely	  reflects	  increased	  cell	  numbers	  in	  the	  relevant	  gut	  regions	  compared	  to	  adjacent	  uninvolved	  segments,	  it	  is	  still	  valuable	  as	  it	  reflects	  a	  relevant	  measure	  of	  disease	  activity	  in	  a	  quantifiable,	  reproducible	  manner	  that	  also	  responds	  to	  change.	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5.3	  ALTERNATIVE	  PET	  RADIOLIGANDS	  	  	  	   In	  	  parallel	  	  to	  	  the	  	  FDG-­‐-­‐-­‐PET	  	  clinical	  	  imaging	  	  study,	  	  a	  	  separate	  	  line	  	  of	  	  my	  	  research	  	  involved	  evaluating	  	  	  the	  	  	  expression	  	  	  of	  	  	  molecular	  	  	  targets	  	  	  for	  	  	  alternative	  	  	  radioligands,	  	  	  which	  	  	  are,	  ostensibly,	  	  more	  	  specific	  	  to	  	  the	  	  inflammatory	  	  pathway.	  	  Immunohistochemical	  	  assessment	  was	  	  performed	  	  on	  	  stored	  	  tissue	  	  to	  	  assess	  	  the	  	  mucosal	  	  as	  	  well	  	  as	  	  transmural	  	  expression	  	  of	  TSPO	  	  and	  	  CD25,	   the	  	  principal	  subunit	  of	   the	  	  IL-­‐-­‐-­‐2	  	  receptor.	  The	  	  findings	  	  showed	  	  that	  TSPO	  expression	  	  in	  	  normal	  	  gut	  	  is	  	  considerable	  	  but	  	  the	  	  increased	  	  expression	  	  in	  	  diseased	  	  tissue	  proposed	  	  	  by	  	  	  previous	  	  	  studies208	  	  	  	  was	  	  	  not	  	  	  confirmed.	  	  	  On	  	  	  the	  	  	  other	  	  	  hand,	  	  	  transmural	  expression	  of	  IL-­‐-­‐-­‐2R,	  showed	  an	  appreciable	  increase	  with	  increasing	  inflammatory	  scores,	   in	  keeping	  with	  previous	  studies	  219,240.	  	  	   Subsequent	   attempts	  were	  made	   to	   extend	   these	   results	   using	   radioligand	   autoradiography	  in	  	  inflamed	  	  and	  	  normal	  	  sections	  	  from	  	  prospectively	  	  recruited	  	  resection	  	  specimens.	  	  Only	  non-­‐-­‐-­‐significant	  	  	   increases	  	  	   in	  	  	  TSPO	  	  	  radioligand	  	  	  binding	  	  	   to	  	  	   the	  	  	   inflamed	  	  	  tissue	  	  	  were	  demonstrated.	  Unfortunately,	  due	  to	  experimental	   limitations	  (in	  combination	  with	   the	  high	  costs	  	  	  limiting	  	  	  consumables)	  	  	  satisfactory	  	  	  autoradiographic	  	  	  quantification	  	  	  of	  	  	  CD25	  	  	  over-­‐-­‐-­‐	  expression	  in	  diseased	  versus	  normal	  sections	  was	  not	  achieved.	  	  	   Several	  	  different	  	  approaches	  	  can	  	  be	  	  taken	  	  to	  	  achieve	  	  a	  	  higher	  	  degree	  	  of	  	  specific	  	  125I-­‐-­‐-­‐IL2	  binding.	  A	  higher	   concentration	  of	  hr-­‐-­‐-­‐IL-­‐-­‐-­‐2	   can	  possibly	   achieve	   a	  better	  block.	  Alternatively,	  an	  antibody	  against	  CD25	  may	  prove	  more	  successful	   in	  saturating	  specific	   sites.	   If	   this	  also	  fails	  	  to	  	  provide	  	  a	  	  specific	  	  bind,	  	  then	  	  saturation	  	  binding	  	  studies	  	  on	  	  tissue	  	  homogenates,	  similar	  to	  that	  performed	  with	  PBR28	  can	  also	  be	  attempted.	  	  This	  would	  inform	  on	  BMAX	  and	  Kd	  	  but	  would	  not	  provide	  details	  on	  the	  spatial	  localisation	  of	  the	  signal.	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The	  	  results	  	  on	  	  TSPO	  	  concentrations	   in	  	  normal	  versus	   inflamed	  	  specimens	  raise	  	  interesting	  research	  questions.	  Firstly,	   the	  reason	  for	  this	  significant	  expression	  of	  TSPO	  in	  enterocytes,	  and	  	  	  any	  	  	  associations	  	  	  in	  	  	  the	  	  	  local	  	  	  immune	  	  	  response	  	  	  are	  	  	  certainly	  	  	  worth	  	  	  exploring.	  Saturation-­‐-­‐-­‐binding	   studies	   on	   cultured	   cell	   populations	   can	   help	   specify	   the	   precise	   cellular	  origins	   of	  TSPO	   in	   intestinal	   tissue148,255.	   From	   there,	   hypotheses	   on	   its	   functionality	   can	  be	  tested.	  	  	   In	  	  contrast	  	  to	  	  TSPO,	  	  IL-­‐-­‐-­‐2R	  	  holds	  	  more	  	  promise	  	  as	  	  a	  	  target	  	  of	  	  molecular	  	  PET	  	  imaging.	  	  The	  over-­‐-­‐-­‐expression	   of	   the	   receptor	   in	   inflamed	   bowel	   and	   good	   co-­‐-­‐-­‐localisation	  with	   clusters	   of	  differentiation	   specific	   to	   leucocytes	   (CD45)	   and	  T-­‐-­‐-­‐cells	   in	  particular	   (CD3)	   suggest	   that	   the	  receptor	  can	  	  lend	  	  itself	  as	  a	  	  more	  	  accurate	  	  marker	  	  of	   inflammatory	  	  activity.	  	  	  Further	  work	  will	  be	  required	  to	  specify	  the	  binding	  potential	  of	  the	  interaction	  in	  normal	  versus	  diseased	  specimens	  	  and,	  	  if	  	  a	  	  difference	  	  is	  	  confirmed,	  	  static	  	  and	  	  dynamic	  	  imaging	  	  studies	  	  can	  	  be	  justified.	  	  	  
5.4 QUANTITATIVE	  OUTCOME	  MEASURES	  OF	  MAGNETIC	  RESONANCE	  IMAGING	  
	  
	  
	   The	  	  hypothesis	  	  that	  	  quantitative	  	  MRI	  measures	  	  of	  disease	  	  activity	  	  such	  	  anatomical	  activity	  scores,	  diffusion	  weighted	  imaging	  parameters,	  small	  bowel	  motility	  and	  DCE	  MRI	  measures	  can	   act	   as	   surrogate	   endpoints	   of	   disease	   response	   following	   3	  months	   of	   anti-­‐-­‐-­‐TNF	   therapy	  were	  tested	  	  	   5.4.1 WHAT	  WAS	  ALREADY	  KNOWN	  	  	  	   Studies	  have	  shown	  that	  bowel	  wall	  thickness	  and	  signal	  intensity	  in	  T2	  sequences	   correlate	  with	  histologic	  markers	  of	  disease	  activity71–73.	  Moreover	  composite	  scores	  such	  as	  MaRIA	  and	   MEGS	   show	   good	   correlation	   with	   endoscopic	   scores	   74,75,	   and	   faecal	   calprotectin192	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respectively.	   Functional	   endpoints	   such	   as	   motility	   and	   DCE	   endpoints	   have	   shown	  significant	  differences	  in	  normal	  versus	  diseased	  segments.	  Finally,	  ADC,	  a	  measure	  of	  water	  diffusivity	   across	   tissue,	   has	   shown	   high	   sensitivity	   and	   specificity	   figures	   in	   identifying	  segments	  with	  inflammation.	  	  	   To	  date,	  studies	  on	  the	  role	  of	  MRI	  as	  a	  tool	  to	  monitor	  disease	  activity	  in	  Crohn’s	  disease	  are	  very	  	   limited	  	   110,199,256.	  	  Nevertheless,	  	  at	  	   least	  	   in	  	   the	  	  UK	  	   IBD	  	  practice,	  	   there	  	   is	  	  extensive	  empirical	  	  use	  	  of	  	  serial	  	  MRI	  	  enterography	  	  to	  	  monitor	  	  disease	  	  progress.	  	  The	  	  only	  	  evidence	  that	  	  can	  	  support	  	  this	  	  practice	  	  stems	  	  from	  	  the	  	  single	  	  timepoint	  	  studies	  	  which	  	  suggest	  	  good	  correlation	  	  	  between	  	  	  MRI	  	  	  measures	  	  	   such	  	  	   as	  	  	  bowel	  	  	  wall	  	  	   thickness,	  	  	   contrast	  	  	  hyper-­‐-­‐-­‐	  enhancement	  	  and	  	  mesenteric	  	  vascular	  	  changes	  	  71–73	  	  and	  	  histologic	  	  measures	  	  of	  	  activity,	  	  as	  well	  as	  MaRIA	  score	  and	  endoscopic	  scores	  74,75.	  The	  latter	   is	  still	  a	  research	  tool	  without	  an	  established	  role	  in	  clinical	  practice.	  Current	  clinical	  guidelines,	  however,	  highlight	  the	  lack	  of	  evidence	  in	  support	  of	  the	  use	  of	  MRI	  in	  this	  context	  118.	  	  	   One	  major	  advantage	  of	  MRI	   is	   that	   it	   allows	  us	   to	   serially	  assess	  disease	  progress	  not	  only	  in	  the	  mucosa	  but	  also	  in	  the	  full	  thickness	  of	  the	  bowel	  wall	  and	  adjacent	  mesentery.	  This	  is	  a	  major	   step	   forward	   in	  our	  understanding	  of	   the	  natural	  history	  of	   the	  disease.	  Our	   access	  to	  the	  mucosa	  through	  endoscopic	  visualisation	  and	  biopsying	  has	  been	  possible	  for	  over	  40	  years	  	  257.	  	  The	  	  potential	  	  of	  	  the	  	  mucosa	  	  to	  	  ‘heal’	  	  or	  	  normalise	  	  both	  	  endoscopically258	  	  	  and	  histologically259	  	  has	  been	  repeatedly	  demonstrated,	  and	   the	   importance	  of	   this	   in	  predicting	  long	  	  term	  	  disease	  	  outcomes	  	  has	  	  been	  	  the	  	  subject	  	  of	  	  intense	  	  study	  	  in	  	  	  	   recent	  	  years.	  	  In	  contrast	   to	   this,	  before	   the	  advent	  of	  cross-­‐-­‐-­‐sectional	   imaging	   there	  had	  been	  no	  opportunity	  to	  	  serially	  	  assess	  	  the	  	  transmural	  	  component	  	  of	  	  the	  	  disease	  	  process.	  	  This	  	  could	  	  only	  	  be	  studied	   in	   resection	   or	   post-­‐-­‐-­‐mortem	   specimens,	  which	   give	   no	   information	   on	   the	   potential	  of	  lesions	  to	  reversibility.	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Before	  	  existing	  	  imaging	  	  modalities	  	  are	  	  ‘put	  	  to	  	  the	  	  test’	  	  on	  	  their	  	  abilities	  	  to	  	  demonstrate	  transmural	  healing	   in	  these	  patients	   it	   is	   important	  to	  consider	  firstly	  whether	  this	  outcome	  is	  	  at	  	  all	  	  possible,	  	  and	  	  secondly	  	  determine	  	  the	  	  time-­‐-­‐-­‐course	  	  that	  	  such	  	  an	  	  endpoint	  	  can	  	  be	  achieved	  in.	  	  	   So	  far	  it	  has	  been	  shown	  that	  lesional	  bowel	  wall	  thickness	  remains	  significantly	  higher	  than	  that	   in	  normal	  bowel	   in	  patients	  who	  are	   in	  clinical	  remission	  at	  8	  months256.	  Van	  Assche	  et	  al.	  	  showed	  	  that	  	  MRI	  	  appearances	  	  had	  	  completely	  	  normalised	  	  only	  	   in	  	  a	  	  small	  	  minority	  (2/15)	  	  of	  	  a	  	  cohort	  	  with	  	  terminal	  	  ileal	  	  involvement,	  	  following	  	  treatment	  	  with	  	  IFX	  	  for	  	  26	  weeks199.	   Importantly,	   these	  	  two	  	  subjects	  	  were	  	  the	  	  ones	  	  with	  	  the	  	  mildest	  	  changes	  	  at	  	  index	  scanning.	  	  Ordas	  	  et	  	  al.	  	  showed	  	  that	  	  some	  	  improvement	  	  in	  	  most	  	  markers	  	  of	  	  transmural	  disease	  can	  be	  observed	  12	  weeks	  into	  therapy,	  and	  these	  were	  seen	  in	  parallel	  to	  resolution	  of	  	  	  mucosal	  	  	  ulcers110.	  	  	  This	  	  	  was	  	  	  however	  	  	  a	  	  	  secondary	  	  	  endpoint	  	  	  of	  	  	  the	  	  	  study	  	  	  looking	  qualitatively	  	  the	  	  persistence	  	  or	  	  absence	  	  of	  	  morphological	  	  markers	  	  rather	  	  than	  	  an	  	  in-­‐-­‐-­‐depth	  scrutiny	  of	  transmural	  scores.	  	  	   5.4.2 CONTRIBUTION	  OF	  THIS	  PROJECT	  AND	  FUTURE	  DIRECTIONS	  	  	  	   This	  	  project	  	  produces	  	  a	  	  simultaneous	  	  examination	  	  of	  	  a	  	   large	  	  number	  	  of	  	  MRI	  	  outcome	  measures.	  	  An	  	  assessment	  	  of	  	  morphological	  	  scores	  	  such	  	  as	  	  MaRIA	  	  and	  	  MEGS,	  	  alongside	  newly-­‐-­‐-­‐proposed	  	  functional	  	  endpoints	  	  such	  	  as	  	  the	  	  ADC,	  	  DCE	  	  MR	  	  and	  	  motility	  	  measures	  	  for	  the	  characterisation	  of	  tissue	  responses	  was	  performed	  for	  the	  first	  time	  in	  the	  same	  patient	  group.	  	  	   The	   test-­‐-­‐-­‐retest	  reliability	  appears	   to	  be	  very	  high	   in	  most	  MRI	  measures,	  with	   the	  exception	  of	  DCE,	  which	  also	  demonstrate	   the	  poorest	   responsiveness	  scores.	  The	  validity	  of	  DCE	  as	  a	  marker	  	  	  of	  	  	  inflammatory	  	  	  activity	  	  	  is	  	  	  also	  	  	  questionable	  	  	  as	  	  	  evidenced	  	  	  by	  	  	  poor	  	  	  static	  	  	  and	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dynamic	  	  	  	  	  correlation	  	  	  	  	  with	  	  	  	  	  all	  	  	  	  	  clinico-­‐-­‐-­‐pathological	  	  	  	  	  markers	  	  	  	  	  of	  	  	  	  	  this	  	  	  	  	  study,	  	  	  	  	  and	  histopathological	  markers	  of	   inflammation	   reported	  by	  other	   studies93.	   It	   appears	   therefore	  that	  DCE	  MRI	  is	  not	  a	  suitable	  technique	  to	  monitor	  disease	  activity	  over	  time.	  	  	   The	  	  performance	  	  diffusion-­‐-­‐-­‐weighted	  	   imaging,	  	  ADC,	  	  was	  	   somewhat	  	  more	  	  ambiguous.	  	   It	  showed	  	  	  an	  	  	  acceptable	  	  	  variability	  	  	  of	  	  	  21%	  	  	  on	  	  	  test-­‐-­‐-­‐retest,	  	  	  but	  	  	  the	  	  	  responsiveness	  	  	  was	  significantly	  	  more	  	  modest	  	  than	  	  other	  	  measures.	  	  An	  	  interesting	  	  finding	  	  that	  	  merits	  	  further	  investigation	  	  is	  	  the	  	  fact	  	  that	  	  almost	  	  half	  	  of	  	  diseased	  	  segments	  	  showed	  	  a	  	  drop	  	  in	  	  diffusivity	  within	   the	  12-­‐-­‐-­‐week	   interval.	   	   	  This,	   as	  well	   as	   suggestions	   in	   the	   literature	   that	   the	  measure	  may	  	  also	  	  reflect	  	  other	  	  aspects	  	  of	  	  the	  	  pathophysiology	  	  e.g.	  	  fibrosis	  	  103,	  	  cast	  	  doubts	  	  on	  	  the	  validity	  	  of	  	  the	  	  endpoint	  	  for	  	  actually	  	  measuring	  	  inflammatory	  	  load.	  	  One	  	  possible	  	  way	  	  of	  quantifying	  the	  relative	  contribution	  of	   fibrosis	  and	  inflammation	  in	  the	  reduction	  of	  ADC	  in	  diseased	  	  segments	  	  would	  	  be	  	  a	  	  prospective	  	  study	  	   in	  	  CD	  	  patients	  	  undergoing	  	  resection.	  Preoperative	  DWI	   imaging	  can	  be	  correlated	  with	   location-­‐-­‐-­‐matched	  histopathological	   scores	  of	  	  fibrosis	  	  and	  	  inflammation,	  	  as	  	  was	  	  performed	  	  for	  	  other	  	  radiographic	  	  signs	  	  that	  	  correlate	  with	  inflammatory	  activity	  and	  fibrostenosis	  71–73.	  	  	   Assessment	  of	  small	   intestinal	  motility	  in	  this	  small	  cohort	  shows	  a	  significant	  improvement	  in	  	  responders	  	  at	  	  12	  	  weeks,	  	  as	  	  well	  	  as	  	  a	  	  favourable	  	  responsiveness	  	  for	  	  the	  	  marker.	  	  This	  probably	  	  	  suggests	  	  	  a	  	  	  tendency	  	  	  for	  	  	  physiological	  	  	  function	  	  	  to	  	  	  restore	  	  	  before	  	  	  any	  	  	  of	  	  	  the	  measures	  of	  GI	  morphology.	  Another	  example	  of	  a	  physiological	  process	   that	  shown	  a	  rapid	  response	  	  to	  	  therapy	  	  is	  	  gut	  	  barrier	  	  function	  	  which	  	  has	  	  been	  	  shown	  	  to	  	  almost	  	  normalise	  within	  	  4	  	  weeks	  	  of	  	  a	  	  single	  	  anti-­‐-­‐-­‐TNF	  	   infusion	  	  260.	  	  This	  	  early	  	  signal	  	  on	  	  the	  	   longitudinal	  performance	  of	  motility	   as	   a	  marker	   is	   certainly	   encouraging	   and	  worthy	  of	   further	   studies	  alongside	  norphological	  measures	  (see	  below).	  	  There	  is	  probably	  limited	  applicability	  of	  the	  method	  	  to	  	  colonic	  	  disease,	  	  however,	  	  as	  	  contractions	  	  are	  	  much	  	  more	  	  infrequent	  	  261	  	  and	  	  the	  free-­‐-­‐-­‐breathing	  algorithms	  required	  to	  capture	  these	  still	  pose	  significant	  challenges	  262.	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   Morphological	  	  endpoints	  	  such	  	  as	  	  MaRIA	  	  and	  	  MEGS,	  	  were	  	  more	  	  far	  	  more	  	  reliable	  	  than	  functional	  measures	   in	   this	  cohort	  with	   figures	  comparable	   to	  SUVMEAN	  in	  PET.	  Some	  work	   is	  still	  	  	  required	  	  	  to	  	  	  validate	  	  	  these	  	  	  as	  	  	  monitors	  	  	  of	  	  	  inflammatory	  	  	  load.	  	  	  MaRIA,	  	  	  has	  	  	  been	  thoroughly	  	  	  validated	  	  	  against	  	  	  a	  	  	  mucosal	  	  	  endoscopic	  	  	  marker	  	  	  (MH)	  	  	  both	  	  	  statically	  	  	  and	  longitudinally,	  and	  MEGS	  was	  validated	  against	  FC,	  which	  was	  not	  reproduced	  in	  this	  cohort.	  Additional	  	  studies	  	  are	  	  still	  	  required	  	  that	  	  directly	  	  correlate	  	  the	  	  change	  	  of	  	  the	  	  measures	  	  to	  either	  a	   concurrent	  or	  a	   future	   clinically	  meaningful	  endpoint.	   In	   this	   study,	  neither	  marker	  correlated	  	  with	  	  absolute	  	  HBI	  	  at	  	  baseline	  	  or	  	  its	  	  change	  	  over	  	  a	  	  12-­‐-­‐-­‐week	  	  interval.	  	  Moreover,	  the	  	  responsiveness	  	  of	  	  the	  	  measures	  	  was	  	  modest.	  	  Important	  	  insight	  	  was	  	  gained	  	  through	  	  a	  more	   in-­‐-­‐-­‐depth	   dissection	   of	   the	   behaviour	   of	   the	   various	   components	   of	   these	   scores.	  More	  specifically,	  	  partial	  	  resolution	  	  of	  	  perimural	  	  and	  	  mural	  	  oedema	  	  was	  	  noted,	  	  while	  	  complete	  resolution	  was	  less	  frequent.	  Ulcers	  typically	  persisted	  during	  the	  three	  months,	  particularly	  in	  	  colonic	  	  mucosa.	  	  Mural	  	  enhancement,	  	  loss	  	  of	  	  haustrations	  	  and	  	  the	  	  length	  	  of	  	  diseased	  segments	  showed	  modest	  changes	  between	  the	  baseline	  and	  the	  follow-­‐-­‐-­‐up	  scan.	  	  	   Future	  	  work	  	  on	  	  morphological	  	  measures	  	  should	  	  focus	  	  on	  	  strengthening	  	  their	  	  validity	  	  by	  demonstrating	  associations	  with	   clinically	   robust	  outcomes.	  A	   sensible	   study	   in	   this	   context	  could	  be	  one	  of	   serial	  MRIs	   in	   a	   single	  pre	   and	  post-­‐-­‐-­‐treatment	   cohort	   to	  decide	   the	  optimal	  time	  	  of	  	  correlation	  	  of	  	  MRI	  	  measures	  	  with	  	  clinico-­‐-­‐-­‐pathological	  	  response.	  	  An	  	  extension	  	  arm	  where	  	  	  endpoints	  	  	  such	  	  	  as	  	  	  steroid	  	  	  avoidance,	  	  	  surgeries	  	  	  and	  	  	  hospitalisations	  	  	  are	  	  	  also	  considered	  would	  certainly	  be	  valuable.	  	  	   In	  total,	  MRI,	  at	  least	  in	  isolation,	  is	  probably	  not	  a	  suitable	  tool	  to	  assess	  early	  response	  to	  treatment.	  As	  discussed	  elsewhere	  in	  this	  thesis,	  the	  prevailing	  notion	  in	  the	  natural	  history	  of	  CD	  is	  that	  of	  a	  constantly	  progressive,	  albeit	  often	  silent,	  disease	  process	  which	  ultimately	  leads	   to	   significant	   bowel	   damage	   8,15.	   There	   is	   still	   therefore	   a	   need	   to	  monitor	   the	   full	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thickness	  	  of	  	  the	  	  bowel	  	  wall	  	  even	  	  at	  	  longer	  	  intervals,	  	  and	  	  hence	  	  further	  	  studies	  	  required	  	  to	  systematically	  	  characterise	  	  the	  	  evolution	  	  of	  	  all	  	  the	  	  morphological	  	  measures	  	  along	  	  with	  motility,	  over	  longer	  time-­‐-­‐-­‐periods.	  
Finally,	   a	   significant	   volume	  of	   research	  has	   recently	   been	  performed	   in	   the	   examination	  of	  the	  	  potential	  	  benefits	  	  of	  	  combining	  	  PET	  	  and	  	  MRI	  	  modalities.	  	  There	  	  are	  	  two	  	  strategies	  	  in	  doing	   so.	  Firstly,	  PET	  and	  MRI	   can	  be	  performed	   sequentially	   in	  different	   scanners,	   and	   the	  images	   co-­‐-­‐-­‐registered	   using	   appropriate	   software.	   Alternatively,	   the	   scanning	   can	   take	   place	  in	  	  	  new,	  	  	  hybrid	  	  	  PET-­‐-­‐-­‐MRI	  	  	  machines	  	  	  with	  	  	  a	  	  	  novel	  	  	  configuration	  	  	  of	  	  	  detectors,	  	  	  which	  simultaneously	  	  	  acquire	  	  	  functional	  	  	  PET	  	  	  data	  	  	  and	  	  	  anatomical	  	  	  images.	  	  	  This	  	  	  technique	  	  	  is	  already	  	  finding	  	  clinical	  	  application	  	  in	  	  oncology,	  	  where	  	  more	  	  accurate	  	  TNM	  	  staging	  	  for	  	  a	  variety	  	  of	  	  cancers	  	  has	  	  been	  	  achieved	  	  263.	  	  The	  	  newest	  	  generation	  	  of	  	  PET	  	  MRI	  	  scanners	  	  also	  offers	  	  a	  	  PET	  	  time	  	  of	  	  flight	  	  camera	  	  that	  	  has	  	  a	  	  significantly	  	  higher	  	  sensitivity	  	  that	  	  the	  	  PET	  camera	  used	  for	  my	  study264.	  
It	   is	  highly	   likely	   that	   sequential	  or	   simultaneous	  acquisition	  of	   functional	   and	  anatomical	  data	  using	  these	  machines	  can	  produce	  outcome	  measures	  that	  combine	  the	  reliability	  and	  anatomic	   precision	   of	  MRI	   data	  with	   the	   responsiveness	   observed	   for	   several	   of	   the	   PET	  measures.	  Exploring	  this	  technology	  is	  an	  exciting	  prospect	  which	  could	  potentially	  lead	   to	  accurate	  characterisation	  of	  Crohn’s	  disease	  inflammatory	  activity	  and	  structural	  burden.	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5.5 REVIEW	  OF	  EXPERIMENTAL	  METHODS	  AND	  LESSONS	  FOR	  FUTURE	  WORK	  
	  
	  
	   This	  project,	   in	  common	  with	  many	  others,	  changed	  direction	  during	  the	  study	  sometimes	  due	  to	  circumstances	  outside	  my	  control.	  In	  addition,	  as	  with	  all	  research	  projects,	  there	   are	  a	  number	  of	  aspects	  which	  in	  retrospect	  could	  have	  been	  performed	  in	  a	  different	  way,	  and	  which	  provide	  useful	  lessons	  in	  how	  to	  plan	  and	  execute	  similar	  studies	  in	  the	  future.	  	  	   5.5.1 CLINICAL	  STUDY	  (CHAPTERS	  2	  &	  3)	  	  	  	   5.5.1.1	  18F-­‐-­‐-­‐IL2	  	  	  	   The	  	  original	  	  aim	  	  of	  	  the	  	  clinical	  	  study	  	  was	  	  to	  	  use	  	  an	  	  18F-­‐-­‐-­‐IL2	  	  probe	  	  under	  	  development	  	  in	  Groningen	  University,	  to	  examine	  the	  hypothesis	  that	  this	  probe	  can	  quantify	  the	  differential	  expression	  	  of	  	  the	  	  IL-­‐-­‐-­‐2R	  	  in	  	  Crohn’s	  	  lesions	  	  versus	  	  un-­‐-­‐-­‐inflamed	  	  tissue	  	  using	  	  clinical	  	  PET	  scanning.	  	  The	  	  aim	  	  therefore	  	  was	  	  to	  	  demonstrate	  	  the	  	  differential	  	  expression	  	  of	  	  IL-­‐-­‐-­‐2R	  	  and	  binding	  	  potential	  	  of	  	  radio-­‐-­‐-­‐labelled	  	  IL-­‐-­‐-­‐2	  	  ex-­‐-­‐-­‐vivo	  	  before	  	  designing	  	  a	  	  pilot,	  	  ‘proof-­‐-­‐-­‐of-­‐-­‐-­‐concept’	  study	  to	  investigate	  this	  new	  radio-­‐-­‐-­‐chemical	  in	  a	  cohort	  of	  Crohn’s	  patients.	  	  	   Approximately	  a	  year	   into	  my	  fellowship	  the	  production	  at	  Groningen	  was	  completed.	  Upon	  attempting	  	  to	  	  replicate	  	  the	  	  production	  	  of	  	  18F-­‐-­‐-­‐IL2	  	  locally,	  	  it	  	  became	  	  clear	  	  that	  	  the	  	  molecule	  was	  being	  split	  in	  two	  at	  some	  stage	  during	  its	  synthesis.	  This	  raised	  important	  safety	  issues	  as	  	  the	  	  pharmacodynamics	  	  of	  	  the	  	  split	  	  product	  	  would	  	  have	  	  been	  	  impossible	  	  to	  	  predict,	  	  and	  the	  	  clinical	  	  scanning	  	  project	  	  was	  	  abandoned	  	  pending	  	  a	  	  full	  	  review	  	  of	  	  the	  	  radio-­‐-­‐-­‐chemical	  method.	  	  	   Several	  	  discussions	  	  during	  	  research	  	  planning	  	  meetings	  	  concluded	  	  that	  	  this	  	  setback	  	  would	  have	  pushed	  	  the	  project	  well	  outside	   its	  original	   timeline	  and	  	  that	  a	   revision	  of	   the	   18F-­‐-­‐-­‐IL2	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production	  	  process	  	  could	  	  not	  	  be	  	  awaited.	  	  Two	  	  decisions	  	  were	  	  made:	  	  Firstly,	  	  to	  	  persevere	  with	  the	  ex-­‐-­‐-­‐vivo	  component	  of	  the	  project,	  which	  would	  still	  be	  valuable	  once	  an	  appropriate	  radio-­‐-­‐-­‐tracer	  	  became	  	  available.	  	  Secondly,	  	  it	  	  was	  	  decided	  	  that	  	  the	  	  whole	  	  clinical	  	  scanning	  study	  	  should	  	  be	  	  redesigned,	  	  with	  	   the	  	   focus	  	  on	  	  exploring	  	  knowledge	  	  gaps	  	   in	  	  currently	  available	  techniques	  such	  as	  FDG-­‐-­‐-­‐PET	  and	  MRI.	  	  	   This	  	  process	  	  made	  	  me	  	  realise	  	  early	  	  in	  	  my	  	  Fellowship	  	  that	  	  major	  	  setbacks	  	  are	  	  frequent	  	  in	  research	  	  and	  	  that	  	  adaptability	  	  in	  	  these	  	  circumstances	  	  is	  	  crucial.	  	  I	  	  was	  	  pleased	  	  to	  	  maintain	  the	   laboratory	  component	  of	   the	   IL-­‐-­‐-­‐2	  work,	  even	   though	   it	  would	  not	  be	  of	  direct	   relevance	  to	  the	  clinical	  study.	  In	  retrospect,	  I	  believe	  that	  the	  resulting	  study	  on	  current	  FDG-­‐-­‐-­‐PET	  and	  MRI	  	  endpoints	  	  was	  	  a	  	  more	  	  useful	  	  training	  	  experience	  	  firstly	  	  because	  	  I	  	  was	  	  exposed	  	  in	  	  the	  complexities	  	  of	  	  larger	  	  recruitment,	  	  and	  	  statistical	  	  and	  	  methodological	  	  considerations	  	  of	  longitudinal	  assessment,	  and	  secondly	  because	  it	  produced	  a	  range	  of	  important	  findings.	  	  	   5.5.1.2 RECRUITMENT	  	  	  	   Another	  	  important	  	  difficulty	  	  was	  	  in	  	  participant	  	  recruitment.	  	  At	  	  the	  	  planning	  	  stages	  	  of	  	  the	  study	  	  it	  	  was	  	  estimated	  	  that	  	  20	  	  of	  	  the	  	  40	  	  patients	  	  anticipated	  	  to	  	  start	  	  anti-­‐-­‐-­‐TNF	  	  therapy	  	  for	  Crohn’s	  	  	  disease	  	  	  at	  	  	  Imperial	  	  	  College	  	  	  Healthcare	  	  	  Trust	  	  	  over	  	  	  an	  	  	  18-­‐-­‐-­‐month	  	  	  period	  	  	  of	  recruitment	  	  would	  	  agree	  	  to	  	  participate	  	  in	  	  our	  	  study	  	  (also	  	  deemed	  	  adequate	  	  using	  	  power	  calculations).	  	  In	  	  practice,	  	  early	  	  uptake	  	  by	  	  potential	  	  participants	  	  was	  	  significantly	  	  slower	  	  at	  about	  	  30%.	  	  The	  	  decision	  	  was	  	  then	  	  made	  	  and	  	  ethical	  	  approval	  	  was	  	  obtained	  	  to	  	  incentivise	  potential	  participants	  by	  offering	  reimbursement	  of	  £170	  for	  each	  of	  the	  two	  scanning	  visits.	  This	  	  had	  	  an	  	  immediate	  	  positive	  	  effect	  	  on	  	  recruitment	  	  rates.	  	  Moreover,	  	  during	  	  the	  	  last	  	  5	  months	  	  of	  	  recruitment,	  	  permission	  	  was	  	  obtained	  	  for	  	  an	  	  additional	  	  centre	  	  to	  	  contribute	  patients	  to	  the	  study.	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A	  major	  learning	  point	  from	  this	  was	  that	  recruitment	  is	  a	  major	  factor	  of	  delay	  in	  projects	  with	  strict	  timelines,	  and	  strategies	  that	  can	  expedite	  it	  should	  be	  implemented	  as	  early	  as	  possible.	  Moreover,	  I	  appreciated	  that	  applications	  to	  the	  REC	  for	  amendments	  and	  external	  R&D	   departments	   to	   broaden	   the	   recruitment	   base	   are	   timely	   processes,	   which	   are	   best	  avoided	  by	  optimising	  the	  recruitment	  strategy	  in	  the	  planning	  stages	  of	  a	  study.	  	  	   5.5.1.3 DETERMINATION	  OF	  THE	  GOLD-­‐-­‐-­‐STANDARD	  	  	  	   This	  was	  a	  major	  point	  of	  contention	  during	  the	  planning	  of	  the	  scanning	  study.	  This	   is	  an	  issue	   that	   is	  shared	  with	  all	  studies	  examining	  novel	  biomarkers	   in	  CD.	  One	  option	  was	   to	  use	  endoscopy	  and	  CDEIS	  scoring	  concurrently	  to	  the	  two	  scans.	  This	   is	   the	  best	  validated	  technique	  against	  which	  all	  the	  scanning	  endpoints	  could	  have	  been	  compared.	  Factors	   that	  weighed	  against	  its	  use	  were	  the	  invasiveness	  of	  the	  test,	  and	  as	  such	  its	  potential	  negative	  effect	   on	   recruitment,	   as	   well	   as	   the	   inability	   to	   inform	   on	   components	   of	   disease	   load	  assessed	   by	   the	   scanning	   methods	   such	   as	   small	   bowel	   lesions	   proximal	   to	   the	   terminal	  ileum	  or	  on	  tissue	  planes	  deeper	  than	  the	  mucosa.	  	  	   In	  	  planning	  	  future	  	  studies,	  	  an	  	  alternative	  	  strategy	  	  to	  	  that	  	  of	  	  exclusive	  	  reliance	  	  on	  	  HBI	  	  to	  determine	  	  our	  	  responder	  	  and	  	  non-­‐-­‐-­‐responder	  	  group	  	  could	  	  be	  	  a	  	  consensus	  	  panel	  	  including	  other	  	  markers	  	  such	  	  as	  	  CRP	  	  and	  	  FC	  	  to	  	  determine	  	  the	  	  response	  	  status	  	  of	  	  each	  	  individual	  patient.	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5.5.1.4 VOLUME	  OF	  INTEREST	  PLACEMENT	  	  	  	   The	  	  VOIs	  	  both	  	  in	  	  PET	  	  scans	  	  and	  	  MRIs	  	  were	  	  drawn	  	  by	  	  myself	  	  and	  	  then	  	  corroborated	  	  by	  	  a	  Consultant	  	   in	  	  Nuclear	  	  Medicine	  	  or	  	  an	  	  MRI	  	  radiologist	  	  respectively.	  	  This	  	  approach	  	  was	  chosen	   in	   an	   attempt	   to	  maximise	  my	   training	   in	   the	   techniques	   of	   scanning	   interpretation	  and	  	  VOI	  	  derivation.	  	  	  	  	  	  A	  	  more	  	  robust	  	  way	  	  of	  	  producing	  	  the	  	  VOIs	  	  may	  	  have	  	  been	  	  for	  	  the	  experts	  	  to	  	  derive	  	  theirs	  	  independently	  	  and	  	  subsequently	  	  compare	  	  these	  	  with	  	  my	  	  own	  	  in	  	  a	  blinded	  fashion.	  This	  would	  also	  have	  allowed	  a	  formal	  inter-­‐-­‐-­‐observer	  variability	  estimation.	  A	  	  similar	  	  point	  	  can	  	  be	  	  made	  	  for	  	  the	  	  method	  	  of	  	  histological	  	  and	  	  immunohistochemichal	  scoring	  of	  the	  biopsies	  by	  the	  junior	  and	  senior	  histopathologist.	  	  	   5.5.1.5 ASSESSMENT	  OF	  LUMINAL	  COMPONENT	  OF	  FDG	  SIGNAL	  	  	  	   The	  observation	  that	  the	  highest	  signal	   intensity	  is	  observed	  from	  the	  centre	  of	  an	  intestinal	  section,	  and	  the	  hypothesis	  of	  a	   luminal	  component	  of	  FDG	  signal	  was	  suggested	  at	  the	  later	  stages	  of	  the	  study.	  At	  that	  stage	  there	  was	  only	  a	  limited	  number	  of	  patients	  remaining	  who	  had	  	  distal	  	  distribution	  	  of	  	  CD	  	  (n=3)	  	  on	  	  which	  	  this	  	  hypothesis	  	  could	  	  be	  	  tested	  	  using	  	  the	  	  pre	  and	  	  	  post	  	  	  enema	  	  	  study.	  	  	  Moreover,	  	  	  the	  	  	  direct	  	  	  method	  	  	  of	  	  	  measuring	  	  	  radio-­‐-­‐-­‐activity	  	  	  in	  eliminated	  	  bowel	  	  contents	  	  and	  	  expressing	  	  it	  	  as	  	  a	  	  fraction	  	  of	  	  the	  	  total	  	  FDG	  	  activity	  	  in	  	  that	  segment	  was	  only	   implemented	   in	   the	   latter	   two	  patients,	  while	   the	   first	   underwent	   repeat	  PET	  	  scanning	  	  following	  	  the	  	  enema	  	  administration	  	  which	  	  introduced	  	  significant	  	  sources	  	  of	  error	  in	  the	  interpretation.	  	  	   This	  highlights	  the	  importance	  of	  a	  thorough	  interim	  analysis	  of	  the	  images	  or	  other	  data	   as	  this	   hypothesis	   could	   have	   been	   formulated	   earlier	   in	   the	   process,	   and	   tested	   on	   a	   larger	  number	  of	  participants,	  hence	  producing	  more	  conclusive	  results.	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5.5.2. LABORATORY	  STUDIES	  (CHAPTER	  4)	  	  	  	   5.5.2.1 POOR	  DEFINITION	  OF	  THE	  IHC	  CONTROL	  GROUPS	  	  	  	   In	   order	   to	   retrieve	   appropriate	   FFPE	   biopsies	   and	   sections	   for	   the	   immunohistochemichal	  expression	  	  of	  	  TSPO	  	  and	  	  IL-­‐-­‐-­‐2R,	  	  the	  	  electronic	  	  database	  	  of	  	  the	  	  Histopathology	  	  Department	  was	   interrogated	   for	   ‘findings’.	  GI	  specimens	  coded	  as	   ‘normal	  bowel’	  were	  used	  as	  controls	  without	  	  	  assessment	  	  	  of	  	  	  the	  	  	  demographics	  	  	  or	  	  	  indication	  	  	  of	  	  	  the	  	  	  endoscopy/surgery.	  	  	  	  	  A	  potential	   source	  of	  error	  here	  could	  have	  been	   that	  un-­‐-­‐-­‐inflamed	  samples	   from	  patients	  with	  either	  	  IBD	  	  or	  	  other	  	  inflammatory	  	  conditions	  	  may	  	  have	  	  been	  	  included	  	  in	  	  the	  	  control	  	  group	  masking	  	  	  any	  	  	  differences	  	  	  between	  	  	  it	  	  	  and	  	  	  the	  	  	  CD	  	  	  samples.	  	  	  A	  	  	  cross-­‐-­‐-­‐interrogation	  	  	  of	  	  	  the	  endoscopic	  	  database	  	  would	  	  have	  	  ensured	  	  that	  	  normal	  	  specimens	  	  are	  	  not	  	  derived	  	  from	  	  CD	  patients.	  The	  strict	  definition	  of	   the	  control	  group	   is	  a	  crucial	  step	   in	  study	  design,	  and	  care	  must	  be	  exercised	  in	  its	  detailed	  designation.	  	  	   5.5.2.2 SUBOPTIMAL	  OPTIMISATION	  OF	  THE	  TECHNIQUE	  OF	  SNAP-­‐-­‐-­‐FREEZING	  	  	  	   My	  training	  on	  tissue	  snap-­‐-­‐-­‐freezing	  and	  subsequent	  sectioning	  on	  the	  cryotome	  was	  done	  on	  porcine	  	  tonsils,	  	  which	  	  were	  	  available	  	  at	  	  the	  	  lab	  	  at	  	  the	  	  time.	  	  When	  	  the	  	  first	  	  human	  	  gut	  specimens	  	  were	  	  collected,	  	  several	  	  difficulties	  	  arose.	  	  Firstly,	  	  the	  	  method	  	  of	  	  immersing	  	  	  the	  tissue	  	  in	  	  the	  	  isopentane/dry	  	  ice	  	  solution	  	  resulted	  	  in	  	  the	  	  folding	  	  and	  	  malrotation	  	  of	  	  the	  specimen.	  	  This	  	  step	  	  could	  	  not	  	  have	  	  been	  	  reversed	  	  and	  	  repeated.	  	  After	  	  several	  	  attempts,	  	  a	  variation	  	  of	  	  the	  	  process	  	  where	  	  the	  	  snap-­‐-­‐-­‐freezing	  	  solution	  	  was	  	  poured	  	  over	  	  the	  	  fixed	  	  gut	  section	  was	  implemented,	  producing	  much	  better	  tissue	  orientation.	  Secondly,	  as	  the	  various	  gut	  	  	   layers	  	  	  are	  	  	  of	  	  	  very	  	  	  different	  	  	  consistencies,	  	  	  sectioning	  	  	  on	  	  	   the	  	  	  cryotome	  	  	  proved	  significantly	  	  more	  	  challenging	  	  than	  	  with	  	  the	  	  porcine	  	  tonsils.	  	  It	  	  would	  	  have	  	  been	  	  much	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preferable	  if	  the	  training	  had	  taken	  place	  in	  animal	  gut	  specimens,	  as	  those	  challenges	   could	  have	  been	  resolved	  before	  working	  with	  the	  limited	  human	  tissue	  that	  was	  available.	  	  	   5.5.2.3 LIMITED	  AMOUNT	  OF	  FRESH	  TISSUE	  	   Another	  major	   limitation	  	  of	   the	  autoradiographic	  and	  	  homogenate	  binding	   studies	  was	   the	  amount	  	  of	  	  tissue	  	  obtained	  	  from	  	  each	  	  participant.	  	  My	  	  concern	  	  when	  	  applying	  	  for	  	  ethics	  approval	  was	  to	  avoid	  the	  criticism	  of	  compromising	  the	  clinical	  histo-­‐-­‐-­‐pathological	  reporting	  of	   the	   specimens	  by	   removing	   too	  much	   tissue	  at	   the	   time	  of	   the	  operation.	   It	   subsequently	  transpired	  	  that	  	  the	  	  approved	  	  thickness	  	  of	  	  5mm	  	  from	  	  each	  	  section	  	  impacted	  	  negatively	  	  on	  both	  the	  number	  of	  sections	  for	  autoradiography	  as	  well	  as	  the	  tissue	  that	  was	  subsequently	  available	  for	  homogenisation.	  	  	   The	  	  lesson	  	  from	  	  this	  	  was	  	  that	  	  while	  	  it	  	  is	  	  important	  	  to	  	  demonstrate	  	  to	  	  the	  	  REC	  	  that	  	  the	  impact	  of	  a	  research	  project	  on	  clinical	  care	  is	  minimised,	  it	  is	  equally	  vital	  that	  the	  quality	  of	  experimental	   data	   resulting	   from	  	  the	   study	   is	   optimised.	   In	   retrospect,	   section	   thickness	   of	  20-­‐-­‐-­‐25mm	  	  	  	  instead	  	  of	  	  the	  	  proposed	  	  5mm	  	  would	  	  have	  	  enabled	  	  me	  	  to	  	  produce	  	  much	  	  more	  robust	  data	  without	  impacting	  on	  the	  histo-­‐-­‐-­‐pathological	  reporting	  of	  the	  specimens.	  	  	   In	   conclusion,	  most	  of	   the	  above	   learning	  points	   are	  a	   testament	   to	   the	   importance	  of	   the	  planning	  stages	  of	  each	  study.	  The	  planning	  meetings	  are	  opportunities	   for	  weaknesses	   in	  the	   hypotheses,	   study	   design,	   methodology	   and	   proposed	   analysis	   to	   be	   identified	   and	  addressed	  early	  and	  effectively.	  If	  this	  is	  not	  achieved	  then	  their	  impact	  on	  the	  output	  of	   the	  project	   is	   often	   irreversible.	   An	   additional	   learning	   point	   is	   that	   adaptability	   during	   the	  execution	  of	  a	  research	  project	  is	  very	  important	  so	  that	  adjustments,	  when	  required,	  can	  be	  made	  early	  rather	  than	  late.	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5.6	  CONCLUSION	  
In	  	  	  conclusion,	  	  Crohn’s	  	  	  disease	  	  	  is	  	  	  a	  	  	  condition	  	  	  with	  	  	  a	  	  	  rapidly	  	  	  modifiable	  	  	  inflammatory	  component,	   and	   significant	   long-­‐-­‐-­‐term	   structural	   sequelae.	   Through	   this	   project	   I	   attempted	  to	  demonstrate	  the	  need	  for	  new	  outcome	  measures	  that	  can	  improve	  monitoring	  of	  disease	  activity,	   assessment	  of	   therapeutic	   success,	  as	  well	  as	   the	  efficiency	  of	   the	  processes	   in	  new	  drug	   development.	   This	   study	   shows	   that	   both	   anatomical	  MRI	   scores	   as	  well	   as	   functional	  PET	  	  	  	  measures,	  	  	  	  either	  	  	  	  using	  	  	  	  FDG	  	  	  	  or	  	  	  	  alternative	  	  	  	  radioligands	  	  	  	  more	  	  	  	  specific	  	  	  	  to	  	  	  	  the	  inflammatory	  	  pathway,	  	  have	  	  the	  	  potential	  	  to	  	  fulfill	  	  some	  	  of	  	  these	  	  roles.	  	  These	  	  pilot	  	  results	  can	  	  be	  	  used	  	  as	  	  a	  	  guide	  	  to	  	  determine	  	  appropriate	  	  combinations	  	  of	  	  outcome	  	  measures	  	  and	  scanning	  	  intervals,	  	  in	  	  order	  	  to	  	  conduct	  	  larger	  	  studies	  	  that	  	  could	  	  further	  	  establish	  	  them	  	  as	  valid	  instruments	  in	  clinical	  practice	  or	  early	  clinical	  trials.	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Dear Dr Russo 
 
Study Title: Investigation into the differences on the expression of 
 Translocator Protein and Interleukin-2 in stored biopsy 
 and tissue specimens of healthy bowel and bowel from 
 Crohn's Disease patients, as assessed by 
 immunohistochemistry. 
REC reference number: 10/H0801/59 
 
The Research Ethics Committee reviewed the above application at the meeting held on 15 
November 2010. Thank you for attending to discuss the study. 
 
Ethical opinion  
You were told that the Committee found no ethical issues with this project, you said 
that there was an excellent laboratory available with the pre-2006 tissue which could 
be used for the project, and that you did not believe that there would be any 
significant changes in that tissue compared to that collected post-2006. 
 
The members of the Committee present gave a favourable ethical opinion of the 
above research on the basis described in the application form, protocol and supporting 
documentation, subject to the conditions specified below. 
 
Ethical review of research sites  
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
 
 
Conditions of the favourable opinion  
The favourable opinion is subject to the following conditions being met prior to the start 
of the study. 
 
Management permission or approval must be obtained from each host organisation prior 
to the start of the study at the site concerned. 
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be obtained from the relevant care organisation(s) in accordance with NHS research 
governance arrangements. Guidance on applying for NHS permission for research is 
available in the Integrated Research Application System or at 
http://www.rdforum.nhs.uk. 
 
Where the only involvement of the NHS organisation is as a Participant Identification Centre 
(PIC), management permission for research is not required but the R&D office should be 
 
for PICs is available in IRAS. Further advice should be sought from the R&D office where 
necessary. 
 
Sponsors are not required to notify the Committee of approvals from host organisations. 
 
It is responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
The documents reviewed and approved at the meeting were:  
 Document   Version   Date  
 Investigator CV   Dr Russo     
 Protocol  2 October 2010 28 October 2010 
 cv of supervisor      01 June 2010 
 REC application  56854/161571/1/482  29 October 2010 
 Summary/Synopsis  1   29 October 2010 
 Letter from Sponsor   CRO1773 26 October 2010 
 Evidence of insurance or indemnity   PIMP00510 29 July 2010 
 
Membership of the Committee  
The members of the Ethics Committee who were present at the meeting are below. 
 
Statement of compliance  
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
After ethical review  
Now that you have completed the application process please visit the National Research 
Ethics Service website > After Review 
 
You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure. If you wish to make 
your views known please use the feedback form available on the website. 
 
guidance for r  
guidance on reporting requirements for studies with a favourable opinion, including: 
 
Notifying substantial amendments 
Adding new sites and investigators 
Progress and safety reports   
Notifying the end of the study  
 
The NRES website also provides guidance on these topics, which is updated in the light 
of changes in reporting requirements or procedures. 
 
 
We would also like to inform you that we consult regularly with stakeholders to improve our 
service. If you would like to join our Reference Group please email 
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referencegroup@nres.npsa.nhs.uk. 
 
10/H0801/59 Please quote this number on all correspondence 
 








pp. Dr Shelley Dolan          
Chair           
Email: Rosalind.cooke@imperial.nhs.uk      
            
Enclosures: guidance for researchers      
            
Copy to: Lucy Parker, Imperial College      
     South West London REC 1      
  Attendance at Committee meeting on 15 November 2010      
 Committee Members:          
 Name   Profession   Present    
 Mr Roger AHern   Medical Statistician Yes  
 Dr. Sonya  Babu-Narayan  Cardiologist Specialist Registrar Yes  
 Mr Jeremy Butler   NHS Non Executive Director Yes  
 Dr Robin Chung   Academic Medicine Trainee doctor and Engineer Yes  
 Dr Shelley Dolan   Chief Nurse Yes  
 Dr Adam Jacobs   Medical Statistician No  
 Mr Simon Jordan   Consultant Thoracic Surgeon No  
 Mr Philip  Kimberley   Clinical Governance Information Manager Yes  
 Mrs Patricia Pank   Retired University Lecturer Yes  
 Dr Nazima  Pathan   Consultant PICU No  
 Mrs Paula Rogers   Research Nurse Manager No  
 Ms Cate Savidge   CT Scanning Superintendent Yes  
 Dr Elliot Shinebourne   Consultant Paediatric Cardiologist Yes  
 Dr Mary Taj   Consultant Paediatric in Oncologist Yes  
Also in attendance:           
 Name    Position (or reason for attending)      
 Mrs Rosalind Cooke    Co-ordinator      










NRES Committee South East Coast - Surrey 
HRA 
Research Ethics Committee (REC) London Centre 
Ground Floor  




Telephone: 020 797 22552 
Facsimile: 020 797 22592 
20 August 2012 
 
Dr Evangelos Russo 
Imanova, Burlington Danes Building 
Hammersmith Campus 
Du Cane Road 
W12 0NN 
 
Dear Dr Russo 
 
Study title: Longitudinal assessment of tissue responses to 
anti-TNFα therapy in Crohn's Disease 
REC reference: 12/LO/1018 
 
The Research Ethics Committee reviewed the above application at the meeting held on 




The following issues were discussed with you. 
 
i. The Committee enquired whether the PET scan and oncology would detect chemo and 
will not affect clinical practice. The Committee discussed the biological with you and you 
explained that the clinical team look at different pathways and may not stop the biological 
all together.   
ii. The Committee queried whether the PET and CT are intended for the abdomen and 
chest; you explained that it will be looking at the abdomen and pelvis.   
iii. The Committee queried the amount of radiation, you explained that the radiation 
satisfies clinical practice.   
iv. The Committee queried whether the colonoscopy would be a higher risk in chromes, 
you reassured the Committee that it isn’t and summarised the risk and procedures.   
v. The Committee explained that the sharing of data with pharmaceutical companies 
should be in the consent form.  
 
The members of the Committee present gave a favourable ethical opinion of the 
above research on the basis described in the application form, protocol and 
supporting documentation, subject to the conditions specified below.  
 
Ethical review of research sites  
 
NHS Sites  
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start 
of the study (see “Conditions of the favourable opinion” below).  





Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start 
of the study. 
 
Management permission or approval must be obtained from each host organisation prior 
to the start of the study at the site concerned. 
 
Management permission (“R&D approval”) should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the 
Integrated Research Application System or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with 
the procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
1. The PIS needs to include safety guidelines and risks including driving after having 
the procedure.   
2. In the section ‘will my taking part in the study be kept confidential’ there is missing 
text which should read ‘on hospital computers’.  
 
It is responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable).  
 
You should notify the REC in writing once all conditions have been met (except for 
site approvals from host organisations) and provide copies of any revised 
documentation with updated version numbers. Confirmation should also be 
provided to host organisations together with relevant documentation  
 
Approved documents  
 








Covering Letter  06 June 2012 
 
     
Evidence of insurance or indemnity  28 July 2011 
 
     
GP/Consultant Information Sheets 1 10 May 2012 
 
      
Investigator CV Evangelos    
 
 Russo    
 
Letter from Sponsor  30 May 2012 
 
     
Letter from Statistician  23 February 2012 
 
      
Other: NIHR CRN Portfolio Application Form 3.4    
 
     
Other: Non-NHS SSI 3.4 01 June 2012 
 
     
Other: Letter from Funder  29 May 2012 
 
      
Other: Supervisor CV: Timothy Orchard     
 
     
Participant Consent Form 1 30 May 2012 
 
       





Participant Information Sheet 1 30 May 2012 
    
Protocol 1 06 June 2012 
    
Questionnaire: Validated: HBI    
    
REC application 100826/3308 30 May 2012 
 69/1/529   
Referees or other scientific critique report  29 March 2012 
   
Summary/Synopsis  29 May 2012 
    
 
Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting are listed on 
the attached sheet. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK. 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments  
• Adding new sites and investigators  
• Notification of serious breaches of the protocol  
• Progress and safety reports  
• Notifying the end of the study  
 
The NRES website also provides guidance on these topics, which is updated in the light 




You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure. If you wish to make 
your views known please use the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review 
 
12/LO/1018 Please quote this number on all correspondence 
 








Prof David Russell-Jones 









Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments 
“After ethical review – guidance for researchers” 
 
Copy to: Ms Becky  Ward, AHSC Joint Research Compliance Office 





 NRES Committee South East Coast - Surrey 
 Attendance at Committee meeting on 10 July 2012 
Committee Members:    
    
Name Profession Present Notes 
Dr Julia Boyle Director Surrey Yes  
  CRC/Pharmacologist   
Miss Elizabeth  Cheshire Consultant in Emergency No  
  Medicine   
Dr Matthew Dickinson Consultant Anaesthetist No  
    
Mrs Margaret Handyside Lay Member Yes  
    
Dr Stephen Houston Consultant Medical Yes  
  Oncologist   
Ms Wendy Joy Lay Member Yes  
    
Mrs Chrissie Lawson Nurse Specialist Yes  
     
Dr Charles Li Consultant Physician Yes  
     
Ms Georgina Marshall Coordinator Yes  
    
Mr Michael Morris Lay Member Yes  
    
Dr JHP Powell Consultant Physician Yes  
    
Prof David Russell-Jones Professor of Diabetes Yes  
  and Endocrinology   
Mrs Ann Sayer Lay Member Yes  
    
Dr L Selby General Practitioner No  
     
Dr Jane Stuart Public Health Yes  
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Volunteer Information Sheet 
 
You will be given a copy of this Information Sheet to keep. 
 
Radioligands for TSPO and IL2 in Crohn’s Disease 
 
Chief Investigator: Dr Evangelos Russo 
 
You are being invited to take part in a research study. Here is some 
information to help you decide whether or not to take part. Please read the 
following information carefully and discuss it with friends, relatives and your 
General Practitioner (GP) if you wish. Ask us if there is anything you do not 
understand or if you would like further information. Please take your time to 
decide whether or not you wish to take part in this study.   
 
What is the purpose of the study? 
 
Our aim is to investigate in the laboratory how gut cells from patients with 
Crohn’s Disease interact with chemical imaging agents used to demonstrate 
inflammation . These cells will be obtained from sections of bowel removed at 
operation. The agents we are investigating are already in use in the imaging 
of other inflammatory conditions. If our study shows that these agents attach 
themselves preferentially to inflamed gut cells, then we will investigate using 
them in scanning techniques to help detect and monitor Crohn’s Disease. 
 
Why have I been chosen? 
 
The reason we have approached you for this study is because you and your 
Gastroenterology physician have decided that the best course of action for 
your symptoms is to have an operation to remove a diseased bowel segment. 
 
Do I have to take part? 
 
No, it is up to you to decide whether or not to take part. If you do decide to 
take part you will be given this information sheet to keep and be asked to sign 
a consent form. You will always be able to withdraw at any time and without 
giving a reason.  
 
What will happen to me if I take part? 
 
1. Blood test:  
You will be asked to donate a blood sample (maximum 50ml, 3 
tablespoons) before surgery. 
2. Intestinal samples 
Surgery to remove a diseased segment  routinely involves removing all 
the diseased part as well as a rim of healthy bowel on each side, as 
surgeons always prefer joining together healthy bowel edges after 
resection. Parts, but not all of this diseased area and healthy rim of  
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bowel are then examined under the microscope by histopathology 
specialists as a routine.  
If you agree to take part in our study, the histopathologists will provide 
us with one small part of the diseased section and one small part of the 
healthy edge which is not necessary for their analysis. We would like to 
emphasise that if you chose to participate in our study, this will NOT 
result in your surgeon removing any additional bowel during your 
surgery than he/she would normally remove. We would also like to 
reassure you that , if you decide to donate these parts of tissue for our 




What do I have to do? 
 
To take part in the study you will need to provide us with a blood sample 
around the time of your operation (this can be obtained at the same time as 
blood tests requested by your clinical team). In addition, you have to give your 
permission for the pathology department of the hospital to provide us with the 
two specimens described above. This can be done by signing our consent 
form. 
 
What is being tested? 
 
We are testing to see if the inflamed and non-inflamed sections of your bowel 
wall respond differently to our imaging markers. 
 
Where will the tests take place? 
 
Your specimens and blood sample will be frozen and stored at the Burlington 
Dane Building, Imperial College, Hammersmith Hospital Campus, and 
analysed  at Imperial College. Other onsite laboratories may also be used, 
such as the Biology laboratories at the GlaxoSmithKline Clinical Imaging 
Centre on the Hammersmith Hospital site. 
 
What will happen to my samples after this project is completed? 
 
Unused blood or tissue samples will be will remain anonymised (given a study 
code) and stored. These samples may be used in relevant future projects, 
provided appropriate ethical approval is granted. 
Your samples may be stored for a maximum of 15 years in authorized storage 
facilities of the university following which they will be destroyed.  
 
 
What are the possible disadvantages and risks of taking part? 
 
Blood tests can cause brief discomfort, and bruising which may persist several 
days.  
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What are the possible benefits of taking part? 
 
You are not expected to gain any direct personal benefit in terms of improved 
health, fitness or sense of well-being from taking part in this study. Therefore 
we will not be informing our participants individually about the results of our 
experiments. 
 
What if something goes wrong because of this study? 
 
Imperial College London holds insurance policies which apply to this study.  If 
you experience serious and enduring harm or injury as a result of taking part 
in this study, you may be eligible to claim compensation without having to 
prove that Imperial College is at fault.  This does not affect your legal rights to 
seek compensation. If you are harmed due to someone’s negligence, then 
you may have grounds for a legal action.  Regardless of this, if you wish to 
complain, or have any concerns about any aspect of the way you have been 
treated during the course of this study then you should immediately inform the 
Investigator (Evangelos Russo 0208 008 6178).  The normal National Health 
Service complaint complaints mechanisms are also available to you.  If you 
are still not satisfied with the response, you may contact the Imperial AHSC 
Joint Research Office.   
 
 
What will happen if I don’t want to carry on with the study? 
 
Since this research study is voluntary, you are free to withdraw at any time, 
without giving a reason. If you wish to withdraw from our study, we may still 
use your specimens and blood sample unless you specifically request that we 
destroy them. 
 
Will my taking part in this study be kept confidential? 
 
All information that is collected about you during the course of the study will 
be kept confidential to the extent permitted by law. If you join the study, some 
parts of the data collected for the study will be looked at by authorized 
persons at Imperial College London.  They may also be looked at by 
representatives of regulatory authorities and by authorized people (from the 
Trust, other NHS bodies) to check that the study is being carried out correctly. 
All will have a duty of confidentiality to you as a research participant and 
nothing that could reveal your identity will be disclosed outside the research 
site.   
 
What will happen to the results of the research study? 
 
We will aim to publish the results of this study in an appropriate medical 
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Who is organising and funding the research? 
 
This research is organised by Imperial College London. The project is co-
ordinated by the Chief Investigator, Dr Evangelos Russo, whose salary is paid 
by Imperial College London, The Wellcome Trust and GlaxoSmithKline. No 
member of the research team is being paid to individually recruit people. 
 
Expenses and payments 
 
There will be no payments for participating in this study. 
 
 
Who has reviewed the study? 
 
This research study has been reviewed by an ethics committee - a committee 
of people separate from your doctor, whose primary concerns are the safety, 
rights and welfare of patients on this study. The South East London 5 ethics 
committee has reviewed and approved all written materials about this study 
including this information sheet.  
 
Contact for Further Information 
 
Please ask any questions now that you wish to. A copy of this information and 
of the consent forms will be given to you to keep. If any questions occur to you 
later, or you have other concerns or would like to discuss any aspect of the 
study, please contact the following persons: 
 
Evangelos Russo – 0208 008 6178 
 
THIS INFORMATION SHEET IS VALID FOR USE UNTIL:  
 
Signed (REC Chairman)               Date
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Title of project:       Radioligands for TSPO and IL2 in Crohn’s Disease 
 




Study Number:   
The participant should complete this whole sheet himself or herself. 
(please initial each statement if it applies to you) 
 
I have read the Information Sheet (version 2, 09 Feb 2011)            
 
 
I have been given the opportunity to ask questions and 
discuss this study.          
 
I have received satisfactory answers to all my questions.     
 
I have received enough information about the study.      
 
I agree that my medical information can be shared and that blood  
samples and tissue from my gut may be frozen and stored during  
the course of the study, as explained in the sheet for research participants.  
 
I understand that sections of any of my notes may be looked at by  
responsible individuals from Imperial College London, the Trust or from  
regulatory authorities where it is relevant to my taking part in this research.  
I give permission for these individuals to access my records that  
are relevant to this research. 
 
I understand that I am free to withdraw from 
this research study at any time, without having to give a reason for 
withdrawing and without affecting my future medical care.  
 
I agree to allow the research team to obtain a blood sample and two  
segments from  the part of bowel removed during surgery, which  I  
donate for research purposes.   
 
The study has been explained to me by:  
Prof/Dr/Mr/Mrs/Ms_______________________________________ 
 
I agree to take part in this study. 
 
Signed.................................................................................Date................................. 
(NAME IN BLOCK 
CAPITALS).............................................................................................…………….. 
 
Investigator’s signature....................................................…Date: .............................. 
(NAME IN BLOCK 
CAPITALS)...................................................................................……………………... 
 
1 copy for participant 
1 copy for investigator 
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1 copy to be filed in notes where relevant 
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We would like to invite you to take part in our research study. Before you decide we 
would like you to understand why the research is being done and what it would 
involve for you.  
A member of our team will go through the information sheet with you and answer 
any questions you may have. You may wish to talk to others about the study to help 
you make your decision. Remember that even if you agree to take part, you may 
change your mind at any time and leave the study without having to give a reason.  
 
What is the purpose of the study? 
This study is part of an Imperial College Research degree  (PhD) on “The application 
of novel imaging modalities in the investigation of clinical outcomes in Crohn’s 
Disease” 
We are trying to understand the effect the new “anti-TNF” treatment you are about 
to start on has on the inflammation of your bowel. We want to assess this effect by 
testing chemicals in your blood and your faeces, as well as doing special scans of 
your bowels that help us see inflammation. 
 
Title:  Longitudinal assessment of tissue responses to anti-TNF therapy in Crohn’s Disease  
Protocol Number: CRO1973 
Version:  9, 28 January 2014 
Date Approved:  
Imanova	  Imaging	  Unit	  
Hammersmith	  Hospital	  
Du	  Cane	  Road	  
London	  
W12	  0NN	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Why have I been invited? 
You and your gastroenterologist have decided that the best course of action to 
manage your Crohn’s Disease is to start one of the powerful “anti-TNF” 
medications.  To help us understand how to better use this kind of medicine in the 
future, we are studying its effects on chemicals in the blood and on special kinds of 
images.  As you are just about to start one of these medicines, we are inviting you to 
participate in our study so that we can watch how things change over the first weeks 
that the medicine is used. 
Do I have to take part? 
No. It is up to you to decide if you want to take part in this study.  If you decide to 
take part you will be asked to sign a consent form. You will be given a copy of this 
for you to keep.   
Your General Practitioner (GP) will also be informed that you have volunteered for 
this study and will be asked if he/she knows any reason why you should not take 
part.   
You would still be free to withdraw from the study at any time.  
The investigator or study doctor also could ask you not to participate in the study if 
he or she feels that your health might be affected by the study, if useful results will 
not be able to be obtained or for other administrative reasons.   
 
What will happen to me if I take part? 
This study involves your participation on 5 different occasions.  
 
Screening Visit 
Outpatient department of your treating hospital or Imanova ImagingCentre. 
 
If you agree to take part in this study you will be asked to come to a screening visit, 
when we will discuss any medical problems you have had and give you a brief 
medical examination. We will ask you about your health, symptoms, information 
about any medications you are taking, smoking of cigarettes, use of alcohol and 
drugs, as well as the history of any similar disorders in your family. In addition, 
during screening, blood and urine samples (including a urine pregnancy test) will be 
taken for routine safety tests. No more than 30ml of blood (5 teaspoon) will be 
obtained at this visit. We will also ask you to bring a stool sample on the day, in a 
specialised contained which will be provided in clinic. Finally, we will give you a 
brief questionnaire and examine you to assess the severity of your Crohn’s. The 
whole of the screening visit should not last longer than 60 minutes in total. 
 
If no problems are identified that would prevent you from safely contributing useful 
results for the study, you will be invited to come to the Imanova Imaging Centre at 
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the Hammersmith Hospital in London for two scanning visits. Wherever possible, 
for your convenience, we will try to combine the Screening Visit and the Scanning 
Visit 1 (see below), and they will both take place at the Imaging Centre.  
 
Scanning Visit 1 
Imanova ImagingCentre, Hammersmith Hospital campus 
 
This visit will take place within 2 weeks of your screening visit. It will be at the 
Imanova Imaging Centre based at Hammersmith Hospital. It should last no longer 
than 5 hours and will involve the following: 
1) Being registered as a patient at Hammersmith Hospital. The research team 
will organize this for you 
2) A repeat of the same questionnaire and physical examination to re-assess the 
severity of your Crohn’s disease at the time of the visit 
3) A blood test (no more than 20ml or 3.5 teaspoons) 
4) A stool test (You will be asked to bring in a sample on the day) 
5) A urine pregnancy test (if positive then no scanning will take place) 
6) A positron emission tomography or “PET” scan 
7) An Magnetic Resonance Imaging or “MRI” scan (optional) 
 
Scanning Visit 2 
Imanova ImagingCentre, Hammersmith Hospital campus 
 
This will take place either 6 or 12 weeks after starting your new anti-TNF treatment. 
It will be identical to the first scanning visit. 
 
Study Visit  3 
Imanova ImagingCentre or Outpatient department of your treating hospital 
 
This will take place approximately 4 months after starting the anti-TNF treatment 
and it can take place either at Imanova Imaging Centre or the outpatient clinic of the 
hospital where your Crohn’s Disease is looked after. No additional scanning will 
take place at this visit.  It should last no longer than 1 hour and will involve the 
following 
 
1) The same questionnaire and physical examination to assess the severity of 
your Crohn’s disease 
2) A blood test (no more than 20ml or 3.5 teaspoons) 
3) A stool test (You will be asked to bring a sample on the day) 








Final Study Visit 
Endoscopy Department of your treating hospital  
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This visit will take place approximately 6 months after the anti-TNF treatment has 
started. It may happen sooner if your physician decides that the treatment is not 
helping you enough to continue. It will happen at the endoscopy department of the 
hospital where your Crohn’s Disease is looked after. It should last no longer than 4 
hours, although the colonoscopy itself takes approximately 40 minutes. It will 
involve the following: 
 
1) The same questionnaire and physical examination to re-assess the severity of 
your Crohn’s disease 
2) A blood test (no more than 40ml or 7 teaspoons) 
3) A stool test (You will be asked to bring a sample on the day) 
4) A colonoscopy 
5) A discussion around the medication you have taken for your Crohn’s 
 
 
What does the PET Scan involve? 
“PET” or Positron Emission Tomography relies on a sensitive machine that can “see” 
small amounts of radiation released from a sugar molecule (FDG or [18F]fluoro-
deoxyglucose),   which we will inject into your body to be taken up in areas of 
inflammation in your bowel. When this sugar molecule is taken up by the cells, the 
small amounts of radiation released can be detected by the PET scanner to produce 
three-dimensional images showing us where they are in the body. 
 
Before the beginning of the PET scan, you will have a “cannula” inserted in a vein. 
Cannulae are very small (about the thickness of a piece of string), flexible plastic 
tubes which are inserted through the skin into a blood vessel to make it easier to 
withdraw blood samples or inject a medicine.   
 
After the cannula has been inserted, approximately 20ml of blood will be withdrawn 
for tests and then you will be injected with the sugar molecule known as FDG and 
then you will ask to rest in a quiet room for 60 minutes, while it is  absorbed in the 
tissues. During that time you will be asked to drink approximately 800ml (1 and one 
half pints) of a contrast  solution that helps to open up the small bowel so that it is 
easier to see in the scan. Once the 60 minutes have passed, and before you are moved 
into the scanner, you will be given a medicine (buscopan) through the cannula that 
stops the bowel from contracting during the scan.  
 
Immediately afterwards, you will be placed on the scanning bed of the PET scanner. 
Soft foam pads will be placed around your head and upper body to make you more 
comfortable and to help you to remain still during the scan. Once you are 
comfortable, the bed will be moved into the scanner.  
 
While you are lying still in the scanner, you may experience stiffness, discomfort 
from the pressure of the bed or mild backache.  The foam pads provided should help 
to reduce this and the staff will help you to gently shift your position, if necessary.  
Staff will always be on hand to help you and to minimize any discomfort. 
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The PET scan will last up to 30 minutes, during which you should try to keep as still 
as possible. If necessary, the scan can be interrupted in order to have a break. 
 
On some occasions, where radioactivity accumulates in the lower end of the bowel 
we may want to find out if this is coming from bowel tissue or if it’s mixed in with 
the stool. The study doctor may therefore ask for your  an enema. This will bring 
about a bowel movement. Subsequently, when you’re ready, we will invite you to 
re-enter the scanner for another 10 minutesThis component of the PET scan is 
entirely optional. 
 
For the rest of the day, it is advised that you drink plenty of fluids (about 1 and one 
half pints), and you may eat as normal. You should empty your bladder frequently.  
For the rest of that day only, the sugar molecule injected into your body will be 
giving off very tiny amounts of radiation, so you should not sit next to pregnant 
women or children for long periods. 
 
What does the MRI Scan involve? 
The MRI part of this study is optional and you can decide not to have an MRI scan 
and still take part in the study. 
MRI is a special technique that uses powerful magnets, radio waves and computers 
to produce detailed images (or scans) of the inside of the body. If you agree to take 
part in the MRI part of the study after the PET scan you will be asked to drink an 
additional of up to 1600ml (approximately 3 pints) of the same contrast  solution , or 
as close to that amount as you can tolerate.  After approximately 90 minutes you will 
be asked to lie on your back on a table, which slides inside a cylinder-shaped 
machine. The radiographer may use pillows or straps to adjust your position and 
help you to stay still.   You will then be placed in the middle of the scanner. The 
machine is open ended so you won't be completely enclosed at any time. The tunnel 
in the scanner is just over one metre (about four feet) long. 
Your radiographer will operate the scanner from behind a window and will be able 
to see and hear you during the scan. The MRI scanner makes a loud knocking or 
buzzing sounds throughout the scan. You will usually be given earplugs or 
headphones to wear, and you can listen to music during the scan. It can take several 
minutes for each image to be taken, so it's important to lie very still and breathe 
gently. Your radiographer will ask you to hold your breath at certain times during 
the scan. 
After the first series of scans, you will be given another dose of buscopan through 
the cannula and undergo another short set of scans in the MRI machine.  The final 
dose of buscopan will then be given, together with a special dye (contrast medium) 
called gadolinium, also injected through your cannula. This dye is used during the 
scan to produce more detailed images. You will then be asked to undergo another 
series of scans and again your radiographer will ask you to hold your breath at 
certain times during the scan. 
 Version   9 28 January 2014 
	    
	  
	   	  
After the end of the scan, the cannula will be removed from your arm. After 
completion of the MRI you will usually be able to go home when you feel ready. 
None of the procedures that take place during the scanning visit should interfere  
with your ability to drive home if you want to. 
 
 
What does the colonoscopy involve? 
A colonoscopy is a test where a doctor looks into your large bowel. It is very likely 
that you would have had one or more in the past as part of your Crohn’s diagnostic 
work-up. 
Colonoscopy is usually done as an outpatient or day case. It is a routine test which is 
commonly done. You will usually be given a sedative to help you to relax. This is 
usually given by an injection into a vein in the back of your hand. The sedative can 
make you drowsy but it does not 'put you to sleep'. It is not a general anaesthetic. 
 
You lie on your side on a couch. The operator will gently push the end of the 
colonoscope into your anus and up into the colon. Modern colonoscopes transmit 
pictures through a camera attachment on to a TV monitor for the operator to look at.  
 
The operator may take biopsies (small samples) of some parts of the inside lining of 
the colon - depending on why the test is done. This is painless. The biopsy samples 
are sent to the lab for testing, and to look at under the microscope. At the end of the 
procedure the colonoscope is gently pulled out. 
You should get instructions from the hospital department before your test. The sort 
of instructions given include: 
• The colon needs to be empty so that the operator can get a clear view. You 
will be instructed on how to take a special diet for a few days before the test. 
You will also be given some laxatives to take. 
• You will need somebody to accompany you home, as you will be drowsy 
with the sedative. 
As you may remember from previous colonoscopies, we do request that an adult 
friend or relative is available to accompany you home after the test, unless you select 
not to have any sedation during the procedure. We would advise that you refrain 




What are the possible disadvantages and risks of taking part? 
• The PET molecule 
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FDG is a PET molecule used extensively in clinical practice. It is used in very 
small amounts and you should not feel different after receiving it.  It has an 
excellent safety profile.  
  
• PET Scanning and Radiation 
 
Each PET scan will involve exposure to radiation.  It is a very small dose of 
radiation – about the same as you would get naturally from the environment in 
three years.  The exact amount you will receive throughout both scans is 
estimated at 11.2 mSv. If you agree to be re-scanned following an enema, this will 
add 1.2mSv to the additional dose, bringing the total up to 12.4mSv For 
comparison purposes, the UK legal limit set by the Ionising Radiations 
Regulations (1999) for a classified person who works with radiation to be exposed 
to in any given year is higher, at 20mSv. 
However, this radiation  does carry a very small,  theoretical risk of increasing 
your chance of getting cancer.  Cancer is common: 1 in 4 people – 25% - will die of 
cancer.  Your exposure could increase your risk by 0.05% (i.e., five of one hundred 
parts of 1%) so that your theoretical risk could rise from 25% to 25.05%.  Although 
this statistical risk exists, follow up studies of people who work with radiation 
and who are exposed to bigger doses have found no increased cases of cancer.   
If you were to participate in further studies which involve the use of radiation you 
should inform the study team that you have been exposed to up to  12.4mSv of 
ionising radiation in this study. 
IF YOU PARTICIPATE IN OUR STUDY, WE ADVISE THAT YOU SHOULD 
NOT PARTICIPATE IN FURTHER RESEARCH STUDIES INVOLVING 
IONISING RADIATION FOR THE NEXT 3 YEARS 
• Administration of the enema 
An enema is fluid that is placed in the rectum through the anus (back passage) to 
clear the bowel. The phosphate enema that you will be given is a single dose 
disposable enema that will clean the section of your bowel that will be re-scanned 
subsequently.  
It is usually very well tolerated. Rare side-effects include rectal bleeding, 
blistering, burning and itching. 
 
• MRI SCAN 
An MRI is a very safe test and there are no known complications or side-effects 
from the magnetic field used during the scan.  You may feel slightly 
claustrophobic and uncomfortable from being inside the scanner. In addition if 
you have any metal implants for example, heart pacemaker, an inner ear hearing 
aid (cochlear implant), an intra-uterine contraceptive device or coil, shrapnel or 
gunshot wounds, a body piercing or tattoos that have been done using a metallic 
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ink you may not be able to have a MRI scan.  The contrast  solution you will 
drink prior to the MRI may give you short-lived diarrhoea.  This isn't a complete 
list - your radiographer will go through a safety checklist with you before the 
scan.  
 
• MRI dye (gadolinium) 
It's possible to have an allergic reaction to the dye used, though this is very 
unlikely. If you have any itching or shortness of breath during the scan, tell your 
radiographer immediately. Medicines are available to treat the allergic reaction. 
Patients with severe kidney disease and those who have had, or who are awaiting, 
liver transplantation are at risk of a disease called nephrogenic systemic fibrosis  
(NSF) after gadolinium administration, this can cause, skin pains and blisters 
amongst other symptoms and possibly death.  You will be screened before 
scanning to make sure you do not have kidney disease. If you do not have kidney 
disease, then you are at no increased risk of developing this condition. 
 
Other common side effects of the dye may include; dizziness, headache, a change 
in taster sensation, vomiting, nausea, pain, feeling hot , feeling cold  and problems 
at the injection site which could include; coldness, swelling, warmth, pain and 
irritation.  Ask your radiographer to explain how these risks apply to you.  If 
you're worried about this or anything to do with the MRI scan please talk to your 
radiographer. 
 
• Cannulation and blood sampling 
Insertion of a cannula into a vein may cause brief discomfort as the cannulae 
penetrates the skin (like a needle), but there should be no further discomfort.   
Risks of any cannulation include minor local bleeding and bruising. Very rarely, a 
blood clot could form around the cannula.   
A maximum of 200 mL (approx 11 tablespoons) of blood will be taken during the 




• Intravenous buscopan 
 
Buscopan is a drug given intravenously to prevent the bowel from contracting 
during the scan. Its effects are very short-lived, and therefore the dose will have 
to be repeated during the scan. Just after you have a dose, you may experience 
mouth dryness for a few minutes, or, more occasionally, your heart rate may go 
up for a few minutes after each dose. We will be asking you if you have been 
shown to suffer from raised eye pressure (glaucoma) in which case we will not be 
giving you buscopan.  
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• Colonoscopy 
As with every procedure, there are some risks associated with colonoscopy.  
Side-effects: These are the unwanted, but mostly temporary effects you may get 
after having the procedure. After having a colonoscopy you may feel bloated and 
uncomfortable due to trapped wind. You may find that lying on your front can 
sometimes help. Trapped wind usually passes after a few hours. You may also 
bleed a little from your back passage if you have had a biopsy or polyp removed. 
Complications: Complications are when problems occur during or after the 
procedure. A very small minority - far less than 1%-  are affected by any of these 
complications listed below.  
• You may have a reaction to the sedation, which can affect your breathing or 
your heart. You will be monitored throughout the procedure and treated 
quickly if these problems develop.  
• The colonoscope and the other instruments used during the procedure can 
cause a tear in the bowel. This happens in less than 1 in 1000 people who do 
not have any polyps removed during colonoscopy. If this happens you may 
need an operation to repair it.  












Are there any lifestyle restrictions? 
If you are a woman of childbearing potential, or a man whose female partner is of 
childbearing potential, you should follow the guidelines below to ensure that 
pregnancy is avoided during the course of this study. From the time of the first PET 
scan until 2 weeks after the second PET, you should either be sexually inactive, or 
use one of the contraceptive methods listed below.  
• Oral contraceptive 
• Injectable progestogen  
• Implants of levonorgestrel 
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• Estrogenic vaginal ring 
• Percutaneous contraceptive patches 
• Intrauterine device (IUD) or intrauterine system (IUS)  
• Double barrier method:  condom and occlusive cap (diaphragm or 




What are the possible benefits of taking part? 
This study will not help you, but the information we get from this study may help 
improve the way that we care for people with Crohn’s disease in the future. The 
screening tests may be of benefit to you if we find an important medical problem, 
but they could reveal something you would prefer not to know about. Imperial 
College will be the owner of the study results and may use the results to get patents, 
or make a profit in other ways. You will not be paid any part of this. 
 
Will I receive payment for being part of this study? 
 
You will receive reimbursement for all your travel expenses, as well as meals / 
refreshments during each visit. In addition, you will receive compensation of £170 






What if something abnormal is picked up on the scans? 
The PET scan and MRI (if you undergo this) will be over and above the imaging you 
would normally have as part of your usual care. The images of your bowel obtained 
for this project will therefore not be formally reported by a radiologist. However, if 
these images pick up anything which could impact on your future health and well-
being, the images will be sent for review by a radiologist. If the abnormality is felt to 
be potentially important, a member of the research team will contact your GP, so 
they may arrange further investigation if necessary. We cannot guarantee however 
that an abnormality (if present) will definitely be detected 
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What if the blood tests show an unexpected abnormality? 
Similarly, if the blood tests are abnormal we will inform you and inform your GP so 
that you can get appropriate advice or treatment. 
 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions: 
Dr. Evangelos Russo: 07733 236009 
Prof   Tim Orchard: 0776 9606039 
If you feel unwell, you can contact the Principal Investigator, Dr. Evangelos Russo, 
to ask for advice.  If the situation will require further assistance, you may be 
suggested to contact your GP, or, in some cases, to go to an A&E department. If the 
situation is serious or potentially life threatening, you will be suggested to dial 999 










What if something goes wrong? 
 
Imperial College London holds insurance policies which apply to this study.  If you 
experience serious and enduring harm or injury as a result of taking part in this 
study, you may be eligible to claim compensation without having to prove that 
Imperial College is at fault.  This does not affect your legal rights to seek 
compensation. 
If you are harmed due to someone's negligence, then you may have grounds for a 
legal action.  Regardless of this, if you wish to complain, or have any concerns about 
any aspect of the way you have been treated during the course of this study then 
you should immediately inform the Investigator Evangelos Russo.  The normal 
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National Health Service complaint complaints mechanisms are also available to 
you.  If you are still not satisfied with the response, you may contact the Imperial 




Will my taking part in the study be kept confidential? 
Yes.  All information which is collected about you during the course of the research 
will be kept strictly confidential.  This information is covered by the Data Protection 
Act and will be stored on hospital and university as well as research centre 
computers protected by passwords and data encryption.  Any information about 
you which leaves the hospital will have your name and address removed so that you 
cannot be recognised from it.  A sheet of paper with your name and date of birth 
linking you to your study ID will be kept in a locked drawer in a room accessible by 
swipe card only within Imperial College and will be accessible only to the research 
team doing the study.   
The radiographers at Imanova Imaging Centre will have your name entered into the 
Radiology Information System so that they can keep a record of who is scanned but 
this information will be restricted to authorised individuals.  Participants in the 
study will need to be registered as patients with the Hammersmith Hospital as part 
of the agreement for resuscitation cover.    We will also contact your GP by letter to 
inform them of your participation.  We will inform your GP for you if we find 
anything clinically abnormal in the blood tests or on the scans.  Research studies are 
monitored to make sure that the research is conducted ethically and properly.  
People involved in monitoring the research study may have access to your personal 
information.    
How long is the study data kept? 
Imperial College London will keep the data in anonymised form for 10 years and it 
may be used in other studies.  Imanova will keep the data in anonymised form for 15 
years. 
 
What will happen to the images obtained and any samples I give? 
The PET and MRI images and associated information will be anonymised and 
studied by researchers at the Imanova and Imperial College. To ensure the greatest 
benefit from your contributions, we also may share anonymised images and 
associated information with scientists at other universities and companies including 
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GlaxoSmithKline, which has contributed partial support for this study and which 
carry out related research in other centres. 
As mentioned earlier, if you choose to take part in this study, you will be asked to 
give blood, urine and stool samples. Blood samples will be collected by trained staff. 
Urine and stool will be collected by you, as instructed by study nurses.  
Some tests will be performed by the study team at Imperial College or within the 
Imanova Imaging Unit, which is on the Hammersmith Hospital site. We will also ask 
other organisations (such as a university, hospital or company) to perform other 
parts of the tests. However, when your samples are transferred, any labelling that 
might allow you to be identified will be carefully removed. These samples will then 
be frozen and stored ready for analysis.  Your samples will be kept in locked storage 
and may be stored for up to 10 years from the end of the study. Any sample 
remaining at that time will be destroyed.   
If in the future you decide to withdraw from the study, your samples will be stored 
and analysed unless you ask to destroy them.  
 
What will happen to the results of this study? 
A brief summary of the results will be made available to the treatment service you 
are attending. The data and results of this study also will be shared with other 
scientists, although your name will not be used and you will not be otherwise 
identified in doing this or on any report or publication related to the study.  The 
results of this study will be presented at scientific conferences and published in a 
scientific journal (we expect this to happen about one to two years after the end of 
the study).  Data obtained from your blood tests, and scanning data may be used in 
an anonymous form for future research.  You will not be contacted by anyone 
carrying out such research and they will not be given access to your medical records.  
 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any point without the need to give a reason. If 
you choose to withdraw from the study at any point there will be no penalty or loss 
of benefits. Any medical care you receive outside of the study will not be affected. 
Information collected may still be used. Your stored blood or tissue samples will still 
be analysed unless you ask us to destroy them. 
	  
 
Who has reviewed the study? 
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All research is looked at by an independent group of people called a Research Ethics 
committee, to protect your interests. This study has been reviewed and given 
approval to continue by the South East Coast- Surrey Research Ethics Committee. 
 
 
Further information and contact details 
If you have any questions or concerns about this study you can contact the Principal 
Investigator Evangelos Russo on 07733236009. If you do experience an adverse event 
which you or your family consider serious or potentially life threatening dial 999 
and call for an ambulance. Do not delay treatment by trying to contact the doctor in 
charge of the study. 
If you would like further information about research or advice as to whether you 
should take part you can contact the NHS Patient Advice and Liaison Services 
(PALS). Or alternatively you can discuss with your GP or consultant if you should 
enter the study. 
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Patient identification number for this trial: 
Study number/Title of project:  CRO1973/. Longitudinal assessment of tissue 
responses to anti-TNF therapy in Crohn’s Disease 
 




1. I confirm that I have read and understand the information sheet dated    28 January 
2014 for the above study. I have had the study sufficiently explained to me and had 




2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason without my medical care or legal rights being 
affected. In the event of my withdrawal, I understand the research team still analyse 




3. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from Imperial College London, Imanova, 
regulatory authorities or from the NHS trust, where it is relevant to my taking part in 
this research. I give permission for these individuals to have access to my records. 
 
 
4. I understand that my anonymised images/anonymised data may be shared with 
Scientists at other universities and companies (including GlaxoSmithKline), here and 
in other countries. 
 
 
5. I agree to my GP being informed of my participation in the study and I authorise my 
GP to disclose details of any relevant medical or drug history in confidence. 
 
 
6. I agree that the Unit/Study Physicians may notify my General Practitioner of any 
abnormalities detected during the study after discussing these with me and that the 
Physician may consult with other Imanova and non-Imanova staff as appropriate for 
my care should I suffer a serious adverse event during the study. 
 
 
7. I have read and understand the compensation arrangements for this study as  
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specified in the information sheet 
 
8. I agree to be registered at the Hammersmith Hospital as a patient 
 
 




10. I have read, understand and agree to the contraception requirements for the duration 
of the study. 
 
11. I agree that my blood samples may be collected, frozen, tested and stored as 
explained in the sheet for research participants. I understand that my blood samples 
could be transferred outside the European Union. I agree that my samples may be 
stored for use in ethically approved projects in the future. 
 
 
12. It has been explained to me that the procedures and/or compounds being tested in 
this study may involve risks to me which are currently unforeseeable. 
 
13. I am not participating in any other studies and understand that other drug trial units 
may be contacted about my participation in/registration for studies elsewhere.  I 
understand that I will be registered on The Over-volunteering Prevention System 
(TOPS) at screening, to record my intention to participate in this study. 
 
 
14. I agree to take part in the above study.  
15. I agree to take part in the optional MRI part of the study  




  Name of Patient Date/time Signature 
Name of Person 
taking consent 
Date/time Signature 
